# Patent

## Title
3-carbamoyl-2-pyridone derivatives

## Abstract

The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I):




wherein R1, R2, R3, R4, and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

## Background
This is a divisional of Application No. 11/628,804, filed Aug. 29, 2007 now U.S. Pat. No. 8,178,681, which is a National Stage Entry of PCT/JP2005/020248, filed Oct. 28, 2005, and claims priority of Japanese Application No. 2004-313497, filed Oct. 28, 2004 and Japanese Application No. 2005-159995, filed May 31, 2005, the contents of all of which are incorporated herein by reference.


TECHNICAL FIELD
The present invention relates to 3-carbamoyl-2-pyridone derivatives having an agonistic activity to the cannabinoid receptor, its pharmaceutical compositions, and its medicine applications.
BACKGROUND ART
Cannabinoid (CB) was discovered as the main active substance contained in marijuana in 1960 and its main behavior was an activity in the central nervous system bringing about illusion, euphoria, sensory confusion of time and space, and the like by being ingested.
It has been found that a seven times transmembrane G protein bonded cannabinoid type 1 (CBI) receptor exists in the central nervous system such as the brain in 1990, and besides agonists to the receptor take part in the adjustment of a higher-order function of the brain by restrainedly controlling the neurotransmitter discharge with the signal transmission system in the cell such as controlling adenylate cyclase activity, controlling N- and P/Q types Ca 2+ channels, activating voltage gated K+ channel, and activating MAP kinase activity through the receptor, it has been also found that the receptor exists also in peripheral tissues and has minor activities in non-nervous systems such as an anti-inflammatory activity, and the alleviation of hypotonia bulbi and muscular spasm. Further, a cannabinoid type 2 receptor (CB2) was found to be distributed over immune tissues such as the spleen and agonists to this receptor were found to surpress an activation of immunocyte or inflammatory cells to exhibit an immunosuppressive activity, an anti-inflammatory activity and analgesic activity (Non-patent literature 1). From these facts, the application of agonists to the cannabinoid receptors to medicines has become to be examined widely.
As applications as medicines of agonists to the cannabinoid receptors, the medical treatment for an allergic disease of quinolone derivatives (Patent literatures 1, 2, 3, 4, and 5), 3,4-dihydroisoquinoline derivatives (Patent literature 6), pyridone derivatives (Patent literature 7), and further quinolone derivatives (Patent literature 8) have been described. Moreover, an anti-pruritic activity is disclosed in Patent literatures 10 and 11.
Itching is a kind of biological reaction, and peripheral itching and central itching are known. For example, sweet itchs including inflammatory reactions such as an edema, atopic dermatitis, hives, senile xerosis, and contact dermatitis are peripheral itching caused when nerve endings (itching receptors) of sensory nerve fibers existing in the epidermal-dermal junction are activated by a chemical, physical, or electric stimulus and the like. On the other hand, refractory pruritus such as systemic pruritus of a renal failure patient, which is derived from the hemodialysis, is thought to be central itching that is caused by an opioid peptide uniting with the receptor.
Medicines presently used as an anti-pruritus agent include, for example, diphenhydramine and crotamiton. The former is not effective in other itching though it is effective in the edema and hives that histamine took part as an antihistaminic. Moreover, though the latter adds anti-inflammatory activity by adding a steroid drug and is used as ointment for itching of eczema and the like, the action mechanism is uncertain.
By the way, atopic dermatitis is a cutaneous disease being accompanied by very strong pruritus and skin inflammation in the background of the atopic disposition and accompanied by the decrease in the barrier function, and the wax and wane are repeated. At present, as for medicines that soothe the inflammation and the effectiveness is proven, there are only two kinds, that is, steroids for internal use and for external application, and calcineurin inhibitory medicines that are called the immunosuppressive activity agents or immunoregulation agents for external use such as tacrolimus and eridale. However, there are severe faults such as the existence of steroid refractory patients, various systemic and locality side effects, and rebounds in the steroid. Moreover, though the immunoregulation agent for external use, the action mechanism of which is quite different from the steroid for external application, is highly effective especially for exanthemata in the face and the cervical region, it has peculiar skin stimulation and is a taboo for using especially in epidermolysis surface seen in atopic dermatitis and the like, and an advanced specialty and attention are demanded when using it. These medicines to the atopic dermatitis are symptomatic treatment medicines which aim at moderate solution of the symptom, and not those which aim at the treatment going back even the cause (Non-patent literature 2).
On the other hand, itching is understood as a sense which causes the impulse of wonting to scratch, and scratching off, a blow, and the like, which are accompanied by itching, are often the most complicating factors of atopic dermatitis. That is, if pruritus can be controlled, not only itching, which is the most suffering of the patient, can be softened to improve QOL (Quality of life), but also an indirect effect that an exanthema is improved by controlling scratching off can be expected. For these reasons, the development of a safe anti-pruritus agent that enables the loss in quantity or cessation of the symptomatic treatment medicine and is strong and can endure the chronic administration is wated for.
As one mode of such a medicine, a medicine for external application that acts only on the applied region and can avoid the systemic action by the internal use is cited. That is, compared with oral agents that the medicines are obsorbed from an alimentary canal, an endermic liniment for external application becomes possible to absorb the medicine directly from the disorder affected part by the noninvasive zero-order discharge, to avoid the first-pass effect in the liver, to avoid dosage dependent systemic side effects, and to control medicinal concentration in the disorfer affected part for long periods of time, and the merit of the medicine is considered that it can be used safely for cutaneous diseases often seen especially in elderly people, sick people, and infants. In fact, though the steroid drug has a strong anti-inflammatory activity and an anti-pruritic activity that accompanies it, it is not used as an oral medicine except for the remission of extremely severe symptoms. On the one hand, it is well known that the skin has a remarkably strong barrier function for a lot of medicines, so that effective medicines in oral administration are not necessarily effective even in dermal administration.
The present inventors have eagerly made progress in their studies, resulting in finding that the application of a 3-carbamoyl-2-pyridone derivative shown in the following on the skin of the disorder affected part makes the derivative act directly to the cannabinoid receptor existing in the periphery to reveal excellent anti-pruritic activity.
Though pyridone derivatives similar to the said compounds of the present invention are commercially available from Interbioscreen Corp., Interchim Corp., Asinex Corp., and Ambinter Sarl Corp. as reagents, pharmacological activity on these compounds has not described.
(Patent Literature 1)
International Publication No. 99/02499 Pamphlet
(Patent Literature 2)
International Publication No. 00/40562 Pamphlet
(Patent Literature 3)
International Publication No. 2004/103974 Pamphlet
(Patent Literature 4)
International Publication No. 04/103974 Pamphlet
(Patent Literature 5)
International Publication No. 04/104000 Pamphlet
(Patent Literature 6)
International Publication No. 02/10135 Pamphlet
(Patent Literature 7)
International Publication No. 02/053543 Pamphlet
(Patent Literature 8)
International Publication No. 03/061699 Pamphlet
(Patent Literature 9)
International Publication No. 02/065997 Pamphlet
(Patent Literature 10)
International Publication No. 03/035109 Pamphlet
(Patent Literature 11)
International Publication No. 03/070277 Pamphlet
(Non-Patent Literature 1)
Nature, 1993, vol. 365, p. 61-65
(Non-Patent Literature 2)
Japanese dermatology association's atopic dermatitis treatment guideline, 2004 revised edition, “Japanese skin society magazine”, 2004, p. 114-135
DISCLOSURE OF INVENTION
Compounds having an agonistic activity to the cannabinoid receptor; particularly compounds being excellent in transdermal absorbency or oral absorbency will be offered. Especially, pharmaceutical compositions, atopic dermatitis therapeutic drugs, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which contain the said compound as an active ingredient, will be offered.
The present inventors found 3-carbamoyl-2-pyridone derivatives shown in the following, which have a strong agonistic activity to the cannabinoid receptor, are low in inhibition activity for enzyle (CYP), are low in the central nerve side effects, are excellent in photostability, and/or have excellent transdermal absorbency or oral absorbency. Moreover, the pharmaceutical composition, which contains the said compound as an active ingredient, was found to be effective as an atopic dermatitis therapeutic drug, an anti-pruritus agent, especially anti-pruritus agents for oral use and for external application.
That is, the present invention relates to: 1) a compound of the formula (I):




    wherein, R1 is C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group A, C2-C8 alkenyl, or C2-C8 alkynyl;
    R2 is C1-C6 alkyl or C1-C6 alkoxy C1-C6 alkyl;
    R3 is C1-C6 alkyl or C1-C6 alkoxy; or
    R2 and R3 taken together with the adjacent carbon atoms may form an optionally substituted non-aromatic 5 to 10 membered carbon ring which may be replaced by one group selected from —O—, —S—, —SO—, and —SO2—;
    R4 is hydrogen or hydroxy;
    G is a group represented by formula:






    wherein R5 is hydrogen or C1-C6 alkyl;
    X1 is a single bond, C1-C4 alkylene optionally substituted with one to three substituents selected from substituents group B, C2-C4 alkenylene optionally substituted with one to three substituents selected from substituent group B, or C2-C4 alkynylene optionally substituted with one to three substituents selected from substituent group B;
    X2 is C1-C8 alkylene which may be replaced by one or two groups of —O— or —NR6— wherein R6 is hydrogen, C1-C8 alkyl, or benzyl, and optionally substituted with one to three substituents selected from substituent group B, C3-C8 cycloalkanediyl optionally substituted with one or two substituents selected from substituent group C, C3-C8 cycloalkenediyl optionally substituted with one or two substituents selected from substituent group C, aryldiyl optionally substituted with one or two substituents selected from substituent group C, heteroaryldiyl optionally substituted with one or two substituents selected from substituent group C, or non-aromatic heterocyclediyl optionally substituted with one or two substituents selected from substituent group C;
    X3 is a single bond, C1-C4 alkylene which may be replaced by a heteroatom, and optionally substituted with one to three substituents selected from substituent group B, C2-C4 alkenylene optionally substituted with one to three substituents selected from substituent group B, C2-C4 alkynylene optionally substituted with one to three substituents selected from substituent group B, or carbonyl;

the group represented by formula:







is a group selected from the groups represented by the formulas:





    wherein Ra is C1-C8 alkyl and n is 0, 1, or 2;

the group represented by formula:







is a group selected from the groups represented by the formulas:





    wherein Rb is hydrogen or C1-C8 alkyl; p is 0, 1, or 2; q is an integer of 1 to 4; Y is —O—, —S—, —N(R6)— wherein R6 is hydrogen or C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group D, or a group selected from the groups represented by formulas:






    wherein R7 is C1-C8 alkyl; m is 1 or 2;


Z is hydrogen, C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group D, C3-C12 cycloalkyl optionally substituted with one or two substituents selected from substituent group C, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, amino optionally substituted with one or two substituents selected from substituent group E, C1-C8 alkylsulfonyl, C6-C14 arylsulfony optionally substituted with one to three substituents selected from substituent group F, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group E, a group represented by the formula: —C(NH2)—NR8—CO—NR8R9 wherein R8 and R9 is each independently hydrogen or C1-C8 alkyl, or a group represented by the formula: —C(═W)—R10 wherein R10 is C1-C8 alkyl, hydroxy C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group E, hydrazino optionally substituted with one or two substituents selected from substituent group E, C6-Cl4 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, or non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group E ; W is an oxygen atom or a sulfur atom;
substituent group A: halogen, C3-C8 cycloalkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, oxo, amino optionally substituted with one or two substituents selected from substituent group E, cyano, azide, nitro, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group F, and a group represented by the formula: —C(═O)—R11 wherein R11 is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group E, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, or non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group F;

substituent group B: halogen, C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group A, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkylene which may be replaced by one group of —O—, hydroxy, C1-C8 alkoxy, C1-C8 alkylthio, halo C1-C8 alkoxy, oxo, amino optionally substituted with one or two substituents selected from substituent group E, cyano, azide, nitro, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group F, and a group represented by the formula: —C(═O)—R12 wherein R12 is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group E, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, or non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group F;

substituent group C: halogen, C1-C8 alkyl, halo C1-C8 alkyl, C1-C8 alkoxy, halo C1-C8 alkoxy, oxo, cyano, azide, nitro, and phenyl;

substituent group D: halogen, C1-C8 alkyl, halo C1-C8 alkyl, C3-C8 cycloalkyl, hydroxy, C1-C8 alkoxy, hydroxy C1-C8 alkoxy, C1-C8 alkylthio, halo C1-C8 alkoxy, oxo, amino optionally substituted with one or two substituents selected from substituent group E, carboxy, cyano, azide, nitro, tri(C1-C8 alkyl)ammonium, di(C1-C8 alkyl)benzyl ammonium, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group F, a group represented by the formula: —C(═O)—R13 wherein R13 is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group E, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, or non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group F, and a group represented by the formula: —O—C(═O)—R14 wherein R14 is C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkyloxy, C6-C14 aryloxy optionally substituted with one to three substituents selected from substituent group F, heteroaryloxy optionally substituted with one to three substituents selected from substituent group F, amino optionally substituted with one or two substituents selected from substituent group E, piperidino, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, or non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group F;

substituent group E: C1-C8 alkyl, (C1-C8 alkyl) carbonyl, (C1-C8 alkoxy) carbonyl, (C6-C14 aryl) carbonyl, heteroaryl carbonyl, (amino optionally substituted with one or two groups of C1-C8 alkyl or C6-C14 aryl) carbonyl, C1-C8 alkylsulfonyl, C6-C14 arylsulfonyl, and heteroarylsulfonyl;

substituent group F: halogen, C1-C8 alkyl, halo C1-C8 alkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, methylenedioxy, benzyloxy, carbamoyl optionally substituted with one or two C1-C8 alkyl, cyano, azide, nitro, oxo, and phenyl;

provided that, when —X1-X2-X3—C(═O)—Y-Z is a group represented by the formula (II):





R2 and R3 do not form 6 membered non-aromatic carbon ring taken together with the adjacent carbon atoms;

a pharmaceutically acceptable salt or a solvate thereof,

2) the compound according to 1), wherein R1 is C1-C5 alkyl optionally substituted with one to three substituents selected from substituent group A or C4-C5 alkenyl, a pharmaceutically acceptable salt or a solvate thereof,

3) the compound according to 1), wherein R1 is n-butyl, isopnetyl, 3-methyl-2-butenyl, 4,4,4-trifluorobutyl, 2-methyloxyethyl, cyclohexylmethyl, or (phenyl optionally substituted with one to three substituents selected from substituent group F)methyl, a pharmaceutically acceptable salt or a solvate thereof,

4) the compound according to any one of 1) to 3), wherein R2 is C1-C4 alkyl, or C1-C4 alkyloxy C1-C4 alkyl, and R3 is C1-C4 alkyl or C1-C4 alkyloxy, a pharmaceutically acceptable salt or a solvate thereof,

5) the compound according to any one of 1) to 3), wherein R2 is ethyl, n-propyl, isopropyl, or methyloxymethyl, and R3 is methyl, ethyl, or methyloxy, a pharmaceutically acceptable salt or a solvate thereof,

6) the compound according to any one of 1) to 3), wherein R2 and R3 taken together with the adjacent carbon atoms form a non-aromatic 7 to 10 membered carbon ring optionally substituted with C1-C4 alkyl, a pharmaceutically acceptable salt or a solvate thereof,

7) the compound according to any one of 1) to 3), wherein R2 and R3 taken together with the adjacent carbon atoms form a non-aromatic 8 membered carbon ring, a pharmaceutically acceptable salt or a solvate thereof,

8) the compound according to any one of 1) to 7), wherein R4 is hydrogen, a pharmaceutically acceptable salt or a solvate thereof,

9) the compound according to any one of 1) to 8), wherein R5 is hydrogen, a pharmaceutically acceptable salt or a solvate thereof,

10) the compound according to any 1) to 9), wherein X1 and V are a single bond, and X2 is straight-chain C1-C4 alkylene optionally substituted with one to two substituents selected from substituent group B, a pharmaceutically acceptable salt or a solvate thereof,

11) the compound according to any one of 1) to 9), wherein X1 and X3 each is independently a single bond or C1-C3 alkylene, and X2 is C3-C8 cycloalkanediyl optionally substituted with one to two substituents selected from substituent group C, a pharmaceutically acceptable salt or a solvate thereof,

12) the compound according to any one of 1) to 9), wherein X1 is a single bond, X3 is C1-C3 alkylene or C2-C3 alkenylene, and X2 is heteroaryldiyl optionally substituted with one to two substituents selected from substituent group C, a pharmaceutically acceptable salt or a solvate thereof,

13) the compound according to any one of 1) to 12), wherein Y is —O—, Z is hydrogen or C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group D, a pharmaceutically acceptable salt or a solvate thereof,

14) the compound according to any one of 1) to 12), wherein Y is —N(R6)— wherein R6 is as defined in 1), a pharmaceutically acceptable salt or a solvate thereof,

15) the compound according to any one of 1) to 12), wherein Y is a group represented by the formula:





wherein m is as defined in 1), a pharmaceutically acceptable salt or a solvate thereof,

16) a compound of the formula (II)





wherein R1A is C1-C6 alkyl optionally substituted with one to three substituents selected from substituent group G, C3-C6 alkenyl, or C3-C6 alkynyl;

R2A is C1-C4 alkyl or C1-C4 alkoxy C1-C4 alkyl;

R3A is C1-C4 alkyl or C1-C4 alkoxy; or

R2A and R3A taken together with the adjacent carbon atoms may form an optionally substituted non-aromatic 5 to 10 membered carbon ring;

R4A is hydrogen or hydroxy;

R15A is hydrogen or C1-C4 alkyl;

X1A is a single bond or C1-C3 alkylene;

X2A is straight-chain C1-C4 alkylene optionally substituted with one to two substituents selected from substituent group H, C3-C8 cycloalkanediyl optionally substituted with one to two substituents selected from substituent group I, or heteroaryldiyl optionally substituted with one to two substituents selected from substituent group I;

X3A is a single bond, C1-C3 alkylene, or C2-C3 alkenylene; substituent group G: halogen, C3-C8 cycloalkyl, C1-C8 alkoxy, halo C1-C8 alkoxy, cyano, azide, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group J, and heteroaryl optionally substituted with one to three substituents selected from substituent group J;

substituent group H: halogen, C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group G, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkylene which may be replaced by one group of —O—, C1-C8 alkoxy, C1-C8 alkylthio, halo C1-C8 alkoxy, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group J, heteroaryl optionally substituted with one to three substituents selected from substituent group J, and non-aromatic heterocyclic group optionally substituted with one to three substituents selected from substituent group J;

substituent group I: halogen, C1-C8 alkyl, and phenyl;

substituent group J: halogen, C1-C8 alkyl, halo C1-C8 alkyl, C1-C8 alkoxy, halo C1-C8 alkoxy, cyano, nitro, and phenyl;

a pharmaceutically acceptable salt or a solvate thereof,

17) the compound according to 16) wherein the group represented by the formula:





is a group selected from the groups represented by the formulas:














wherein Me is methyl; Et is ethyl; n-Pr is n-propyl; i-Pr is isopropyl, the group represented by the formula:





is a group selected from the groups represented by the formulas:








wherein Me is methyl; Et is ethyl; n-Pr is n-propyl; i-Pr is isopropyl; R15A is as defined in 16);

a pharmaceutically acceptable salt or a solvate thereof,

18) the compound according to 17), wherein R15A is hydrogen, a pharmaceutically acceptable salt or a solvate thereof,

19) a pharmaceutical composition containing the compound according to any one of 1) to 18) as an active ingredient,

20) the pharmaceutical composition according to 19), which is an atopic dermatitis treating agent,

21) the pharmaceutical composition according to 19), which is an anti-pruritus agent,

22) use of a compound, and a pharmaceutically acceptable salt or a solvate thereof according to any one of 1) to 18) for preparation of a medicament for preventing and/or treating atopic dermatitis,

23) a method of preventing and/or treating atopic dermatitis in a mammal including human, which comprises administrating to said mammal a therapeutical effective amount of the compound, and a pharmaceutically acceptable salt or a solvate thereof according to any one of 1) to 18), thereby alleviating its symptoms,

24) use of the compound, and a pharmaceutically acceptable salt or solvates according to any one of 1) to 18) for preparation of medicament for preventing and/or treating itching,

25) a method of alleviating itching a mammal including human, which comprises administrating to said mammal a therapeutical effective amount of the compound and a pharmaceutically acceptable salt or a solvate thereof according to any one of 1) to 18), and

26) a compound of the formula:














wherein R16B is hydroxy, C1-C4 alkyloxy, or chloro;

and a pharmaceutically acceptable salt or a solvate thereof.

Moreover, the following inventions are included in the present invention.
The invention relates to {1} a compound of the formula (BB):




wherein RBa is C1-C8 alkyl is optionally substituted with one to three substituents selected from substituent group A, C2-C8 alkenyl, or C2-C8 alkynyl;

RBb is C1-C6 alkyl;

RBc is C1-C6 alkyl or C1-C6 alkoxy; or

RBb and RBc may together with adjacent carbon atoms form an optionally substituted non-aromatic 5 to 10 membered carbon ring which may be replaced by one group selected from —O—, —S—, —SO—, and —SO2—;

RBd is hydrogen or hydroxy;

GB is a group represented by the formula:





wherein RBe is hydrogen or C1-C6 alkyl;

XBa is a single bond or C1-C4 alkylene optionally substituted with one to three substituents selected from substituent group B;

XBb is C1-C8 alkylene which may be replaced by one or two groups of —O— or —NRBf— wherein RBf is hydrogen, C1-C8 alkyl, or benzyl, and optionally substituted with one to three substituents selected from substituent group BBb, C3-C8 cycloalkanediyl optionally substituted with one or two substituents selected from substituent group CBc, C3-C8 cycloalkenediyl optionally substituted with one or two substituents selected from substituent group CBc, aryldiyl optionally substituted with one or two substituents selected from substituent group C, heteroaryldiyl optionally substituted with one or two substituents selected from substituent group CBc, or non-aromatic heterocyclediyl optionally substituted with one or two substituents selected from substituent group CBc;

XBc is a single bond, C1-C4 alkylene which may de replaced by heteroatom, and optionally substituted with one to three substituents selected from substituent group BBb, C2-C4 alkenylene optionally substituted with one to three substituents selected from substituent group BBb, or carbonyl;

ring GBa is a group selected from the groups represented by the formulas:





wherein RBj is C1-C8 alkyl; n is 0, 1, or 2;

ring GBb is a group selected from the groups represented by the formulas:





wherein RBk is hydrogen or C1-C8 alkyl; s is 0, 1, or 2; t is an integer of 1 to 4;

YBa is —O—, —S—, —N(RBz)— where in RBz is hydrogen or C1-C8 alkyl optionally substituted with one to three substituents selected from substituents group DBd, or

a group selected from the groups represented by the formulas:





wherein RBg is C1-C8 alkyl; m is 1 or 2;

ZBa is a group shown by hydrogen, C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group DBd, C3-C12 cycloalkyl optionally substituted with one or two substituents selected from substituent group CBc, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, amino optionally substituted with one or two substituents selected from substituent group EBe, C1-C8 alkylsulfonyl, C6-C14 arylsulfonyl optionally substituted with one to three substituents selected from substituent group FBf, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group EBe, a group represented by the formula: —C(NH2)—NRBha—CO—NRBhbRBi wherein RBha, RBhb, and RBi each is independently hydrogen or C1-C8 alkyl, or a group represented by the formula: —C(═WBa)—RBl wherein RBl is C1-C8 alkyl optionally substituted with one to two substituents selected from substituent group DBd, hydroxy C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group EBe, hydrazino optionally substituted with one or two substituents selected from substituent group EBe, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group EBe; WBa is an oxygen atom or a sulfur atom;

substituent group ABe: halogen, C3 to C8 cycloalkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, oxo, amino optionally substituted with one or two substituents selected from substituent group EBe, cyano, azide, nitro, C1-C8 alkylsulfonyl, C6-C14 arylsulfonyl optionally substituted with one to three substituents selected from substituent group FBf, heteroarylsulfonyl optionally substituted with one to three substituents selected from substituent group FBf, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group FBf, and a group represented by the formula: —C(═O)—RBm wherein RBm is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group EBe, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group FBf;

substituent group BBb; halogen, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkylene, hydroxy, C1-C8 alkoxy, C1-C8 alkylthio, halo C1-C8 alkoxy, oxo, amino optionally substituted with one or two substituents selected from substituent group EBe, cyano, azide, nitro, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, or heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group FBf, and a group represented by the formula: —C(═O)—Bn wherein RBn is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group EBe, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group FBf;

substituent group CBc; halogen, C1-C8 alkyl, halo C1-C8 alkyl, C1-C8 alkoxy, halo C1-C8 alkoxy, oxo, cyano, azide, nitro, and phenyl;

substituent group DBd halogen, C1-C8 alkyl, halo C1-C8 alkyl, C3 to C8 cycloalkyl, hydroxy, C1-C8 alkoxy, hydroxy C1-C8 alkoxy, C1-C8 alkylthio, halo C1-C8 alkoxy, oxo, amino optionally substituted with one or two substituents selected from substituent group EBe, carboxy, cyano, azide, nitro, tri(C1-C8 alkyl)ammonium, di(C1-C8 alkyl)benzylammonium, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group FBf, a group represented by the formula: —(═O)—13 wherein R13 is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group E, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group F, heteroaryl optionally substituted with one to three substituents selected from substituent group F, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group F, and a group represented by the formula: —C(═O)—Bp wherein RBp is C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkyloxy, C6-C14 aryloxy optionally substituted with one to three substituents selected from substituent group FBf, heteroaryloxy optionally substituted with one to three substituents selected from substituent group FBf, amino optionally substituted with one or two substituents selected from substituent group EBe, piperidino, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group FBf, heteroaryl optionally substituted with one to three substituents selected from substituent group FBf, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group FBf;

substituent group EBe: C1-C8 alkyl, (C1-C8 alkyl)carbonyl, (C1-C8 alkoxy)carbonyl, (C6-C14 aryl)carbonyl, heteroarylcarbonyl, (amino optionally substituted with one or two C1-C8 alkyl or C6-C14 aryl)carbonyl, C1-C8 alkylsulfonyl, C6-C14 arylsulfonyl, and heteroarylsulfonyl;

substituent group FBf: halogen, C1-C8 alkyl, halo C1-C8 alkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, methylenedioxy, benzyloxy, carbamoyl optionally substituted with one or two C1-C8 alkyl, cyano, azide, nitro, oxo, and phenyl;

provided that, when -XBa-XBb-XBc—C(═)-YBa-ZBe is a group represented by the formula (BB),





RBb and RBc do not form 6 membered non-aromatic carbon ring taken together with the adjacent carbon atoms;

a pharmaceutically acceptable salt or a solvate thereof,

{2} the compound according to {1}, wherein RBa is C1-C4 alkyl optionally substituted with one to three substituents selected from substituent group ABa, a pharmaceutically acceptable salt or a solvate thereof,

{3} the compound according to {1} or {2}, wherein RBa is n-butyl, cyclohexylmethyl, or (phenyl optionally substituted with one to three substituents selected from substituent group FBf methyl, a pharmaceutically acceptable salt or a solvate thereof,

{4} the compound according to any to {1} to {3}, wherein RBb and RBc each is independently C1-C4 alkyl, a pharmaceutically acceptable salt or a solvate thereof,

{5} the compound according to any one of {1} to {3}, wherein RBb and RBc taken together with the adjacent carbon atoms form a non-aromatic 7 to 10 membered carbon ring optionally substituted with C1-C4 alkyl, a pharmaceutically acceptable salt or a solvate thereof,

{6} the compound according to any one of {1} to {5}, wherein RBd is hydrogen, a pharmaceutically acceptable salt or a solvate thereof,

{7} the compound according to any one of {1} to {6}, wherein RBe is hydrogen, a pharmaceutically acceptable salt or a solvate thereof,

{8} the compound according to any one of {1} to {7}, wherein XBa and XBc are single bonds, and XBb is straight chain C1-C4 alkylene optionally substituted with one substituent selected from C1-C6 alkyl optionally substituted with one substituent selected from substituent group BBb and substituent group BBb, a pharmaceutically acceptable salt or a solvate thereof, {9} the compound according to any one of {1} to {7}, wherein XBb is heteroaryldiyl optionally substituted with one to two substituents selected from substituents group CBc, a pharmaceutically acceptable salt or a solvate thereof,

{10} the compound according to any one of {1} to {9}, wherein YBa is —O—, and ZBa is hydrogen or C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group D, a pharmaceutically acceptable salt or a solvate thereof,

{11} the compound according to any one of {1} to {9}, wherein YBa is —N(RBz)— wherein RBz is as defined in {1}, a pharmaceutically acceptable salt or a solvate thereof,

{12} the compound according to any one of {1} to {9}, wherein YBa is a group represented by the formula:





wherein u is as defined in {1};

a pharmaceutically acceptable salt or a solvate thereof,

{13} a pharmaceutical composition containing the compound according to any one of {1} to {12} as an active ingredient,

{14} the pharmaceutical composition according to {13} which is useful as an anti-pruritus agent,

{15} the pharmaceutical composition according to {13} which is useful as an antiasthmatic agent,

{16} the pharmaceutical composition according to {1} which is useful as a chronic obstructive pulmonary disease therapeutic agent.

Moreover, the following inventions are included in the present invention. The invention relates to [1] a compound of the formula (A):




wherein Ra is C1-C8 alkyl is optionally substituted with one to three pieces of substituents selected from substituents group Aa, C2-C8 alkenyl, or C2-C8 alkynyl;

Rb is C1-C6 alkyl;

Rc is C1-C6 alkyl or C1-C6 alkoxy; or

Rb and Rc taken together with the adjacent carbon atoms may form a 5 to 10 membered cycloalkene having one double bond, which may be replaced by one group selected from —O—, —S—, —SO—, and —SO2— in the ring;

Rd is hydrogen or hydroxy;

G is a group represented by the formula:





wherein Re is hydrogen or C1-C6 alkyl;

Xa is a single bond or C1-C4 alkylene;

Xb is C1-C8 alkylene which may be replaced by one or two groups of —O—, or —N(Rf)— wherein Rf is hydrogen and C1-C8 alkyl or aralkyl, and optionally substituted with one to three substituents selected from substituents group Bb, C3-C8 cycloalkanediyl optionally substituted with one or two substituents selected from substituent group Cc, C3-C8 cycloalkenediyl optionally substituted with one or two substituents selected from substituent group Cc, aryldiyl optionally substituted with one or two substituents selected from substituent group Cc, heteroaryldiyl optionally substituted with one or two substituents selected from substituent group Cc, or non-aromatic heterocyclediyl optionally substituted with one or two substituents selected from substituent group Cc;

Xc is a single bond, C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or carbonyl;

ring Ga is a group selected from the groups represented by the formulas:





wherein Rj is hydrogen or C1-C8 alkyl;

ring Gb is a group represented by the formula:





wherein Rk is C1-C8 alkyl; s is 0, 1, or 2; t is an integer of 1 to 4; Ya is —O—, —S—, —N(Rz)— wherein Rz is hydrogen or C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group Dd, or a group selected from the groups represented by the formulas:





wherein Rg is C1-C8 alkyl; u is 1 or 2;

Za is hydrogen, C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group Dd, amino optionally substituted with one or two substituents selected from substituent group Ee, C1-C8 alkylsulfonyl, C6-C14 arylsulfonyl optionally substituted with one to three substituents selected from substituent group Ff, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ee, a group represented by the formula: —C(NH2)—NRha—CO—NRhbRi wherein Rha, Rhb, and Ri each is independently hydrogen or C1-C8 alkyl, or a group represented by the formula: —C(═Wa)—Rl wherein Rl is C1-C8 alkyl optionally substituted with one or two substituents selected from substituent group Dd, hydroxy C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group Ee, hydrazino optionally substituted with one or two substituents selected from substituent group Ee, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ee; Wa is an oxygen atom or a sulfur atom; substituent group Aa; halogen, C3-C8 cycloalkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, amino optionally substituted with one or two substituents selected from substituent group Ee, cyano, azide, nitro, C1-C8 alkylsulfonyl, C6-C14 arylsulfonyl optionally substituted with one to three substituents selected from substituent group Ff, heteroarylsulfonyl optionally substituted with one to three substituents selected from substituent group Ff, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ff, and a group represented by the formula: —C(═O)—Rm wherein Rm is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group Ee, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ff;

substituent group Bb: halogen, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkylene, hydroxy, C1-C8 alkoxy, C1-C8 alkylthio, halo C1-C8 alkoxy, amino optionally substituted with one or two substituents selected from substituent group Ee, cyano, azide, nitro, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, or heteroaryl optionally substituted with one to three pieces of substituents selected from substituent group Ff, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ff, and a group represented by the formula: —C(═O)—Rn wherein Rn is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group Ee, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group F;

substituent group Cc: halogen, C1-C8 alkyl, halo C1-C8 alkyl, C1-C8 alkoxy, halo C1-C8 alkoxy, cyano, azide, nitro, and phenyl;

substituent group Dd: halogen, C1-C8 alkyl, halo C1-C8 alkyl, C3-C8 cycloalkyl, hydroxy, C1-C8 alkoxy, hydroxy C1-C8 alkoxy, C1-C8 alkylthio, halo C1-C8 alkoxy, amino optionally substituted with one or two substituents selected from substituent group Ee, carboxy, cyano, azide, nitro, tri(C1-C8 alkyl)ammonium, di(C1-C8 alkyl)benzyl ammonium, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ff, a group represented by the formula: —C(═O)—Rp wherein Rp is hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, amino optionally substituted with one or two substituents selected from substituent group Ee, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ff, and a group represented by the formula: —O—C(═O)—Rq wherein Rq is C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkyloxy, C6-C14 aryloxy optionally substituted with one to three substituents selected from substituent group Ff, heteroaryloxy optionally substituted with one to three substituents selected from substituent group Ff, amino optionally substituted with one or two substituents selected from substituent group Ee, piperidino, C6-C14 aryl optionally substituted with one to three substituents selected from substituent group Ff, heteroaryl optionally substituted with one to three substituents selected from substituent group Ff, or non-aromatic heterocycle groups optionally substituted with one to three substituents selected from substituent group Ff;

substituent group Ee: C1-C8 alkyl, (C1-C8 alkyl)carbonyl, (C1-C8 alkoxy)carbonyl, (C6-C14 aryl)carbonyl, heteroarylcarbony, amino carbonyl optionally substituted with one or two C1-C8 alkyl or C6-C14 aryl, C1-C8 alkylsulfonyl, C6-C14 arylsulfony, and heteroarylsulfonyl;

substituent group Ff: halogen, C1-C8 alkyl, halo C1-C8 alkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, methylenedioxy, benzyloxy, carbamoyl optionally substituted with one or two C1-C8 alkyl, cyano, azide, nitro, oxo, and phenyl;

however, when —Xa-Xb-Xc—C(═O)—Ya-Za is a group represented by the formula (B):





the case where Rb and Re do not form 6 membered non-aromatic carbon ring taken together with the adjacent carbon atoms;

a pharmaceutically acceptable salt or a solvate thereof,

[2] the compound according to [1], wherein Ra is C1-C4 alkyl optionally substituted with one to three substituents selected from substituents group Aa, a pharmaceutically acceptable salt or a solvate thereof,

[3] the compound according to [1] or [2], wherein Ra is n-butyl, cyclohexylmethyl, or phenylmethyl optionally substituted with one to three substituents selected from substituent group Ff, a pharmaceutically acceptable salt or a solvate thereof,

[4] the compound according to [1] to [3], wherein Rb and Rc each is independently C1-C4 alkyl, a pharmaceutically acceptable salt or a solvate thereof,

[5] the compound according to any one of [1] to [3], wherein Rb and Rc taken together with the adjacent carbon atoms form 7 to 10 membered cycloalkene, a pharmaceutically acceptable salt or a solvate thereof,

[6] the compound according to any one of [1] to [5], wherein R4 is hydrogen, a pharmaceutically acceptable salt or a solvate thereof,

[7] the compound according to any one of [1] to [6], wherein Re is hydrogen, a pharmaceutically acceptable salt or a solvate thereof,

[8] the compound according to any one of [1] to [7], wherein Xa and Xc are single bonds, and Xb is C1-C4 alkylene optionally substituted with one substituent selected from C1-C6 alkyl optionally substituted with a group selected from substituent group Bb and one substituent selected from substituent Bb, a pharmaceutically acceptable salt or a solvate thereof,

[9] the compound according to any one of [1] to [7], wherein Xb is heteroaryldiyl optionally substituted with one to two substituents selected from substituent group C, a pharmaceutically acceptable salt or a solvate thereof,

[10] the compound according to any one of [1] to [9], wherein Ya is —O—, and Za is hydrogen or C1-C8 alkyl optionally substituted with one to three substituents selected from substituent group D, a pharmaceutically acceptable salt or a solvate thereof,

[11] the compound according to any one of [1] to [9], wherein Ya is —N(Rz)— wherein Ra is as defined in [1], a pharmaceutically acceptable salt or a solvate thereof,

[12] the compound according to any one of [1] to [9], wherein Ya is a group represented by the formula:





wherein u is as defined in [1];

a pharmaceutically acceptable salt or a solvate thereof,

[13] a pharmaceutical composition containing the compound according to any one of [1] to [12] as an active ingredient,

[14] an anti-pruroitus agent containing the compound according to any one of [1] to [12] as an active ingredient.

The meaning of each term will be explained below. Each term is used in the united meaning in the present description, and is used in the same meaning when used alone or when used being combined with other terms.
The term “halogen” includes the fluorine atom, the chlorine atom, the bromine atom, and the iodine atom.
The term “heteroatoms” includes the nitrogen atom, an oxygen atom, and a sulfur atom.
The term “alkyl” includes a C1-C10 straight or branched alkyl. For example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like can be listed. When the number of carbons is specified, the “alkyl”, which has the number of carbons within the ranges of the number, is meant.
The term “haloalkyl” includes a C1-C10 straight or branched alkyl in which one or more halogen are replaced at optional positions that can be replaced. For example, chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, chloroethyl (e.g., 2-chloroethyl and the like), dichloroethyl (e.g., 1,2-dichloroethyl, 2,2-dichloroethyl and the like), chloropropyl (e.g., 2-chloropropyl, 3-chloropropyl and the like), and the like can be listed. When the number of carbons is specified, the “haloalkyl”, which has the number of carbons within the ranges of the number, is meant.
The term “hydroxyalkyl” includes a C1-C10 straight or branched alkyl in which one or more hydroxy groups are replaced at optional positions that can be replaced. For example, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 6-hydroxyhexyl, 7-hydroxyheptyl, 8-hydroxyoctyl, and the like can be listed. When the number of carbons is specified, the “hydroxyalkyl”, which has the number of carbons within the ranges of the number, is meant.
The alkyl of “alkylthio” is as defined the above “alkyl”. As “alkylthio”, for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, t-butylthio, n-pentylthio, n-hexylthio, and the like can be listed. When the number of carbons is specified, the “alkylthio”, which has the number of carbons within the ranges of the number, is meant.
The alkyl of “alkylcarbonyl” is as defined the above “alkyl”. As “alkylcarbonyl”, for example, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, lauroyl, and the like can be listed. When the number of carbons is specified, the “alkylcarbonyl”, which has the number of carbons within the ranges of the number, is meant.
The alkyl of “alkylsulfonyl” is as defined the above “alkyl”. As alkylsulfonyl, for example, methanesulfonyl, ethanesulfonyl, and the like can be listed. When the number of carbons is specified, the “alkylsulfonyl”, which has the number of carbons within the ranges of the number, is meant.
The term “cycloalkyl” includes a C3-C12 cycloalkyl. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like can be listed. When the number of carbons is specified, the “cycloalkyl”, which has the number of carbons within the ranges of the number, is meant.
The term “alkenyl” includes a C2-C10 straight or branched alkyl containing one or more double bonds. For example, vinyl, 1-propenyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1,3-butadienyl, 3-methyl-2-butenyl, and the like can be listed. When the number of carbons is specified, the “alkenyl”, which has the number of carbons within the ranges of the number, is meant.
The term “alkynyl” includes a C2-C10 straight or branched alkyl containing one or more triple bonds. For example, ethynyl, propargyl, and the like can be listed. When the number of carbons is specified, the “alkynyl”, which has the number of carbons within the ranges of the number, is meant.
The alkyl of “alkoxy” is as defined the above “alkyl”. As alkoxy, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy, n-octyloxy, and the like can be listed. When the number of carbons is specified, the “alkoxy”, which has the number of carbons within the ranges of the number, is meant.
The term “haloalkoxy” includes the above-mentioned alkoxy in which one or more halogen are replaced at optional positions that can be replaced. For example, dichloromethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy (2,2,2-trifluoroethoxy and the like), and the like can be listed. When the number of carbons is specified, the “haloalkoxy”, which has the number of carbons within the ranges of the number, is meant.
The cycloalkyl of “cycloalkyloxy” is as defined the above “cycloalkyl”. As “cycloalkyloxy”, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy, and the like can be listed. When the number of carbons is specified, the “cycloalkyl”, which has the number of carbons within the ranges of the number, is meant.
The alkyl of “alkoxycarbonyl” is as defined the above “alkoxy”. As “alkoxycarbonyl”, for example, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl, n-butoxycarbonyl, i-butoxycarbonyl, n-hexyloxycarbonyl, n-heptyloxycarbonyl, n-octyloxycarbonyl, and the like can be listed. When the number of carbons is specified, the “alkoxycarbonyl”, which has the number of carbons within the ranges of the number, is meant.
The term “alkylene” includes a C1-C10 straight or branched alkylene. For example, methylene, ethylene, 1-methylethylene, 1-ethylethylene, 1,1-dimethylethylene, 1,2-dimethylethylene, 1,1-diethylethylene, 1,2-diethylethylene, 1-ethyl-2-methylethylene, trimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 1,2-dimethyltrimethylene, 2,2-dimethyltrimethylene, 1-ethyltrimethylene, 2-ethyltrimethylene, 1,1-diethyltrimethylene, 1,2-diethyltrimethylene, 2,2-diethyltrimethylene, 2,2-di-n-propyltrimethylene, 2-ethyl-2-methyltrimethylene, tetramethylene, 1-methyltetramethylene, 2-methyltetramethylene, 1,1-dimethyltetramethylene, 1,2-dimethyltetramethylene, 2,2-dimethyltetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, and the like can be listed. When the number of carbons is specified, the “alkylene”, which has the number of carbons within the ranges of the number, is meant.
The term “straight alkylene” includes a straight alkylene that is not branched. For example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, and the like can be listed. When the number of carbons is specified, the “straight alkylene”, which has the number of carbons within the ranges of the number, is meant.
The term “alkenylene” includes a C2-C10 straight or branched alkylene having one or more double bonds. For example, vinylene, 1-propenylene, allylene, isopropenylene, 1-butenylene, 2-butenylene, 3-butenylene, 2-pentenylene, 1,3-butadienylene, 3-methyl-2-butenylene, and the like can be listed. When the number of carbons is specified, the “alkenylene”, which has the number of carbons within the ranges of the number, is meant.
The term “alkynylene” includes a C2-C10 straight or branched alkylene having one or more triple bonds. For example, ethynylene, 1-propynylene, and the like can be listed. When the number of carbons is specified, the “alkynylene”, which has the number of carbons within the ranges of the number, is meant.
The term “cycloalkanediyl” includes a C3-C10 monocyclic or bicyclic cycloalkanediyl. For example, cyclopropanediyl, cyclobutanediyl, cyclopentanediyl, cyclohexanediyl, cycloheptanediyl, cyclooctanediyl, bicyclo[2,2,2]octanediyl, bicyclo[2,2,1]heptanediyl, adamantyldiyl, and the like can be listed. The same carbon atom may have two bonding hands. For example, cyclohexane-1,1-diyl and the like can be listed. When the number of carbons is specified, the “cycloalkanediyl”, which has members within the ranges of the number, is meant.
The term “cycloalkenediyl” includes a C3-C10 cycloalkenediyl. For example, cyclopropenediyl, cyclobutenediyl, cyclopentenediyl, cyclohexenediyl, cycloheptenediyl, cyclooctenediyl, and the like can be listed. If it is possible, the same carbon atom may have two bonding hand. For example, 2-cyclohexene-1,1-diyl and the like can be listed. When the number of carbons is specified, the “cycloalkenediyl”, which has members within the ranges of the number, is meant.
The term “aryl” includes a C6-14 aryl. For example, phenyl, naphthyl, anthryl, phenanthryl, and the like can be listed. When the number of carbons is specified, the “aryl”, which has members within the ranges of the number, is meant.
The term “aralkyl” includes a group in which the above “alkyl” is replaced with the above “aryl”. For example, benzyl, phenylethyl (e.g., 1-phenylethyl, 2-phenylethy), phenylpropyl (1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, and the like), naphthylmethyl (e.g., 1-naphthylmethyl, 2-naphthylmethyl, and the like) can be listed.
The term “aryldiyl” includes a C6-C14 aryldiyl. For example, phenylene, naphthylene, anthrylene, phenanthrylene, and the like can be listed. When the number of carbons is specified, the “aryldiyl”, which has members within the ranges of the number, is meant.
The aryl of “aryloxy” is as defined the above “aryl”. As “aryloxy”, for example, phenoxy, naphthoxy (e.g., 1-naphthoxy, 2-naphthoxy, and the like), anthryloxy (e.g., 1-anthryloxy, 2-anthryloxy, and the like), phenanthryloxy (e.g., 1-phenanthryloxy, 2-phenanthryloxy, and the like), and the like can be listed. When the number of carbons is specified, the “aryloxy”, which has members within the ranges of the number, is meant.
The aryl of “arylcarbonyl” is as defined the above “aryl”. As “arylcarbonyl”, for example, benzoyl, naphthoyl, and the like can be listed. When the number of carbons is specified, the “arylcarbonyl”, which has members within the ranges of the number, is meant.
The aryl of “arylsulfonyl” is as defined the above “aryl”. As “arylsulfonyl”, for example, phenylsulfonyl, naphthylsulfonyl, and the like can be listed. When the number of carbons is specified, the “arylsulfonyl”, which has the number of carbons within the ranges of the number, is meant.
The term “heteroaryl” includes a C1-C9 heteroaryl having one to four nitrogen atom(s), oxygen atom(s), and/or sulfur atom(s), for example, furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 1-imidazoly, 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-4-yl), tetrazolyl (e.g., 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiadiazolyl, isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), furazanyl (e.g., 3-furazanyl), pyrazinyl (e.g., 2-pyrazinyl), oxadiazolyl (e.g., 1,3,4-oxadiazol-2-yl), benzofuryl (e.g., 2-benzo[b]furyl, 3-benzo[b]furyl, 4-benzo[b]furyl, 5-benzo[b]furyl, 6-benzo[b]furyl, 7-benzo[b]furyl), benzothienyl (e.g., 2-benzo[b]thienyl, 3-benzo[b]thienyl, 4-benzo[b]thienyl, 5-benzo[b]thienyl, 6-benzo[b]thienyl, 7-benzo[b]thienyl), benzimidazolyl (e.g., 1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl), dibenzofuryl, benzoxazolyl, quinoxalyl (e.g., 2-quinoxalyl, 5-quinoxalyl, 6-quinoxalyl), cinnolyl (e.g., 3-cinnolyl, 4-cinnolyl, 5-cinnolyl, 6-cinnolyl, 7-cinnolyl, 8-cinnolyl), quinazolyl (e.g., 2-quinazolyl, 4-quinazolyl, 5-quinazolyl, 6-quinazolyl, 7-quinazolyl, 8-quinazolyl), quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), phthalazinyl (e.g., 1-phthalazinyl, 5-phthalazinyl, 6-phthalazinyl), isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), puryl, pteridinyl (e.g., 2-pteridinyl, 4-pteridinyl, 6-pteridinyl, 7-pteridinyl), carbazolyl, phenanthridinyl, acridinyl (e.g., 1-acridinyl, 2-acridinyl, 3-acridinyl, 4-acridinyl, 9-acridinyl), indolyl (e.g., 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), isoindolyl, phenazinyl (e.g., 1-phenazinyl, 2-phenazinyl), phenothiadinyl (e.g., 1-phenothiadinyl, 2-phenothiadinyl, 3-phenothiadinyl, 4-phenothiadinyl) or the like.
The term “heteroaryldiyl” includes a C1-C9 heteroaryldiyl having one to four nitrogen atom(s), oxygen atom(s), and/or sulfur atom(s), for example, furandiyl, thiophenediyl, pyrrolediyl, imidazolediyl, pyrazolediyl, triazolediyl, tetrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, thiadiazolediyl, isothiazolediyl, pyridinediyl, pyridazinediyl, pyrimidinediyl, furazandiyl, pyrazinediyl, oxadiazolediyl, benzofurandiyl, benzothiophenediyl, benzimidazolediyl, dibenzofurandiyl, benzoxazolediyl, quinoxalinediyl, cinnolinediyl, quinazolinediyl, quinolinediyl, phthalazinediyl, isoquinolinediyl, purinediyl, pteridinediyl, carbazolunediyl, phenanthridinediyl, acridinediyl, indolinediyl, isoindolinediyl, phenazinediyl, phenothiadinediyl, or the like.
As preferable heteroaryldiyl of X2, thiazole-1,4-diyl, thiazole-1,5-diyl, thiazole-3,5-diyl, pyridine-2,5-diyl, pyrimidine-2,5-diyl, and the like can be listed.
The heteroaryl of “heteroarylcarbonyl” is as defined the above “heteroaryl”. As “heteroarylcarbonyl”, for example, pyridylcarbonyl and the like can be listed.
The heteroaryl of “heteroarylsulfonyl” is as defined the above “heteroaryl”. As “heteroarylsulfonyl”, for example, furylsulfonyl, thienylsulfonyl, pyrrolylsulfonyl, imidazolylsulfonyl, pyrazolylsulfonyl, triazolylsulfonyl, tetrazolylsulfonyl, oxazolylsulfonyl, isoxazolylsulfonyl, thiazolylsulfonyl, thiadiazolylsulfonyl, isothiazolylsulfonyl, pyridylsulfonyl, pyridazinylsulfonyl, pyrimidinylsulfonyl, furazanylsulfonyl, pyrazinylsulfonyl, oxadiazoltlsulfonyl, benzofurylsulfonyl, benzothienylsulfonyl, benzimidazolylsulfonyl, dibenzofurylsulfonyl, benzoxazolylsulfonyl, quinoxalylsulfonyl, cinnolylsulfonyl, quinazolylsulfonyl, quinolylsulfonyl, phthalazinylsulfonyl, isoquinolylsulfonyl, purylsulfonyl, pteridinylsulfonyl, carbazolylsulfonyl, phenanthridinylsulfonyl, acridinylsulfonyl, indolylsulfonyl, isoindolylsulfonyl, phenazinylsulfonyl, phenothiadinylsulfonyl, or the like can be listed.
The term “non-aromatic heterocyclic group” includes a C1-C9 non-aromatic ring having one to four nitrogen atom(s), oxygen atom(s), and/or sulfur atom(s), for example, oxirane, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidino, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-imidazolinyl, 2-imidazolinyl, 4-imidazolinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, piperidino, 2-piperidyl, 3-piperidyl, 4-piperidyl, piperazino, 2-piperazinyl, 2-morpholinyl, 3-morpholinyl, morpholino, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, or the like.
The term “non-aromatic heterocyclediyl” includes a C1-C9 non-aromatic ring diyl having one to four nitrogen atom(s), oxygen atom(s), and/or sulfur atom(s), for example, pyrrolinediyl, pyrrolidinediyl, imidazolinediyl, imidazolidinediyl, pyrazolinediyl, pyrazolidinediyl, piperidinediyl, piperazinediyl, morpholinediyl, tetrahydropyrandiyl, or the like.
As “5-10 membered cycloalkene having one double bond, which may contain a group selected from —O—, —S—, —SO—, and —SO2— in the ring”, for example, cyclopentene, dihydropyran, dihydrothiopyran, dihydrothiopyran-1-oxide; dihydrothiopyran-1,1-dioxide, cyclohexene, cycloheptene, cyclooctene, cyclononene, cyclodecene, and the like can be listed. 7 to 10 membered cycloalkene is preferable, and, for example, cycloheptene, cyclooctene, cyclononene, and cyclodecene can be listed.
“Optionally substituted alkyl”, “Optionally substituted: aryl”, “Optionally substituted: heteroaryl”, “Optionally substituted: non-aromatic heterocycle group”, “Optionally substituted: alkylene”, “Optionally substituted: aryloxy”, “Optionally substituted: heteroaryloxy”, “Optionally substituted: arylsulfonyl”, “optionally replaced heteroarylsulfonyl”, “Optionally substituted: cycloalkanediyl”, “Optionally substituted: cycloalkenediyl”, “Optionally substituted: aryldiyl”, “Optionally substituted: heteroaryldiyl”, “optionally replace non-aromatic heterocyclediyl”, “Optionally substituted: amino”, “Optionally substituted: hydrazine” include being unsubstituted or having a substituents.
When substituents are possessed, arbitrary positions, which can be replaced, may be replaced respectively with the same substituents or the different substituents of one or more possible numbers.
The substituents include, for example, hydroxy, carboxy, halogen (fluorine atom, chlorine atom, bromine atom, iodine atom), haloalkyl (e.g., CF3, CH2CF3, CH2CCl3, and the like), haloalkoxy, alkyl (e.g., methyl, ethyl, isopropyl, t-butyl, and the like), alkenyl (e.g., binyl), formyl, acyl (e.g., acetyl, propionyl, butyryl, pivaloyl, benzoyl, pyridinecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, and the like), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like), alkylene (e.g., trimethylene, pentamethylene, hexamethylene, and the like), alkenylene (e.g., 2-propene-1,3-diyl, 3-pentene-1,5-diyl, 3-hexene-1,6-diyl, and the like), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, and the like), alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, and the like), nitro, nitroso, oxo, Optionally substituted: amino (e.g., amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, and the like), formylamino, acylamino (e.g., acetylamino, benzoylamino, and the like)), azide, aryl (e.g., phenyl and the like), aryloxy (e.g., phenoxy), cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapto, alkylthio (e.g., methylthio, ethylthio, and the like), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), arylsulfonyl (e.g., benzenesulfonyl and the like), Optionally substituted: carbamoyl, sulfamoyl, formyloxy, haloformyl, oxalo, mercapto, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazine, ureido, amidino, guanidino, formyloxy, thioxo, alkoxyalkoxy, alkylthioalkoxy, and the like.
When the number of the substituents or the kinds of the substituents are specified, it means that the substitution may be carried out within the specified range.
A preferable compound of the formula (I) is such a compound that has each of the following partial structures of a) to r) independently, or has them in any one of their possible combination. a) R1 is C1-C5 alkyl is optionally substituted with one to three substituents selected from the above-mentioned substituent group A or C4-C5 alkenyl, b) R1 is C1-C5 alkyl optionally substituted with one to three substituents selected from the above-mentioned substituent group A, c) R1 is n-butyl, isopentyl, 3-methyl-2-butenyl, 4,4,4-trifluorobutyl, 2-methyloxyethyl, cyclohexylmethyl, or (phenyl optionally substituted with one to three substituents selected from the above-mentioned substituent group F)methyl, d) R2 is C1-C4 alkyl or C1-C4 alkyloxy C1-C4 alkyl, e) R2 is C1-C4 alkyl, f) R3 is C1-C4 alkyl or C1-C4 alkyloxy, g) R3 is C1-C4 alkyl, h) R2 and R3 taken together with the adjacent carbon atoms form a 7 to 10 membered cycloalkene, i) R2 and R3 taken together with the adjacent carbon atoms form a 8 membered cycloalkene, j) R4 is hydrogen or a hydroxy group, k) R4 is hydrogen, l) R5 is hydrogen, m) X1 and X3 are single bonds, and X2 is C1-C4 alkylene optionally substituted with one to two substituents selected from the above-mentioned substituent group B, X1 and X3 each is independently a single bond or C1-C3 alkylene, and X2 is C3-C8 cycloalkanediyl optionally substituted with one to two substituents selected from the above-mentioned substituent group C, o) X1 is a single bond, X3 is C1-C3 alkylene or C2-C3 alkenylene, X2 is heteroaryldiyl optionally substituted with one to two substituents selected from the above-mentioned substituent group C, p) Y is —O—, and Z is hydrogen or C1-C8 alkyl optionally substituted with one to three substituents selected from the above-mentioned substituent group D, q) Y is —N(R6)— wherein R6 is as defined the above, r) Y is preferable to be a group represented by the formula:




wherein m is as defined above, but it is not limited to these.

Preferable combinations will be specifically illustrated as follows.
(R1, R2, R3, R4, R5, (X1, X2, X3), (Y, Z)) is preferable to be, (a, d, f, j, l, m, p), (a, d, f, j, l, n, p), (a, d, f, j, l, o, p), (a, d, f, k, l, m, p), (a, d, f, k, l, n, p), (a, d, f, k, l, o, p), (a, d, g, j, l, m, p), (a, d, g, j, l, n, p), (a, d, g, j, l, o, p), (a, d, g, k, l, m, p), (a, d, g, k, l, n, p), (a, d, g, k, l, o, p), (a, e, f, j, l, m, p), (a, e, f, j, l, n, p), (a, e, f, j, l, o, p), (a, e, f, k, l, m, p), (a, e, f, k, l, n, p), (a, e, f, k, l, o, p), (a, e, g, j, l, m, p), (a, e, g, j, l, n, p), (a, e, g, j, l, o, p), (a, e, g, k, l, m, p), (a, e, g, k, l, n, p), (a, e, g, k, l, o, p), (b, d, f, j, l, in, p), (b, d, f, j, l, n, p), (b, d, f, j, l, o, p), (b, d, f, k, l, m, p), (b, d, f, k, l, n, p), (b, d, f, k, l, o, p), (b, d, g, j, l, m, p), (b, d, g, j, l, n, p), (b, d, g, j, l, o, p), (b, d, g, k, l, m, p), (b, d, g, k, l, n, p), (b, d, g, k, l, o, p), (b, e, f, j, l, in, p), (b, e, f, j, l, n, p), (b, e, f, j, l, o, p), (b, e, f, k, l, m, p), (b, e, f, k, l, n, p), (b, e, f, k, l, o, p), (b, e, g, j, l, m, p), (b, e, g, j, l, n, p), (b, e, g, j, l, o, p), (b, e, g, k, l, m, p), (b, e, g, k, l, n, p), (b, e, g, k, l, o, p), (c, d, f, j, l, m, p), (c, d, f, j, l, n, p), (c, d, f, j, l, o, p), (c, d, f, k, l, in, p), (c, d, f, k, l, n, p), (c, d, f, k, l, o, p), (c, d, g, j, l, m, p), (c, d, g, j, l, n, p), (c, d, g, j, l, o, p), (c, d, g, k, l, m, p), (c, d, g, k, l, n, p), (c, d, g, k, l, o, p), (c, e, f, j, l, in, p), (c, e, f, j, l, n, p), (c, e, f, j, l, o, p), (c, e, f, k, l, in, p), (c, e, f, k, l, n, p), (c, e, f, k, l, o, p), (c, e, g, j, l, m, p), (c, e, g, j, l, n, p), (c, e, g, j, l, o, p), (c, e, g, k, l, in, p), (c, e, g, k, l, n, p), or (c, e, g, k, l, o, p),
(R1, R2, R3, R4, R5, (X1, X2, X3), Y) is preferable to be (a, d, f, j, l, m, q), (a, d, f, j, l, m, r), (a, d, f, j, l, n, q), (a, d, f, j, l, n, r), (a, d, f, j, l, o, q), (a, d, f, j, l, o, r), (a, d, f, k, l, in, q), (a, d, f, k, l, m, r), (a, d, f, k, l, n, q), (a, d, f, k, l, n, r), (a, d, f, k, l, o, q), (a, d, f, k, l, o, r), (a, d, g, j, l, m, q), (a, d, g, j, l, m, r), (a, d, g, j, l, n, q), (a, d, g, j, l, n, r), (a, d, g, j, l, o, q), (a, d, g, j, l, o, r), (a, d, g, k, l, m, q), (a, d, g, k, l, m, r), (a, d, g, k, l, n, q), (a, d, g, k, l, n, r), (a, d, g, k, l, o, q), (a, d, g, k, l, o, r), (a, e, f, j, l, in, q), (a, e, f, j, l, m, r), (a, e, f, j, l, n, q), (a, e, f, j, l, n, r), (a, e, f, j, l, o, q), (a, e, f, j, l, o, r), (a, e, f, k, l, in, q), (a, e, f, k, l, m, r), (a, e, f, k, l, n, q), (a, e, f, k, l, n, r), (a, e, f, k, l, o, q), (a, e, f, k, l, o, r), (a, e, g, j, l, m, q), (a, e, g, j, l, m, r), (a, e, g, j, l, n, q), (a, e, g, j, l, n, r), (a, e, g, j, l, o, q), (a, e, g, j, l, o, r), (a, e, g, k, l, m, q), (a, e, g, k, l, m, r), (a, e, g, k, l, n, q), (a, e, g, k, l, n, r), (a, e, g, k, l, o, q), (a, e, g, k, l, o, r), (b, d, f, j, l, m, q), d, f, j, l, m, r), (b, d, f, j, l, n, q), (b, d, f, j, l, n, r), (b, d, f, j, l, o, q), (b, d, f, j, l, o, r), (b, d, f, k, l, in, q), (b, d, f, k, l, m, r), (b, d, f, k, l, n, q), (b, d, f, k, l, n, r), (b, d, f, k, l, o, q), (b, d, f, k, l, o, r), (b, d, g, j, l, m, q), (b, d, g, j, l, in, r), (b, d, g, j, l, n, q), (b, d, g, j, l, n, r), (b, d, g, j, l, o, q), (b, d, g, j, l, o, r), (b, d, g, k, l, m, q), (b, d, g, k, l, m, r), (b, d, g, k, l, n, q), (b, d, g, k, l, n, r), (b, d, g, k, l, o, q), (b, d, g, k, l, o, r), (b, e, f, j, l, m, q), (b, e, f, j, l, m, r), (b, e, f, j, l, n, q), (b, e, f, j, l, n, r), (b, e, f, j, l, o, q), (b, e, f, j, l, o, r), (b, e, f, k, l, m, q), (b, e, f, k, l, m, r), (b, e, f, k, l, n, q), (b, e, f, k, l, n, r), (b, e, f, k, l, o, q), (b, e, f, k, l, o, r), (b, e, g, j, l, m, q), (b, e, g, j, l, m, r), (b, e, g, j, l, n, q), (b, e, g, j, l, n, r), (b, e, g, j, l, o, q), (b, e, g, j, l, o, r), (b, e, g, k, l, m, q), (b, e, g, k, l, m, r), (b, e, g, k, l, n, q), (b, e, g, k, l, n, r), (b, e, g, k, l, o, q), (b, e, g, k, l, o, r), (c, d, f, j, l, m, q), (c, d, f, j, l, m, r), (c, d, f, j, l, n, q), (c, d, f, j, l, n, r), (c, d, f, j, l, o, q), (c, d, f, j, l, o, r), (c, d, f, k, l, m, q), (c, d, f, k, l, m, r), (c, d, f, k, l, n, q), (c, d, f, k, l, n, r), (c, d, f, k, l, o, q), (c, d, f, k, l, o, r), (c, d, g, j, l, m, q), (c, d, g, j, l, m, r), (c, d, g, j, I, n, q), (c, d, g, j, l, n, r), (c, d, g, j, l, o, q), (c, d, g, j, l, o, r), (c, d, g, k, l, m, q), (c, d, g, k, l, m, r), (c, d, g, k, l, n, q), (c, d, g, k, l, n, r), (c, d, g, k, l, o, q), (c, d, g, k, l, o, r), (c, e, f, j, l, in, q), (c, e, f, j, l, m, r), (c, e, f, j, l, n, q), (c, e, f, j, l, n, r), (c, e, f, j, l, o, q), (c, e, f, j, l, o, r), (c, e, f, k, l, in, q), (c, e, f, k, l, m, r), (c, e, f, k, l, n, q), (c, e, f, k, l, n, r), (c, e, f, k, l, o, q), (c, e, f, k, l, o, r), (c, e, g, j, l, m, q), (c, e, g, j, l, m, r), (c, e, g, j, l, n, q), (c, e, g, j, l, n, r), (c, e, g, j, l, o, q), (c, e, g, j, l, o, r), (c, e, g, k, l, in, q), (c, e, g, k, l, m, r), (c, e, g, k, l, n, q), (c, e, g, k, l, n, r), (c, e, g, k, l, o, q), or (c, e, g, k, l, o, r),
(R1, (R2-R3), R4, R5, (X1, X2, X3), (Y, Z)) is preferable to be (a, h, j, l, m, p), (a, h, j, l, n, p), (a, h, j, l, o, p), (a, h, k, l, m, p), (a, h, k, l, n, p), (a, h, k, l, o, p), (a, i, j, l, in, p), (a, i, j, l, n, p), (a, i, j, l, o, p), (a, i, k, l, in, p), (a, i, k, l, n, p), (a, i, k, l, o, p), (b, h, j, l, in, p), (b, h, j, l, n, p), (b, h, j, l, o, p), (b, h, k, l, m, p), (b, h, k, l, n, p), (b, h, k, l, o, p), (b, i, j, l, m, p), (b, i, j, l, n, p), (b, i, j, l, o, p), (b, i, k, l, m, p), (b, i, k, l, n, p), (b, i, k, l, o, p), (c, h, j, l, m, p), (c, h, j, l, n, p), (c, h, j, l, o, p), (c, h, k, l, m, p), (c, h, k, l, n, p), (c, h, k, l, o, p), (c, i, j, l, m, p), (c, i, j, l, n, p), (c, i, j, l, o, p), (c, i, k, l, in, p), (c, i, k, l, n, p), or (c, i, k, l, o, p), or,
(R1, (R2-R3), R4, R5, (X1, X2, X3), Y) is preferable to be (a, h, j, l, m, q), (a, h, j, l, m, r), (a, h, j, l, n, q), (a, h, j, l, n, r), (a, h, j, l, o, q), (a, h, j, l, o, r), (a, h, k, l, m, q), (a, h, k, l, in, r), (a, h, k, l, n, q), (a, h, k, l, n, r), (a, h, k, l, o, q), (a, h, k, l, o, r), (a, i, j, l, m, q), (a, i, j, l, m, r), (a, i, j, l, n, q), (a, i, j, l, n, r), (a, i, j, l, o, q), (a, i, j, l, o, r), (a, i, k, l, in, q), (a, i, k, l, m, r), (a, i, k, l, n, q), (a, i, k, l, n, r), (a, i, k, l, o, q), (a, i, k, l, o, r), (b, h, j, l, m, q), (b, h, j, l, in, r), (b, h, j, l, n, q), (b, h, j, l, n, r), (b, h, j, l, o, q), (b, h, j, l, o, r), (b, h, k, l, m, q), (b, h, k, l, m, r), (b, h, k, l, n, q), (b, h, k, l, n, r), (b, h, k, l, o, q), (b, h, k, l, o, r), (b, i, j, l, q), (b, i, j, l, m, r), (b, i, j, l, n, q), (b, i, j, l, n, r), (b, i, j, l, o, q), (b, i, j, l, o, r), (b, i, k, l, in, q), (b, i, k, l, m, r), (b, i, k, l, n, q), (b, i, k, l, n, r), (b, i, k, l, o, q), (b, i, k, l, o, r), (c, h, j, l, m, q), (c, h, j, l, m, r), (c, h, j, l, n, q), (c, h, j, l, n, r), (c, h, j, l, o, q), (c, h, j, l, o, r), (c, h, k, l, m, q), (c, h, k, l, m, r), (c, h, k, l, n, q), (c, h, k, l, n, r), (c, h, k, l, o, q), (c, h, k, l, o, r), (c, i, j, l, m, q), (c, i, j, l, m, r), (c, i, j, l, n, q), (c, i, j, l, n, r), (c, i, j, l, o, q), (c, i, j, l, o, r), (c, i, k, l, in, q), (c, i, k, l, m, r), (c, i, k, l, n, q), (c, i, k, l, n, r), (c, i, k, l, o, q), or (c, i, k, l, o, r).
Moreover, in the formula (II), a compound having a possible combination of partial structure A and partial structure B shown below is preferable.






















Specifically, a preferable compound has the combination of (partial structure A, partial structure B) of (A-1, N-1), (A-1, Q-1), (A-1, Q-2), (A-1, Q-3), (A-1, Q-4), (A-1, R-1), (A-1, R-2), (A-1, S-1), (A-1, S-2), (A-1, S-3), (A-1, S-4), (A-1, T-1), (A-1, T-2), (A-1, T-3), (A-1, T-4), (A-1, T-5), (A-1, U-1), (A-1, U-2), (A-1, V-1), (A-1, W-1), (A-1, X-1), (A-1, X-2), (A-1, X-3), (A-1, X-4), (A-1, Y-1), (A-1, Z-1), (A-1, Z-2), (A-2, N-1), (A-2, Q-1), (A-2, Q-2), (A-2, Q-3), (A-2, Q-4), (A-2, R-1), (A-2, R-2), (A-2, S-1), (A-2, S-2), (A-2, S-3), (A-2, S-4), (A-2, T-1), (A-2, T-2), (A-2, T-3), (A-2, T-4), (A-2, T-5), (A-2, U-1), (A-2, U-2), (A-2, V-1), (A-2, W-1), (A-2, X-1), (A-2, X-2), (A-2, X-3), (A-2, X-4), (A-2, Y-1), (A-2, Z-1), (A-2, Z-2), (A-3, N-1), (A-3, Q-1), (A-3, Q-2), (A-3, Q-3), (A-3, Q-4), (A-3, R-1), (A-3, R-2), (A-3, S-1), (A-3, S-2), (A-3, S-3), (A-3, S-4), (A-3, T-1), (A-3, T-2), (A-3, T-3), (A-3, T-4), (A-3, T-5), (A-3, U-1), (A-3, U-2), (A-3, V-1), (A-3, W-1), (A-3, X-1), (A-3, X-2), (A-3, X-3), (A-3, X-4), (A-3, Y-1), (A-3, Z-1), (A-3, Z-2), (A-4, N-1), (A-4, Q-1), (A-4, Q-2), (A-4, Q-3), (A-4, Q-4), (A-4, R-1), (A-4, R-2), (A-4, S-1), (A-4, S-2), (A-4, S-3), (A-4, S-4), (A-4, T-1), (A-4, T-2), (A-4, T-3), (A-4, T-4), (A-4, T-5), (A-4, U-1), (A-4, U-2), (A-4, V-1), (A-4, W-1), (A-4, X-1), (A-4, X-2), (A-4, X-3), (A-4, X-4), (A-4, Y-1), (A-4, Z-1), (A-4, Z-2), (A-5, N-1), (A-5, Q-1), (A-5, Q-2), (A-5, Q-3), (A-5, Q-4), (A-5, R-1), (A-5, R-2), (A-5, S-1), (A-5, S-2), (A-5, S-3), (A-5, S-4), (A-5, T-1), (A-5, T-2), (A-5, T-3), (A-5, T-4), (A-5, T-5), (A-5, U-1), (A-5, U-2), (A-5, V-1), (A-5, W-1), (A-5, X-1), (A-5, X-2), (A-5, X-3), (A-5, X-4), (A-5, Y-1), (A-5, Z-1), (A-5, Z-2), (A-6, N-1), (A-6, Q-1), (A-6, Q-2), (A-6, Q-3), (A-6, Q-4), (A-6, R-1), (A-6, R-2), (A-6, S-1), (A-6, S-2), (A-6, S-3), (A-6, S-4), (A-6, T-1), (A-6, T-2), (A-6, T-3), (A-6, T-4), (A-6, T-5), (A-6, U-1), (A-6, U-2), (A-6, V-1), (A-6, W-1), (A-6, X-1), (A-6, X-2), (A-6, X-3), (A-6, X-4), (A-6, Y-1), (A-6, Z-1), (A-6, Z-2), (A-7, N-1), (A-7, Q-1), (A-7, Q-2), (A-7, Q-3), (A-7, Q-4), (A-7, R-1), (A-7, R-2), (A-7, S-1), (A-7, S-2), (A-7, S-3), (A-7, S-4), (A-7, T-1), (A-7, T-2), (A-7, T-3), (A-7, T-4), (A-7, T-5), (A-7, U-1), (A-7, U-2), (A-7, V-1), (A-7, W-1), (A-7, X-1), (A-7, X-2), (A-7, X-3), (A-7, X-4), (A-7, Y-1), (A-7, Z-1), (A-7, Z-2), (A-8, N-1), (A-8, Q-1), (A-8, Q-2), (A-8, Q-3), (A-8, Q-4), (A-8, R-1), (A-8, R-2), (A-8, S-1), (A-8, S-2), (A-8, S-3), (A-8, S-4), (A-8, T-1), (A-8, T-2), (A-8, T-3), (A-8, T-4), (A-8, T-5), (A-8, U-1), (A-8, U-2), (A-8, V-1), (A-8, W-1), (A-8, X-1), (A-8, X-2), (A-8, X-3), (A-8, X-4), (A-8, Y-1), (A-8, Z-1), (A-8, Z-2), (A-9, N-1), (A-9, Q-1), (A-9, Q-2), (A-9, Q-3), (A-9, Q-4), (A-9, R-1), (A-9, R-2), (A-9, S-1), (A-9, S-2), (A-9, S-3), (A-9, S-4), (A-9, T-1), (A-9, T-2), (A-9, T-3), (A-9, T-4), (A-9, T-5), (A-9, U-1), (A-9, U-2), (A-9, V-1), (A-9, W-1), (A-9, X-1), (A-9, X-2), (A-9, X-3), (A-9, X-4), (A-9, Y-1), (A-9, Z-1), (A-9, Z-2), (B-1, N-1), (B-1, Q-1), (R-1, Q-2), (B-1, Q-3), (B-1, Q-4), (B-1, R-1), (B-1, R-2), (B-1, S-1), (B-1, S-2), (B-1, S-3), (B-1, S-4), (B-1, T-1), (B-1, T-2), (B-1, T-3), (B-1, T-4), (B-1, T-5), (B-1, U-1), (B-1, U-2), (B-1, V-1), (B-1, W-1), (B-1, X-1), (B-1, X-2), (B-1, X-3), (B-1, X-4), (B-1, Y-1), (B-1, Z-1), (B-1, Z-2), (B-2, N-1), (B-2, Q-1), (B-2, Q-2), (B-2, Q-3), (B-2, Q-4), (B-2, R-1), (B-2, R-2), (B-2, S-1), (B-2, S-2), (B-2, S-3), (B-2, S-4), (B-2, T-1), (B-2, T-2), (B-2, T-3), (B-2, T-4), (B-2, T-5), (B-2, U-1), (B-2, U-2), (B-2, V-1), (B-2, W-1), (B-2, X-1), (B-2, X-2), (B-2, X-3), (B-2, X-4), (B-2, Y-1), (B-2, Z-1), (B-2, Z-2), (B-3, N-1), (B-3, Q-1), (B-3, Q-2), (B-3, Q-3), (B-3, Q-4), (B-3, R-1), (B-3, R-2), (B-3, S-1), (B-3, S-2), (B-3, S-3), (B-3, S-4), (B-3, T-1), (B-3, T-2), (B-3, T-3), (B-3, T-4), (B-3, T-5), (B-3, U-1), (B-3, U-2), (B-3, V-1), (B-3, W-1), (B-3, X-1), (B-3, X-2), (B-3, X-3), (B-3, X-4), (B-3, Y-1), (B-3, Z-1), (B-3, Z-2), (B-4, N-1), (B-4, Q-1), (B-4, Q-2), (B-4, Q-3), (B-4, Q-4), (B-4, R-1), (B-4, R-2), (B-4, S-1), (B-4, S-2), (B-4, S-3), (B-4, S-4), (B-4, T-1), (B-4, T-2), (B-4, T-3), (B-4, T-4), (B-4, T-5), (B-4, U-1), (B-4, U-2), (B-4, V-1), (B-4, W-1), (B-4, X-1), (B-4, X-2), (B-4, X-3), (B-4, X-4), (B-4, Y-1), (B-4, Z-1), (B-4, Z-2), (B-5, N-1), (B-5, Q-1), (B-5, Q-2), (B-5, Q-3), (B-5, Q-4), (B-5, R-1), (B-5, R-2), (B-5, S-1), (B-5, S-2), (B-5, S-3), (B-5, S-4), (B-5, T-1), (B-5, T-2), (B-5, T-3), (B-5, T-4), (B-5, T-5), (B-5, U-1), (B-5, U-2), (B-5, V-1), (B-5, W-1), (B-5, X-1), (B-5, X-2), (B-5, X-3), (B-5, X-4), (B-5, Y-1), (B-5, Z-1), (B-5, Z-2), (B-6, N-1), (B-6, Q-1), (B-6, Q-2), (B-6, Q-3), (B-6, Q-4), (B-6, R-1), (B-6, R-2), (B-6, S-1), (B-6, S-2), (B-6, S-3), (B-6, S-4), (B-6, T-1), (B-6, T-2), (B-6, T-3), (B-6, T-4), (B-6, T-5), (B-6, U-1), (B-6, U-2), (B-6, V-1), (B-6, W-1), (B-6, X-1), (B-6, X-2), (B-6, X-3), (B-6, X-4), (B-6, Y-1), (B-6, Z-1), (B-6, Z-2), (B-7, N-1), (B-7, Q-1), (B-7, Q-2), (B-7, Q-3), (B-7, Q-4), (B-7, R-1), (B-7, R-2), (B-7, S-1), (B-7, S-2), (B-7, S-3), (B-7, S-4), (B-7, T-1), (B-7, T-2), (B-7, T-3), (B-7, T-4), (B-7, T-5), (B-7, U-1), (B-7, U-2), (B-7, V-1), (B-7, W-1), (B-7, X-1), (B-7, X-2), (B-7, X-3), (B-7, X-4), (B-7, Y-1), (B-7, Z-1), (B-7, Z-2), (B-8, N-1), (B-8, Q-1), (B-8, Q-2), (B-8, Q-3), (B-8, Q-4), (B-8, R-1), (B-8, R-2), (B-8, S-1), (B-8, S-2), (B-8, S-3), (B-8, S-4), (B-8, T-1), (B-8, T-2), (B-8, T-3), (B-8, T-4), (B-8, T-5), (B-8, U-1), (B-8, U-2), (B-8, V-1), (B-8, W-1), (B-8, X-1), (B-8, X-2), (B-8, X-3), (B-8, X-4), (B-8, Y-1), (B-8, Z-1), (B-8, Z-2), (B-9, N-1), (B-9, Q-1), (B-9, Q-2), (8-9, Q-3), (B-9, Q-4), (B-9, R-1), (B-9, R-2), (B-9, S-1), (B-9, S-2), (B-9, S-3), (B-9, S-4), (B-9, T-1), (B-9, T-2), (B-9, T-3), (B-9, T-4), (B-9, T-5), (B-9, U-1), (B-9, U-2), (B-9, V-1), (B-9, W-1), (B-9, X-1), (B-9, X-2), (B-9, X-3), (B-9, X-4), (B-9, Y-1), (B-9, Z-1), (B-9, Z-2), (C-1, N-1), (C-1, Q-1), (C-1, Q-2), (C-1, Q-3), (C-1, Q-4), (C-1, R-1), (C-1, R-2), (C-1, S-1), (C-1, S-2), (C-1, S-3), (C-1, S-4), (C-1, T-1), (C-1, T-2), (C-1, T-3), (C-1, T-4), (C-1, T-5), (C-1, U-1), (C-1, U-2), (C-1, V-1), (C-1, W-1), (C-1, X-1), (C-1, X-2), C-1, X-3), (C-1, X-4), (C-1, Y-1), (C-1, Z-1), (C-1, Z-2), (C-5, N-1), (C-5, Q-1), (C-5, Q-2), (C-5, Q-3), (C-5, Q-4), (C-5, R-1), (C-5, R-2), (C-5, S-1), (C-5, S-2), (C-5, S-3), (C-5, S-4), (C-5, T-1), (C-5, T-2), (C-5, T-3), (C-5, T-4), (C-5, T-5), (C-5, U-1), (C-5, U-2), (C-5, V-1), (C-5, W-1), (C-5, X-1), (C-5, X-2), (C-5, X-3), (C-5, X-4), (C-5, Y-1), (C-5, Z-1), (C-5, Z-2), (C-6, N-1), (C-6, Q-1), (C-6, Q-2), (C-6, Q-3), (C-6, Q-4), (C-6, R-1), (C-6, R-2), (C-6, S-1), (C-6, S-2), (C-6, S-3), (C-6, S-4), (C-6, T-1), (C-6, T-2), (C-6, T-3), (C-6, T-4), (C-6, T-5), (C-6, U-1), (C-6, U-2), (C-6, V-1), (C-6, W-1), (C-6, X-1), (C-6, X-2), (C-6, X-3), (C-6, X-4), (C-6, Y-1), (C-6, Z-1), (C-6, Z-2), (C-7, N-1), (C-7, Q-1), (C-7, Q-2), (C-7, Q-3), (C-7, Q-4), (C-7, R-1), (C-7, R-2), (C-7, S-1), (C-7, S-2), (C-7, S-3), (C-7, S-4), (C-7, T-1), (C-7, T-2), (C-7, T-3), (C-7, T-4), (C-7, T-5), (C-7, U-1), (C-7, U-2), (C-7, V-1), (C-7, W-1), (C-7, X-1), (C-7, X-2), (C-7, X-3), (C-7, X-4), (C-7, Y-1), (C-7, Z-1), (C-7, Z-2), (D-6, N-1), (D-6, Q-1), (D-6, Q-2), (D-6, Q-3), (D-6, Q-4), (D-6, R-1), (D-6, R-2), (D-6, S-1), (D-6, S-2), (D-6, S-3), (D-6, S-4), (D-6, T-1), (D-6, T-2), (D-6, T-3), (D-6, T-4), (D-6, T-5), (D-6, U-1), (D-6, U-2), (D-6, V-1), (D-6, W-1), (D-6, X-1), (D-6, X-2), (D-6, X-3), (D-6, X-4), (D-6, Y-1), (D-6, Z-1), (D-6, Z-2), (D-7, N-1), (D-7, Q-1), (D-7, Q-2), (D-7, Q-3), (D-7, Q-4), (D-7, R-1), (D-7, R-2), (D-7, S-1), (D-7, S-2), (D-7, S-3), (D-7, S-4), (D-7, T-1), (D-7, T-2), (D-7, T-3), (D-7, T-4), (D-7, T-5), (D-7, U-1), (D-7, U-2), (D-7, V-1), (D-7, W-1), (D-7, X-1), (D-7, X-2), (D-7, X-3), (D-7, X-4), (D-7, Y-1), (D-7, Z-1), (D-7, Z-2), (E-1, N-1), (E-1, Q-1), (E-1, Q-2), (E-1, Q-3), (E-1, Q-4), (E-1, R-1), (E-1, R-2), (E-1, S-1), (E-1, S-2), (E-1, S-3), (E-1, S-4), (E-1, T-1), (E-1, T-2), (E-1, T-3), (E-1, T-4), (E-1, T-5), (E-1, U-1), (E-1, U-2), (E-1, V-1), (E-1, W-1), (E-1, X-1), (E-1, X-2), (E-1, X-3), (E-1, X-4), (E-1, Y-1), (E-1, Z-1), (E-1, Z-2), (B-11, N-1), (B-11, Q-1), (B-11, Q-2), (B-11, Q-3), (B-11, Q-4), (B-11, R-1), (B-11, R-2), (B-11, S-1), (B-11, S-2), (B-11, S-3), (B-11, S-4), (B-11, T-1), (B-11, T-2), (B-11, T-3), (B-11, T-4), (B-11, T-5), (B-11, U-1), (B-11, U-2), (B-11, V-1), (B-11, W-1), (B-11, X-1), (B-11, X-2), (B-11, X-3), (B-11, X-4), (B-11, Y-1), (B-11, Z-1), (B-11, Z-2), (B-12, N-1), (B-12, Q-1), (B-12, Q-2), (B-12, Q-3), (B-12, Q-4), (B-12, R-1), (B-12, R-2), (B-12, S-1), (B-12, S-2), (B-12, S-3), (B-12, S-4), (B-12, T-1), (B-12, T-2), (B-12, T-3), (B-12, T-4), (B-12, T-5), (B-12, U-1), (B-12, U-2), (B-12, V-1), (B-12, W-1), (B-12, X-1), (B-12, X-2), (B-12, X-3), (B-12, X-4), (B-12, Y-1), (B-12, Z-1), (B-12, Z-2), (B-13, N-1), (B-13, Q-1), (B-13, Q-2), (B-13, Q-3), (B-13, Q-4), (B-13, R-1), (B-13, R-2), (B-13, S-1), (B-13, S-2), (B-13, S-3), (B-13, S-4), (B-13, T-1), (B-13, T-2), (B-13, T-3), (B-13, T-4), (B-13, T-5), (B-13, U-1), (B-13, U-2), (B-13, V-1), (B-13, W-1), (B-13, X-1), (B-13, X-2), (B-13, X-3), (B-13, X-4), (B-13, Y-1), (B-13, Z-1), or (B-13, Z-2).
Preferable compounds will be illustrated as follows.

    (1) methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate,
    (2) 5-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-valeric acid,
    (3) (E)-3-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-4-hexene acid,
    (4) methyl 2-{[5,6-dimethyl-1-(2-morpholine-4-yl-ethyl)-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (5) 1-[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexane carboxylic acid,
    (6) methyl{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetoxy}-(2,2-dimethyl-[1,3]dioxolan-4-yl)-acetate,
    (7) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydroxypyridine-3-carbonyl)-amino]-4-methylsulphanyl-butyrate,
    (8) methyl 4-{[2-oxo-(tetrahydro-furan-2-ylmethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (9) 1-[(1-cyclohexylmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid,
    (10) 2-{[1-(4-cyano-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylic acid,
    (11) 2-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3,3-dimethyl-butyric acid,
    (12) {[1-(2-methoxy-ethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (13) 2-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyric acid,
    (14) 4-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyl}-1,1-dimethyl-piperazine-1-ium,
    (15) 3-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-4,4,4-trifluoro-butyric acid,
    (16) ({2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyl}-methyl-amino)-acetic acid,
    (17) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclopent-1-en-carboxylic acid,
    (18) 1-{[6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-cyclohexanecarboxylic acid,
    (19) {[1-(4-cyano-butyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (20) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid 1,1-dimethyl-2-oxo-2-[N′-carbamoylhydrazino]-ethyl}-amide,
    (21) [(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-phenylacetic acid,
    (22) methyl {[1-(2-chloro-benzyl)-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-phenyl acetate,
    (23) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-methyl-1-[(pyridine-3-carbothioyl)-carbamoyl]-ethyl}-amide,
    (24) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-phenyl-[1,3]dioxane-5-yl ester,
    (25) methyl biphenyl-4-yl-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (26) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-phenyl-propionic acid,
    (27) 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid,
    (28) {[1-(2-cyano-ethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (29) 1-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonmyl)-amino]-cyclohexanecarboxylic acid,
    (30) dimethyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-succinate,
    (31) 4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid,
    (32) methyl 1-{[1-(1-ethyl-pyrrolidine-2-2-ylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (33) 2-[(1-benzo[1,3]dioxol-5-ylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyric acid,
    (34) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methylcarbamoyl}-1-methyl-ethyl)-amide,
    (35) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethyl}-amide,
    (36) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3,3-dimethyl-butyric acid,
    (37) methyl {[1-(4-methoxybenzyl)-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-phenyl acetate,
    (38) ethyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydroxypyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (39) 1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclopropanecarboxylic acid,
    (40) ethyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-cyclopentanecarboxylate,
    (41) 2-[(1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid,
    (42) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyric acid,
    (43) diethyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-glutarate,
    (44) methyl[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-phenyl acetate,
    (45) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyric acid,
    (46) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (47) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-methyl-1-(morpholine-4-ylcarbamoyl)-ethyl]-amide,
    (48) {[6-ethyl-1-(4-fluoro-benzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-phenylacetic acid,
    (49) 2-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyric acid,
    (50) {2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiazole-4-yl}-acetic acid,
    (51) methyl[(1-butyl-2-oxo-2,5,6,7,8,9-hexahydroquinoline-1H-cyclohepta[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (52) methyl {[1-(3-chloro-benzyl)-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-phenyl acetate,
    (53) {[1-(4-cyano-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (54) methyl(benzyl-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-ethyl}-amino)-acetate,
    (55) methyl 3-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-phenyl-propionate,
    (56) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[2-(4-methoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethyl}-amide,
    (57) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(2-benzo[1,3]dioxol-5-yl-ethylcarbamoyl)-1-methyl-ethyl]-amide,
    (58) [(1-butyl-2-oxo-1,2,5,6,7,8,9,10,11,12-decahydrocyclodeca[b]pyridine-3-carbonyl)-amino]-phenylacetic acid,
    (59) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-(4-methoxy-phenyl)-acetate,
    (60) methyl 2-{[1-(3-methoxycarbonylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]amino}-2-methyl-propionate,
    (61) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-methyl-1-thiobenzoylcarbamoyl-ethyl)-amide,
    (62) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-oxo-2-[(pyridine-2-carbonyl)-amino]-ethyl}-amide,
    (63) methyl 2-{[1-(1-ethyl-pyrrolidine-2-2-ylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (64) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {2-[4-(2-hydroxy-ethyl)-piperazine-1-yl]-1,1-dimethyl-2-oxo-ethyl}-amide,
    (65) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-(4-hydroxy-phenyl)-acetate,
    (66) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(4-hydroxy-phenyl)-acetic acid,
    (67) methyl {[1-(2-methoxy-ethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (68) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-decahydrocycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-pyridine-2-yl-ethyl ester
    (69) 1-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylic acid,
    (70) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-methyl-1-(methylcarbamoylmethyl-carbamoyl)-ethyl]amide,
    (71) methyl 2-[(1-heptyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (72) methyl {[5,6-dimethyl-2-oxo-1-(4-trifluoromethyl-benzyl)-1,2-dihydropyridine-3-carbonyl]-amino}-phenyl acetate,
    (73) methyl 2-{[1-(3-acetylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-2-methyl-propionate,
    (74) ethyl 2-{[1-(3-methoxycarnonyamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (75) methyl {2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-ethylamino}-acetate,
    (76) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-4-methyl-thiazole-5-carboxylic acid,
    (77) 4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2,2-dimethyl-butyric acid,
    (78) methyl 2-[(1-butyl-5,6-dimethyl-2-exo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (79) {[1-(4-fluorobenzyl)-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-phenylacetic acid,
    (80) benzyl-(2-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-ethyl)-dimethyl-ammonium,
    (81) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-benzenesulfonylhydrazino-1,1-dimethyl-2-oxo-ethyl)-amide,
    (82) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-oxo-2-[N′-(pyridine-3-carbonyl)-hydrazino]-ethyl}-amide,
    (83) 3,3-dimethyl-2-{[2-oxo-1-(tetrahydrofuran-2-ylmethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyric acid,
    (84) methyl[(1-butyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-phenyl acetate,
    (85) methyl {[1-(3-methanesulfonylpropyl)-2-oxo-1,2,5,6,7,8,9,10-cotahydro-cycloocta[b]pyridine-3-carbonyl]amino}-phenyl acetate,
    (86) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-morpholine-4-yl-ethyl ester
    (87) {[1-(3-cyano-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (88) dibutyl-(2-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-ethyl)-methyl-ammonium iodide,
    (89) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-isobutyryl-piperazine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (90) 4,4,4-trifluoro-3-{[1-(4-fluoro-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyric acid,
    (91) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-4,4-dimethyl-valeric acid,
    (92) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-methanesulfonyl-1,1-dimethyl-2-oxo-ethyl)-amide,
    (93) methyl 2-[(1-butyl-2-oxo-1,5,7,8-tetrahydro-2H-pyrano[4,3-b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (94) methyl {2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionylamino}-acetate,
    (95) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-methyl-1-(2-morpholine-4-yl-ethylcarbamoyl)-ethyl]-amide,
    (96) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(2-hydroxy-1,1-bis-hydroxymethyl-ethylcarbamoyl)-1-methyl-ethyl]-amide,
    (97) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid 1,1-dimethyl-2-oxo-2-[N′-isopropylcarbamoylhydrazino]-ethyl}-amide,
    (98) {[6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]amino}-thiophene-2-yl-acetic acid,
    (99) methyl[(1-furan-2-ylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (100) methyl benzofuran-2-yl-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (101) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-carbazole-9-yl-ethyl ester,
    (102) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-oxo-2-(3-propylcarbamoyl-piperidine-1-yl)-ethyl]-amide,
    (103) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[(imino-ureido-methyl)-carbamoyl]-1-methyl-ethyl}-amide,
    (104) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[bis-(2-hydroxy-ethyl)-carbamoyl]-1-methyl-ethyl}-amide,
    (105) methyl 3-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (106) methyl {[1-(2-cyano-ethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (107) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-(2-oxo-pyrrolidine-1-yl)-ethyl ester,
    (108) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-acetylamino-ethyl ester,
    (109) (1-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyl}-piperidine-4-yl)-carbamic acid tert-butyl ester,
    (110) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(3-butylcarbamoyl-piperidine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (111) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-naphthalene-1-yl-acetic acid,
    (112) (4-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-butyl)-trimethyl-ammonium iodide,
    (113) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(2-carbamoyl-ethylcarbamoyl)-1-methyl-ethyl]-amide,
    (114) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-methanesulfonylpiperadine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (115) methyl[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (116) methyl[(1-isobutyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (117) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(2-methoxy-phenyl)-acetic acid,
    (118) ethyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclopent-1-en-carboxylate,
    (119) methyl 4-{[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-methyl}-cyclohexanecarboxylate,
    (120) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-methyl-1-[1-(propane-2-sulfonyl)-piperidine-4-ylcarbamoyl]-ethyl}-amide,
    (121) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid 1,1-dimethyl-2-oxo-2-[(pyridine-3-carbonyl)-amino]-ethyl}-amide,
    (122) methyl {[2-oxo-1-(4-trifluoromethyl-benzyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (123) methyl 2-{[1-(1-ethyl-pyrrolidine-2-2-ylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]amino}-3-methyl-butyrate,
    (124) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid phenylcarbamoyloxy methyl ester,
    (125) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-benzoylamino-1,1-dimethyl-2-oxo-ethyl)-amide,
    (126) methyl[(1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexyl-acetate,
    (127) methyl 2-[(5,6-dimethyl-2-oxo-1-pyridine-4-ylmethyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (128) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-isopropylsulfonylhydrazino-1,1-dimethyl-2-oxo-ethyl)-amide,
    (129) methyl {[1-(4-methyl-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (130) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(3-carbamoyl-piperidine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (131) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-methanesulfonylhydrazino-1,1-dimethyl-2-oxo-ethyl)-amide,
    (132) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-acetylpiperazine-1-yl-1,1-dimethyl-2-oxo-ethyl)amide,
    (133) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-4-methyl-valerate,
    (134) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-carbamoyl-1-methyl-ethyl)-amide,
    (135) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid 1,1-dimethyl-2-oxo-2-[N′-(thiophene-2-carbonyl)-hydrazino]-ethyl}-amide,
    (136) methyl {[1-(3-acetylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (137) methyl 4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-benzoate,
    (138) methyl 6-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-hexanoate,
    (139) (2-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-ethyl)-trimethyl-ammonium iodide,
    (140) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[2-(4-hydroxy-phenyl)-ethylcarbamoyl]-1-methyl-ethyl}-amide,
    (141) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (142) 1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid,
    (143) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-naphthalene-1-yl-acetate,
    (144) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[2-(3,4-dihydroxy-phenyl)-ethylcarbamoyl]-1-methyl-ethyl}-amide,
    (145) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-propionate,
    (146) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-oxo-2-[(pyridine-4-carbonyl)-amino]-ethyl}-amide,
    (147) {1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexyl}-acetic acid,
    (148) ethyl 1-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyl}-piperizine-4-carboxylate,
    (149) [(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-3-yl-acetic acid,
    (150) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(carbamoylmethyl-carbamoyl)-1-methyl-ethyl]amide,
    (151) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-oxo-2-[4-(propane-2-sulfonyl)-piperazine-1-yl]-ethyl}-amide,
    (152) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-methyl-1-thioacetylcarbamoyl-ethyl)-amide,
    (153) (2-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-ethyl)-triethyl-ammonium iodide,
    (154) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid,
    (155) 2-O-oxo-1-(tetrahydrofuran-2-yl-methyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]amino}-cyclohexanecarboxylic acid,
    (156) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-3-yl-acetic acid,
    (157) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(4-carbamoyl-phenylcarbamoyl)-1-methyl-ethyl]-amide,
    (158) methyl[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-phenyl acetate,
    (159) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-tert-butoxycarbonylamino-ethyl ester,
    (160) methyl[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(4-hydroxy-phenyl)-acetate,
    (161) methyl benzo[b]thiophene-2-yl-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (162) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-(4-hydroxy-phenyl)-propionate,
    (163) methyl 3-[(1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (164) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-methylsulfanyl-ethyl ester,
    (165) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-pyrrolidine-1-yl-ethyl ester,
    (166) 4-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyl}-piperazine-1-carboxylic acid tert-butyl ester,
    (167) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-hydrazinocarbonyl-piperidine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (168) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-(1H-indole-2-yl)-propionate,
    (169) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(cyanomethyl-carbamoyl)-1-methyl-ethyl]-amide,
    (170) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (171) {[1-(4-chloro-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (172) (3-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-propyl)-trimethyl-ammonium iodide,
    (173) [(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenylacetic acid,
    (174) butyl-(2-{(2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-ethyl)-dimethyl-ammonium,
    (175) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-methanesulfonylamino-piperidine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (176)
    (177) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-4-methylsulfanyl-butyrate,
    (178) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-(4-methyl-piperazine-1-yl)-2-oxo-ethyl]-amide,
    (179) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-methyl-1-phenylcarbamoyl-ethyl)-amide,
    (180) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {2-[4-(3-isopropyl-ureido)-piperidine-1-yl]-1,1-dimethyl-2-oxo-ethyl}-amide,
    (181) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-oxo-2-[4-(piperidine-1-carbonyl)-piperidine-1-yl]-ethyl}-amide,
    (182) 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-phenyl-propionic acid
    (183) dimethyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-succinate,
    (184) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(4-fluoro-phenyl)-acetic acid,
    (185) 1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {[(2-hydroxy-ethyl)-methyl-carbamoyl]-phenyl-methyl}-amide,
    (186) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(4-methanesulfonylamino-phenylcarbamoyl)-1-methyl-ethyl]-amide,
    (187) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-methyl-butyrate,
    (188) methyl {[1-(3-cyano-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (189) methyl 2-methyl-2-{[2-oxo-1-(2-piperidine-1-yl-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-propionate,
    (190) ethyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (191) methyl 2-methyl-2-{[2-oxo-1-(2-oxo-[1,3]-dioxolan-4-ylmethy)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-propionate,
    (192) [(1-benzyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenylacetic acid,
    (193) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1,1-dimethyl-2-{4-[methyl-(propane-2-sulfonyl)-amino]-piperidine-1-yl}-2-oxo-ethyl)-amide,
    (194) 3-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-5-methyl-hexanoic acid,
    (195) methyl 2-{[1-(1-ethyl-pyrrolidine-2-2-ylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-4,4-dimethyl-valerate,
    (196) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(2-hydroxy-1-hydroxymethyl-ethylcarbamoyl)-1-methyl-ethyl]-amide,
    (197) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(N′-benzoyl-hydrazino)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (198) {[1-(3-methy-butyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]amino}-phenylacetic acid,
    (199) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy-valeric acid methyl ester,
    (200) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-carbamoyl-piperidine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (201) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[2-(4-hydroxy-3-methoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethyl}-amide,
    (202) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(2,3-dihydroxy-propylcarbamoyl)-1-methyl-ethyl]-amide,
    (203) methyl {2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-ethoxy}-acetate,
    (204) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-hydrazinocarbonyl-1-methyl-ethyl)-amide,
    (205) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-oxo-2-[4-(propane-2-sulfonylamino)-piperidine-1-yl]-ethyl}-amide,
    (206) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-benzylcarbamoyl-1-methyl-ethyl)-amide,
    (207) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-2-methyl-propionate,
    (208) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-[4-(2-methyl-propane-2-sulfonylamino)-piperidine-1-yl]-2-oxo-ethyl}-amide,
    (209) methyl 3-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-phenyl-propionate,
    (210) ethyl 2-{[1-(3-acetylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (211) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 1-diethylcarbamoyloxy-ethyl ester,
    (212) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(5-carbamoyl-pyridine-2-ylcarbamoyl)-1-methyl-ethyl]-amide,
    (213) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(2-acetylamino-ethylcarbamoyl)-1-methyl-ethyl]-amide,
    (214) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-isopropylcarbamoyl-piperazine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (215) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(2-hydroxy-ethylcarbamoyl)-1-methyl-ethyl]-amide,
    (216) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(2-methoxy-phenyl)-acetate,
    (217) methyl 1-(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-pyrrolidine-2-carboxylate,
    (218) methyl 1-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (219) methyl({2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyl}-methyl-amino)-acetate,
    (220) {2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiazole-4-yl}-acetic acid ethyl ester,
    (221) ethyl 3-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-propionate,
    (222) {[1-(3-methyl-butyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-thiophene-2-yl-acetic acid,
    (223) [(1-butyl-2-oxo-1,2,5,6,7,8,9,10,11,12-decahydrocyclodeca[b]pyridine-3-carbonyl)-amino]-phenylacetic acid,
    (224) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (225) methyl 4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (226) methyl[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (227) methyl[(1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (228) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-furan-2-yl-acetic acid,
    (229) {2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiazole-4-yl}-oxo-acetic acid ethyl ester,
    (230) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-4-methyl-thiazole-5-carboxylic acid ethyl ester,
    (231) dimethyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-succinate,
    (232) methyl([1-(4-cyano-butyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (233) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-phenyl acetate,
    (234) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-4-methylsulfanyl-butyrate,
    (235) methyl 3-methyl-2-{[2-oxo-1-(2-piperidine-1-yl-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate,
    (236) ethyl 2-{[2-oxo-1-(tetrahydrofuran-2-ylmethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (237) ethyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-cyclohexane carboxylate,
    (238) ethyl 3-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-benzoate,
    (239) methyl 2-methyl-2-{[2-oxo-1-(tetrahydrofuran-2-ylmethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-propionate,
    (240) methyl 5-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-valerate,
    (241) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,5,7,8-tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (242) 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3,3-dimethyl-butyric acid 2-hydroxy-1-hydroxymethyl-ethyl ester,
    (243) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid diethylcarbamoyloxymethyl ester,
    (244) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(6-hydroxy-hexylcarbamoyl)-1-methyl-ethyl]-amide,
    (245) methyl[(1-cyclohexylmethyl-2-oxo-2,5,6,7,8,9-hexahydroquinoline-1H-cyclohepta[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (246) methyl 2-[(1-cyclohexylmethyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (247) 1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid {1-[bis-(2-hydroxy-ethyl)-carbamoyl]-2,2-dimethyl-propyl}-amide,
    (248) methyl 2-[(1-allyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (249) ethyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (250) methyl 3-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-propionate,
    (251) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2,2,2-trifluoro-ethyl ester,
    (252) 1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {(2-[(2-hydroxy-ethyl)-methyl-carbamoyl]-cyclohexyl}-amide,
    (253) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-dibutylamino-ethyl ester,
    (254) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[2-(3,4-bis-benzyloxy-phenyl)-ethylcarbamoyl]-1-methyl-ethyl}-amide,
    (255) methyl[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-phenyl acetate,
    (256) methyl 2-[(1,6-dibutyl-2-oxo-5-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (257) methyl {[1-(4-cyano-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (258) 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyric acid 2-hydroxy-1-hydroxymethyl-ethyl ester,
    (259) {[1-(3-cyano-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (260) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(5-hydroxy-pentylcarbamoyl)-1-methyl-ethyl]-amide,
    (261) (S)-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-2-yl-acetic acid,
    (262) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-methyl benzoate,
    (263) 4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-butyrate,
    (264) 1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid [1-(2-hydroxy-1-hydroxymethyl-ethylcarbamoyl)-2,2-dimethyl-propyl]-amide,
    (265) {[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-furan-2-yl-acetic acid,
    (266) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-hydroxy-piperidine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (267) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-diethylamino-ethyl ester,
    (268) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-(4-methylcarbamoyl-piperidine-1-yl)-2-oxo-ethyl]-amide,
    (269) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-(4-hydroxyphenyl)-propionate,
    (270) methyl 2-[(1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-methyl-butyrate,
    (271) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenylacetic acid,
    (272) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-methyl-butyrate,
    (273) methyl 2-[(1-[1,3]dioxane-2-ylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (274) methyl[(1-butyl-2-oxo-1,2,5,6,7,8,9,10,11,12-decahydrocyclodeca[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (275) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(4-hydroxy-phenyl)-acetate,
    (276) methyl 2-{[1-(3-methanesulfonylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-2-methyl-propionate,
    (277) methyl 1-[(1,6-dibutyl-2-oxo-5-propyl-1,2-dihidoropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (278) {[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenylacetic acid,
    (279) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-2-yl-acetic acid,
    (280) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(3-hydroxy-propylcarbamoyl)-1-methyl-ethyl]-amide,
    (281) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(4-methoxyphenyl)-acetate,
    (282) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-[4-(2-hydroxy-ethylcarbamoyl)-piperidine-1-yl]-1,1-dimethyl-2-oxo-ethyl}-amide,
    (283) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-valerate,
    (284) methyl 2-[(1-cyclohexylmethyl-5-methoxy-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (285) methyl 2-[(1-[1,3]dioxolan-2-ylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (286) 2-[(1-butyl-2-oxo-2,5,6,7-tetrahydro-1H-[1]pyridine-3-carbonyl)-amino]-3-methyl-butyric acid methyl ester,
    (287) methyl {[1-(4-fluorobenzyl)-5,6-dimethyl-2-oxo-1,2-dihydro pyridine-3-carbonyl]-amino}-phenyl acetate,
    (288) methyl 1-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (289) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-dimethylamino-ethyl ester,
    (290) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid butylcarbamoyloxyethyl ester,
    (291) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 4-dimethylamino-butyl ester,
    (292) methyl 2-[(1-benzo[1,3]dioxol-5-ylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (293) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(1-methanesulfonylpiperidine-4-ylcarbamoyl)-1-methyl-ethyl]-amide,
    (294) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(1-benzenesulfonyl-piperidine-4-ylcarbamoyl)-1-methyl-ethyl]-amide,
    (295) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[(2,3-dihydroxy-propyl)-methyl-carbamoyl]-1-methyl-ethyl}-amide,
    (296) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-methyl-butyrate,
    (297) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 1-cyclohexyloxycarbonyloxy-ethyl ester,
    (298) piperidine-1-carboxylic acid 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxymethyl ester,
    (299) 1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid [1-(2-hydroxy-ethylcarbamoyl)-2,2-dimethyl-propyl]-amide,
    (300) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-thiazole-4-yl-propionate,
    (301) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(3-hydroxy-2,2-dimethyl-propylcarbamoyl)-1-methyl-ethyl]-amide,
    (302) methyl {[1-(4-chlorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (303) methyl 3-methyl-2-{[2-oxo-1-(2-piperidine-1-yl-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate,
    (304) methyl (4-chloro-phenyl)-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (305) methyl {[1-(4-chlorobenzyl)-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-phenyl acetate,
    (306) methyl 2-{[1-(3-methanesulfonylpropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (307) methyl 2-[(1,6-dibutyl-2-oxo-5-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (308) ethyl 2-{[1-(4-cyano-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (309) {[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-thiophen-2-yl-acetic acid,
    (310) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(4-hydroxy-butylcarbamoyl)-1-methyl-ethyl]-amide,
    (311) 1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[(2-hydroxy-ethyl)-methyl-carbamoyl]-2-methyl-propyl}-amide,
    (312) 1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {(-[(2-hydroxy-ethyl)-methyl-carbamoyl]-2,2-dimethyl-propyl)-amide,
    (313) methyl 2-[(1-butyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-4-methyl-valerate,
    (314) methyl 2-{[5,6-dimethyl-1-(3-methyl-butyl)-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (315) methyl 2-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-2-methyl-propionate,
    (316) 1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid {(-[(2-hydroxy-ethyl)-methyl-carbamoyl]-2-methyl-propyl)-amide,
    (317) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 1-butylcarbamyloxy-ethyl ester,
    (318) 1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid {1-[(2,3-dihydroxy-propyl)-methyl-carbamoyl]-2,2-dimethyl-propyl}-amide,
    (319) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[2-(2-hydroxy-ethoxy)-ethylcarbamoyl]-1-methyl-ethyl}-amide,
    (320) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-acetylamino-1,1-dimethyl-2-oxo-ethyl)-amide,
    (321) {2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiazole-4-yl}-oxoacetic acid,
    (322) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (4-carbamoylmethyl-thiazol-2-yl)-amide,
    (323) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-succinate,
    (324) methyl 2-[(1-cyclohexylmethyl-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (325) methyl 1-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (326) methyl 1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclopentanecarboxylate,
    (327) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-4,4-dimethyl-valerate,
    (328) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3,3-dimethyl-butyrate,
    (329) methyl 2-[(1-cyclohexylmethyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (330) methyl 2-[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (331) methyl 2-[(1-butyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (332) methyl 1-[(1-butyl-6-ethyl-5-methyl-2-oxo-1,2-dihydro pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (333) methyl 1-[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihidoropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (334) methyl 1-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (335) methyl 1-[(1-cyclohexylmethyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (336) methyl 1-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (337) methyl 3-methyl-2-{[2-oxo-1-(tetrahydrofuran-2-ylmethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate,
    (338) methyl 1-{[2-oxo-1-(tetrahydrofuran-2-ylmethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (339) methyl 3,3-dimethyl-2-{[2-oxo-1-(tetrahydrofuran-2-ylmethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate,
    (340) methyl 2-[(1-cyclohexylmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (341) methyl 1-[(1-cyclohexylmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (342) ethyl 2-[(1-cyclohexylmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (343) methyl {[1-(3-methyl-butyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (344) methyl 2-{[1-(2-methoxy-ethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (345) methyl 2-[(1-butyl-2-oxo-2,5,6,7,8,9-hexahydroquinoline-1H-cyclohepta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (346) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-methyl-butyrate,
    (347) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-4-methyl-valerate,
    (348) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-4-methyl-valerate,
    (349) ethyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (350) isopropyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (351) methyl 2-[(1-allyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (352) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2,2-dimethyl-[1,3]-dioxolan-4-ylmethyl ester,
    (353) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-hydroxy-1-hydroxymethyl-ethyl ester,
    (354) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2,3-dihydroxy-propyl ester,
    (355) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-phenyl-propionate,
    (356) methyl 2-[(4-cyclohexylmethyl-3-oxo-3,4,5,6,7,8-hexahydro-naphthalene-2-carbonyl)-amino]-3-phenyl-propionate,
    (357) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-methyl-valerate,
    (358) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-3-methyl-valerate,
    (359) methoxymethyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (360) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-dimethylcarbamoyl-1-methyl-ethyl)-amide,
    (361) methyl 2-[(1-cyclohexylmethyl-2-oxo-2,5,6,7,8,9-hexahydroquinoline-1H-cyclohepta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (362) methyl 1-[(1-butyl-2-oxo-2,5,6,7,8,9-hexahydroquinoline-1H-cyclohepta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (363) methyl 1-[(1-cyclohexylmethyl-2-oxo-2,5,6,7,8,9-hexahydroquinoline-1H-cyclohepta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (364) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10,11,12-decahydrocyclodeca[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (365) methyl[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-phenyl acetate,
    (366) methyl[(1-cyclohexylmethyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-phenyl acetate,
    (367) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-2-methyl-propionate,
    (368) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-phenyl acetate,
    (369) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (370) methyl 1-{[1-(4-fluorobenzyl)-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (371) methyl 2-{[6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (372) methyl 2-{[5-ethyl-1-(4-fluorobenzyl)-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (373) phenyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (374) methyl 1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (375) methyl 1-[(1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (376) ethyl 2-[(1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (377) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[(2-hydroxy-ethyl)-methyl-carbamoyl]-1-methyl-ethyl}-amide,
    (378) ethyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (379) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3,3-dimethyl-butyrate,
    (380) methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (381) methyl 2-[(1-cyclohexylmethyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (382) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-oxo-tetrahydrofuran-3-yl)-amide,
    (383) methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3,3-dimethyl-butyrate,
    (384) methyl 2-[(1-cyclohexylmethyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3,3-dimethyl-butyrate,
    (385) methyl {[5-ethyl-1-(4-fluorobenzyl)-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl]-amino}-phenylacetate,
    (386) methyl {[6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-phenylacetate,
    (387) S-methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-thiopropionate,
    (388) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 5-methyl-2-oxo-[1,3]-dioxol-4-ylmethyl ester,
    (389) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-oxo-[1,3]dioxolan-4-yl ester,
    (390) methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propul-1,2-dihydropyridine-3-carbonyl)-amino]-4-methyl-valerate,
    (391) methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (392) methyl 2-{[1-(3-azide-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-2-methyl-propionate,
    (393) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(methoxy-methyl-carbamoyl)-1-methyl-ethyl]-amide,
    (394) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (395) methyl 2-{[1-(2-cyano-ethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (396) 2-[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3,3-dimethyl-butyric acid 2-hydroxy-1-hydroxymethyl-ethyl ester,
    (397) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-3-yl-acetate,
    (398) methyl 2-{[1-(3-cyano-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (399) methyl[(1-benzyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenylacetate,
    (400) methyl(R)-cyclohexyl-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (401) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(1-isopropylcarbamoyl-piperidine-4-ylcarbamoyl)-1-methyl-ethyl]-amide,
    (402) 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3,3-dimethyl-butyric acid 2-hydroxy-1-hydroxymethyl-ethyl ester,
    (403) 2-[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyric acid 2-hydroxy-1-hydroxymethyl-ethyl ester,
    (404) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 1-isopropoxycarbonyloxy-ethyl ester,
    (405) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 3-dimethylamino-propyl ester,
    (406) methyl(R)-2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-propionate,
    (407) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-(2,5-dioxo-pyrrolidine-1-yl)-ethyl ester,
    (408) methyl(R)-2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (409) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (410) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-valerate,
    (411) methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (412) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (413) methyl 1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclopropanecarboxylate,
    (414) [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid 2-fluoroethyl ester,
    (415) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 1-(ethoxycarbonyloxy)ethyl ester,
    (416) methyl[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-3-yl-acetate,
    (417) methyl 2-{[1-(4-cyano-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (418) methyl {[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-phenyl acetate,
    (419) methyl 2-{[1-(4-cyano-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]amino}-2-methyl-propionate,
    (420) 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid isobutylcarbamoyloxymethyl ester,
    (421) methyl 2-{[1-(4-cyano-butyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (422) methyl 2-{[1-(4-methoxy-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (423) methyl(S)-2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (424) methyl 2-[(1-cyclohexylmethyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-4-methyl-valerate,
    (425) methyl 2-[1-(4-fluorobenzyl)-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (426) methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-phenyl-propionate,
    (427) methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-3-methyl-valerate,
    (428) methyl 1-{[6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (429) methyl 1-{[5-ethyl-1-(4-fluorobenzyl)-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (430) diethyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-malonate,
    (431) methyl[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-2-yl-acetate,
    (432) [(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophen-2-yl-acetic acid,
    (433) methyl 2-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (434) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophen-2-yl-acetate,
    (435) methyl 2-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3,3-dimethyl-butyrate,
    (436) methyl {[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-furan-2-yl-acetate,
    (437) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-(4-fluoro-phenyl)-acetate,
    (438) methyl 3-methyl-2-{[2-oxo-1-(4-trifluoromethyl-benzyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate,
    (439) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-phenyl acetate,
    (440) methyl 3-methyl-2-{[1-(4-methyl-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate,
    (441) methyl 1-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexanecarboxylate,
    (442) methyl 2-[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonyl)-amino]-2-methyl-propionate,
    (443) methyl 1-[(1-furan-2-ylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]cyclohexanecarboxylate,
    (444) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-oxo-2-(4-propylcarbamoyl-piperidine-1-yl)-ethyl]-amide,
    (445) methyl(S)-2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-propionate,
    (446) methyl(S)-cyclohexyl-1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate,
    (447) methyl 1-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (448) ethyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate,
    (449) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (450) methyl 2-[(1-butyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (451) methyl 2-[(1-cyclohexylmethyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-4-methyl-valerate,
    (452) methyl 2-[(1-cyclohexylmethyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-3,3-dimethyl-butyrate,
    (453) methyl {[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-thiophene-2-yl-acetate,
    (454) methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-furan-2-yl-acetate,
    (455) methyl {[6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]-amino}-thiophen-2-yl-acetate,
    (456) methyl 2-[(1-benzyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate,
    (457) methyl {[1-(3-methyl-butyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-thiophen-2-yl-acetate,
    (458) methyl 2-{[1-(4-chloro-benzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-3-methyl-butyrate,
    (459) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (4-carbamoyl-thiazole-2-yl)-amide,
    (460) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (4-aminooxalyl-thiazole-2-yl)-amide,
    (461) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(4-benzenesulfonylamino-piperidine-1-yl)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (462) 1-{[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-methyl}-cyclohexanecarboxylic acid,
    (463) (S)-3-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-5-methyl-hexanoic acid,
    (464) (1-{[1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-cyclohexyl)-acetic acid,
    (465) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-[3-(2-hydroxy-ethylcarbamoyl)-piperidine-1-yl]-1,1-dimethyl-2-oxo-ethyl}-amide,
    (466) {5-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiophene-3-yl}-acetic acid,
    (467) (1-{[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-methyl}-cyclohexyl)-acetic acid,
    (468) 4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-4-methyl-valeric acid,
    (469) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-oxo-2-(2-pyridine-4-yl-acetyl-1-amino)-ethyl]-amide,
    (470) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [2-(2,2-dimethoxy-propionylamino)-1,1-dimethyl-2-oxo-ethyl]-amide,
    (471) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-(2-morpholine-4-yl-acetylamino)-2-oxo-ethyl]-amide,
    (471) {2-[(1-benzyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-thiazole-4-yl}-acetic acid,
    (472) 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-oxo-2-(3-pentylcarbamoyl-piperidine-1-yl)-ethyl]-amide,
    (473) 1-cyclohexylmethyl-2-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1,1-dimethyl-2-[4-(morpholine-4-carbonyl)-piperidine-1-yl]-2-oxo-ethyl}-amide,

Effect of Invention



In general, the compounds of the present invention have strong activity for both of the CB1 and CB2 receptors or either of them. In general, the strength of the activity can be indicated by the bonding activity (Ki value) to the receptor, the smaller the Ki value, the stronger the activity is (in vitro activity). Though the compounds of the present invention generally have the very wide range of bonding activity in the order of 0.1 nM to 5000 nM to both or either of the receptors, and the degrees of the selectivity to the both receptors (the ratio of Ki values to the CB1 and CB2 receptors) are also various, when applying the compound on the skin, the effect of restraining itching can be expected (in vivo activity) if the Ki value is about 50 nM or less. Consequently, a compound having a Ki value of 50 nM or less can be considered to be a preferable compound. As for the actual anti-pruritic activity of the compound of the present invention, when the compound to be inspected is dissolved in a solvent and applied on the skin with a compound 40/80 which causes itching, the effect can be confirmed by the density needed torestrain itching by 50% or more compared with the control group. It can be thought that the compound is the most preferable compound If itching can be restrained 50% or more significantly in the density of the active ingredient 3% or less.
Moreover, itching can be restrained also by the oral administration.
The compounds of the present invention have such features as low inhibition activity for enzyme (CYP), low central nerve side effects, excellent photostability, and the like.


BEST MODE FOR CARRYING OUT THE INVENTION
The compounds related to the present invention can be manufactured by the processes described below.
In the following descriptions, the following abbreviations will be used.

    Me: methyl
    Et: ethyl
    n-Pr: n-propyl
    i-Pr: isopropyl
    n-Bu: n-butyl
    Ac: acetyl
    DBU: 1,8-diazabicyclo[5,4,0]undecene
    DMF: dimethylformamide
    DMSO: dimethylsulfoxide
    HOBt: 1-hydroxybenzotriazole
    Ms: methanesulfonyl
    Diglyme: diethylene glycol dimethyl ether
    Triglyme: triethylene glycol dimethyl ether
    TFA: trifluoroacetic acid
    TLC: thin-layer chromatography
    THF: tetrahydrofuran
    Ts: para-toluenesulfonyl
    WSCD: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlorides


The compounds of the present invention can be synthesized through compounds (v) with a carboxyl group in the third position as key intermediates. These key intermediates are synthesized by either of the methods shown in the route 1 to 3, and R1, R2, R3, and R4 are introduced in the process of the method. Though R1 to R4 become directly partial structures in the compound of the present invention, it is also possible that chemically transformable functional groups are incorporated beforehand and they are properly transformed into necessary functional groups for the compound of the present invention. This example will be described later.




wherein R1, R2, R3, and R4 are as defined above.

Route 1: This method is suitable for synthesis of a compound in which R2 is an alkyl, and R3 is an alkyl or an alkoxy. Ketone (I) and formate (R4═H) are dissolved in a solvent such as ether or the like and stirred together with a sodium methoxide methanol solution at temperatures from ice temperature to room temperature for 12 to 24 hours, then β-diketone can be obtained as sodium salt (II). When the compound (II) is suspended in DMF without being purified and refluxed together with acetic acid being excessive a little, the catalytic amount of piperidine and cyanoacetamide derivative (III) for from several to 24 hours, 3-cyanopyridone derivative (IV) is obtained. At this time, if a suitable functional group is previously introduced in R1, it can be transformed into various kinds of functional groups in the later phase. When an isomer is formed, both or only the necessary isomer may be taken out by the silica gel chromatography or the recrystallization at the phase of compound (IV). When the nitrile group of IV is refluxed for several to 24 hours in the water containing alcohol together with sodium hydroxide or potassium hydroxide in 1 to several equivalent weights, the aimed 3-carboxylic acid (V) is obtained. The end point of the reaction is decided by the vanishment of the raw material with TLC or HPLC. V can generally be made to be a key intermediate with sufficient purity by the recrystallization.




wherein R1 and R4 are as defined above; R2 and R3 taken together with the adjacent carbon atoms form a 5 to 10 membered cycloalkene which may contain one group selected from —O—, —S—, —SO—, and —SO2— in the ring.

Route 2: This method is particularly suitable for synthesis of a compound in which R2 and R3 are bonded in cyclic. That is, when a cyclic ketone body (VI) is warmed together with primary amine (VII) in a high boiling point solvent such as toluene, diglyme, or triglyme for 3 to 24 hours at the reflux temperature of the solvent while being dehydrated with the use of a dehydrator of Dean Stark, animine (VIII) is obtained. When the boiling point of the compound (VII) is low, it is also possible that the compound (VI) and the compound (VII) are stirred at room temperature with the catalytic amount of an acid catalyst such as concentrated hydrochloric acid or concentrated sulfuric acid to be transformed into the corresponding compound (VIII). Moreover, even if the methylene group in the compound (VI) is replaced with an oxygen atom or a sulfur atom, the reaction progresses similarly. In addition, when a suitable functional group is introduced into R1 beforehand, the group can be transformed into any one of various functional groups at an arbitrary phase. Methoxymethylene dimethyl malonate is added to the compound (VIII) and refluxed for 1 to 10 hours, a 3-methyl ester body (IX) in which R4 is hydrogen is obtained. When trimethyl methanetricarboxylate is used instead of the malonic ester, 3-methyl ester (X) in which R4 is the hydroxy group is obtained. In this case, the use of a high bp: solvent such as triglyme is preferable. Though it is preferable to refine the compound (IX) and the compound (X) by the silica gel chromatography or the recrystallization, generally, they are not refined, and the aimed key intermediate (V) can be induced by immediately adding the necessary amount of a water containing alcohol solvent such as methanol or ethanol, or a solvent of THF or the like when the compounds being insoluble in alcohol, and stirring with the slightly excessive amount or several equivalent weight of lithium hydroxide, sodium hydroxide, potassium hydroxide, or the like for 0.5 to several hours. The compound (V) synthesized by this method can generally be made to be a key intermediate with enough purity by the recrystallization.




wherein R1, R2, and R3 are as defined above; R is a C1-C6 alkyl.

Route 3: When ketone (I or VI) and dimethylformamide dialkyl acetal are warmed at 100° C. to the reflux temperature of the solvent for 12 to 24 hours, ketoimine (XI) is obtained. As dimethylformamide dialkyl acetal, dimethylformamide dimethyl acetal, which is a commercial item easily obtainable, is generally used. When the compound (XI) is nor refined and is stirred with cyano acetic ester in a solvent such as methanol at room temperature, an ester body (XII) is precipitated as a hardly soluble solid. Compound (XII) is dissolved in DMF, THF, DMSO, or these compounds and is stirred with the slightly excessive amount of sodium hydride at room temperature to 60° C. for 0.5 to several hours. After that, when an alkylating agent (R1—X) is added and stirred at room temperature to 50° C. for one to several hours, the compound (XIII) and compound (XIV) which are substituted for the first place or the second place are generally formed at the rate of 1:1. At this time, a suitable functional group can be introduced into R1 beforehand. As X of an alkylating agent, chlorine, bromine, iodine, the toluenesulfonyloxy group, the methanesulfonyloxy group, and the like are preferable. The compound (XIV) can be easily removed by the silics gel chromatography or the recrystallization. Then, the compound (XIII) is hydrolyzed by the above-mentioned method, leading to a key intermediate (V).
The compound (V), which can be synthesized by the above-mentioned method, is a key intermediate which can be used as a raw material for synthesizing all of the compounds of the present invention, and the manufacturing method will be described more in detail by the referential examples. However, the manufacturing method of the compound (V) is not limited only to these three routes.
Next, as an example in which a suitable functional group is incorporated beforehand and transformed to the desired functional group at a suitable phase, the method of introducing the amino group into the end of R1 will be described.




wherein R1, R2, R3, and R4 are as defined above; A′ is a C1-C8 alkylene group optionally substituted with one to two substituents selected from the above-mentioned substituent group A.

The 3-ester (XVII) is obtained from a compound (I) or a compound (VI) and a compound (XV) by the method of route 1 or 2. The hydroxy group can be transformed to various functional groups. For example, when compound (XVII) is reacted in a solvent such as THF or methylene chloride with the chlorinated toluene sulfonate and chlorinated methane sulfonate in the presence of a tertiary base such as pyridine or triethyl amine at temperatures from ice temperature to room temperature, a tosylate body or a mesylate body which corresponds respectively is obtained. These substituents can easily receive the nucleophilic substitution reaction as a leaving group to be transformed into other functional groups. For example, when these substituents are reacted with sodium azide in a solvent such as DMF or DMSO at temperatures of 100° C. to the reflux temperature of the solvent, they can be transformed into azide (XVIII). The azide is easily reduced with catalytic reduction, or by triphenylphosphine and the like to form an amino (XIX). The compound (XIX) is further not only transformed easily into various functional groups such as secondary amine, tertiary amine, an amide, a sulfonamide, and a carbamate, which are widely used as partial structures in pharmaceuticals, but made to be new intermediates by introducing proper protecting groups. Though it does not needed to explain the methods of concretely transforming these functional groups for those skilled in the art, concrete methods have been given in, for example, Harrison, I., Harrison, S., Compendium of Organic Synthesis Vol I-II, Wiley-Interscience, NY (1971, 1977), Hegedus, L. S., Wade, L., Compendium of Organic Synthesis Vol III, John Wiley & Sons, NY (1977), Sandler, S. R., Karo, W., Organic Functional Group Preparations, 2nd Ed., Academic Press, NY (1983), Experimental chemistry course, 4th Ed., Organic synthesis I-V, Maruzen (1992), and others. Carboxylic acids (V), in which R1 is modified, can be obtained by hydrolyzing various compounds (XX) manufactured in such ways. As for other functional groups, the above-mentioned methods have only to be followed basically.
Next, the methods of transforming key intermediates (V) into 3-carbamoyl (XXII to XXV), which are features for the compounds of the present invention, will be described. It does not needed to explain the methods of transforming carboxylic acids into acid amide bodies for those skilled in the art. Concretely, though it is sufficient only to follow the methods described in the following documents, for example, Harrison, I., Harrison, S., Compendium of Organic Synthesis Vol I-II, Wiley-Interscience, NY (1971, 1977), Hegedus, L. S., Wade, L., Compendium of Organic Synthesis Vol III, John Wiley & Sons, NY (1977), Sandler, S. R., Karo, W., Organic Functional Group Preparations, 2nd Ed., Academic Press, NY (1983), Experimental chemistry course, 4th Ed., Organic synthesis I-V, Maruzen (1992), and others, acid amide bodies can be usually manufactured acid by the following methods.




wherein R1, R2, R3, R4, R5, X1, X2, X3, Y, Z, G, G1, and G2 are as defined above.

Carboxylic acid (V) is reacted with oxalyl chloride in a solvent such as dichloromethane or THF in the presence of the catalytic amount of DMF at room temperature and transformed into the acid chloride. Instead of using oxalyl chloride, carboxylic acid (V) can also be transformed into the acid chloride by refluxing it with thionyl chloride in a nonpolar solvent such as benzene or methylene chloride, or without using a solvent. When the acid chloride is not refined and reacted with an amine body (XXI) in a solvent such as methylene chloride or THF in the presence of a base such as triethyl amine or pyridine at temperatures from cooling with ice to room temperature for one to six hours, amide (XXII) is obtained. When the amino group of the compound (XXI) is a salt such as an inorganic acid, tertiary amine only has to be added simultaneously in the reaction mixture in the enough amount of neutralizing the salt. The compound (XXII) can also be manufactured directly from the compound (XXI) and the compound (V) in the presence of an activator such as, for example, WSCD-HOBt. When the progress of the reaction is late, the irradiation of the microwave is effective, and even such a reaction as does not progress under a usual condition ends within tens of minutes. The separation of a product difficult to be isolated can also be facilitated with the use of a reagent fixed to a polymer carrier.
Compounds (XXI) can be classified into compounds (XXIII), compounds (XXIV), and compounds (XV) according to the kinds of G. Furthermore, the part of -Y-Z can be transformed into various functional groups with the use of the definite method if necessary. For example, when -Y-Z is alkoxy in a compound (XXIII) or a compound (XXIV), after the alkoxy is transformed into acid halide with the use of a carboxylic acid XXVI obtained by the hydrolysis, the acid halide can be reacted with alcohols, mercaptans or amines to form compounds (XXIII) in which Y becomes an oxygen atom, a sulfur atom, and a nitrogen atom, respectively. In this case, the amidation method previously described can be applied.




wherein R1, R2, R3, R4, R5, Xi, X2, X3, Y, and Z are as defined above.

When the asymmetric center exists in the alpha place in the carbonyl and the racemization progresses in the process of the hydrolysis, a protecting group such as, for example, the benzhydryl group or the tertiary butyl group, which can receive easily the acid hydrolysis at room temperature, is introduced as Z and the hydrolysis may be carried out in a mild acid condition. The compounds of the present invention have a wide variety of structures, and the compounds (XXIII) are not only compounds of the present invention but also very useful as intermediates for manufacturing more complex derivatives and will be described in detail in examples.
Examples of manufacturing various compounds of the present invention using carboxylic acids (XXVI) include, for example, manufacturing amide bodies (XXVIII) by the reactions with compounds (XXVII) which have the amino group. In this time, for example, if a protected amino group exists in the terminal, after canceling the protection, another substituent can be newly introduced and the amino group can also be transformed easily into various functional groups widely used as partial structures in pharmaceuticals such as an amid body, a sulfonamide body, and a carbamate body.
In the present invention, not only a compound of the present invention, which has the cannabinoid receptor agonist action, but also the salt allowed in medicine manufacture or a solvate thereof can be used.
When an optical isomer, a stereoisomer, and a geometrical isomer exist in a compound of the present invention, all isomers are included.
As for salts allowed in medicine manufacture, basic salts include, for example, alkali metal salts such as sodium salt and potassium salt; alkaline-earth metal salts such as calcium salt and magnesium salt; ammonium salts; aliphatic amine salts such as trimethylamine salt, triethylamine salt, dicyclohexylamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, and procaine salt; aralkylamine salts such as N,N-dibenzylethylenediamine; heterocycle aromatic amines such as pyridine salt, picoline salt, quinoline salt, and isoquinoline salt; quaternary ammonium salts such as tetramethylammonium salt, tetramethylammonium salt, benzyltrimethylammonium salts, benzyltriethylammonium salt, benzyltributylammonium salt, methyltrioctylammonium salt, and tetrabutylammonium salt; basic amino acid salts such as arginine salt and lysine salt: acid salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates, carbonates, hydrogencarbonates, and perchlorates; organic acid salts such as acetates, propionates, lactates, maleates, fumarates, tartrates, malates, citrates, and ascorbates; sulfonates such as methanesulfonates, isethionates, benzenesulfonates, and p-toluenesulfonates; amino acids such as aspartates, and glutamates.
The solvates mean solvates of the compound of the present invention or those of the salts allowed in medicine manufacture, and, for example, monosolvates, disolvates, monohydrates, dihydrates, and the like are enumerated.
The anti-pruritus agent concerned with the present invention can be used as a therapeutic agent for itching such as pruritus at the time of, allergic or nonallergic, for example, atopic dermatitis, hives, contact dermatitis, psoriasis vulgaris, senile xerosis, kidney dialysis, or hepatic failure. Further, suppressing itching is also useful for preventing the disease and the injury secondarily generated by the scratch action, the beating, and the like attendant upon itching.
The compounds of the present invention are excellent in stability, photostability and disposition, and can be used for other diseases, in which the toxicity such as the enzyme inhibition (CYP) and the central nerve side effects is low and the cannabinoid receptor agonist takes part, for the purpose of treatment or prevention. For example, the description in Nature, vol. 365, p. 61 to 65, (1993) indicates that the cannabinoid receptor agonist has anti-inflammatory activity and analgesic activity, the description in Journal of Cannabis Therapeutics, vol. 2, No. 1, p. 59 to 71 (2002) indicates that the cannabinoid receptor agonist has bronchodilatory activity, and the description in International Publication No. 03/035109, pamphlet indicates that the cannabimoid receptor agonist has anti-pruritic activity.
That is, the compounds of the present invention can be used as an anti-pruritus agent, an anti-inflammatory agent, an antiallergic agent, an analgesic agent, pain therapy agents (annociceptivity pain therapeutic agent, a neuropathic pain therapeutic agent, a psychogenic pain therapeutic agent, an acute pain therapeutic agent, a chronic pain therapeutic agent, and the like), an immunodeficiency therapeutic agent, an immunosuppressive agent, an immunoregulatory agent, an autoimmune disease therapeutic agent, a chronic articular rheumatism therapeutic agent, an osteoarthritis therapeutic agent, a multiple sclerosis therapeutic agent, antiasthmatic agents (an inhibitor for inflammatory cellular infiltration in the respiratory tract, an inhibitor for hyperirritability in the respiratory tract, a bronchodilator, a mucus secretion retardant, and the like), a chronic obstructive pulmonary disease therapeutic agent, a pulmonary emphysema therapeutic agent, pulmonary fibrosis therapeutic agent, a cough suppressant, an allergic rhinitis therapeutic agent, dermatitis therapeutic agents (an atopic dermatitis therapeutic agent, a hives therapeutic agent, a contact dermatitis therapeutic agent, a psoriasis vulgaris therapeutic agent), an inflammatory bowel disease therapeutic agent, an arteriosclerosis therapeutic agent, a glaucoma therapeutic agent, an anorexia therapeutic agent, and the like.
In the treatment of the disease concerned with the present invention, the compounds of the present invention can be used together with or combining with other therapeutic agents. In the treatment of itching such as pruritus at the time of, allergic or nonallergic, for example, atopic dermatitis, hives, contact dermatitis, psoriasis vulgaris, senile xerosis, kidney dialysis, or hepatic failure, as anti-pruritus agents, the compounds of the present invention can also be used together with or combining with a corticosteroid receptor agonist, an immunosuppressive agent, a PDE IV inhibitory agent, an IgE antibody generation retardant, a histamine H1 receptor antagonist, a histamine H4 receptor antagonist, a chemokine receptor antagonist, a VLA-4 antagonist, a nonsteroidal anti-inflammatory agent, or a PPARgamma agonist.
Moreover, in the respiratory disease, the compounds of the present invention can also be used together with or combining with a corticosteroid receptor agonist, an immunosuppressive agent, a PDE IV inhibitory agent, an IgE antibody generation retardant, a histamine H1 receptor antagonist, a histamine H4 receptor antagonist, a chemokine receptor antagonist, a VLA-4 antagonist, a nonsteroidal anti-inflammatory agent, a PPARgamma agonist, a leukotriene receptor antagonist, a leukotriene synthesis inhibitor, a prostaglandin receptor antagonist, a thromboxane A2 receptor antagonist, a beta2 receptor antagonist, an anticholinergic drug, a mast cell isolation depressant, and a cough suppressant.
To use a compound of the present invention for treatment, the compound is made to be a drug product for usual oral or parenteral administration. The pharmaceutical composition containing a compound of the present invention can take the forms for oral and parenteral administration. That is, the composition can also be made to be oral administration drug products such as a tablet, a capsule, a granule, powdered medicine, and syrup, and parenteral administration drug products including solutions for injection such as intravenous injection, intramuscular injection, and hypodermic injection, or drug products for dermal administration such as suspension, an inhalant, eye-drops, nose drops, a suppository, a gel agent, an ointment, or a droplet distributed ointment.
These drug products can be manufactured using suitable carriers, vehicles, solvents, bases, and the like which are already known to those skilled in the art. For example, in case of a tablet, an active ingredient and an auxiliary ingredient are compressed or formed together. As an auxiliary ingredient, a vehicle which is allowed in the drug product, for example, a bonding agent (for instance, cornstarch and the like), fillers (for instance, lactose, microcrystalline cellulose, and the like), disintegrating agents (for instance, starch sodium glycolate and the like), or lubricants (for instance, magnesium stearate and the like) are used. The tablet may be properly coated. In case of liquid preparations such as syrup, a liquid medicine, and a suspension agent, for example, suspending agents (for instance, methyl cellulose and the like), emulsifying agents (for instance, lecithin and the like), and preservative are used. In case of drug products for injection, they may be either in the form of solution, suspension, or oily or aqueous emulsion, and these may contain an emulsion stabilizer, a dispersant, or the like. When being used as an inhalant, theae drug products are used as a liquid medicine which can adjust to an inhaler, and when also being used as eye-drops, these drug products are used as a liquid medicine or a suspending agent. When being used as a gel agent, an active ingredient, a solvent, and a gelling agent are stirred together to be pectized. When being used as a droplet distributed ointment, an active ingredient, a solvent, an ointment base, and the like are used.
Though the dosage of the compound of the present invention differs according to the administering form, the patient's symptom, age, weight, and the sex, or a medicine to be used together (in case of being), and the like, and finally is entrusted to the doctor's judgement, in case of the oral administration, the daily dosage is 0.01 to 100 mg per 1 kg in body weight, preferably 0.01 to 10 mg, and more preferably 0.1 to 10 mg, and in case of parenteral administration, the daily dosage is 0.001 to 100 mg per 1 kg in body weight, preferably 0.001 to 1 mg, and more preferably 0.01 to 1 mg. These daily dosages have only to be administered by being divided into one to four times.
To make the above-mentioned description more concretely, reference examples and examples are given as follows. However, the methods for synthesizing the compounds of the present invention should not be limited to the methods described here
EXAMPLES
As 3-pyridone carboxylic acid, those obtained from the market or synthesized by the following synthesis methods were used
Example 1
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta [b]pyridine-3-carboxylic acid (AA01)




Under the nitrogen gas atmosphere, a solution of cyclooctanone (15 g, 118 mmol) and cyclohexylmethylamine (16.1 g, 142 mmol) in toluene (300 mL) was refluxed under azeotropic dehydration for 6 hours. After that, diethyl ethoxymethylenemalonate (24 mL, 142 mmol) was added, and the mixture was further refluxed for 2 hours. After the reaction mixture had been removed by distillation under reduced pressure, the residue was dissolved in the mixed solvent of THF (200 mL) and methanol (200 mL), then a 2M sodium hydroxide aqueous solution was added and the mixture was stirred for 2 hours at room temperature. The reaction mixture was removed by distillation under reduced pressure, water was added to the residue and the water layer was washed with diethyl ether one time. Then, after 2 M hydrochloric acid was added to the water layer to acidify it, the water layer was extracted with ethyl acetate. The organic layer was washed with water and then dried with anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure and a pale yellow solid (AA01, 21.5 g, 57%, mp: 162-163° C.) was obtained
NMR: (DMSO-d6) 1.00-1.88 (m, 19H), 2.71 (t, 2H, J=5.7), 3.00 (t, 2H, J=5.7), 4.05 (d, 2H, J=6.3), 8.20 (s, 1H).
Example 2
Synthesis of 1-(4-fluorobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-carboxylic acid (AA02)




Under the nitrogen gas atmosphere, a solution of cyclooctanone (7.55 g, 59.8 mmol) and perfluorobenzylamine (8.20 g, 71.8 mmol) in toluene (100 mL) was refluxed under azeotropic dehydration for 6 hours. After that, diethyl ethoxymethylenemalonate (12.1 mL, 59.8 mmol) was added, and the mixture was further refluxed for 2 hours. After the reaction mixture had been removed by distillation under reduced pressure, THF (100 mL), methanol (100 mL), and a 2M sodium hydroxide aqueous solution were added to the residue in order, and the mixture was stirred for 2 hours at room temperature. The reaction mixture was removed by distillation under reduced pressure, water was added to the residue and was washed with diethyl ether one time. Then, 2 M hydrochloric acid was added to the water layer and was extracted with ethyl acetate. The organic layer was washed with water and then dried with anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure and a pale yellow solid (AA02, 9.8 g, 50%, mp: 170-172° C.) was obtained.
NMR: (CDCl3) 1.36-1.88 (m, 8H), 2.67 (t, 2H, J=6.0), 2.88 (t, 2H, J=6.0), 5.46 (s, 2H), 7.00-7.16 (m, 4H), 8.37 (s, 1H), 14.47 (br s, 1H).
Example 3
Synthesis of 1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydro-pyridine-3-carboxylic acid (AA03)




Under the nitrogen gas atmosphere, a solution of 4-heptanone (5.0 mM, 35.75 mmol), n-butylamine (4.25 mL, 4.29 mmol), and three drops of concentrated hydrochloric acid was stirred for 18.5 hours at room temperature. After that, water was added and the mixture was extracted with ethyl acetate. After the organic layer had been washed with water and then dried with anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure. The obtained oily matter was dissolved in 2-methoxyethyl ether (40 mL), and heated and stirred with dimethyl methoxymethylenemalonate (5.66 g, 32.5 mmol) at 120° C. for 3 hours. After the solvent had been removed by distillation under reduced pressure, the residue was refined with silica gel (100 g) column chromatography (ethyl acetate-hexane of 1:1 in mixing ratio and then that of 2:1), and a ark reddish-brown oily substance was obtained. The substance was dissolved in THF (20 mL) without purification, and a 1M lithium hydroxide aqueous solution (15.18 mL) and water (4.82 mL) were added, and then the mixture was stirred for 2 hours at room temperature. After that, the mixture was diluted with water and washed with diethyl ether. After 2M hydrochloric acid had been added to the water layer to acidify it, the water layer was extracted with ethyl acetate. The organic layer was washed with water and then dried with anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure and a pale yellow solid (AA03, 1.68 g, 18%) was obtained.
NMR: (CDCl3) 1.01 (t, 3H, J=7.5), 1.12 (t, 3H, J=7.5), 1.22 (t, 3H, J=7.5), 1.40-1.90 (m, 6H), 2.53 (q, 2H, J=7.5), 2.70 (m, 2H), 4.13 (t, 2H, J=7.5), 8.33 (s, 1H), 14.79 (br s, 1H).
Example 4
Synthesis of methyl 1-(4-cyanobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA04)




1) Synthesis of methyl 2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate
Under the nitrogen gas atmosphere, a solution of cyclooctanone (15.87 mL, 120 mmol) and DMF dimethyl acetal was heated and stirred at 100° C. for 12 hours. After that, the solvent was removed by distillation under reduced pressure and a pale yellow oily matter (16.54 g) was obtained. This was dissolved in methanol (50 mL), and methyl cyanoacetate (8.87 mL, 100.37 mmol) was added and stirred at room temperature. The precipitated solid was separated by filtration and washed with diethyl ether, and the desired compound was obtained as a colorless solid (13.8 g, 49%, and mp: 220-224° C.).
NMR: (CDCl3) 1.58-1.88 (m, 8H), 2.59 (t, 2H, J=6.0), 2.82 (t, 2H, J=6.0), 3.90 (s, 3H), 8.04 (s, 1H), 12.39 (br, 1H).
2) Synthesis of methyl 1-(4-cyanobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA04)
Under the nitrogen gas atmosphere, methyl 2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (300 mg, 1.27 mmol) was dissolved in DMF (5 mL), sodium hydride (61 mg, 1.53 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. After that, 4-cyanobenzylamine (274.9 mg, 1.40 mmol) was added, and the mixture was further stirred at room temperature for 1 hour. Subsequently, water and 5% citric acid were added to the reaction mixture, and the obtained mixture was extracted with ethyl acetate. The organic layer was washed with water and then dried with anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was refined with silica gel (10 g) column chromatography (ethyl acetate-hexane of 1:1 in mixing ratio), and colorless solid of methyl 1-(4-cyanobenzyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA04, 100 mg, 22%, mp: 72-75° C.) and colorless solid of methyl 2-(4-cyanophenoxy)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine-3-carboxylate (123 mg, 28%, mp: 122-123° C.) were obtained.
AA04
NMR: CDCl3 1.38-1.93 (m, 8H), 2.61 (t, 2H, J=6.0), 2.75 (t, 2H, J=6.0), 3.90 (s, 3H), 5.44 (br, 2H), 7.23 (d, 2H, J=8.4), 7.60 (d, 2H, J=8.4), 8.01 (s, 1H)).
methyl 2-(4-cyanophenoxy)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine-3-carboxylate
NMR: (CDCl3) 1.28-1.34 (m, 4H), 1.60-1.80 (m, 4H), 2.72 (t, 2H, J=6.3), 2.85 (t, 2H, J=6.3), 3.91 (s, 3H), 5.56 (s, 2H), 7.65 (s, 4H), 7.92 (s, 1H).
Example 5
Synthesis of methyl 1-(3-cyanopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA05)




Under the nitrogen gas atmosphere, 2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-methyl carboxylate (8 g, 34 mmol), which had been obtained in Example 4, was dissolved in DMF (160 mL), sodium hydride (1.63 g, 40.8 mmol) was added, and the mixture was stirred at 50° C. for 1 hour. After that, the mixture was returned to be at room temperature, and 4-bromobutyronitrile (3.71 mL, 37.4 mmol) was added and the mixture was stirred at 50° C. for 2 hours. After that, water and 5% citric acid were added, and the obtained mixture was extracted with ethyl acetate. After the organic layer had been washed with water and dried with anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the residue was refined with silica gel (160 g) column chromatography (ethyl acetate-hexane of 3:7 in mixing ratio), and colorless oily matter (AA05, 3.71 g, 36%, mp: 82-84° C.) and a corresponding O-alkyl (39%) were obtained.
AA05
NMR: (CDCl3) 1.38-1.93 (m, 8H), 2.04-2.16 (m, 2H), 2.55 (t, 2H, J=5.7), 2.60 (t, 2H, J=6.0), 2.90 (t, 2H, J=6.0), 3.90 (s, 3H), 4.21 (t, 2H, J=6.0)), 8.01 (s, 1H).
Example 6
Synthesis of ethyl 1-benzyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate (AA06)




A toluene solution (50 mL) of 3-pentanone (5.00 g, 58.1 mmol) and benzylamine (6.23 g, 58.1 mmol) was heated and refluxed under azeotropic dehydration for 3 hours. After that, diethyl ethoxymethylenemalonate (12.56 g, 58.1 mmol) was added, and the mixture was further continued to be heated and refluxed for 5 hours. The solvent was removed by distillation under reduced pressure, and the residue was refined with silica gel (300 g) column chromatography (ethyl acetate-hexane of 1:5 in mixing ratio and then those of 1:3 and 2:1), and pale yellow oily matter (AA06, 1.92 g, 11.0%) was obtained.
NMR: (CDCl3) 1.12 (t, 3H, J=7.7), 1.38 (t, 3H, J=7.2), 2.15 (s, 3H), 2.64 (q, 2H, J=7.5), 4.36 (q, 2H, J=7.2), 5.43 (br, 2H), 7.11 (d, 2H, J=6.9), 7.20-7.32 (m, 3H), 8.04 (s, 1H).
Example 7
Synthesis of 1-benzyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (AA07)




2M sodium hydroxide solution (7.9 mL, 15.8 mmol) was added to a methanol/THF (7.9 mL/7.9 mL) solution of ethyl 1-benzyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate (AA06, 1.92 g, 6.3 mmol), which had been obtained in Example 6, at room temperature and stirred at the same temperature for 2 hours. The reaction mixture was diluted with water (10 mL) and washed with ether (20 mL). 2M hydrochloric acid (8 mL, 16 mmol) was added to the water layer and the obtained mixture was extracted with ethyl acetate (20 mL) two times. The organic layer was washed with water (20 mL) two times and then dried with anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and yellow oily 1-benzyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (AA07, 1.43 g) was obtained. The product was let alone for a night and was crystallized. The crystal was recrystallized from ethyl acetate and a white columnar crystal (AA07, 1.00 g, 58.5%) was obtained.
Mp: 113-114° C.
NMR: (CDCl3) 1.18 (t, 3H, J=7.7), 2.24 (s, 3H), 2.73 (q, 2H, J=7.5), 5.49 (br s, 2H), 7.09 (m, 2H), 7.29-7.38 (m, 3H), 8.38 (s, 1H), 14.53 (br s, 1H).
Example 8
Synthesis of ethyl 1-cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carboxylate (AA08)




After a toluene (40 mL) solution of tetrahydrothiopyran-4-one (5.05 g, 43.5 mmol) and aminomethylcyclohexane (5.41 g, 47.8 mM) was heated and refluxed under azeotropic dehydration for 4 hours, diethyl ethoxymethylenemalonate (9.40 g, 43.5 mmol) was added, and the mixture was further continued to be heated and refluxed for 17 hours. The solvent was removed by distillation under reduced pressure, and the residue was refined with silica gel (160 g) column chromatography (ethyl acetate-toluene of 1:5 in mixing ratio and then that of 2:3), and red oily ethyl 1-cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carboxylate (AA08, 8.17 g, 31.5%) was obtained.
NMR: (CDCl3) 1.00-1.25 (m, 5H), 1.38 (t, 3H, J=7.2), 1.60-1.96 (m, 6H), 2.90-3.03 (m, 4H), 3.62 (s, 2H), 3.93 (br, 2H), 4.36 (q, 2H, J=7.2), 7.89 (s, 1H).
Example 9
Synthesis of 1-cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carboxylic acid (AA09)




4M sodium hydroxide solution (15.2 mL, 60.8 mM) was added to a methanol (30 mL) solution of ethyl 1-cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carboxylate (AA08, 8.16 g, 24.3 mmol), which had been obtained in Example 8, at room temperature, and the mixture was heated and refluxed for 30 minutes. The reaction mixture was diluted with water (100 mL) and washed with ether (100 mL). 5M hydrochloric acid (13 mL, 65 mmol) was added to the water layer, the precipitated crystal was separated by filtration and washed with water, and the brown crystal of 1-cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carboxylic acid (6.78 g) was obtained. The crystal was recrystallized from ethanol-water to give light brown crystalline powder (AA09, 6.30 g, 84.3%).
Mp: 144-145° C.
NMR: (DMSO-d6) 0.99-1.25 (m, 5H), 1.46-1.87 (m, 6H), 2.97 (t, 2H, J=6.0), 3.15 (t, 2H, J=6.0). 3.78 (s, 2H), 4.07 (br, 2H), 8.24 (s, 1H), 14.84 (s, 1H).
Example 11
Synthesis of 1,5-dibutyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (AA11)




Under the nitrogen gas atmosphere, a mixture of 28% sodium methoxide methanol solution (39 mL, 202 mmol) and ether (260 mL) was cooled to 3° C. in an ice bath, and the mixture of 2-heptanone (22.84 g, 200 mmol) and ethyl formate (16.15 g, 218 mmol) was dropped in about 20 minutes. After that, being stirred at the same temperature for 30 minutes, then the mixture was returned to be at room temperature and was further stirred for 20 hours afterwards. The precipitated product was removed by filtration and washed enough with ether (about 620 g). The mother liquor and the washing layer were combined and concentrated to give a crude product of 29.34 g. This crude product was repeatedly washed with hexane and ether, and powdered yellow ocher sodium salt of 3-[1-hydroxymethylidyne]-heptan-2-one (11.33 g, 34.5%) was obtained.
This salt (2.13 g, 13 mmol) was suspended in DMF (10 mL), and n-butylcyanoacetamide (1.40 g, 10 mmol), acetic acid (0.75 mL, 13.1 mmol), piperidine (0.20 mL, 2.02 mmol) were added in order at room temperature, and the mixture was refluxed at 135° C. for 7 hours. After that, the reaction mixture was let alone at room temperature for 13 hours and then poured into ice water, and the obtained mixture was extracted with ethyl acetate two times. The organic layer was washed with diluted hydrochloric acid one time and with water two times, and then died with anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and a red oily crude product of 2.03 g was obtained. This crude product was refined by the silica gel chromatography, and the desired 1,5-dibutyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (AA11, 420 mg, 17.3%) and 1-butyl-2-oxo-6-pentyl-1,2-dihydropyridine-3-carbonitrile (230 mg, 9.4%) were obtained.
AA 11
NMR: (CDCl3) 0.95 (t, 3H, J=6.9, 0.98 (t, 3H, J=6.9), 1.5-1.7 (m, 8H), 2.42 (s, 3H), ca 2.4 (m, 2H), 4.08 (2H, m), 7.57 (1H, s)).
1-butyl-2-oxo-6-pentyl-1,2-dihydropyridine-3-carbonitrile
NMR: (CDCl3) 0.94 (t, 3H, J=6.8), 0.98 (t, 3H, J=7.2), 1.3-1.7 (m, 10H), 2.66 (m, 2H), 4.04 (m, 2H), 6.11 (ABd, 1H, J=7.5), 7.67 (ABd, 1H, J=7.5)) was obtained.
Example 12
Synthesis of 1,5-dibutyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (AA12)




1,5-dibutyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (AA11, 420 mg, 1.705 mmol), which had been obtained in Example 11, was dissolved in 80% aqueous ethanol solution and the solution was refluxed together with potassium hydroxide (770 mg, 13.7 mmol) for 22 hours. The solvent was removed by distillation under reduced pressure, water was added to the residue, and the obtained mixture was washed with ethyl acetate one time. The water layer was acidified by 2M hydrochloric acid (3 mL), and the precipitated solid was separated by filtration and was washed with water. Then the solid was air-dried, and an yellow ocher solid of 1,5-dibutyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (AA12, 352 mg, 78%, mp: 106-108° C.) was obtained.
NMR: (CDCl3) 0.95 (t, 3H, J=7.2), 1.01 (t, 3H, J=7.3), 1.3-1.8 (m, 8H), 2.49 (s, 3H), 2.51 (t, 2H, J=7.5), 4.17 (m, 2H), 8.29 (s, 1H).
Example 13
Synthesis of 1-butyl-6-methyl-2-oxo-5-pentyl-1,2-dihydropyridine-3-carboxylic acid (AA13)




AA13 was synthesized from 2-octanone by the same method as that in Example 12.
Mp: 106-109° C.
NMR: (CDCl3) 0.93 (t, 3H, J=6.9), 1.01 (t, 3H, J=7.2), 1.3-1.8 (m, 10H), 2.49 (s, 3H), 2.50 (m, 2H), 4.17 (2, 2H), 8.29 (s, 1H), 14.77 (brs, 1H).
Example 14
Synthesis of 1-benzyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (AA14)




AA14 was synthesized from 2-butanone by the same method as that in Example 12.
Mp: 148-151° C.
NMR: 2.21 (s, 3H), 2.38 (s, 3H), 5.50 (s, 2H), 7.1-7.15 (m, 2H), 7.2-7.4 (m, 3H), 8.37 (s, 1H), 14.57 (brs, 1H).
Example 15
Synthesis of 1-butyl-6-ethyl-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (AA15)




AA15 was synthesized from 2-pentanone by the same method as that in Example 12.
Mp: 121° C.
NMR: (CDCl3) 1.00 (t, 3H, J=7.2), 1.27 (t, 3H, J=7.6), 2.79 (m, 2H), 1.71 (m, 2H), 2.23 (s, 3H), 2.79 (q, 2H, J=7.6), 8.29 (s, 1H), 14.77 (brs, 1H).
Example 16
Synthesis of ethyl 1-cyclohextkmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA16)




The toluene (30 mL) solution of cyclooctanone (4.23 g, 33.52 mmol) and aminomethylcyclohexane (4.36 mL, 33.52 mmol) was refluxed under azeotropic dehydration for 15 hours. After the reaction mixture had been let alone and cooled to room temperature, the mixture was concentrated under reduced pressure. The residue was distilled under reduced pressure and 5.90 g of colorless oily matter (80%, bp: 120-122° C.) was obtained.
This matter (1.15 g, 5.19 mmol) was stirred in triglyme (7 mL) together with triethylmethane tricarboxylic acid (0.88 mL, 4.15 mmol) at 135° C. for 36 hours. Diluted hydrochloric acid was added to the reaction mixture, and the mixture was extracted with toluene. The organic layer was washed with water and saturated saline, dried, and concentrated, and then the residue was refined with silica gel column chromatography (hexane-ethyl acetate (15-25%)), and obtained as a colorless solid (AA16, 667 mg, 45%).
NMR: (CDCl3) 0.89-1.98 (m, 22H), 2.60-2.96 (m, 4H), 4.20-4.35 (m, 2H), 4.45 (q, 2H, J=7.2), 13.71 (s, 1H).
Example 17
Synthesis of methyl 1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA17)




A concentrated hydrochloric acid was added to a mixture of cyclooctanone (3.84 g, 30.43 mmol) and butylamine (3.01 mL, 30.43 mmol) by two drops, and the mixture was stirred at room temperature for 15 hours. Diluted sodium carbonate aqueous solution and ethyl acetate were added in the reaction mixture to separate the mixture, and the organic layer was washed with water and saturated saline. After the organic layer had been dried, the solvent was removed by distillation and 4.72 g of colorless oily matter was obtained (86%). This imine (4.67 g, 25.76 mmol) was reacted as mentioned above together with trimethylmethane tricarboxylic acid (3.42 g, 18 mM) in trigrim (40 mL), and viscous yellow oily matter (AA17, 2.62 g, 47%) was obtained.
NMR: (CDCl3) 0.96 (t, 2H, J=7.2), 1.36-1.81 (m, 12H), 2.67 (m, 2H), 2.86 (t, 2H, J=6.0), 3.94-4.02 (m, 2H), 13.55 (s, 1H).
Example 18
Synthesis of ethyl 1-(3-hydroxypropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA 18)




Cyclooctanone (10.00 g, 79.18 mmol) was dissolved in toluene (140 mL) and was refluxed together with 2-amino-1-propanol (6.10 mL, 79.75 mmol) under azeotropic dehydration for 14.5 hours. After that, diethyl ethoxymethylenemalonate (16.0 mL, 79.18 mmol) was added, and the solution was refluxed further for 5.5 hors. The solution was concentrated under reduced pressure until the amount of the solvent became about half, and the residue was eluted and refined with silica gel (192 g) column chromatography (ethyl acetate-hexane (1:1), ethyl acetate, ethyl acetate-methanol (4:1) in order), thus brown oily matter (AA18, 13.63 g, 56%) was obtained.
NMR: (CDCl3) 1.35-1.55 (m, 4H), 1.38 (t, 3H, J=7.2), 1.63-1.83 (m, 4H), 1.86-1.97 (m, 2H), 2.58-2.62 (m, 2H), 2.88-2.93 (m, 2H), 3.52-3.55 (m, 2H), 4.32 (brs, 2H), 4.37 (q, 2H, J=7.2), 7.95 (s, 1H).
Example 19
Synthesis of ethyl 1-(3-methanesulfonylpropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA19)




Ethyl 1-(3-hydroxypropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA18, 13.63 g, 44.34 mmol), which had been obtained in Example 15, was dissolved in anhydrous THF (105 mL), and triethylamine (9.28 mL, 66.53 mmol) and methanesulfonyl chloride (4.12 mL, 53.23 mmol) were added while stirring and cooling the solution with ice, and further the mixture was stirred for 45 minutes. After the reaction mixture had been acidified by being poured into diluted aqueous hydrochloric acid solution, the liaction liquid was extracted with ethyl acetate. The organic layer was washed with water, a saturated sodium bicarbonate aqueous solution, and water, and then dried with anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was eluted and refined with silica gel (176 g) column chromatography (ethyl acetate, and then ethyl acetate-methanol (9:1) in order), and light orange color oily matter (AA19, 7.85 g, 46%) was obtained.
NMR: (CDCl3) 1.35-1.58 (m, 7H), 1.62-1.84 (m, 4H), 2.14-2.26 (m, 2H), 2.58-2.62 (m, 2H), 2.86-2.90 (m, 2H), 3.06 (s, 3H), 4.20-4.29 (m, 2H), 4.32-4.44 (m, 4H), 7.96 (s, 1H).
Example 20
Synthesis of ethyl 1-(3-azidepropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA20)




Ethyl 1-(3-methanesulfonylpropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA19, 7.85 g, 20.36 mmol), which had been obtained in Example 19, was dissolved in anhydrous DMF (60 mL), and sodium azide (2.13 g, 32.76 mmol) was added to the solution while cooling the solution with ice and the mixture was further stirred for 40 minutes. After that, the mixture was returned to be at room temperature and further stirred for 16 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water, and dried with anhydrous magnesium sulfate. Then, the solvent was removed by distillation and yellow oily matter (AA20, 6.74 g, 99.5%) was obtained.
NMR: (CDCl3) 1.35-1.55 (m, 4H), 1.39 (t, 3H, J=7.2), 1.62-1.83 (m, 4H), 1.93-2.04 (m, 2H), 2.57-2.61 (m, 2H), 2.87-2.91 (m, 2H), 3.46 (t, 2H, J=6.3), 4.13-4.21 (m, 2H), 4.37 (q, 2H, J=7.2), 7.96 (s, 1H);
IR (chloroform): 2100, 1728, 1693, 1650, 1591, 1543, 1482, 1453, 1439, 1414, 1380, 1363, 1351, 1319
Example 21
Synthesis of ethyl 1-(3-methanesulfonylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA21)




Ethyl 1-(3-azidepropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA20, 3.25 g, 9.78 mmol), which had been obtained in Example 20, was dissolved in anhydrous THF (33 mL), and water (16 mL) and then triphenylphosphine (3.08 g, 11.73 mmol) were added and the mixture was refluxed for 1 hour and 30 minutes. The reaction mixture was acidified by adding diluted aqueous hydrochloric acid solution and then washed with ethyl ether. The water layer was removed by distillation, and a pale yellow solid was obtained. The solid was suspended in anhydrous THF (50 mL), and triethylamine (4.10 mL, 29.40 mmol) and methanesulfonyl chloride (1.67 mL, 21.58 mmol) were added while stirring and cooling the solution with ice, and the mixture was stirred for 50 minutes. After that, the mixture was returned to be at room temperature and further stirred for 2 hours. After the reaction mixture had been poured into diluted aqueous hydrochloric acid solution to acidify the mixture, the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium bicarbonate water, and then dried with anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was eluted and refined with silica gel (42 g) column chromatography (ethyl acetate, and then ethyl acetate-methanol (17:3) in order), and a pale yellow residue (1.90 g) was obtained. This residue was recrystallized with the use of ethyl acetate-hexane, and a colorless prism-like crystal (AA21, 1.69 g, 45%) was obtained. Mp: 138-139° C.
NMR: (CDCl3) 1.35-1.54 (m, 4H), 1.38 (s, 3H), 1.62-1.82 (m, 4H), 1.92-2.03 (m, 2H), 2.57-2.61 (m, 2H), 2.84-2.91 (m, 2H), 2.96 (s, 3H), 3.08-3.16 (m, 2H), 4.21-4.30 (m, 2H), 4.35 (q, 2H, J=7.2), 5.84 (brs, 1H), 7.93 (s, 1H);
IR (chloroform): 3235, 1727, 1695, 1646, 1589, 1543, 1481, 1453, 1440, 1411, 1363, 1328;
Elemental analysis (C18H28N2O5S)
Calculated (%): C, 56.23; H, 7.34; N, 7.29; S, 8.34
Analitical (%): C, 56.11; H, 7.28; N, 7.28; S, 8.07
Example 22
Synthesis of 1-(3-methanesulfonylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA22)




Ethyl 1-(3-methanesulfonylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate. (AA21, 1.66 g, 4.33 mmol), which had been obtained in Example 21, was dissolved in methanol (17 mL), and 4M sodium hydroxide aqueous solution (4.32 mL, 17.40 mmol) was added and the mixture was warmed at 50° C. for 5 hours. The reaction mixture was poured into water. After the water layer had been washed with ethyl ether, the layer was acidified with 2M aqueous hydrochloric acid solution and extracted with ethyl acetate. The organic layer was washed with water and then dried with anhydrous magnesium sulfate, and a colorless needle crystal (AA22, 1.52 g, 98%) was obtained.
Mp: 197-198° C.
NMR: (DMSO-d6) 1.28-1.49 (m, 4H), 1.55-1.67 (m, 2H), 1.69-1.92 (m, 4H), 2.68-2.76 (m, 2H), 2.92 (s, 3H), 2.97-3.14 (m, 4H), 4.14-4.24 (m, 2H), 7.16 (t, 1H, J=6.0), 8.21 (s, 1H), 14.90 (s, 1H);
IR (nujol): 3203, 2675, 1701, 1622, 1551, 1463, 1442, 1415, 1374, 1316;
Elemental analysis (C16H24N2O5S)
Calculated (%): C, 53.91; H, 6.79; N, 7.86; S, 9.00
Analitical (%): C, 53.87; H, 6.67; N, 7.89; S, 8.90
Example 23
Synthesis of ethyl 1-(3-acetylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA23)




Ethyl 1-(3-azidepropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA20, 1.73 g, 5.21 mmol), which had been obtained in Example 20, was dissolved in THF (17 mL), and water (8.5 mL) and then triphenylphosphine (1.64 g, 6.25 mmol) were added and the mixture was refluxed for 90 minutes. The reaction mixture was poured into water and washed with ethyl ether. The water layer was concentrated under reduced pressure and a yellow oily amine body (1.58 g) was obtained. This amine body was dissolved in anhydrous THF (15 mL), and pyridine (0.83 mL, 10.26 mmol) and methyl chlorocarbonate were added while stirring and cooling the solution with ice, and the mixture was stirred for 50 minutes. After that, the mixture was further stirred at room temperature for two hours and 20 minutes. After the reaction mixture had been poured into diluted aqueous hydrochloric acid solution to acidify the mixture, the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium bicarbonate water, and then dried with anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was eluted and refined with silica gel (66 g) column chromatography (ethyl acetate, and then ethyl acetate-methanol (4:1) in order), and a pale yellow solid (AA23, 643 mg) was obtained. This solid was recrystallized with ethyl acetate-hexane, and a pale yellow needle crystal (AA23, 568 mg, 30%) was obtained.
Mp: 103-104° C.
NMR: (CDCl3) 1.36-1.54 (m, 4H), 1.38 (t, 3H, J=7.2), 1.62-1.82 (m, 4H), 1.83-1.94 (m, 2H), 2.56-2.60 (m, 2H), 2.84-2.88 (m, 2H), 3.16-3.27 (m, 2H), 3.66 (s, 3H), 4.12-4.23 (m, 2H), 4.36 (q, 2H, J=7.2), 5.64 (brs, 1H), 7.93 (s, 1H).
Example 24
Synthesis of 1-(3-acetylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA24)




Ethyl 1-(3-acetylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA23, 560 mg, 1.54 mmol), which had been obtained in Example 23, was dissolved in methanol (6 mL), and 4M aqueous sodium hydroxide solution (1.15 mL, 4.63 mmol) was added and the mixture was stirred at room temperature for one hour and 50 minutes. The reaction mixture was poured into water and washed with ethyl ether. The water layer was acidified with 2M aqueous hydrochloric acid solution and extracted with ethyl acetate. After the organic layer had been washed with water and dried with anhydrous magnesium sulfate, the solvent was removed by distillation and colorless oily matter (AA24, 544 mg) was obtained. This oily matter was recrystallized with the use of ethyl acetate-hexane, and a colorless needle crystal (AA24, 502 mg, 97%) was obtained.
Mp: 148-149° C.
NMR: (CDCl3) 1.35-1.56 (m, 4H), 1.60-1.86 (m, 4H), 1.88-2.01 (m, 2H), 2.65-2.69 (m, 2H), 2.93-2.97 (m, 2H), 3.24 (q, 2H, J=6.3), 3.69 (s, 3H), 4.20-4.30 (m, 2H), 5.44 (brs, 1H), 8.30 (s, 1H), 14.54 (s, 1H);
IR (chloroform): 3451, 2693, 1721, 1626, 1567, 1544, 1513, 1464, 1412, 1381, 1364, 1333, 1316;
Elemental analysis (C17H24N2O5)
Calculated (%): C, 60.70; H, 7.19; N, 8.33
Analitical (%): C, 60.52; H, 7.11; N, 8.32
The following 3-pyridone carboxylic acids (AA25 to AA41) were synthesized by the use of a similar method to the above-mentioned one. The structural formulas and the data of NMR were described in Table 1 to 3.









TABLE 1





Comp.




No.
Structure
1H-NMR(DMSO-d6/TMS) δ







AA25




1.00-1.30(m, 5H), 1.22(t, 3H, J = 7.5), 1.55- 1.90(m, 6H), 2.24(s, 3H), 2.82(q, 2H, J = 7.2), 3.90-4.20(m, 2H), 8.29(s, 1H)


 


AA26




1.00(t, 3H, J = 7.5), 1.35-1.55(m, 6H), 1.60- 1.86(m, 6H), 2.63-2.71(m, 2H), 2.90-2.99(m, 2H), 3.99-4.21(m, 2H), 8.27(s, 1H), 14.78(br s, 1H)


 


AA27




1.10(t, 3H, J = 7.5), 1.20-1.28(m, 4H), 1.52- 1.64(m, 2H), 2.51-2.59(q, 2H, J = 7.5), 2.84- 2.90(m, 2H), 3.30(s, 3H), 3.72(t, 2H, J = 5.1), 4.36(t, 2H, J = 5.1), 8.36(s, 1H)


 


AA28




1.32-1.54(m, 4H), 1.66(m, 4H), 2.67(t, 2H, J = 6.0), 3.11(t, 2H, J = 6.0), 3.30(s, 3H), 3.72(t, 2H, J = 5.4), 4.40(t, 2H, J = 5.4), 8.30(s, 1H), 14.64(br, 1H)


 


AA29




1.35-1.90(m, 8H), 1.90-2.10(m, 2H), 2.15- 2.40(m, 2H), 2.60-2.75(m, 2H), 2.85-3.00(m, 2H), 4.15-4.30(m, 2H), 8.30(s, 1H)


 


AA30




1.02(d, 6H, J = 6.6), 1.40-1.85(m, 12H), 2.67 (m, 2H), 2.93(m, 2H), 4.16(m, 2H), 8.27(s, 1H)


 


AA31




0.98(d, 6H, J = 6.6), 1.39(t, 3H, J = 6.3), 1.43- 1.80(m, 11H), 2.58(m, 2H), 2.85(m, 2H), 4.09(m, 2H), 4.37(d, 2H, J = 6.6), 7.93(s, 1H)


















TABLE 2





Comp.




No.
Structure
1H-NMR(DMSO-d0/TMS) δ







AA32




1.02(d, 6H, J = 6.6), 1.28(t, 3H, J = 7.5), 1.56- 1.66(m, 2H), 1.78(m, 1H), 2.23(s, 3H), 2.79(q, 2H, J = 7.5), 4.10-4.21(m, 2H), 8.28(s, 1H)


 


AA33




0.99(d, 6H, J = 6.6), 1.22(t, 3H, J = 7.5), 1.38(t, 3H, J = 7.5), 1.54-1.79(m, 3H), 2.14(s, 3H), 2.70(q, 2H, J = 7.5), 4.09(m, 2H), 4.36(q, 2H, J = 7.5), 4.36(d, 2H, J = 7.5), 7.95(s, 1H)


 


AA34




CDCl3 1.21(t, 3H, J = 7.7), 2.25(s, 3H), 2.73(q, 2H, J = 7.4), 5.42(br s, 2H), 6.86(m, 1H), 6.96(ddd, 1H, J = 10.8, 7.4 and 2.3), 7.15(dt, 1H, J = 9.9 and 8.3), 8.39(s, 1H), 14.31(br s, 1H)


 


AA35




1.37-1.55(m, 4H), 1.65-1.80(m, 4H), 2.64- 2.72(m, 2H), 2.82-2.91(m, 2H), 5.42(s, 2H), 6.85(m, 1H), 6.95(m, 1H), 7.15(m, 1H), 8.38(s, 1H), 14.34(br s, 1H)


 


AA36




1.39(t, 3H, J = 7.2), 1.35-1.54(m, 4H), 1.63- 1.75(m, 4H), 2.55-2.65(m, 2H), 2.73-2.82(m, 2H), 4.37(q, 2H, J = 7.2), 5.35(s, 2H), 6.86(m, 1H), 6.95(m, 1H), 7.09(m, 1H), 8.03(s, 1H)


 


AA37




CDCl3 1.21(t, 3H, J = 7.7), 2.25(s, 3H), 2.72(q, 2H, J = 7.6), 5.46(br s, 2H), 6.81-6.96(m, 3H), 8.39(s, 1H), 14.35(br s, 1H)


 


AA38




1.36-1.55(m, 4H), 1.66-1.81(m, 4H), 2.64- 2.72(m, 2H), 2.82-2.89(m, 2H), 5.46(s, 2H), 6.79-6.96(m, 3H), 8.38(s, 1H), 14.38(br s, 1H)


















TABLE 3





Comp.




No.
Structure
1H-NMR(DMSO-d6/TMS) δ







AA39




1.39(t, 3H, J = 7.2), 1.35-1.53(m, 4H), 1.63- 1.75(m, 4H), 2.56-2.63(m, 2H), 2.71-2.80(m, 2H), 4.38(q, 2H, J = 7.2), 5.40(s, 2H), 6.72- 6.87(m, 2H), 6.95(m, 1H), 8.02(s, 1H)


 


AA40




DMSO-d6 1.05(t, 3H, J = 7.5), 2.24(s, 3H), 2.75(q, 2H, J = 7.5), 5.48(s, 2H), 7.15-7.25(m, 4H), 8.32(s, 1H), 14.68(s, 1H)


 


AA41




CDCl3 1.20(t, 3H, J = 7.7), 2.24(s, 3H), 2.72(q, 2H, J = 7.7), 5.44(br s, 2H), 7.05(d, 2H, J = 8.7), 7.33(d, 2H, J = 8.4), 8.38(s, 1H), 14.39(br s, 1H)









As amine derivatives, those obtained from the market or synthesized by the following synthesis methods were used.
Example 25
Synthesis of N-α-(2-benzo[b]thienyl)glycine methyl ester hydrochloride (BB01)




According to the method described in Tetrahedron, Vol. 53, No. 48, pp. 16463-16470, 1997, N-α-(2-benzo[b]thienyl)glycine hydrochloride (2.694 g, 9.17 mmol) was suspended in methanol (27 mL), and thionyl chloride (2.02 mL, 27.69 mmol) was dropped in 5 minutes while stirring and cooling the suspension with ice. After that, the mixture was stirred at room temperature for 63 hours. The solvent was removed by distillation under reduced pressure, and the residue was washed with acetone and a colorless crystal (BB01, 2.546 g, 89%) was obtained.
Mp: 196-198° C.
NMR: (DMSO-d6) 3.78 (s, 3H), 5.79 (s, 1H), 7.38-7.46 (m, 2H), 7.68 (s, 1H), 7.92 (m, 1H), 8.01 (m, 1H), 9.36 (brs, 3H).
Example 26
Synthesis of N-α-(4-biphenyl)glycine methyl ester hydrochloride (BB02)




According to the method described in Tetrahedron, Vol, 53, No. 48, pp. 16463-16470, 1997, N-α-(4-biphenyl)glycine hydrochloride (2.148 g, 9.17 mmol) was suspended in methanol (24 mL), and thionyl chloride (1.67 mL, 22.90 mmol) was dropped in 5 minutes while cooling the suspension with ice. After that, the mixture was stirred at room temperature for 20 hours, and a colorless crystal (BB02, 1.760 g, 69%) was obtained.
Mp: 224-225° C.
NMR: (DMSO-d6) 3.74 (s, 3H), 5.35 (s, 1H), 7.40 (m, 1H), 7.46-7.61 (m, 2H), 7.58-7.61 (m, 2H), 7.68-7.71 (m, 2H), 7.75-7.78 (m, 2H), 9.08 (brs, 3H).
Example 27
Synthesis of ethyl 4-amino-3-trifluoromethyl-phenoxy-acetate (BB03)




1) Synthesis of ethyl 4-nitro-3-trifluoromethyl-phenoxy-acetate
Ethyl bromoacetate (1.2 g, 10.9 mmol) was added in the suspension of 4-nitro-3-trifluoromethyl phenol (2.0 g, 9.66 mmol) and potassium carbonate (2.0 g, 14.5 mmol) in acetone, and the mixture was attired at room temperature for 6 hours. After the reaction mixture had been poured in ice water and acidified with 2N hydrochloric acid, the mixture was extracted with ethyl acetate. The organic layer was washed with 5% sodium hydrogencarbonate aqueous solution and then with water, and dried with anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and 4-nitro-3-trifluoromethyl-phenoxyethyl acetate (3.24 g (theoretical amount: 2.83 g), 100%) was obtained as a yellow solid and was used in the next reaction without purification.
NMR: (CDCl3) 1.32 (t, 3H, J=7.2), 4.30 (q, 2H, J=7.2), 4.75 (s, 2H), 7.10 (dd, 1H, J=2.7, 9.0), 7.33 (d, 1H, J=2.4), 8.01 (d, 1H, 9.0).
2) Synthesis of ethyl 4-amino-3-trifluoromethyl-phenoxy-acetate
In the ethyl acetate (30 mL) solution of 4-nitro-3-trifluoromethyl-phenoxyethyl acetate (3.24 g (theoretical amount: 2.83 g, 9.66 mmol) which had been obtained in 1), 10% palladium carbon (0.3 g) was added and hydrogen was added. After the catalyst had been separated by filtration, the solvent was removed by distillation under reduced pressure and crude 4-amino-3-trifluoromethyl-phenoxyethyl acetate (BB03, 3.08 g (theoretical amount: 2.54 g) 100%) was obtained as oily matter.
NMR: (CDCl3) 1.30 (t, 3H, J=7.2), 4.27 (q, 2H, J=7.2), 4.56 (s, 2H), 6.76 (d, 1H, J=8.7), 6.96 (dd, 1H, J=3.0, 9.0), 7.01 (d, 1H, J=2.7).
Experimental Example 28
Synthesis of methyl 4-amino-tetrahydro-pyran-4-carboxylate monohydrochloride (BB04)




Thionyl chloride (4.02 mL, 55.1 mmol) was added in the dehydrated methanol (100 mL) solution of 4-amino-4-carboxytetrahydro-pyran monohydrochloride (5.00 g, 27.5 mmol) in an ice bath, and the mixture was heated and refluxed for 2.5 hours. The solvent was removed by distillation under reduced pressure, and the obtained crude product was washed with ethyl acetate and then dried under reduced pressure to give a colorless solid (BB04, 5.06 g).
NMR: (DMSO) 1.84-1.93 (m, 2H), 2.02-2.09 (m, 2H), 3.57-3.69 (m, 2H), 3.79 (s, 3H), 3.80-3.88 (m, 2H), 8.89 (brs, 3H).
Experimental Example 29
Synthesis of ethyl 3-(4-amino-tetrahydro-pyran-4-yl)-propionate monohydrochloride (BB05)




1) Synthesis of ethyl 4-t-butoxycarbonylamino-tetrahydro-pyran-4-carboxylate
Triethylamine (5.41 mL, 38.8 mM) and di-t-butyl dicarbonate (7.13 mL, 31.0 mmol) were dropped in order in the dehydrated 1,4-dioxane (50 mL) solution of methyl 4-amino-tetrahydro-pyran-4-carboxylate monohydrochloride (5.06 g, 25.8 mmol) in an ice bath. After the reaction mixture had been stirred at room temperature for 6 hours, di-t-butyl dicarbonate (2.97 mL, 12.9 mmol) was added in the reaction mixture in the ice bath and the mixture was further stirred at room temperature for a night. After the reaction mixture had been poured into 2N hydrochloric acid aqueous solution (12 mL), the mixture was extracted with ethyl acetate. The organic layer was washed with water, saturated aqueous sodium hydrogencarbonate solution, and saturated saline in order, and then dried with anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was refined with silica gel column chromatography (the ethyl acetate-hexane solution of 3:7 to 1:0 in mixing ratio) to give colorless oily matter (5.24 g).
NMR: (CDCl3) 1.44 (s, 9H), 1.86-1.90 (m, 2H), 2.14-2.24 (m, 2H), 3.64-3.72 (m, 2H), 3.75 (s, 3H), 3.78-3.84 (m, 2H), 4.78 (brs, 1H).
2) Synthesis of t-butyl (4-formyl-tetrahydro-pyran-4-yl)-carbamate
The toluene solution of diisobutylaluminum hydride (72.3 mL, 73.0 mmol) was dropped in the dehydrated toluene (50 mL) solution of methyl 4-t-butoxycarbonylamino-tetrahydro-pyran-4-carboxylate (4.74 g, 18.3 mmol) which had been obtained in 1) at −78° C. for 1 hour. After the reaction mixture had been stirred at the same temperature for 20 minutes, saturated aqueous ammonium chloride solution (20 mL) was dropped in 10 minutes and the mixture was stirred at room temperature for 15 minutes. Then, methanol (3 mL) was added and the mixture was further stirred at room temperature for 20 minutes. The precipitated insoluble matter was removed by filtration with Celite, and the filtrate was extracted with ethyl acetate. The organic layer was washed with water and saturated saline in order, and then dried with anhydrous magnesium sulfate. The crude product was refined with silica gel column chromatography (the ethyl acetate-hexane solution of 3:7 to 1:0 in mixing ratio) to give the desired product of colorless oily matter (2.00 g) and N-t-butyl-(4-hydroxymethyl-tetrahydro-pyran-4-yl)-carbamate (1.32 g).
NMR: (CDCl3) 1.45 (s, 9H), 1.70-1.75 (m, 2H), 1.99-2.08 (m, 2H), 3.64-3.72 (m, 2H), 3.78-3.87 (m, 2H), 4.88 (brs, 1H), 9.48 (s, 1H).
3) Synthesis of ethyl 3-(4-t-butoxycarbonylamino-tetrahydro-pyran-4-yl)-acrylate
In the dehydrated THF (50 mL) solution of N-t-butyl-(4-formyl-tetrahydro-pyran-4-yl)-carbamate (2.0 g, 8.7 mmol) which had been obtained in 2), (carboethoxymethylene)triphenylphosphorane (3.19 g, 9.2 mmol) was added at room temperature. The reaction mixture was heated and refluxed Under the nitrogen gas atmosphere for 6.5 hours, and (carboethoxymethylene)triphenylphosphorane (3.19 g, 9.2 mmol) was added and the reaction mixture was further heated and refluxed for 17 hours. After the solvent was removed by distillation under reduced pressure, the residue was refined with silica gel column chromatography (the ethyl acetate-hexane solution of 3:7 to 1:0 in mixing ratio) to give colorless oily matter (2.71 g).
NMR: (CDCl3) 1.29 (t, 3H, J=7.2 Hz), 1.44 (s, 9H), 1.82-1.91 (m, 2H), 1.97-2.01 (m, 2H), 3.65-3.83 (m, 4H), 4.20 (q, 2H, J=7.2 Hz), 4.57 (s, 1H), 5.89 (d, 1H, J=15.9 Hz), 6.94 (d, 1H, J=15.9 Hz).
4) Synthesis of ethyl 3-(4-t-butoxycarbonylamino-tetrahydro-pyran-4-yl)-propionate
In the ethyl acetate (30 mL) and methanol (12 mL) mixed solution of ethyl 3-(4-t-butoxycarbonylamino-tetrahydro-pyran-4-yl)-acrylate which had been obtained in 3), 5% palladium carbon catalyst was added at room temperature. The reaction mixture was stirred under the hydrogen gas stream at room temperature for 75 minutes. The palladium catalyst was removed by filtration with Celite, and the filtrate was concentrated and dried up to give colorless oily matter (2.69 g).
NMR: (CDCl3) 1.26 (t, 3H, J=7.2 Hz), 1.44 (s, 9H), 1.61-1.67 (m, 2H), 1.91-1.95 (m, 2H), 2.05-2.11 (m, 2H), 2.28-2.33 (m, 2H), 3.57-3.79 (m, 4H), 4.13 (q, 2H, J=7.2 Hz), 4.29 (brs, 1H).
5) Synthesis of ethyl 3-(4-amino-tetrahydro-pyran-4-yl)-propionate monohydrochloride (BB05)
4N hydrochloric acid-ethyl acetate solution (12.9 mL, 51.6 mmol) was added in a ethyl acetate (40 mL) solution of ethyl 3-(4-t-butoxycarbonylamino-tetrahydro-pyran-4-yl)-propionate (2.59 g, 8.6 mmol), which had been obtained in 4), in an ice bath. The reaction mixture was stirred at room temperature for 4 hours, and 4N hydrochloric acid-ethyl acetate solution (4.3 mL, 17.2 mmol) was added and the reaction mixture was further stirred at room temperature for 1 hour. The formed solid was filtered to give a colorless solid (BB05, 1.28 g).
NMR: (DMSO) 1.20 (t, 3H, J=7.2 Hz), 1.67-1.69 (m, 4H), 1.96-2.02 (m, 2H), 2.44-2.47 (m, 2H), 3.49-3.57 (m, 2H), 3.69-3.76 (m, 2H), 4.08 (q, 2H, J=7.2 Hz), 8.16 (brs, 3H).
Experimental Example 30
Synthesis of methyl 1-amino-4,4-dimethyl-cyclohexanecarboxylate monohydrochloride (BB06)




1) Synthesis of 1,1-dimethyl-4-methylene-cyclohexane
Methyltriphenylphosphonium bromide (2.97 g, 8.3 mmol) was added in the dehydrated DMSO (8 mL) solution of sodium hydride (0.35 g, 8.7 mmol) in an ice bath. The reaction mixture was stirred at room temperature for 10 minutes, and the dehydrated DMSO solution (1.5 mL) of 4,4-dimethyl-cyclohexanone (1.0 g, 7.9 mmol) was added slowly in an ice bath. The reaction mixture was stirred at room temperature for 18 hours and poured into ice water. The organic layer was extracted with diethyl ether, and then the layer was washed with water and dried with anhydrous magnesium sulfate, and removed by filtration. The filtrate was concentrated until becoming about half in volume. The formed insoluble matter was removed by filtration, then the filtrate was removed by distillation under reduced pressure, and colorless oily matter (0.91 g) was obtained.
NMR: (CDCl3) 0.94 (s, 6H), 1.35 (t, 4H, J=6.6 Hz), 2.15 (t, 4H, J=6.9 Hz), 4.58 (s, 2H).
2) Synthesis of 7,7-dimethyl-1-aza-spiro[3.5]nonan-2-one
Chlorosulfonyl isocyanoic acid (0.67 mL, 7.7 mmol) was dropped into the dehydrated diethyl ether (11 mL) solution of 1,1-dimethyl-4-methylene-cyclohexane (0.91 g, 7.4 mmol), which had been obtained in 1), in an ice bath. The reaction mixture was stirred at room temperature for 1 hour, and chlorosulfonyl isocyanoic acid (0.67 mL, 7.7 mmol) was added in the reaction requid in the ice bath and further stirred at room temperature for 1e hour. After chlorosulfonyl isocyanoic acid (0.32 mL, 3.7 mmol) had been added in the reaction mixture in the ice bath and further stirred at room temperature for 2 hours, the aqueous solution (4.5 mL) containing sodium thiosulfate pentahydrate (4.56 g, 18.4 mmol) and 10% potassium hydroxide solution was added alternately in the reaction mixture in the ice bath and the pH was adjusted to be about 10, and then the reaction mixture was stirred for 2 hours. The insoluble matter was removed by filtration, and the filtrate was extracted with chloroform. Then the organic layer was washed with water and dried with anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure and a colorless solid (0.75 g) was obtained.
NMR: (DMSO) 0.89 (s, 6H), 1.18-1.38 (m, 4H), 1.55-1.61 (m, 4H), 2.50-2.52 (m, 2H), 8.19 (brs, 1H)
3) Synthesis of methyl 1-amino-4,4-dimethyl-cyclohexanecarboxylate monohydrochloride
Concentrated hydrochloric acid (0.55 mL) was added in the methanol (14 mL) solution of 7,7-dimethyl-1-aza-spiro[3.5]nonan-2-one (0.75 g, 4.5 mmol) which had been obtained in 2) at room temperature. After the reaction mixture had been heated and refluxed for 9 hours, the solvent was removed by distillation under reduced pressure and a colorless solid (BB06, 1.05 g) was obtained.
NMR: (DMSO) 0.89 (s, 3H), 0.91 (s, 3H), 1.24-1.40 (m, 6H), 1.65-1.73 (m, 2H), 2.75 (s, 2H), 3.66 (s, 3H), 8.07 (brs, 3H).
Example 31
Synthesis' of methyl 1-amino-4,4-difluorocyclohexanecarboxylate (BB07) and methyl 1-amino-4-fluoro-3-cyclohexenecarboxylate (BB08)




1) Synthesis' of methyl 1-tert-butoxycarbonylamino-4,4-difluorocyclohexanecarboxylate
Methyl 1-tert-butoxycarbonylamino-4-oxocyclohexanecarboxylate (1.24 g, 4.39 mmol) was dissolved in dichloromethane (13 mL), and DAST ((dimethylamino)sulfur trifluoride) (7.0 mL, 52.65 mmol) was added slowly and then the mixture was stirred at room temperature for 2 days. The reaction mixture was dropped slowly into ice water (80 mL) while stirring, and then the mixture was stirred at 0° C. for 1 hour. Dichloromethane (110 mL) was added, the organic layer was washed with water, and the water layer was extracted with dichloromethane (100 mL). The united organic layer was dried with sodium sulfate and then removed by distillation under reduced pressure. The organic layer was refined with silica gel column chromatography to give a mixture containing the desired matter (556 mg).
1H NMR: (DMSO-d6): 1.36 (s, 9H), 1.8-2.1 (m, 8H), 3.59 (s, 3H), 7.4 (brs, 1H).
19F NMR: (DMSO-d6): −99.9 (d, 1F, J=229), −91.4 (d, 1F, J=236).
2) Synthesis of methyl 1-amino-4,4-difluorocyclohexanecarboxylate (BB07) and methyl 1-amino-4-fluoro-3-cyclohexenecarboxylate (BB08)
Methyl 1-tert-butoxycarbonylamino-4,4-difluorocyclohexanecarboxylate which had been obtained in 1) was dissolved in methanol (2.5 mL), and 10% hydrochloric acid-methanol (3.38 g, 9.27 mmol) was added and the mixture was stirred for 3 days. The reaction mixture was removed by distillation. The proper quantity of diethyl ether was added in the reaction mixture to crystallize it, and the crystal (421 mg) was isolated. The crystal was dissolved in chloroform, and the solution was alkalinized by adding saturated sodium hydrogencarbonate aqueous solution and then extracted with chloroform (30 mL×2). The organic layer was removed by distillation under reduced pressure and refined with silica gel column chromatography to give methyl 1-amino-4,4-difluorocyclohexanecarboxylate (BB07, 191 mg) and methyl 1-amino-4-fluoro-3-cyclohexenecarboxylate (BB08, 55 mg).
methyl 1-amino-4,4-difluorocyclohexanecarboxylate (BB07)
1H NMR: (CDCl3): 1.69-2.29 (m, 10H), 3.74 (s, 3H).
methyl 1-amino-4-fluoro-3-cyclohexenecarboxylate (BB08)
1H NMR: (CDCl3): 1.8-2.7 (m, 6H), 1.97 (brs, 2H), 3.75 (s, 3H), 5.1-5.2 (m, 1H).
Experimental Example 32
Synthesis of methyl 1-amino-4-fluoro-cyclohexanecarboxylate (BB09)




Methyl 1-amino-4-fluoro-3-cyclohexenecarboxylate (52 mg) was dissolved in the mixed solvents of methanol (2 mL) and ethyl acetate (2 mL), and 10% palladium-carbon (35 mg) was added and hydrogen gas was introduced for 14 hours. The insoluble matter was filtered and the solvent was removed by distillation under reduced pressure, and a mixture of the desired matter (BB09, 38 mg) was obtained.
1H NMR: (CDCl3): 1.4-2.3 (m, 10H), 3.72 (s, 3H), 4.6-4.9 (m, 1H).
Experimental Example 33
Synthesis of methyl 1-amino-4,4-difluorocyclohexanecarbozylate monohydrochloride (BB10)




1) Synthesis of methyl 1-benzyloxycarbonylamino-4,4-difluorocyclohexanecarboxylate
Methyl 1-benzyloxycarbonylamino-4-oxocyclohexanecarbonate (1.03 g, 3.37 mmol) was dissolved in dichloromethane (10 mL), and DAST ((dimethylamino)sulfur trifluoride) (4.45 mL, 33.67 mmol) was added slowly in the solution at room temperature, then the mixture was stirred at room temperature for 25 hours. The reaction mixture was dropped slowly into ice water (40 mL) while stirring and the mixture was stirred at 0° C. for 15 minutes. Then, dichloromethane (30 mL) was added, and the organic layer was washed with water (25 mL×2) and the water layer was extracted with dichloromethane (30 mL). The united organic layer was dried with sodium sulfate and then removed by distillation under reduced pressure. The organic layer was refined with silica gel column chromatography to give a mixture containing the desired compound (718 mg).
1H NMR: (CDCl3): 1.8-2.7 (m, 8H), 3.70 (brs, 3H), 4.97-5.16 (m, 3H), 7.29-7.39 (m, 5H).
2) Synthesis of methyl 1-amino-4,4-difluorocyclohexanecarboxylate hydrochloride
Methyl 1-benzyloxycarbonylamino-4,4-difluorocyclohexanecarboxylate which had been obtained in 1) was dissolved in the mixed solvents of ethyl acetate (50 mL) and methanol (25 mL), and 4N hydrochloric acid-ethyl acetate (1.03 mL) was added. Here, 10% palladium-carbon (120 mg) was added and hydrogen gas (4.5 to 5 in atmospheric pressure) was introduced, and the mixture was stirred at room temperature for 2 days. After the insoluble matter had been removed by filtration, the filtrate was removed by distillation under reduced pressure and a crystal containing the desired compound (BB10, 467 mg) was obtained.
1H NMR: (DMSO-d6): 1.8-2.3 (m, 8H), 3.79 (s, 3H), 8.92 (brs, 3H). NMR (DMSO-d6): −97.3 (d, 1F, J=235), −95.3 (d, 1F, J=235).
Example 34
Synthesis of ethyl 2-amino-4-fluoro-4-methyl-valerate (BB11)




Ethyl 2-(benzhydridene-amino)-4-fluoro-4-methyl-valerate (apparently 6.0 g) was dissolved in ethanol (60 mL), and 10% palladium-carbon (2.0 g) was added and hydrogen gas was introduced at room temperature, then the mixture was stirred for 14 hours. After the insoluble matter had been filtered, the solvent was removed by distillation under reduced pressure, methyl-tert-butyl ether (40 mL) and sulfuric acid (1.53 g) dissolved in water (40 mL) were added in the residue while cooling it with ice, and the mixture was stirred for 10 minutes. The organic layer was removed, and the water layer was washed with methyl-tert-butyl ether (30 mL×2). After potassium carbonate (4.14 g, 30.0 mmol) was added in the water layer while cooling it with ice and its pH was made to be 10, the water layer was extracted with the mixture of isopropyl acetate and dichloromethane of 4:1 in mixing ratio (40 mL×4). After the organic layer was dried with magnesium sulfate, the solvent was removed by distillation under reduced pressure and an oily mixture of the desired matter (BB11, 1.08 g) was obtained.
1H NMR: (CDCl3) 1.27 (t, 3H, J=6.9), 1.40 (d, 3H, J=3.0), 1.47 (d, 3H, J=3.0), 1.86 (brs, 2H), 1.8-2.2 (m, 2H), 3.69 (dd, 1H, J=5.1, 7.8), 4.19 (q, 2H, J=7.2).
Example 35
Synthesis of ethyl 4-amino-6-fluoro-6-methyl-valerate hydrochloride (BB12)




1) Synthesis of ethyl 2-benzyloxycarbonylamino-4-fluoro-4-methyl-valerate
2-amino-4-fluoro-4-methyl-ethyl valerate (apparently 0.60 g) was dissolved in tetrahydrofuran (8 mL), and pyridine (0.6 mL, 7.45 mmol) was added. Z-chloride (0.53 mL, 3.72 mM) was further added while cooling with ice, and the mixture was stirred at room temperature for 4.5 hours. Cold water (8 mL) was added in the mixture while cooling it with ice and the pH was adjusted to be 2 by adding 2N aqueous hydrochloric acid solution. The mixture was extracted with ethyl acetate (50 mL×2), and the organic layer was washed using in the order of water (15 mL), saturated aqueous sodium hydrogencarbonate solution (15 mL), and water (15 mL). The organic layer was dried with sodium sulfate and then separated by distillation under reduced pressure and refined with silica gel column chromatography. After that, the eluted solvent was removed by distillation under reduced pressure and the desired oily compound (730 mg) was obtained.
1H NMR: (CDCl3): 1.27 (t, 3H, J=7.2), 1.42 (d, 6H, J=21.6), 1.95-2.22 (m, 2H), 4.20 (q, 2H, J=6.6), 4.47 (dt, 1H, J=4.8, 12.6), 5.12 (s, 2H), 5.42 (d, 1H, J=5.7), 7.3-7.4 (m, 5H).
2) Synthesis of ethyl(E)-4-benzyloxycarbonylamino-6-fluoro-6-methyl-2-valerate
Ethyl 2-benzyloxycarbonylamino-4-fluoro-4-methyl-valerate (1.16 g, 3.73 mmol) which had been obtained in 1) was dissolved in toluene (15.8 mL), and 1.01 M diisobutylaluminumhydride-toluene solution (7.38 mL) was dropped into the solution at −78° C. At the same temperature, the solution was stirred for 1 hour, and saturated aqueous ammonium chloride solution (3 mL) and methanol (1 mL) were dropped into. The temperature of the reaction mixture was raised to room temperature, and water was added and then the reaction mixture was extracted with ethyl acetate (100 mL×2). The organic layer was washed with water (30 mL) and saturated saline (50 mL). The organic layer was dried with sodium sulfate and then removed by distillation under reduced pressure to give an oily mixture (1.15 g). To the oily mixture, tetrahydrofuran (13.8 mL) was added and carbetoxymethylenetriphenylphosphorane (1.04 g, 2.98 mmol) was added, and the mixture was heated and refluxed for two hours. The solvent was removed by distillation under reduced pressure, the residual mixture was refined with silica gel column chromatography, and then the eluted solvent was removed by distillation under reduced pressure and the desired oily compound (599 mg) was obtained.
1H NMR: (CDCl3) 1.29 (t, 3H, J=6.9), 1.41 (d, 6H, J=21.3), 1.8-2.0 (m, 2H), 4.19 (q, 2H, J=7.2), 4.57 (br, 1H), 5.11 (s, 2H), 5.95 (d, 1H, J=15.6), 6.87 (dd, 1H, J=5.1, 15.6), 7.3-7.4 (m, 5H).
3) Synthesis of ethyl 4-amino-6-fluoro-6-methyl-valerate hydrochloride (BB12)
Ethyl(E)-4-benzyloxycarbonylamino-6-fluoro-6-methyl-2-valerate (590 mg, 1.75 mmol) which had been obtained in 2) was dissolved in ethyl acetate (7.1 mL), and 4 N hydrochloric acid-ethyl acetate (0.87 ml, 3.50 mL) and ethanol (3.5 mL) were added. Further, 10% palladium-carbon (100 mg) was added and hydrogen gas was introduced for 3 hours. After the insoluble matter had been filtered, the solvents were removed by distillation under reduced pressure and the desired crystal (BB12, 454 mg) was obtained.
1H NMR (DMSO-d6): 1.19 (t, 3H, J=6.9), 1.37 (d, 6H, J=21.6), 1.8-2.0 (m, 4H), 2.5-3.3 (m, 3H), 4.07 (q, 2H, J=7.2), 7.97 (brs, 3H).
Example 36
Synthesis of (1-amino-cyclohexylmethoxy)-acetic acid hydrochloride (BB13)




1) Synthesis of (1-nitro-cyclohexyl)-methanol
A ethanol (5 mL) solution of nitrocyclohexane (5.00 g, 38.7 mmol) and sodium hydroxide (12.5 g, 0.3 mmol) was heated to 55° C., 35% formalin solution (3.0 mL, 35 mmol) was added, and the mixture was heated and stirred at the same temperature for 1.5 hours. The reaction mixture was diluted with water, 2M hydrochloric acid (0.5 mL, 1 mmol) was added, and the mixture was extracted with ethyl acetate (15 mL) two times. The organic layer was washed with 5% sodium bicarbonate aqueous solution (10 mL) and water (20 mL), and then dried with anhydrous sodium sulfate. The solvents were removed by distillation under reduced pressure, the residue was refined with silica gel column chromatography (Highflash 3L, manufactured by Yamazen Corporation, the mixture of hexane and ethyl acetate of 3:1 in mixing ratio), and colorless oily (1-nitro-cyclohexyl)-methanol (6.96 g) was obtained.
NMR: (d6-DMSO) 1.20-1.72 (m, 8H), 2.17-2.25 (m, 2H), 3.65 (d, 2H, J=4.5), 5.33 (t, 2H, J=5.1).
2) Synthesis of ethyl (1-nitro-cyclohexylmethoxy)-acetate
Under the nitrogen gas atmosphere, NaH (2.32 g, 58 mmol) was added in the DMF (70 mL) solution of (1-nitro-cyclohexyl)-methanol (6.96 g, 35 mmol) which had been obtained in 1) while cooling the solution with ice, and the mixture was stirred for 20 minutes while making the temperature rise naturally. Bromoethyl acetate (9.96 g, 58.0 mmol) was dropped, and the mixture was stirred at room temperature over-night. The reaction mixture was diluted with water (200 mL), 2M hydrochloric acid (20 mL, 40 mmol) was added, and the mixture was extracted with ethyl acetate (50 mL) two times. The organic layer was washed with 5% sodium bicarbonate aqueous solution (20 mL) and water (50 mL), and then dried with anhydrous sodium sulfate. The solvents were removed by distillation under reduced pressure, the residue was refined with silica gel column chromatography (Highflash 4L, manufactured by Yamazen Corporation, the mixture of hexane and ethyl acetate of 5:1 in mixing ratio), and pale yellow oily ethyl (1-nitro-cyclohexylmethoxy)-acetate (5.47 g, 57%) was obtained.
NMR: (d6-DMSO) 1.19 (t, 3H, J=7.2), 1.30-1.65 (m, 6H), 1.80 (m, 2H), 2.20 (dd, 2H, J=14.4 and 5.7), 3.83 (s, 2H), 4.11 (q, 2H, J=7.2), 4.11 (s, 2H).
3) Synthesis of 4-oxa-1-aza-spiro[5.5]-undecan-2-one
Under the nitrogen gas atmosphere, ammonium formate (5.75 g, 91.1 mmol) and 10% Pd-carbon (4.5 mg) was added in the methanol (90 mL) solution of (1-nitro-cyclohexylmethoxy)-ethyl acetate (4.5 g, 18.2 mmol) which had been obtained in 2), and the mixture was heated and stirred at 50° C. over-night. After that, the mixture was filtered with Celite, the filtrate was concentrated under reduced pressure, the residue was refined with silica gel column chromatography (Highflash 3L, manufactured by Yamazen Corporation, and the mixtures of hexane and ethyl acetate of 5:1, 1:1, and 1:2 in mixing ratio), and an orange-colored crystal of 4-oxa-1-aza-spiro[5.5]-undecan-2-one (1.67 g, 54%) was obtained.
NMR: (d6-DMSO) 1.20-1.50 (m, 6H), 1.58 (d, 4H, J=9.9), 3.57 (s, 2H), 3.92 (s, 2H), 8.04 (s, 1H).
4) Synthesis of (1-amino-cyclohexylmethoxy)-acetic acid hydrochloride
In 4-oxa-1-aza-spiro[5.5]-undecan-2-one (1.67 g, 9.9 mmol) which had been obtained in 3), 6N hydrochloric acid (30 mL, 180 mmol) was added, and the mixture was heated and stirred at 100° C. for 1.5 hours. The solvent was removed by distillation under reduced pressure, toluene (100 mL) was added in the remainder, and the azeotropic dehydration operation was conducted two times under reduced pressure to give a pale yellow crystal. Further toluene (50 ml) was added to the crystal and the azeotropic dehydration operation was conducted, and then washing the crystal with ether, the white crystal of (1-amino-cyclohexylmethoxy)-acetic acid hydrochloride (BB13, 1.91 g, 87%) was obtained.
NMR: (d6-DMSO) 1.20-1.80 (m, 10H), 3.61 (s, 2H), 4.12 (s, 2H), 7.96 (s, 3H), 12.77 (br s, 1H).
Example 37
Synthesis of 2-{4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-trifluoromethyl-phenyl}acetic acid (XI-088)




1) Synthesis of diethyl 2-(4-nitro-3-trifluoromethyl-phenyl)-malonate
Sodium hydride (60% oiliness) (0.33 g, 8.25 mmol) was added in the dimethylformamide (20 mL) solution of diethyl malonate (1.23 mL, 8.14 mmol) while cooling the solution with ice, and the mixture was directly stirred for 4 hours. 5-bromo-2-nitrobenzotrifluoride (2.0 g, 7.41 mmol) was added in the reaction mixture while cooling it with ice, and the temperature was raised to room temperature and then the mixture was further heated and stirred at 70° C. for 3 hours. After the reaction solution was poured into ice water and acidified with 2N hydrochloric acid, the solution was extracted with ethyl acetate. After the organic layer had been washed with 5% sodium hydrogencarbonate aqueous solution and then with water and dried over anhydrous sodium sulfate, the solvents were concentrated under reduced pressure. The residue was subjected to silica gel column chromatograph (45 g) and was eluted with the mixture of ethyl acetate and n-hexane of 1:5 in mixing ratio. The eluted liquid was concentrated under reduced pressure and yellow oily diethyl 2-(4-nitro-3-trifluoromethyl-phenyl)-malonate (1.1 g, 42%) was obtained.
NMR: (CDCl3) 1.29 (t, 6H, J=7.2), 4.25 (q, 2H, J=6.9), 4.27 (q, 2H, J=7.2), 4.75 (s, 1H), 7.80-7.92 (m, 3H).
2) Synthesis of diethyl 2-(4-amino-3-trifluoromethyl-phenyl)-malonate
10% palladium carbon (0.1 g) was added in the ethyl acetate (20 mL) solution of diethyl 2-(4-nitro-3-trifluoromethyl-phenyl)-malonate (1.1 g, 3.15 mmol) which had been obtained in 1), and the solution was hydrogenated. After the catalyst was removed by filtration, the solvent was concentrated under reduced pressure and yellow oily diethyl 2-(4-amino-3-trifluoromethyl-phenyl)-malonate (1.38 g (the content of 0.39%), 68%) was obtained, and the product was used in the next reaction without purification.
NMR: (CDCl3) 1.20-1.35 (m, 6H), 4.10-4.30 (m, 4H), 6.77 (d, 1H, J=8.4), 7.34-7.46 (m, 2H).
3) Synthesis of diethyl 2-{4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-trifluoromethyl-phenyl}-malonate
An acid chloride solution was adjusted in such away that 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (0.25 g, 0.79 mmol) which had been obtained in 3) was dissolved in tetrahydrofuran (3 mL), and oxalyl chloride (0.076 mL, 0.87 mmol) and a drop (with a capillary pipet) of dimethylformamide were added and stirred at room temperature for 30 minutes. In the tetrahydrofuran (3 mL) solution of 2-(4-amino-3-trifluoromethyl-phenyl)diethyl malonate (1.38 g (the content is 0.39%), 1.69 mmol), triethylamine (0.33 mL, 2.37 mmol), and then the acid chloride solution adjusted as mentioned above were added and stirred at room temperature for six hours. After the reaction mixture had been poured into ice water and acidified with 2N hydrochloric acid, the mixture was extracted with ethyl acetate. After the organic layer had been washed with 5% sodium hydrogencarbonate aqueous solution and then with water and dried over anhydrous sodium sulfate, the solvents were concentrated under reduced pressure. The residue was subjected to silica gel (30 g) column chromatography (the mixture of ethyl acetate and n-hexane of 1:5 in mixing ratio). The eluted liquid was concentrated under reduced pressure and yellow oily diethyl 2-{4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-trifluoromethyl-phenyl}-malonate (0.29 g, 59%) was obtained.
Mp: 160 to 162° C.
NMR: (CDCl3) 1.27 (t, 6H, J=7.2), 1.05-1.90 (m, 19H), 2.62-2.72 (m, 2H), 2.88-2.97 (m, 2H), 3.90-4.20 (m, 2H), 4.15-4.30 (m, 4H), 4.62 (s, 1H), 7.60 (dd, 1H, J=1.8, 8.4), 7.68 (d, 1H, J=1.8), 8.35 (s, 1H), 8.41 (d, 1H, J=8.4), 12.53 (s, 1H).
4) Synthesis of 2-{4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-trifluoromethyl-phenyl}acetic acid (XI-088)
Diethyl 2-{4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-trifluoromethyl-phenyl}-malonate (0.29 g, 0.47 mmol) which had been obtained in 3) was dissolved in tetrahydrofuran-methanol (1:1) (3.8 mL), and 1N sodium hydroxide aqueous solution (1.9 mL, 1.90 mmol) was added at room temperature and the mixture was stirred for 25 hours. The mixture was further stirred at 80° C. for 9 hours. after that, the reaction mixture was poured into ice water and acidified with 2N hydrochloric acid, then the mixture was extracted with ethyl acetate. The organic layer was washed with water and then dried over anhydrous sodium sulfate, and the solvents were concentrated under reduced pressure. The residue was subjected to silica gel (12 g) column chromatography (the mixture of chloroform, methanol, and water of 32:9:1 in mixing ratio). After the eluted liquid was concentrated under reduced pressure and recrystallized from acetone-water (1:10), a white needle crystal of 2-{4-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-3-trifluoromethyl-phenyl}acetic acid (XI-088, 0.09 g, 37%) was obtained.
NMR: (DMSO-d6) 1.05-1.84 (m, 19H), 2.63-2.77 (m, 2H), 2.90-3.05 (m, 2H), 3.69 (s, 2H), 3.90-4.20 (m, 2H), 7.56 (d, 1H, J=9.0), 7.63 (m, 1H), 8.20 (d, 1H, J=8.7), 8.27 (s, 1H).
Example 38
Synthesis of methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate (I-081)




1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA01, 0.20 g, 0.63 mmol) which had been obtained in Example 1 was dissolved in anhydrous dichloromethane (2.0 mL), and oxalyl chloride (82 μL, 0.95 mmol) and a drop of DMF were added while cooling the solution with ice. After the temperature had been raised to room temperature and the solution stirred for 1 hour, the solvent was removed by distillation under reduced pressure. The residue was dissolved in THF (2.0 mL) and glycine methyl ester hydrochloride (0.119 g, 0.948 mmol) and triethylamine (0.263 mL, 1.89 mmol) were added. After the mixture was stirred at room temperature for 1 hour, water was added and the mixture was extracted with ethyl acetate while cooling the mixture with ice. The organic layer was washed with saturated saline and then dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was refined with silica gel column chromatography and a pale red color crystal of I-081 (195 mg, 80%) was obtained.
Example 39
Synthesis of [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid (I-355)




Methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetate (I-081, 0.12 g, 0.309 mmol) which had been obtained in Example 38 was dissolved in the mixed solvent of methanol (1.0 mL) and THF (1.0 mL), and 2M sodium hydroxide aqueous solution (0.46 mL) was added. After stirring for 1 hour, the solution was neutralized with 2M hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogencarbonate solution and saturated saline and then dried over anhydrous sodium sulfate. The solvents were removed by distillation under reduced pressure, and a colorless crystal of I-355 (120 mg, 100%) was obtained.
IR (KBr): 2926, 2852, 1739, 1657, 1536.
Example 40
Synthesis of methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cyclooct[b]pyridine-3-carbonyl)-amino]-butyrate (III-005)




Under the nitrogen gas atmosphere, 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA01, 0.15 g, 0.47 mM) which had been obtained in Example 1 was dissolved in dichloromethane (1.5 mL), and oxalyl chloride (62 μL, 0.71 mmol) and a drop of DMF were added while cooling the solution with ice, and then the mixture was stirred at room temperature. After 1 hour, the solvent was removed by distillation under reduced pressure, dichloromethane (5 mL) was added in the residue, then methyl 3-aminobutyrate hydrochloride (87.2 mg, 0.568 mmol) and PS-DIEA (manufactured by Argonoto Corporation, 0.31 g, 1.19 mmol) were added. After two days' stirring, MP-isocyanate and PS-carbonate were added. After that, the stirring was conducted for three hours, and then the reaction mixture was filtered and the solvent was removed by distillation under reduced pressure. And, the residue was refined with a flash tube to give a colorless crystal of III-005 (0.1496 g, 76%).
Example 41
Synthesis of [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-butyric acid (III-013)




Methyl[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cyclooct[b]pyridine-3-carbonyl)-amino]-butyrate (III-005, 56.5 mg, 0.136 mmol) which had been obtained in Example 40 was dissolved in methanol (1.5 mL), and 2M aqueous sodium hydroxide solution (0.27 mL, 0.54 mmol) was added and the solution was stirred at room temperature. After 2.5 hours, 2M hydrochloric acid was added to acidify the solution. and the solution was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure and a colorless amorphous III-013 (51.9 mg, 95%) was obtained.
Example 42
Synthesis of [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid fluoromethyl ester (I-311)




[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid (I-355, 0.15 g, 0.40 mmol) which had been obtained in Example 39 was dissolved in 1,1,2-trichloroethane, and fluoroethanol (47 μL, 0.80 mmol) and concentrated sulfuric acid (20 μL, 0.40 mmol) were added Under the nitrogen gas atmosphere and the mixture was heated to 80° C. After 22 hours, the reaction mixture was poured into saturated aqueous sodium hydrogencarbonate solution and extracted with ethyl acetate. After the organic layer had been washed with brine, the solvent was removed by distillation under reduced pressure, and the residue was refined with silica gel column chromatography, and a colorless crystal of 1-311 (101 mg, 60%) was obtained.
IR (KBr): 3235, 2925, 2855, 1763, 1665, 1618, 1580, 1529, 1446, 1212.
Example 43
Synthesis of [(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-acetic acid trifluoromethy ester (I-312)




Under the nitrogen gas atmosphere, 60% sodium hydride which had been washed with hexane (3.05 g, 76.3 mmol) was suspended in diethyl ether (60 mL), and trifluoroethanol (5.56 mL, 76.3 mmol) was added and stirred for 10 minutes while cooling the suspension with ice. After that, triphenylphosphine (10.0 g, 38.1 mmol) was added, and the suspension was further stirred for 5 minutes. Then, bromine (1.95 mL, 38.1 mmol) was added slowly, and the suspension was stirred for 1.5 hours. Subsequently, the insoluble matter was removed by filtration with a glass filter, and the solvent was removed by distillation under reduced pressure. The addition of dichloromethane (30 mL) in the residue made 1.27M ditrifluoromethoxytriphenylphosphate solution. 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (I-355, 0.10 g, 0.267 mmol) which had been obtained in Example 38 was dissolved in dichloromethane (1 mL), and the above-mentioned ditrifluoromethoxytriphenylphosphate (0.25 mL, 0.32 mmol) was added and the mixture was stirred at room temperature. After 1.5 hours, further the same amount of ditrifluoromethoxytriphenylphosphate was added. After stirring for 18 hours, the solvent in the reaction mixture was removed by distillation under reduced pressure, the residue was refined with column chromatography, and a colorless amorphous I-312 (45.4 mg, 37%) was obtained.
Example 44
Synthesis' of methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-2-methyl-propionate (I-084)




Under the nitrogen gas atmosphere, 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA01, 500 mg, 1.57 mmol) which had been obtained in Example 1 was dissolved in methylene chloride (5 mL), and oxalyl chloride (164.9 μL, 1.89 mmol) and DMF (three drops) were added and the mixture was stirred at room temperature for 1 hour. After that, dimethylglycine methyl ester hydrochloride (290.3 mg, 1.89 mmol) and triethylamine (658.5 μL, 4.72 mmol) were added and the mixture was further stirred for 2 hours. Subsequently, water was added, and the mixture was acidified with hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with water and then dried over anhydrous sodium sulfate. The solvents were removed by distillation under reduced pressure and a pale yellow solid of I-084 (607 mg, 93%, mp: 177 to 178° C.) was obtained.
NMR: (CDCl3) 1.00-1.95 (m, 25H), 2.61 (t, 2H, J=5.7), 2.92 (t, 2H, J=5.7), 3.76 (s, 3H), 4.00 (br, 2H), 8.27 (s, 1H), 10.30 (s, 1H).
Example 45
Synthesis' of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358)




Methyl 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino-]-2-methyl-propionate (I-084, 597 mg, 1.43 mmol) which had been obtained in Example 44 was dissolved in the mixed solvent of THF (6 mL) and methanol (6 mL), and the solution was stirred together with 2M sodium hydroxide aqueous solution (1.79 mL, 3.58 mmol) at 60° C. for 1 hour. After the concentration of the mixture, the water layer was washed with diethyl ether and acidified with hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with water and then dried over anhydrous sodium sulfate. The solvents were removed by distillation under reduced pressure and a colorless solid of I-358 (446 mg, 77%, mp: 260-263° C.) was obtained.
Example 46
Synthesis of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro[b]pyridine-3-carbonyl)-amino]-2-methy-propionate 2-dimethylamino ethyl ester (I-325)




Under the nitrogen gas atmosphere, 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 600 mg, 1.49 mmol) which had been obtained in Example 45 was dissolved in DMF (12 mL), and the solution was stirred together with WSCD (325 mg, 1.79 mmol) and HOBt (40.2 mg, 0.298 mmol) at 80° C. for 30 minutes. After that, N,N-dimethylaminoethanol (300 μL, 2.98 mmol) was added and the mixture was heated and stirred at 80° C. for 7 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate, and then the organic layer was washed with water and dried over anhydrous sodium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was refined with silica gel (5 g) column chromatography (the mixture of chloroform-methanol of 9:1 in mixing ratio), and thus a colorless solid of I-325 (629 mg, 76%, mp: 101-103° C.) was obtained.
Example 47
Synthesis of (2-{2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionyloxy}-ethyl)-trimethylammonium iodide (I-326)




In an acetonitrile (10 mL) solution of cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro[b]pyridine-3-carbonyl]-amino]-2-methy-propionic acid 2-dimethylamino ethyl ester (I-325, 200 mg, 0.422 mmol) which had been obtained in Example 46, methyl iodide (262 μL) was added, and the mixture was heated and stirred at 85° C. for 1 hour in a sealed tube. After that, the solvent was removed by distillation under reduced pressure, and a pale yellow oily I-326 (244 mg, 94%) was obtained.
Example 48
Synthesis of 1-cyclohexyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-methanesulfonylamino-1,1-dimethyl-2-oxo-ethyl)-amide (I-003)




Under the nitrogen gas atmosphere, in a methylene chloride (4 mL) solution of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 402 mg, 1.00 mmol) which had been obtained in Example 45, oxalyl chloride (104.7 μL, 1.20 mmol) and DMF (three drops) were added, and the mixture was stirred at room temperature for 1 hour. After that, methanesulfonamide (114 mg, 1.20 mmol) and DBU (448 μL, 3.0 mmol) were added and the mixture was stirred at room temperature for 7 hours. Water was added in the reaction mixture, and the mixture was acidified with hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with saturated sodium hydrogencarbonate aqueous solution and water, and then dried over anhydrous sodium sulfate. After the solvents had been removed by distillation under reduced pressure, the residue was refined with silica gel (10 g) column chromatography (the mixture of ethyl acetate-hexane of 1:1 in mixing ratio), and a colorless solid of I-003 (381 mg, 79%, mp: 186-187° C.) was obtained.
Example 49
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-benzylcarbamoyl-1-methyl ethyl)-amide (I-005)




Under the nitrogen gas atmosphere, in a methylene chloride (3 mL) solution of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 150 mg, 0.373 mmol) which had been obtained in Example 45, oxalyl chloride (39 μL, 0.447 mmol) and DMF (one drop) were added, and the mixture was stirred at room temperature for 1 hour. After that, benzylamine (203 mL, 1.86 mmol) was added and the mixture was further stirred at room temperature for 5 hours. Water was added in the reaction mixture, and then the mixture was acidified with hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogencarbonate solution and water, and then dried over anhydrous sodium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was refined with silica gel (5 column chromatography (the mixture of ethyl acetate-hexane of 3:1 in mixing ratio), thus a colorless solid of I-005 (158 mg, 86%, mp: 132-134° C.) was obtained.
Example 50
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1-(methoxymethylcarbamoyl)-1-methyl-ethyl]-amide (I-024)




Under the nitrogen gas atmosphere, in a methylene chloride (3 mL) solution of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 150 mg, 0.373 mmol) which had been obtained in Example 45, oxalyl chloride (39 μL, 0.447 mmol) and DMF (one drop) were added, and the mixture was stirred at room temperature for 1 hour. Next, N,O-dimethylhydroxyamine hydrochloride (40 mg, 0.409 mmol) and triethylamine (208 μL, 1.49 mmol) were added and the mixture was stirred at room temperature for 3 hours. After that, water was added in the mixture, and the mixture was acidified with hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with saturated sodium hydrogencarbonate aqueous solution and water, and then dried over anhydrous sodium sulfate. After the solvents had been removed by distillation under reduced pressure, the residue was refined with silica gel (5 g) column chromatography (ethyl acetate), and a colorless solid of I-024 (110 mg, 65%, mp: 166 to 168° C.) was obtained.
Example 51
Synthesis of methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydro-pyridine-3-carbonyl)-amino]-2,3-dimethyl-butyrate (I-211)




In an anhydrous THF (4 mL) solution of 1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carboxylic acid (AA03, 425 mg, 1.60 mmol) which had been obtained in Example 3, oxalyl chloride (147 μL, 1.69 mmol) and DMF (8 μL) were added, and the mixture was stirred at room temperature for 1 hour. Next, triethylamine (0.89 mL, 6.38 mmol) and the above-mentioned acid chloride solution were sequentially added in an anhydrous DMF (4 mL) solution of L-tert-leucine methyl ester hydrochloride (349 mg, 1.92 mmol) while stirring and cooling the solution with ice. After that, the mixed solution was stirred at room temperature for 90 minutes. The reaction mixture was acidified by pouring into diluted hydrochloric acid, and then extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate aqueous solution, and water, and then dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was eluted and refined with silica gel (52 g) column chromatography (ethyl acetate-hexane (2:1)) to give a pale yellow oily 1.211 (572 mg, 92%).
IR (CHCl3): 3236, 1738, 1666, 1617, 1578, 1528, 1465, 1437, 1404, 1371, 1323;
[α]D22+28.7±0.7° (c=1.014, MeOH);
Elemental analysis: (C22H36N2O4.0.1MeOH)
Calculated (%): C, 67.07; H, 9.27; N, 7.08;
Analitical (%): C, 66.99; H, 9.27; N, 7.21
Example 52
Synthesis of 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydro-pyridine-3-carbonyl)-amino]-2,3-dimethyl-butyric acid (I-438)




Methyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydro-pyridine-3-carbonyl)-amino]-2,3-dimethyl-butyrate (I-211, 313 mg, 0.797 mmol) which had been obtained in Example 51 was dissolved in methanol (8 mL), and the solution was stirred together with 4M sodium hydroxide aqueous solution (0.8 mL) at 50° C. for 25 hours. The reaction mixture was poured into water, and the water layer was washed with ethyl ether. The water layer was acidified with 2M hydrochloric acid aqueous solution and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate, and then the solvent was removed by distillation and colorless solid matter (331 mg) was obtained. This solid matter was recrystallized with ethyl acetate-hexane, and a colorless prism-like crystal of I-438 (271 mg, 88%) was obtained.
Mp: 140-141° C.
IR (nujol): 2607, 1727, 1657, 1577, 1533, 1467, 1406, 1374, 1334; [α]D22+31.2±0.7° (c=1.007, MeOH);
Elemental analysis: (C21H34N2O4.0.2H2O)
Calculated (%): C, 66.15; H, 9.11; N, 7.28
Analitical (%): C, 66.17; H, 9.12; N, 7.40
Example 53
Synthesis of ethyl 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylate (II-029)




In the anhydrous THF (4 mL) solution of 1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carboxylic acid (AA03, 451 mg, 1.70 mmol) which had been obtained in Example 3, oxalyl chloride (156 μL, 1.79 mmol) and DMF (8 μL) were added, and the mixture was stirred at room temperature for 1 hour. Next, triethylamine (0.95 mL, 6.81 mmol) and then the above-mentioned acid chloride solution were added in the anhydrous DMF (4 mL) solution of 2-amino-1-ethyl cyclohexanecarboxylate hydrochloride (424 mg, 2.04 mmol) while stirring and cooling the solution with ice. After that, the mixed solution was stirred at room temperature for 90 minutes. The reaction mixture was acidified by pouring into diluted hydrochloric acid, and then extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate aqueous solution, and water, and then dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was eluted and refined with silica gel (57 g) column chromatography (ethyl acetate-hexane (2:1)) to give a pale yellow oily II-029 (694 mg, 96%).
IR (CHCl3): 3252, 1724, 1664, 1615, 1578, 1529, 1464, 1406, 1378, 1312;
Elemental analysis: (C24H32N2O4.0.2MeOH)
Calculated: C, 68.39; H, 9.20; N, 6.59;
Analitical: C, 68.32; H, 9.39; N, 6.79
Example 54
Synthesis of 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid (II-056)




In the methanol (9 mL) solution of 2-[(1-butyl-5-ethyl-2-oxo-6-propyl-1,2-dihydropyridine-3-carbonyl)-amino]-ethyl cyclohexanecarboxylate (II-029, 368 mg, 0.88 mmol) which had been obtained in Example 53, 4M sodium hydroxide aqueous solution (0.66 mL, 2.66 mmol) was added, and the mixture was stirred at 50° C. for 25.5 hours. The reaction mixture was poured into water and washed with ethyl ether. The water layer was acidified with 2M hydrochloric acid aqueous solution and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate, and then the solvent was removed by distillation and a colorless foam-like substance (359 mg) was obtained. This substance was recrystallized with ethyl acetate-hexane, and a colorless columnar crystal of 11.056 (296 mg, 86%) was obtained.
Mp: 167-169° C.
IR (nujol): 3190, 3060, 1724, 1656, 1599, 1582, 1538, 1482, 1462, 1409, 1377, 1348, 1319;
Elemental analysis: (C22H34N2O4)
Calculated: C, 67.66; H, 8.78; N, 7.17
Analitical: C, 67.61; H, 8.76; N, 7.32
Example 55
Synthesis of methyl 1-{[(3-methanesulfonylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-methyl-propionate (I-240)




In the anhydrous THF (4 mL) solution of 1-(3-methanesulfonylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA22, 425 mg, 1.19 mmol) which had been obtained in Example 22, oxalyl chloride (109 μL, 1.25 mmol) and DMF (6 μL) were added, and the mixture was stirred at room temperature for 1 hour. Next, triethylamine (0.67 mL, 4.80 mmol) and the above-mentioned acid chloride solution were sequentially added in the anhydrous DMF (4 mL) solution of dimethylglycine methyl ester hydrochloride (220 mg, 1.43 mmol) while stirring and cooling the solution with ice, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was acidified by pouring into diluted hydrochloric acid, and then extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate water, and water, and then dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was eluted and refined with silica gel (48 g) column chromatography (ethyl acetate-hexane (1:1) and then ethyl acetate) to give a colorless foam-like substance (544 mg). This substance was recrystallized with ethyl acetate-methanol-hexane, and a colorless columnar crystal of I-240 (499 mg, 92%, mp: 156.157° C.) was obtained.
NMR: (CDCl3) 1.32-1.54 (m, 4H), 1.60-1.84 (m, 4H), 1.62 (s, 6H), 1.95-2.06 (m, 2H), 2.60-2.64 (m, 2H), 2.88-2.92 (m, 2H), 2.97 (s, 3H), 3.06-3.18 (m, 2H), 3.76 (s, 3H), 4.24-4.36 (m, 2H), 5.74 (t, 1H, J=6.0), 8.30 (s, 1H), 10.17 (s, 1H);
IR (chloroform): 3257, 1738, 1667, 1619, 1577, 1529, 1484, 1458, 1439, 1408, 1384, 1363, 1329;
Elemental analysis: (C21H33N3O6S)
Calculated: C, 55.36; H, 7.30; N, 9.22; S, 7.04
Analitical: C, 55.25; H, 7.39; N, 9.14; S, 6.98
Example 56
Synthesis of 1-{[(3-methanesulfonylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-methyl-propionic acid (I-506)




In a methanol (7 mL) solution of methyl 1-{[(3-methanesulfonylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-methyl-propionate (I-240, 269 mg, 0.59 mmol) which had been obtained in Example 55, 4M sodium hydroxide aqueous solution (0.45 mL, 1.81 mmol) was added, and the mixture was stirred at 50° C. for 17 hours. After that, the reaction mixture was poured into water and washed with ethyl ether. The water layer was acidified with 2M hydrochloric acid aqueous solution and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate, and a colorless foam-like substance (282 mg) was obtained. This substance was recrystallized with ethyl acetate-hexane, and a colorless prism-like crystal of 1.506 (226 mg, 87%, mp: 183-184° C.) was obtained.
NMR: (DMSO-d6) 1.25-1.88 (m, 10H), 1.48 (s, 6H), 2.60-2.70 (m, 2H), 2.90-3.01 (m, 2H), 2.93 (s, 3H), 3.03-3.12 (m, 2H), 4.07-4.18 (m, 2H), 7.15 (t, 1H, J=6.0), 8.09 (s, 1H), 10.22 (s, 1H), 12.40 (brs, 1H);
IR (nujol): 3171, 3029, 1736, 1657, 1581, 1537, 1485, 1460, 1413, 1377, 1364, 1334, 1318;
Elemental analysis: (C20H31N3O6S)
Calculated: C, 54.40; H, 7.08; N, 9.52; S, 7.26
Analitical: C, 54.37; H, 7.02; N, 9.29; S, 7.16
Example 57
Synthesis of methyl 1-{[(3-acetylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-methyl-propionate (I-251)




1-(3-Acetylaminopropyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA23, 240 mg, 0.71 mmol) which had been obtained in Example 23 was dissolved in anhydrous THF (3 mL), oxalyl chloride (65 μL, 0.75 mmol) and DMF (5 μL) were added, and the mixture was stirred at room temperature for 1 hour. Dimethylglycine methyl ester hydrochloride (131 mg, 0.85 mmol) was dissolved in anhydrous DMF (3 mL), and triethylamine (0.40 mL, 2.87 mmol) and then the above-mentioned acid chloride solution were added while stirring and cooling the solution with ice. After that, the mixture was stirred at room temperature for 1 hour. The reaction mixture was acidified by pouring into diluted hydrochloric acid, and then extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate aqueous solution, and water, and then dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was sequentially eluted and refined with silica gel (46 g) column chromatography (ethyl acetate-hexane (2:1) and ethyl acetate) to give a colorless foam-like substance (296 mg). This substance was recrystallized with ethyl acetate-methanol-hexane, and a colorless mineral phosphate-like crystal of I-251 (273 mg, 88%, mp: 135-136° C.) was obtained.
NMR: (CDCl3) 1.32-1.53 (m, 4H), 1.60-1.80 (m, 4H), 1.63 (s, 6H), 11.97 (m, 2H), 2.59-2.63 (m, 2H), 2.86-2.90 (m, 2H), 3.18-3.29 (m, 2H), 3.69 (s, 3H), 3.76 (s, 3H), 4.15-4.27 (m, 2H), 5.50 (m, 1H), 8.28 (s, 1H), 10.24 (s, 1H);
IR (chloroform): 3453, 3256, 1723, 1667, 1619, 1577, 1528, 1484, 1439, 1409, 1384, 1364, 1333;
Elemental analysis: (C22H33N3O6)
Calculated: C, 60.67; H, 7.64; N, 9.65
Analitical: C, 60.49; H, 7.60; N, 9.59
Example 58
Synthesis of 1-{[(3-acethyamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-methyl-propionic acid (I-518)




Methyl 1-{[3-acetylamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-methyl-propionate (AA24, 153 mg, 0.35 mmol) which had been obtained in Example 24 was dissolved in methanol (3 mL), 4M sodium hydroxide aqueous solution (0.26 mL, 1.05 mmol) was added, and the mixture was stirred at 50° C. for 5 hours. After standing to cool, the reaction mixture was poured into water, and the water layer was washed with ethyl ether. The water layer was acidified with 2M aqueous hydrochloric acid solution, and then extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate, and then the solvent was removed by distillation and a colorless oily I-518 (148 mg, 96%) was obtained.
NMR: (DMSO-d6) 1.24-1.82 (m, 10H), 1.48 (s, 6H), 2.60-2.68 (m, 2H), 2.86-2.96 (m, 2H), 3.05-3.16 (m, 2H), 3.53 (s, 3H), 4.00-4.14 (m, 2H), 7.27 (m, 1H), 8.08 (s, 1H), 10.21 (s, 1H), 12.42 (brs, 1H);
IR (KBr): 3391, 1726, 1665, 1620, 1577, 1530, 1456, 1409, 1382, 1362, 1315;
Elemental analysis: (C21H31N3O6.0.1AcOEt.0.4H2O)
Calculated: C, 58.75; H, 7.51; N, 9.60
Analitical: C, 58.81; H, 7.35; N, 9.59
Example 59
The synthesis of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 5-methyl-2-oxo-[1,3]-dioxol-4-ylmethyl ester (-308)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 250 mg, 0.621 mmol) which had been obtained in Example 45, 4-bromomethyl-5-methyl-[1,3]dioxol-2-on (180 mg, 0.933 mmol), and potassium bicarbonate (150 mg, 1.50 mmol) were suspended in DMF (2.5 mL), and the suspension was stirred at room temperature for 15 hours. After that, 5% citric acid aqueous solution was added, and the suspension was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, and dried over sodium sulfate, and then the solvents were removed by distillation. The residue was refined with silica gel column chromatography (hexane-ethyl acetate (30-34%)), and 1.308 was obtained as colorless foam-like matter (318 mg, 99%).
Example 60
Synthesis of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid trans-2-phenyl-[1,3]dioxane-5-yl ester (I-302)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 200 mg, 0.497 mmol) which had been obtained in Example 45 was transformed to the acid chloride using oxalyl chloride-DMF by the usual way, and then pyridine (1 mL) and trans-2-phenyl-[1,3]dioxan-5-ol (180 mg, 1.00 mmol) were added, and the mixture was reacted at room temperature for one hour, subsequently at 50° C. for 1 hour. After that, diluted hydrochloric acid was added in the reaction mixture, and then the mixture was extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bi9-carbonate water, and saturated saline in order, and then dried. After that, the solvent was removed by distillation, and the residue was refined with silica gel column chromatography (hexane-ethyl acetate (40 to 50%)), and further recrystallized from methanol, resulting in obtaining I-302 as a colorless needle crystal (57 mg, 20%, mp: 166-168° C.).
Example 61
Synthesis of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-hydroxy-1-hydroxymethyl-ethyl ester (I-303)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid trans-2-phenyl-[1,3]dioxane-5-yl ester (I-302, 255 mg, 0.451 mmol) which had been obtained in Example 60 was dissolved in the mixture of methanol (1 mL), THF (2 mL), and 2M hydrochloric acid (1 mL), and the solution was stirred at room temperature for 3 hours. The solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and dried, and then the solvents were removed by distillation. The residue was refined with silica gel column chromatography (hexane-ethyl acetate (35-80%)), and further recrystallized from hexane, and I-303 was obtained as a colorless crystal (85 mg, 40%, mp: 123-125° C.).
Example 62
Synthesis of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid 2-oxo-[1,3]dioxolan-4-yl ester (I-309)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (1.358, 250 mg, 0.621 mmol) which had been obtained in Example 45, 4-chloro-[1,3]dioxolan-2-one (84 μL, 0.93 mmol), potassium bicarbonate (186 mg, 1.86 mmol), and a small quantity of potassium iodide were suspended in DMF (2.5 mL), and the suspension was stirred at room temperature for 15 hours. After that, 5% citric acid aqueous solution was added, and the suspension was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, and dried over sodium sulfate, and then the solvents were removed by distillation. The residue was refined with silica gel column chromatography (hexane-ethyl acetate (30%)), and I-309 was obtained as colorless foam-like matter (96 mg, 31%).
Example 63
Synthesis of 2-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-thiopropionic acid S-methyl ester (I-001)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 250 mg, 0.621 mmol) which had been obtained in Example 45 was made to be the acid chloride by the oxalyl chloride-DMF method according to the usual way, and then the acid chloride was dissolved in DMF (2 mL). After that, sodium thiomethoxide (92 mg, 1.24 mmol) was added, and the mixture was reacted for 30 minutes while cooling with ice, and further for 2 hours at room temperature. After that, the same treatment as described above was conducted, and then the residue was refined with silica gel column chromatography (hexane-ethyl acetate (25%)), and I-001 was obtained as a colorless crystal (140 mg, 52%, nip: 196-198° C.).
Example 64
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid {1-[(2-hydroxyethyl)-methyl-carbamoyl]-1-methyl-ethyl}-amide (I-019)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 250 mg, 0.621 mmol) which had been obtained in Example 45, N-methyl ethanolamine (60 μL, 0.745 mmol), WSCD (143 mg, 0.683 mmol), and a small quantity of HOBt were reacted in DMF (2.5 mL) at room temperature for 18 hours. After that, the same treatment as described above was conducted, and then the residue was refined with silica gel column chromatography (ethyl acetate), and I-019 was obtained as a colorless solid (171 mg, 60%, mp: 195-196° C.).
Example 65
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (2-oxo-tetrahydrofuran-3-yl)-amide (I-072)




1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA01, 250 mg, 0.788 mmol) which had been obtained in Example 1 was made to be the acid chloride according to the conventional method, and the acid chloride was dissolved in THF. Then, the solution was dropped into the DMF (2 mL) mixed liquid of 3-amino-dihydro-furan-2-one hydrobromide (187 mg, 1.03 mmol) and triethylamine (0.38 mL, 2.36 mmol) while cooling with ice. After that, the mixture was stirred at the same temperature for 30 minutes, and further stirred continuously at room temperature for 3 hours. The mixture was subjected to the same after-treatment as described above, and then refined with silica gel column chromatography (hexane-ethyl acetate (40 to 60%)), and I-072 was obtained as a colorless solid (242 mg, 77%, mp: 136-140° C.).
Example 66
Synthesis of 1-[(1-cyclohexylmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid methyl ester (I-149)




A toluene (4 mL) solution of ethyl 1-cyclohexylmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylate (AA16, 250 mg, 0.692 mmol) which had been obtained in Example 16, 1-amino-methyl cyclohexanecarboxylate hydrochloride (174 mg, 0.90 mmol), and triethylamine (125 μL, 0.90 mmol) was refluxed for 20 hours. After the reaction mixture had been cooled to room temperature, the insoluble matter was removed by filtration, and the filtrate was concentrated. Then the residue was refined with silica gel column chromatography (hexane-ethyl acetate (10 to 15%)), and I-149 was obtained as colorless foam-like matter (223 mg, 68%).
Example 67
Synthesis of ethyl 2-[(1-cyclohexylmethyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-cyclohexanecarboxylate (II-023)




II-023 was synthesized by the quite similar method to that in Example 66.
Example 68
Synthesis of 1-butyl-4-hydroxy-2-oxo-1,2,5,6,7,8,9,10-octahydro-cyclohepta[b]pyridine-3-carboxylic acid (2-oxo-azepane-3-yl)-amide (I-071)




I-071 was synthesized by the quite similar method to that in Example 66.
Example 69
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-hydrazinocarbonyl-1-methyl-ethyl)-amide (I-050)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 403 mg, 1.00 mmol) which had been obtained in Example 45 was suspended in anhydrous DMF (4 mL), and stirred together with WSCD (422 mg, 2.20 mmol), HOBt (27 mg, 0.20 mmol), and hydrazine monohydrate (58 μL, 1.20 mmol) at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate aqueous solution, and water, and dried over anhydrous magnesium sulfate, and then the solvent was removed by distillation under reduced pressure. The residue was recrystallized with ethyl acetate-methanol-hexane and a colorless needle crystal of I-050 (339 mg, 81%, mp: 177-180° C.) was obtained.
IR (nujol): 3343, 3216, 3177, 1665, 1605, 1579, 1526, 1455, 1410, 1377, 1360, 1333;
Elemental analysis: (C23H36N4O3)
Calculated: C, 66.32; H, 8.71; N, 13.45
Analitical: C, 66.11; H, 8.78; N, 13.20
Example 70
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-methylsulfonylhydrazinocarbonyl-1-methyl-ethyl)-amide (I-052)




1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (1-hydrazinocarbonyl-1-methyl-ethyl)-amide (I-050, 24 g, 2.98 mmol) which had been obtained in Example 69 was suspended in anhydrous THF (13 mL), and pyridine (0.48 mL, 5.94 mmol) and methanesulfonyl chloride (0.35 mL, 4.52 mmol) was added while stirring and cooling the suspension with ice. After that, the mixture was stirred at room temperature for 2 hours and 30 minutes. The reaction mixture was acidified by pouring into diluted hydrochloric acid, and then extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate aqueous solution, and water, and then dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was eluted and refined with silica gel (61 g) column chromatography (ethyl acetate-hexane (1:1) and then ethyl acetate) to give a colorless crystal of I-052 (1.57 g). This was recrystallized with methanol-water and a colorless needle crystal (1.22 g, 80%, mp: 177-178° C.) was obtained.
IR (nujol): 3543, 3287, 3249, 3137, 3037, 3011, 1670, 1618, 1579, 1517, 1484, 1454, 1408, 1389, 1377, 1365, 1341, 1321;
Elemental analysis: (C24H38N4O5S.0.3MeOH.0.4H2O)
Calculated: C, 57.10; H, 7.83; N, 10.96; S, 6.27
Analitical: C, 57.11; H, 7.58; N, 10.95; S, 6.47
Example 71
Synthesis of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid [1,1-dimethyl-2-(4-methyl-piperazine-1-yl)-2-oxo-ethyl]-amide (I-047)




2-[(1-Cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]-2-methyl-propionic acid (I-358, 350 mg, 0.87 mmol) which had been obtained in Example 45 was suspended in anhydrous DMF (5 mL), and WSCD (200 mg, 1.04 mmol), HOBt (24 mg, 0.18 mmol), and N-methyl piperazine (116 μL, 1.05 mmol) were added and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate water, and water, and then dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and the residue was recrystallized with ethyl acetate-methanol-hexane and a colorless needle crystal of I-047 (313 mg, 74%, mp: 183-184° C.) was obtained.
IR (nujol): 3179, 2791, 2761, 2745, 1668, 1639, 1621, 1581, 1548, 1519, 1459, 1442, 1419, 1378, 1360, 1335, 1317;
Elemental analysis: (C28H44N4O3)
Calculated: C, 69.39; H, 9.15; N, 11.56
Analitical: C, 69.27; H, 9.10; N, 11.53
Example 72
Synthesis of methyl 2-[(1-cyclohexylmethyl-2,6-dioxo-1,2,5,6,7,8, hexa hydro-6-thiopyrano[4,3-b]pyridine-3-carbonyl]-amino)-3-methyl-butyrate (I-258)




1-Cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carboxylic acid (AA09) which had been obtained in Example 9 was dissolved in a chloroform (7 mL) solution of methyl 2-[(1-cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-6-thiopyrano[4,3-b]pyridine-3-carbonyl)-amino]-3-methyl-butyrate (I-256, 350 mg, 0.832 mmol) which had been synthesized by the method similar to that in Example 37, and then methchlorobenzoic acid (215 mg, 1.25 mmol) was added while cooling the solution with ice, and the mixture was stirred at the same temperature for 12 minutes. The reaction mixture was washed with saturated aqueous sodium hydrogencarbonate solution and water, and then the organic layer was dried over anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was refined with silica gel (42 g) column chromatography (chloroform-methanol of 50:1 and then that of 25:1), and colorless oily matter (330 mg) was obtained. This oily matter was recrystallized from ethyl acetate-methanol to give the white crystalline powder of I-258 (247 mg, 68.0%, mp: 216-218° C.).
IR (nujol): 3226 (NH), 1736, 1663, 1530 (C═O)
Example 73
Synthesis of methyl 2-[(1-cyclohexylmethyl-2,6,6-trioxo-1,2,5,6,7,8,hexahydro-6-thiopyrano[4,3-b]pyridine-3-carbonyl]-amino)-3-methyl-butyrate (I-257)




1-Cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-2H-thiopyrano[4,3-b]pyridine-3-carboxylic acid (AA09) which had been obtained in Example 9 was dissolved in the chloroform (7 mL) solution of 2-[(1-cyclohexylmethyl-2-oxo-1,5,7,8,tetrahydro-6-thiopyrano[4,3-b]pyridine-3-carbonyl)-amino]-3-methyl-methyl butyrate (I-256, 350 mg, 0.832 mmol) which had been synthesized using a method similar to that of Example 37, and then methchlorobenzoic acid (442 mg, 2.56 mmol) was added while cooling the solution with ice, and the mixture was stirred at the same temperature for 10 minutes. After that, the temperature was raised to room temperature, and the mixture was further stirred for 3 hours. The reaction mixture was washed with saturated sodium hydrogencarbonate aqueous solution and water, and then the organic layer was dried over anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and a white solid of I-257 (428 mg) was obtained. This solid was recrystallized from ethyl acetate-hexane, and white crystalline powder (297 mg, 78.8%, mp: 242.245° C.) was obtained.
IR (nujol): 3235 (NH), 1741, 1662, 1532 (C═O)
Example 74
Synthesis of methyl[(6-ethyl-1-(4-fluoro-benzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-thiophene-2-yl-acetate (I-273)




In an anhydrous THF (3 mL) solution of 6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (289 mg, 1.00 mmol), oxalyl chloride (0.10 mL, 1.15 mmol) and DMF (10 μL) were added at room temperature, and the mixture was stirred for 15 minutes. This THF solution was dropped in the anhydrous DMF (3 mL) solution of N-α-(2-thienyl)glycine methyl ester hydrochloride (208 mg, 1.00 mmol), which had been synthesized using a method similar to that of Example 25, and triethylamine (0.56 mL, 4.00 mmol), while cooling the solution with ice. After that, the mixture was heated to room temperature, and further stirred for four hours. Water and 2M hydrochloric acid (2 mL) were added in the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water two times, and dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and a yellow solid was obtained. This solid was recrystallized from ethyl acetate-hexane, and the straw-color crystalline powder of I-273 (365 mg, 82.5%, mp: 182-184° C.) was obtained.
IR (nujol): 3151 (NH), 1748, 1668, 1510 (C═O)
Example 75
Synthesis of (−)-[(1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl)-amino]phenylacetic acid (I-195)




In an anhydrous THF (3 mL) solution of 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid (AA01, 317 mg, 1.00 mmol) which had been obtained in Example 1, oxalyl chloride (0.10 mL, 1.15 mmol) and DMF (10 μL) were added at room temperature, and the mixture was stirred for 15 minutes. This THF solution was dropped into the anhydrous DMF (3 mL) solution of (−)-α-phenylglycine benzohydrile ester para-toluene sulfonate (514 mg, 1.05 mmol) and triethylamine (0.56 mL, 4.00 mmol), while cooling the solution with ice. After that, the mixture was stirred at the same temperature for 50 minutes and was acidified by adding ice water and then 2M hydrochloride acid (2 mL). After that, the mixture was extracted with ethyl acetate (15 mL). The organic layer was washed with water two times, and dried over anhydrous magnesium sulfate. The solvents were removed by distillation under reduced pressure, and a colorless solid ester body (629 mg) was obtained. This ester body was recrystallized from ethyl acetate-hexane, and white crystalline powder (439 mg, 71.2%) was obtained.
Mp: 178-180° C.
IR (nujol): 3196 (NH), 1745, 1667, 1532 (C═O);
NMR: (CDCl3) 0.98-1.92 (m, 19H), 2.60 (t, 2H, J=6.0), 2.90 (t, 2H, J=6.3). 4.01 (br, 2H), 5.90 (d, 1H, J=6.19), 6.87 (s, 1H), 6.97-7.46 (m, 15H), 8.24 (s, 1H), 11.04 (d, 1H, J=6.9);
[α]D-5.2±0.5° (22° C., C=1.002, CDCl3)
Successively, trifluoroacetic acid (0.4 mL) was added in the dichloromethane (4 mL) solution of the ester (391 mg, 0.634 mM) and anisole (0.8 mL) while cooling the solution with ice, and the mixture was stirred at the same temperature for one hour and 30 minutes. After that, the mixture was heated to room temperature and stirred for 4 hours and 30 minutes, and then the solvent was removed by distillation under reduced pressure. Hexane was added to the residue to solidify it, and then the solid was washed with hexane and white powder (255 mg) was obtained. This powder was recrystallized from ethyl acetate-hexane, and white crystalline powder (I-195, 218 mg, 76.2%, optical purity is 100% ee) was obtained.
Mp: 208-211° C.;
Optical purity measurement conditions: HPLC column; CHIRALCEL OD (Daicel), 4.6φ×250, Moving bed; acetonitrile (0.1% TFA)-water (0.1% TFA)=60:40, Flow rate; 1 ml/min., Detection; UV 254 nm, Retention time; 11.6 minutes;
IR (nujol): 3254 (NH), 1742, 1671, 1518 (C═O);
NMR: (DMSO-d6) 1.00-1.84 (m, 19H), 2.64 (brt, 2H), 2.95 (brt, 2H). 4.00 (br, 2H), 5.48 (d, 1H, J=6.9), 7.31-7.44 (m, 5H), 8.10 (s, 1H), 10.71 (d, 1H, J=6.9), 13.07 (br, 1H);
[α]D-5.4±0.5° (22° C., C=1.006, CH3OH)
Structures and NMR spectrum data of the compounds synthesized by the methods described above will be shown in the following Tables 4 to 287.







TABLE 4













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-027




0.95(t, 3H, J = 6.9), 1.30-1.80(m, 12H), 2.60(t, 2H, J = 6.0), 2.86(t-like, 2H), 3.02 and 3.04(each s, total 3H), 3.07-4.17(m, 6H), 6.06(d, J = 6.9) and 6.19(d, total 1H, J = 5.4), 7.26-7.02(m, 5H), 8.22 and 8.25(each s, total 1H), 10.82(d, J = 5.4) and 11.09(d, total 1H, J = 6.9)


 


I-028




0.94-1.16(m, 9H), 1.32-1.52(m, 6H), 1.60- 1.80(m, 6H), 2.22(m, 1H), 2.39(br, 1H), 2.56- 2.66(m, 2H), 2.85-2.89(m, 2H), 3.01 and 3.28(s, total 3H), 3.22-4.20(m, 6H), 4.82(m, 1H), 8.21 and 8.22(s, total 1H), 10.51 and 10.59(brd, total 1H)


 


I-029




0.98(t, 3H, J = 7.5), 1.38 and 1.15(s, total 9H), 1.32-1.54(m, 6H), 1.58-1.80(m, 6H), 2.30(br, 1H), 2.56-2.64(m, 2H), 2.85-2.89(m, 2H), 3.00 and 3.31(s, total 3H), 3.10-4.30(m, 6H), 4.61(m, 1H), 8.21 and 8.22(s, total 1H), 10.69 and 10.83(brd, total 1H)


 


I-111




0.97(t, 3H, J = 7.5), 1.03(d, 3H, J = 6.9), 1.04(d, 3H, J = 6.9), 1.36-1.80(m, 12H), 2.28(m, 1H), 2.62(brt, 2H), 2.89(brt, 2H), 3.75(s, 3H), 4.12(brm, 2H), 4.67(dd, 1H, J = 5.4 and 8.1), 8.27(s, 1H), 10.46(d, 1H, J = 8.1)


 


I-112




0.97(t, 3H, J = 7.5), 1.03(d, 3H, J = 6.9), 1.04(d, 3H, J = 6.9), 1.36-1.80(m, 12H), 2.28(m, 1H), 2.62(brt, 2H), 2.89(brt, 2H), 3.75(s, 3H), 4.12(brm, 2H), 4.67(dd, 1H, J = 5.4 and 8.1), 8.27(s, 1H), 10.46(d, 1H, J = 8.1)


 


I-113




0.99(t, 3H, J = 7.2), 1.34-1.82(m, 12H), 2.63(brt, 2H), 2.89(brt, 2H), 3.76(s, 3H), 4.11(brt, 2H), 4.22(d, 2H, J = 5.7), 8.28(s, 1H), 10.41(brt, 1H)
















TABLE 5













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-114




0.99(t, 3H, J = 7.5), 1.32-1.80 (m, 12H), 2.61(brt, 2H), 2.87 (brt, 2H), 3.15(dd, 1H, J = 7.2 and 13.8), 3.24(dd, 1H, J = 6.3 and 13.8), 3.68(s, 3H), 4.10(brm, 2H), 4.97(ddd, 1H, J = 5.7, 7.2 and 13.8), 7.18-7.30(m, 5H), 8.23(s, 1H)


 


I-119




0.98(t, 3H, J = 7.2), 1.32-1.80 (m, 12H), 2.61(brt, 2H), 2.88(brt, 2H), 3.74(s, 3H), 4.11(brt, 2H), 5.74(d, 1H, J = 6.6), 7.28-7.51(m, 5H), 8.25(s, 1H), 10.90(d, 1H, J = 6.6)


 


I-124




0.99(t, 3H, J = 7.5), 1.26-1.92 (m, 16H), 2.18-2.22(m, 2H), 2.61(brt, 2H), 2.88(brt, 2H), 3.73(s, 3H), 4.11(brt, 2H), 8.25(s, 1H), 10.39(s, 1H)


 


I-192




0.99(t, 3H, J = 7.2), 1.33-1.54 (m, 6H), 1.59-1.81(m, 6H), 1.62(s, 6H), 2.59-2.63(m, 2H), 2.86-2.90(m, 2H), 3.75(s, 3H), 4.03-4.17(m, 2H), 8.25(s, 1H), 10.32(s, 1H)


 


I-203




0.98(t, 3H, J = 7.2), 1.32-1.53 (m, 6H), 1.60-1.81(m, 6H), 2.62(t, 2H, J = 6.3), 2.88(t, 2H, J = 6.3), 3.73(s, 3H), 4.05-4.18(m, 2H), 8.26 (s, 1H), 10.60(d, 1H, J = 9.0)


 


I-204




0.96(t, 3H, J = 7.2), 1.32-1.53 (m, 6H), 1.58-1.82(m, 6H), 2.62(t, 2H, J = 6.3), 2.89(t, 2H, J = 6.3), 3.72(s, 3H), 4.04-4.19(m, 2H), 5.59(d, 1H, J = 6.6), 6.65(d, 2H, J = 8.7), 7.23(d, 2H, J = 8.7), 7.39(brs, 1H), 8.28(s, 1H), 10.83(d, 1H, J = 6.6)
















TABLE 6













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-243




0.97(t, 3H, J = 7.2), 1.32-1.80(m, 12H), 2.61(brt, 2H), 2.88(brt, 2H), 3.80(s, 3H), 4.11(brt, 2H), 6.02(d, 1H, J = 6.9), 6.97(dd, 1H, J = 3.6 and 5.1), 7.16(m, 1H), 7.26(dd, 1H, J = 1.2 and 5.1), 8.27(s, 1H), 10.89(d, 1H, J = 6.9)


 


I-248




0.98(t, 3H, J = 7.2), 1.32-1.81(m, 12H), 2.62(brt, 2H), 2.88(brt, 2H), 3.77(s, 3H), 4.10(br, 2H), 5.87(d, 1H, J = 6.9), 7.20(dd, 1H, J = 1.5 and 5.1), 7.31(dd, 1H, J = 3.0 and 5.1), 7.38(ddd, 1H, J = 1.5, 3.0 and 5.1), 8.27(s, 1H), 10.83(d, 1H, J = 6.9)


 


I-319




0.99(t, 3H, J = 7.2), 1.08-1.20(m, 9H), 1.32- 1.54(m, 6H), 1.60-1.82(m, 6H), 2.61-2.65(m, 2H), 2.87-2.91(m, 2H), 3.76-4.24(m, 6H), 4.36(d, 1H, J = 6.6), 5.00(m, 1H), 8.24(s, 1H), 10.77(d, 1H, J = 6.6)


 


I-323




0.99(t, 3H, J = 7.5), 1.10(dd, 6H, J = 5.1 and 6.9), 1.34-1.54(m, 6H), 1.60-1.83(m, 6H), 2.28(m, 1H), 2.60-2.66(m, 2H), 2.85-2.94(m, 2H), 3.76-4.22(m, 6H), 4.43(t, 1H, J = 6.3), 4.99(m, 1H), 8.24(s, 1H), 10.62(d, 1H, J = 6.3)


 


I-363




DMSO-d6 0.93(d, 6H, J = 7.2), 0.94(t, 3H, J = 7.2), 1.26-1.78(m, 12H), 2.17(m, 1H), 2.65(brt, 2H), 2.93(brt, 2H), 4.08(brm, 2H), 4.40(dd, 1H, J = 4.8 and 8.4), 8.11(s, 1H), 10.29(d, 1H, J = 8.4), 12.76(brs, 1H)


 


I-364




DMSO-d6 0.93(d, 6H, J = 7.2), 0.94(t, 3H, J = 7.2), 1.25-1.80(m, 12H), 2.17(m, 1H), 2.65(brt, 2H), 2.93(brt, 2H), 4.08(brm, 2H), 4.40(dd, 1H, J = 4.5 and 8.4), 8.11(s, 1H), 10.29(d, 1H, J = 8.4), 12.75(brs, 1H)


 


I-386




DMSO-d6 0.93(t, 3H, J = 7.2), 1.26-1.78(m, 12H), 2.65(brt, 2H), 2.93(brt, 2H), 4.02(d, 2H, J = 5.7), 4.08(brt, 2H), 8.11(s, 1H), 10.11(t, 1H, J = 5.4), 12.67(brs, 1H)
















TABLE 7













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-392




DMSO-d6 0.93(t, 3H, J = 7.2), 1.22-1.78 (m, 12H), 2.64(brt, 2H), 2.92(brt, 2H), 4.07(brt, 2H), 5.49(d, 1H, J = 6.9), 7.31-7.41(m, 5H), 8.09(s, 1H), 10.74(d, 1H, J = 6.9),  13.07(brs, 1H)


 


I-397




DMSO-d6 0.94(t, 3H, J = 7.5), 1.17-1.78 (m, 16H), 1.99-2.06(m, 2H), 2.64(brt, 2H), 2.93(brt, 2H), 4.08(brt, 2H), 8.07(s, 1H), 12.19(s, 1H)


 


I-463




DMSO-d6 0.93(t, 3H, J = 7.2), 1.25-1.78 (m, 12H), 1.48(s, 6H), 2.58-2.68(m, 2H), 2.87-2.97(m, 2H), 3.75(s, 3H), 4.00-4.13(m, 2H), 8.07(s, 1H), 10.23(s, 1H), 12.41(brs, 1H)


 


I-475




DMSO-d6 0.91(t, 3H, J = 7.2), 1.00(s, 9H), 1.26-1.48(m, 6H), 1.52-1.66(m, 4H), 1.67-1.79(m, 2H), 2.60-2.69(m, 2H), 2.88-2.97 (m, 2H), 3.98-4.18(m, 2H), 4.26(d, 1H, J = 8.4), 8.11(s, 1H), 10.42(d, 1H, J = 8.4),  12.64(brs, 1H)


 


I-476




DMSO-d6 0.92(t, 3H, J = 7.5), 1.22-1.47 (m, 6H), 1.50-1.64(m, 4H), 1.66-1.78 (m, 2H), 2.59-2.68(m, 2H), 2.87-2.97 (m, 2H), 3.98-4.12(m, 2H), 5.34(d, 1H, J = 6.9), 6.77(d, 2H, J = 8.7), 7.20(d, 2H, J = 8.7), 8.09(s, 1H), 9.53(s, 1H), 10.57(d, 1H, J = 6.9), 12.87(brs, 1H)


 


I-509




DMSO-d6 0.93(t, 3H, J = 7.2), 1.26-1.78 (m, 12H), 2.65(brt, 2H), 2.93(brt, 2H), 4.07(brt, 2H), 5.76(d, 1H, J = 7.2), 7.03(dd, 1H, J = 3.6 and 5.1), 7.13(m, 1H), 7.51(dd, 1H, J = 1.5 and 5.1), 8.12(s, 1H), 10.73(d, 1H, J = 7.2), 13.32(br, 1H)
















TABLE 8













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-515




DMSO-d6 0.93(t, 3H, J = 7.2), 1.20-1.80(m, 12H), 2.65(brt, 2H), 2.93(brt, 2H), 4.07(br, 2H), 5.59(d, 1H, J = 6.9), 7.13(dd, 1H, J = 1.2 and 3.0), 7.50(m, 1H), 7.58(dd, 1H, J = 3.0 and 5.1), 8.12 (s, 1H), 10.63(d, 1H, J = 6.9), 13.06(br, 1H)


 


II-001




0.99(t, 3H, J = 7.2), 1.26-2.04(m, 20H), 2.62(t-like, 2H), 2.75-2.89(m, 4H), 3.29(s, 3H), 3.51-4.18(m, 5H), 4.88(brm, 1H), 8.17(s, 1H), 10.82(brd, 1H)


 


II-010




0.98(t, 3H, J = 7.5), 1.32-1.54(m, 6H), 1.61-1.81(m, 6H), 2.60-2.64(m, 2H), 2.86-2.90(m, 2H), 2.93-3.08(m, 2H), 3.71(s, 3H), 3.77(s, 3H), 4.02-4.18(m, 2H), 5.10(m, 1H), 8.26(s, 1H), 10.71(d, 1H, J = 8.1)


 


II-026




0.98(t, 3H, J = 7.2), 1.23(t, 3H, J = 7.2), 1.32-1.82(m, 18H), 1.89-2.08(m, 2H), 2.62(t, 2H, J = 6.3), 2.79 (quint, 1H, J = 3.9), 2.87(t, 2H, J = 6.3), 4.03-4.23(m, 4H), 4.54(m, 1H), 8.25(s, 1H), 10.44(d, 1H, J = 8.7)


 


II-052




DMSO-d6 0.93(t, 3H, J = 7.2), 1.16-1.95 (m, 19H), 2.57-2.68 (m, 2H), 2.86-2.95(m, 2H), 3.92-4.06(m, 2H), 4.03(q, 2H, J = 7.2), 4.42(m, 1H), 8.09(s, 1H), 10.25(d, 1H, J = 9.0), 12.10(brs, 1H)


 


II-055




DMSO-d6 0.93(t, 3H, J = 7.5), 1.24-1.48(m, 6H), 1.51-1.66 (m, 4H), 1.67-1.78(m, 2H), 2.59-2.97(m, 6H), 3.96-4.14(m, 2H), 4.79(m, 1H), 8.11(s, 1H), 10.37(d, 1H, J = 8.1), 12.30-13.04(m, 2H)
















TABLE 9













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





III-004




0.94(t, 3H, J = 7.2), 1.18-1.82(m, 12H), 2.71(brt, 2H), 2.98(brt, 2H), 3.79(s, 3H), 4.14(brt, 2H), 7.02(d, 1H, J = 4.2), 7.63(d, J = 4.2, 1H), 8.25(s, 1H), 13.20(s, 1H)


 


III-012




DMSO-d6 0.94(t, 3H, J = 7.2), 1.28-1.81 (m, 12H), 2.71(brt, 2H), 2.98(brt, 2H), 4.13(brt, 2H), 6.98(d, 1H, J = 4.2), 7.55(d, J = 4.2, 1H), 8.26(s, 1H), 12.65(brs, 1H),  13.16(s, 1H)


 


IV-028




DMSO-d6 0.95(t, 3H, J = 7.5), 1.20-1.85 (m, 12H), 2.65-2.75 (m, 2H), 2.91-3.03(m, 2H), 3.61(s, 2H), 4.05-4.20(m, 2H), 7.02(s, 1H), 8.27(s, 1H), 12.00-12.90(br, 1H), 13.47(s, 1H)


 


X-110




DMSO-d6 0.91(t, 3H, J = 7.2), 1.24-1.78(m, 12H),  2.60-2.94(m, 6H), 4.04(m, 2H), 5.14 (brs, 1H), 8.14(s, 1H), 10.40(d, 1H, J = 9.6)


 


X-123




DMSO-d6 0.93(t, 3H, J = 6.9), 1.20-1.82 (m, 16H), 2.20-2.38 (br, 2H), 2.56-2.70(br, 2H), 2.70-2.98(m, 4H), 3.95-4.20(m, 2H), 8.08 (s, 1H), 12.22(br, 1H), 12.58(s, 1H)


 


X-125




DMSO-d6 0.95(t, 3H, J = 7.5), 1.30-1.82 (m, 12H), 2.73(t, 2H, J = 6.3), 3.00(t, 2H, J = 6.3), 3.82(s, 2H), 4.16(t, 2H, J = 7.2), 8.32(s, 1H), 13.84(s, 1H)


 


X-128




DMSO-d6 0.80(t, 6H, J = 7.2), 0.93(t, 3H, J = 7.2), 1.24-1.96(m, 16H), 2.63(br, 2H), 2.77(s, 2H), 2.91(br, 2H), 4.04(br, 2H), 8.08(s, 1H), 9.84(s, 1H), 11.96(s, 1H)
















TABLE 10













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-131




DMSO-d6 0.96(t, 3H, J = 7.2 Hz), 1.30- 1.79(m, 12H), 1.95-2.02(m, 4H), 2.65(br-s, 2H), 2.92(br-s, 2H), 3.51(t, 2H, J = 9.0 Hz), 3.75(t, 2H, J = 9.0 Hz), 4.09(br-s, 2H), 8.08(s, 1H), 10.5(s, 1H), 12.5(br-s, 1H)


 


X-138




DMSO-d6 0.85-0.89(m, 6H), 0.93(t, 3H, J = 7.2), 1.26-1.77(m, 15H), 2.44(t, 2H, J = 5.7), 2.64(br, 2H), 2.91(t, 2H, J = 6.0), 4.04 (br, 2H), 4.34(br, 1H), 8.10(s, 1H), 9.86(d, 1H, J = 8.7), 12.16(s, 1H)


 


X-139




DMSO-d6 0.93(t, 3H, J = 7.5 Hz), 1.30- 1.79(m, 12H), 1.95-2.02(m, 4H), 2.63- 2.73(m, 4H), 2.90-3.01(m, 4H), 4.03(br-s, 2H), 5.79(s, 1H), 7.50-7.64(m, 3H), 8.00(d, 2H, J = 7.2 Hz), 10.5(d, 1H, J = 9.0 Hz), 12.44(br-s, 1H)


 


X-157




DMSO-d6 0.93(t, 3H, J = 7.2), 1.12-1.76(m, 20H), 2.21(brd, 2H, J = 7.2), 2.64(br, 2H), 2.78(s, 2H), 2.91(br, 2H), 4.04(br, 2H), 8.08(s, 1H), 9.96(s, 1H), 11.96(br, 1H)


 


X-202




DMSO-d6 0.86(t, 6H, J = 6.3), 0.93(t, 3H, J = 7.2), 1.22-1.86(m, 17H), 2.20(t, 2H, J = 7.2), 2.56-2.68(m, 2H), 2.86-2.96(m, 2H), 3.96-4.12(m, 3H), 8.10(s, 1H), 9.68(d, 1H, J = 9.0), 11.99(brs, 1H)


 


X-205




DMSO-d6 0.95(t, 3H, J = 7.2), 1.28- 1.82(m12H), 2.66-2.75(m, 2H), 2.93-3.03(m, 2H), 4.06-4.22(m, 2H), 6.58(d, 1H, J = 16.2), 7.59(d, 1H, J = 16.2), 8.22(dd, 1H, J = 2.1 and 8.7), 8.28(s, 1H), 8.30(d, 1H, J = 8.7), 8.62(d, 1H, J = 2.1), 12.42(brs, 1H), 12.82(s, 1H)
















TABLE 11













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-225




DMSO-d6 0.95(t, 3H, J = 7.2), 1.27-1.50(m, 6H), 1.56-1.82(m, 6H), 2.65-2.75(m, 2H), 2.91-3.02(m, 2H), 4.04-4.22(m, 2H), 6.45(d, 1H, J = 15.9), 7.55(d, 1H, J = 15.9), 7.68(d, 2H, J = 8.7), 7.76(d, 2H, J = 8.7), 8.26(s, 1H), 12.31(brs, 1H), 12.46(s, 1H)


 


X-232




DMSO-d6 0.93(t, 3H, J = 7.5), 1.25-1.94(m, 28H), 2.05-2.20(m, 2H), 2.57-2.68(m, 2H), 2.78-2.98(m, 2H), 3.96-4.16(m, 2H), 8.08(s, 1H), 10.05(s, 1H), 12.18(br, 1H)


 


X-235




DMSO-d6 0.93(t, 3H, J = 7.5), 1.25-1.84(m, 18H), 2.00-2.15(m, 2H), 2.56-2.68(m, 2H), 2.82-2.98(m, 4H), 3.96-4.14(m, 2H), 8.08(s, 1H), 9.95(s, 1H), 11.97(br, 1H)


 


XI-004




DMSO-d6 0.94(t, 3H, J = 7.2), 1.22-1.50(m, 6H), 1.52-1.81(m, 6H), 2.61-2.71(m, 2H), 2.89-2.99(m, 2H), 3.96-4.20(m, 2H), 5.44(m, 1H), 8.17(s, 1H), 10.84(d, 1H, J = 8.4), 14.33(br, 1H)


 


XI-013




DMSO-d6 0.94(t, 3H, J = 7.2), 1.27-1.82(m, 12H), 2.64-2.74(m, 2H), 2.91-3.01(m, 2H), 4.05-4.18(m, 2H), 4.65(s, 2H), 6.90(d, 2H, J = 9.0), 7.61(d, 2H, J = 9.0), 8.23(s, 1H), 12.13(s, 1H), 12.98(brs, 1H)


 


XI-130




DMSO-d6 0.93(s, 9H), 0.94(t, 3H, J = 5.4), 1.25-1.48(m, 6H), 1.58(m, 5H), 1.73(m, 3H), 2.64(m, 2H), 2.92(m, 2H), 4.06(m, 2H), 4.49(m, 1H), 8.11(s, 1H), 10.17(d, 1H, J = 6.3)
















TABLE 12













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-131




DMSO-d6 0.89(s, 9H), 0.93(t, 3H, J = 5.4), 1.25-1.48(m, 6H), 1.58 (m, 5H), 1.72(m, 2H), 2.17(m, 1H), 2.64(m, 2H), 2.91(m, 2H), 4.06(m, 2H), 4.27(m, 1H), 8.10(s, 1H), 9.99(d, 1H, J = 7.2)


 


XI-148




DMSO-d6 0.95(t, 3H, J = 7.2), 1.24-1.84(m, 12H), 2.65-2.77(m, 2H), 2.90-3.05(m, 2H), 3.82(s, 2H), 4.05-4.20 (m, 2H), 7.31(s, 1H), 8.28(s, 1H), 12.66 (br s, 1H), 13.39(s, 1H)


 


XI-153




DMSO-d6 0.87(s, 9H), 0.92(t, 3H, J = 7.2), 1.26-1.82(m, 16H), 2.18(t, 2H, J = 7.5), 2.59-2.68(m, 2H),  2.86-2.93(m, 2H), 3.98-4.16(m, 3H), 8.10(s, 1H), 9.77(d, 1H, J = 9.0), 11.99(brs, 1H)


 


XI-166




DMSO-d6 0.94(t, 3H, J = 7.2), 1.10-2.0(m, 20H), 2.20-3.00(m, 6H), 3.95-4.20(m, 2H), 8.05(s, 1H), 10.44(s, 1H)


 


XI-185




DMSO-d6 0.95(t, 3H, J = 7.2), 1.26-1.84(m, 12H), 2.65-2.78(m, 2H), 2.90-3.03(m, 2H), 3.60(s, 2H), 4.06-4.20 (m, 2H), 7.72(dd, 1H, J = 2.1, 8.7), 8.19-8.24 (m, 2H), 8.27(s, 1H), 12.47(br s, 1H), 12.61(s, 1H)


 


XI-188




DMSO-d6 0.93(t, 3H, J = 7.2), 1.3-1.6(m, 22H), 1.72(br, 2H), 2.20(s, 2H), 2.65(t, 2H, J = 4.8), 2.92(t, 2H, J = 5.7), 4.05(br, 1H), 8.11(s, 1H), 10.03(t, 1H, J = 6.3)


 


XI-195




DMSO-d6 0.93(t, 3H, J = 7.5), 1.20-2.30(m, 16H), 2.55-3.00(m, 4H), 2.84(s, 2H), 3.50(t, 2H, J = 11.1), 3.60-4.20(m, 4H), 8.10(s, 1H), 10.13(s, 1H)
















TABLE 13













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-223




DMSO-d6 0.93(t, J = 7.5, 3H), 1.24-1.48(m, 6H), 1.48-1.64(m, 4H), 1.64-1.92(m, 4H), 2.16-2.30(m, 4H), 2.58-2.68(m, 2H), 2.88(s, 2H), 2.84-2.96(m, 2H), 4.04(t, 2H, J = 7.5), 8.06(s, 1H), 10.10(s, 1H), 12.02(br, 1H)


 


XI-230




DMSO-d6 0.93(t, 3H, J = 7.2), 1.26-1.80(m, 14H), 2.00-2.20(m, 6H), 2.60-2.68(m, 2H), 2.88-2.97(m, 2H), 3.40-3.54(m, 2H), 3.63- 3.74(m, 2H), 4.00-4.12(m, 2H), 8.09(s, 1H), 10.00(s, 1H), 12.04(brs, 1H)


 


XI-242




DMSO-d6 0.94(t, 3H, J = 7.4), 1.3-2.3(m, 20H), 2.65(brt, 2H), 2.94(brt, 2H), 4.09(brt, 2H), 8.08(s, 1H), 10.42(s, 1H)


 


XI-289




DMSO-d6 0.95(t, 3H, J = 7.5), 1.25-1.85(m, 12H), 2.65-2.75(m, 2H), 2.92-3.02(m, 2H), 4.06-4.20(m, 2H), 6.73(d, 1H, J = 16.5), 7.57(d, 1H, J = 16.2), 8.25(s, 1H), 9.03(s, 2H), 13.05(s, 1H)
















TABLE 14













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-151




0.99(d, 3H, J = 6.3), 1.00(d, 3H, J = 6.3), 1.32-1.84(m, 11H), 2.60(t, 2H, J = 6.0), 2.87(t, 2H, J = 6.0), 3.74(s, 3H), 4.05-4.20(m, 2H), 5.74 (d, 1H, J = 6.9), 7.24-7.56 (m, 5H), 8.25(s, 1H), 10.90(d, 1H, J = 6.3)


 


I-286




0.99(d, 3H, J = 6.3), 1.00(d, 3H, J = 6.3), 1.32-1.83(m, 11H), 2.62(t-like, 2H), 2.88 (t-like, 2H), 3.80(s, 3H), 4.13(br, 2H), 6.02(d, 1H, J = 6.6), 6.97(dd, 1H, J = 3.3 and 4.8), 7.16(m, 1H), 7.26(dd, 1H, J = 1.2 and 4.8), 8.27(s, 1H), 10.89(d, 1H, J = 6.6)


 


I-424




DMSO-d6 0.96(d, 6H, J = 6.6), 1.25-1.80(m, 11H), 2.58-2.70(m, 2H), 2.85-2.96(m, 2H), 3.98-4.15(m, 2H), 5.49(d, 1H, J = 6.9), 7.30-7.44(m, 5H), 8.09 (s, 1H), 10.71(d, 1H, J = 6.9), 13.07(br, 1H)


 


I-551




DMSO-d6 0.96(d, 6H, J = 6.3), 1.22-1.80(m, 11H), 2.65(brt, 2H), 2.91(brt, 2H), 4.08(br, 2H), 5.77(dd, 1H, J = 0.6 and 7.2), 7.03(dd, 1H, J = 3.6 and 5.1), 7.13(m, 1H), 7.51(dd, 1H, J = 1.2 and 5.1), 8.12(s, 1H), 10.71(d, 1H, J = 7.2), 13.30(br, 1H)


 


XI-109




1.01(d, 6H, J = 6.6), 1.3-1.7(m, 18H), 1.96(dt, 2H, J = 3.9, 14.4), 2.33(d, 2H, J = 13.8), 2.65(dd, 2H, J = 5.7, 5.7), 2.91(dd, 2H, J = 6.3, 6.3), 4.1-4.3 (br, 2H), 8.27(s, 1H), 10.75(s, 1H)


 


XI-118




DMSO-d6 0.98(d, 6H, J = 6.6), 1.35(br, 2H), 1.45(br, 2H), 1.5-1.8(m, 8H), 2.71(brt, 2H), 2.97(brt, 2H), 4.16(br, 2H), 7.02(s, 1H), 8.27(s, 1H), 13.47(s, 1H)
















TABLE 15













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-181




DMSO-d6 0.98(d, 6H, J = 6.6), 1.26-1.86(m, 11H), 2.65-2.80(m, 2H), 2.90-3.05(m, 2H), 3.81(s, 2H), 4.10-4.25 (m, 2H), 8.32(s, 1H), 12.65(br s, 1H), 13.84(s, 1H)


 


XI-182




DMSO-d6 0.98(d, 6H, J = 6.6), 1.26-1.84(m, 11H), 2.65-2.77(m, 2H), 2.90-3.03(m, 2H), 3.82(s, 2H), 4.10-4.25 (m, 2H), 7.31(s, 1H), 8.24(s, 1H), 12.63 (br s, 1H), 13.39(s, 1H)


 


XI-186




DMSO-d6 0.87(s, 9H), 0.95(d, 6H, J = 6.6), 1.26-1.82(m, 15H), 2.18(t, 2H, J = 7.5), 2.58- 2.68(m, 2H), 2.85-2.94 (m, 2H), 4.00-4.16(m, 3H), 8.10(s, 1H), 9.75(d, 1H, J = 9.0), 11.99 (brs, 1H)


 


XI-192




DMSO-d6 0.95(s, 3H), 0.97(s, 3H), 1.10-1.80 (m, 19H), 2.15-3.00(m, 6H), 4.00-4.20(m, 2H), 8.05(s, 1H), 10.43(s, 1H)


 


XI-198




DMSO-d6 0.95(s, 3H), 0.97(s, 3H), 1.25-2.30 (m, 13H), 2.55-3.00(m, 4H), 2.85(s, 2H), 3.50 (t, 2H, J = 11.4), 3.65-4.20(m, 4H), 8.09(s, 1H), 10.11(s, 1H)


 


XI-201




DMSO-d6 0.87(dd, 6H, J = 6.3 and 3.3), 0.95(d, 6H, J = 6.6), 1.28-1.80(m, 14H), 2.44(dd, 2H, J = 6.2 and 5.0), 2.64(t, 2H, J = 5.7), 2.89(t, 2H, J = 5.9), 4.05(br s, 2H), 4.34(m, 1H), 8.10(s, 1H), 9.83(d, 1H, J = 8.7), 12.16(br s, 1H)
















TABLE 16













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-202




DMSO-d6 0.89(s, 9H), 0.96(d, 6H, J = 6.3), 1.26-1.89(m, 11H), 2.16(dd, 1H, J = 14.7 and 10.2), 2.58(dd, 1H, J = 14.7 and 3.9), 2.64(t, 2H, J = 5.4), 2.90(t, 2H, J = 5.7), 4.07(dd, 2H, J = 10.2 and 6.0), 4.27(td, 1H, J = 9.8 and 3.7), 8.09(s, 1H), 9.96(d, 1H, J = 9.6), 12.06(br s, 1H)


 


XI-207




DMSO-d6 0.95(d, 6H, J = 6.6), 1.26-1.79(m, 21H), 2.19(s, 2H), 2.64 (t, 2H, J = 5.1), 2.90(t, 2H, J = 5.9), 3.40(d, 2H, J = 6.3), 4.08(br s, 2H), 8.11(s, 1H), 10.01(t, 1H, J = 6.2), 12.28(br s, 1H)


 


XI-228




DMSO-d6 0.95(d, 6H, J = 6.6), 1.25-1.79(m, 11H), 2.62-2.74(m, 3H), 2.84-2.94(m, 3H), 4.05-4.18(br, 2H), 5.16(m, 1H), 8.16(s, 1H), 10.40(d, 1H, J = 9.0), 12.64(br, 1H)


 


XI-235




DMSO-d6 0.96(d, 6H, J = 7.0), 1.15-1.64(m, 16H), 1.65-1.79(m, 3H), 2.15-2.26(m, 2H), 2.60-2.67(m, 2H), 2.79(s, 2H), 2.86-2.92(m, 2H), 3.98-4.15(m, 2H), 8.08(s, 1H), 9.94(s, 1H), 11.9(s, 1H)


 


XI-236




DMSO-d6 0.96(d, 6H, J = 7.0), 1.27-1.35(m, 2H), 1.37-1.81(m, 13H), 2.02-2.12(m, 2H), 2.58-2.66(m, 2H), 2.81-2.92(m, 4H), 3.96-4.15(m, 2H), 8.02(s, 1H), 9.97(s, 1H), 11.9(s, 1H)


 


XI-237




DMSO-d6 0.96(d, 6H, J = 7.0), 1.27-1.35(m, 2H), 1.37-1.53(m, 4H), 1.53-1.63(m, 2H), 1.66-1.78(m, 3H), 1.80-1.90(m, 2H), 2.15-2.29(m, 4H), 2.59-2.66(m, 2H), 2.85-2.92(m, 4H), 4.02-4.09(m, 2H), 8.10(s, 1H), 10.1(s, 1H), 12.0(s, 1H)
















TABLE 17













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-247




DMSO-d6 0.98(d, 6H,  J = 6.6), 1.26-1.84(m, 11H), 2.65-2.75(m, 2H), 2.90-3.00(m, 2H), 3.60(s, 2H), 4.08-4.20(m, 2H), 7.72(dd, 1H, J = 2.4, 8.4), 8.13-8.26(m, 2H), 8.26 (s, 1H), 12.61(s, 1H)


 


XI-261




0.99(s, 9H), 1.01(d, 6H, J = 7.5), 1.40-1.80(m, 12H), 2.14-2.20(m, 1H), 2.65(t, 2H, J = 5.7), 2.89-2.92(m, 2H), 4.13(m, 2H), 4.53-4.59 (m, 1H), 8.29(s, 1H), 10.61(d, 1H, J = 6.0)


 


XI-263




0.89(d, 3H, J = 6.6), 0.93(t, 3H, J = 6.6), 1.02(d, 6H, J = 6.6), 1.33-1.80(m, 15H), 1.94-2.05(m, 1H), 2.32-2.47(m, 2H), 2.66(t, 2H, J = 6.0), 2.88-2.93(m, 2H), 4.06(m, 1H), 4.19(m, 2H), 8.36(s, 1H), 10.28(s, 1H)
















TABLE 18













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-105




DMSO-d6 1.30-1.90(m, 8H), 1.71(s, 3H), 1.81(s, 3H), 2.65-2.77(m, 2H), 2.87-3.00 (m, 2H), 3.62(s, 2H), 4.82(d, 2H, J = 5.7), 5.11(m, 1H), 7.02(s, 1H), 8.29(s, 1H), 12.40(br s, 1H), 13.40(s, 1H)


 


XI-114




DMSO-d6 1.37(m, 6H), 1.55-1.75(m, 10H), 1.70(s, 3H), 1.77(s, 3H), 2.00-2.07(m, 2H), 2.64(m, 2H), 2.88(m, 2H), 4.76(m, 2H), 5.06(m, 1H), 8.08(s, 1H), 12.20(s, 1H)
















TABLE 19













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-36




DMSO-d6 1.28-1.95(m, 10H), 2.39-2.56(m, 2H), 2.71(br, 2H), 2.99(br, 2H), 3.61(s, 2H), 4.22(t, 2H, J = 7.5), 7.02(s, 1H), 8.29 (s, 1H), 13.39(s, 1H)


 


X-54




DMSO-d6 1.30-1.86(m, 10H), 2.39-2.56(m, 2H), 2.65(br, 2H), 2.94(t, 2H, J = 6.0), 5.49(d, 1H, J = 6.9), 7.32-7.41(m, 5H), 8.11(s, 1H), 10.69(d, 1H, J = 6.9)


 


X-55




DMSO-d6 1.20-2.08(m, 20H), 2.40-2.57(m, 2H), 2.65(br, 2H), 2.94(br, 2H), 4.16(t, 2H, J = 7.5), 8.08(s, 1H), 10.21(s, 1H), 12.23 (br, 1H)


 


X-102




DMSO-d6 0.92(d, 6H, J = 6.6), 1.25-1.88(m, 10H), 2.17(m, 1H), 2.40-2.57(m, 2H), 2.66 (br, 2H), 2.94(br, 2H), 4.16(br, 2H), 4.39(dd, 1H, J = 4.5 and 8.4), 8.13(s, 1H), 10.23(d, 1H, J = 8.4), 12.80(br, 1H)


 


X-103




DMSO-d6 1.28-1.95(m, 10H), 2.40-2.57(m, 2H), 2.73(br, 2H), 3.01(t, 2H, J = 5.4), 3.81(s, 2H), 4.24(t, 2H, J = 7.8), 8.34(s, 1H), 13.75(s, 1H)


 


X-106




DMSO-d6 1.30-1.90(m, 10H), 2.38-2.55(m, 2H), 2.66(t, 2H, J = 6.3), 2.95(t, 2H, J = 6.3), 4.15(t, 2H, J = 7.5), 5.76(d, 1H, J = 6.9), 7.02(dd, 1H, J = 3.6 and 5.1), 7.12(d, 1H, 3.0), 7.50(dd, 1H, J = 1.2 and 5.1), 8.13(s, 1H), 10.67(d, 1H, J = 6.9), 13.32(br, 1H)


 


X-115




DMSO-d6 1.28-1.94(m, 10H), 2.40-2.55(m, 2H), 2.72(br, 2H), 2.99(br, 2H), 3.81(s, 2H), 4.22(t, 2H, J = 6.9), 7.31(s, 1H), 8.29 (s, 1H), 13.32(s, 1H)
















TABLE 20













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-116




DMSO-d6 1.28-1.88(n, 13H), 2.40-2.55(m, 4H), 2.65(br, 2H), 2.93(br, 2H), 4.13(br, 2H), 4.77(br, 1H), 5.55-5.60(m, 2H), 8.12(s, 1H), 9.99(d, 1H, J = 8.4)


 


X-117




DMSO-d6 0.87(m, 6H), 1.24-1.84(m, 13H), 2.37-2.48(m, 4H), 2.65(br, 2H), 2.92(br, 2H), 4.11(br, 2H), 4.33(br, 1H), 8.12(s, 1H), 9.81(d, 1H, J = 8.7)


 


X-129




DMSO-d6 0.81(t, 6H, 7.2), 1.26-1.94(m, 14H), 2.39-2.55(m, 2H), 2.64(br, 2H), 2.77 (s, 2H), 2.92(br, 2H), 4.13(t, 2H, J = 7.8), 8.11(s, 1H), 9.78(s, 1H), 11.97(s, 1H)


 


X-155




DMSO-d6 1.15-1.88(m, 18H), 2.22(d, 2H, J = 8.7), 2.42-2.52(m, 2H), 2.64(br, 2H), 2.78 (s, 2H), 2.93(br, 2H), 4.14(t, 2H, J = 7.8), 8.11(s, 1H), 9.91(s, 1H), 11.82(br, 1H)


 


X-158




DMSO-d6 1.28-1.86(m, 14H), 2.23(br, 2H), 2.37-2.48(m, 2H), 2.64(br, 2H), 2.80(br, 2H), 2.93(br, 2H), 4.12(t, 2H, J = 7.5), 8.10 (s, 1H), 12.26(br, 1H), 12.56(s, 1H)


 


X-169




DMSO-d6 1.28-1.93(m, 10H), 2.41-2.57(m, 2H), 2.71(br, 2H), 2.99(t, 2H, J = 5.4), 4.22 (t, 2H, J = 7.8), 6.58(d, 1H, J = 15.9), 7.59 (d, 1H, J = 16.2), 8.22(dd, 1H, J = 2.1 and 8.7), 8.30(s, 1H), 8.31(d, 1H, J = 9.0), 12.42 (br, 1H), 12.76(s, 1H)
















TABLE 21













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-170




DMSO-d6 1.28-1.93(m, 10H), 2.41-2.53(m, 2H), 2.56(t, 2H, J = 7.5), 2.70(br, 2H), 2.80 (t, 2H, J = 7.5), 2.98(br, 2H), 4.21(t, 2H, J = 7.2), 7.70(dd, 1H, J = 2.4 and 8.4), 8.19(d, 1H, J = 8.4), 8.20(s, 1H), 8.28(s, 1H), 12.18 (br, 1H), 12.50(s, 1H)


 


X-199




DMSO-d6 1.10-1.8(10H, m), 2.71(brs, 2H), 2.99(brs, 2H), 3..34(brs, 2H), 4.22(brs, 2H), 7.01(s, 1H), 8.28(s, 1H), 12.24(s, 1H), 13.36(s, 1H)


 


XI-140




DMSO-d6 0.93(s, 9H), 1.32(m, 2H), 1.43(m, 2H), 1.58(m, 3H), 1.78(m, 5H), 2.45(m, 2H), 2.65(m, 2H), 2.94(m, 2H), 4.16(m, 2H), 4.49(m, 1H), 8.13(s, 1H), 10.11(d, 1H, J = 6.0)


 


XI-141




DMSO-d6 0.89(s, 9H), 1.32(m, 2H), 1.44(m, 2H), 1.60(m, 2H), 1.71(m, 2H), 1.82(m, 2H), 2.18(m, 1H), 2.47(m, 2H), 2.62(m, 3H), 2.93(m, 2H), 4.14(m, 2H), 4.28(m, 1H), 8.12(s, 1H), 9.93(d, 1H, J = 7.2)


 


XI-161




DMSO-d6 0.86(dd, 6H, J = 6.3 and 5.7), 1.27- 1.84(m, 15H), 2.20(t, 2H, J = 7.7), 2.46(m, 2H), 2.65(t, 2H, J = 5.7), 2.92(t, 2H, J = 5.9), 4.03-4.15(m, 3H), 8.12(s, 1H), 9.62(d, 1H, J = 9.0), 12.03(br s, 1H)


 


XI-170




DMSO-d6 1.0-2.0(m, 20H), 2.20-3.05(m, 8H), 4.00-4.25(m, 2H), 8.07(s, 1H), 10.38(t, 1H, J = 5.7)


 


XI-176




DMSO-d6 1.26-1.49(m, 4H), 1.52-1.89(m, 5H), 2.38-2.54(m, 3H), 2.62-2.76(m, 3H), 2.82-3.00(m, 3H), 4.11-4.17(m, 2H), 5.16(m, 1H), 8.18(s, 1H), 10.38(d, 1H, J = 9.0), 12.66(br, 1H)
















TABLE 22













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-178




DMSO-d6 0.87(s, 9H), 1.22-1.90(m, 14H), 2.18(t, 2H, J = 7.5), 2.35-2.52(m, 2H), 2.60- 2.69(m, 2H), 2.88-2.97(m, 2H), 4.02-4.24(m, 3H), 8.12(s, 1H), 9.71(d, 1H, J = 9.0), 11.99(brs, 1H)


 


XI-217




1.40(m, 2H), 1.50(m, 2H), 1.69-2.03(m, 12H), 2.19-2.34(m, 4H), 2.63-2.66(m, 2H), 2.87-2.91(m, 2H), 3.06(s, sH), 4.16-4.21(m, 2H), 8.31(s, 1H), 10.41(s, 1H)


 


XI-226




DMSO-d6 1.22-1.46(m, 4H), 1.52-1.94(m, 8H), 2.22(t, 3H, J = 7.5), 2.36-2.52(m, 2H), 2.60-2.68(m, 2H), 2.88(s, 3H), 2.86-2.98(m, 2H), 4.12(t, 2H, J = 7.5), 8.09(s, 1H), 10.05(s, 1H), 12.01(br, 1H)


 


XI-244




DMSO-d6 1.22-1.89(m, 20H), 2.20(s, 2H), 2.46(m, 2H), 2.65(br s 2H), 2.95(t, 2H, J = 5.1), 3.40(d, 2H, J = 6.3), 4.15(t, 2H, J = 8.4), 8.14(s, 1H), 9.98(t, 1H, J = 6.3), 12.18(br s, 1H)


 


XI-253




DMSO-d6 1.24-1.96(m, 10H), 2.50-2.60(m, 2H), 2.64-2.76(m, 2H), 2.92-3.04(m, 2H), 3.60(s, 2H), 4.15-4.30(m, 2H), 7.72(dd, 1H, J = 2.1, 8.4), 8.19-8.25(m, 2H), 8.28(s, 1H), 12.45(br s, 1H), 12.54(s, 1H)


 


XI-260




1.27-1.77(m, 18H), 1.96-2.04(m, 2H), 2.18- 2.38(m, 6H), 2.61-2.70(m, 2H), 2.86-2.94(m, 2H), 4.15-4.24(m, 2H), 8.31(s, 1H), 9.94(s, 1H)


 


XI-266




DMSO-d6 0.85(s, 3H), 0.90(s, 3H), 1.14- 1.25(m, 8H), 1.25-1.90(m, 8H), 2.05-2.17(m, 2H), 2.38-2.50(m, 3H), 2.64(m, 1H), 2.81(s, 2H), 2.88-3.00(m, 2H), 4.08-4.15(m, 2H), 8.10(s, 1H), 9.90(s, 1H), 11.90(br, 1H)
















TABLE 23













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-283




DMSO-d6 1.22-2.00(m, 12H), 2.10-2.75(m, 6H), 2,85(s, 2H), 2.90-3.00(m, 2H), 3.50(t, 2H, J = 11), 3.64-3.80(m, 2H), 4.05-4.22(m, 2H), 8.11(s, 1H), 10.07(s, 1H)


 


XI-287




DMSO-d6 0.89(s, 9H), 0.91(s, 3H), 1.20- 2.00(m, 18H), 2.40-3.00(m, 6H), 4.10- 4.22(m, 2H), 8.08(s, 1H), 10.23(s, 1H)


 


XI-291




DMSO-d6 1.28-1.98(m, 10H), 2.40-2.60(m, 2H), 2.65-2.77(m, 2H), 2.93-3.05(m, 2H), 4.14-4.30(m, 2H), 6.73(d, 1H, J = 16.2), 7.57(d, 1H, J = 16.2), 8.27(s, 1H), 9.03(s, 2H), 12.30(br s, 1H), 12.98(s, 1H)
















TABLE 24













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-152




1.03(d, 6H, J = 6.9), 1.31-1.79(m, 10H), 2.29(m, 1H), 2.62-2.66 (m, 2H), 3.02-3.06(m, 2H), 3.03(s, 3H), 3.74(s, 3H), 4.36(t, 2H, J = 5.7), 4.69 (dd, 1H, J = 5.4 and 7.8), 8.29 (s, 1H), 10.38(d, 1H, J = 6.3)


 


I-153




1.30-1.78(m, 8H), 2.62(t, 2H, J = 6.0), 3.03(t, 2H, J = 6.0), 3.29(s, 3H), 3.68(t, 2H, J = 5.4), 3.74(s, 3H), 4.34(t, 2H, J = 5.4), 5.74(d, 1H, J = 6.6), 7.30-7.41(m, 3H), 7.47-7.52(m, 2H), 8.28(s, 1H), 10.84(d, 1H, J = 6.6)


 


I-425




DMSO-d6 0.92(d, 6H, J = 6.6), 1.23-1.77(m, 8H), 2.15(m, 1H), 2.62-2.70(m, 2H), 2.94-3.06(m, 2H), 3.23 (s, 3H), 3.62(t, 2H, J = 5.4), 4.22-4.35(m, 2H), 4.39 (dd, 1H, J = 4.5 and 8.4), 8.13(s, 1H), 10.22(d, 1H, J = 8.4), 12.74(br, 1H)


 


I-426




DMSO-d6 1.20-1.78(m, 8H), 2.40-2.64(m, 2H), 2.98-3.05(m, 2H), 3.22(s, 3H), 3.61(t, 2H, J = 5.7), 4.29(t, 2H, J = 5.4), 5.48(d, 1H, J = 6.9), 7.30-7.45(m, 5H), 8.11(s, 1H), 10.68(d, 1H, J = 6.9), 13.06(br, 1H)


 


XI-035




DMSO-d6 1.24-1.50(m, 4H), 1.52-1.84(m, 12H), 2.04-2.17(m, 2H), 2.60-2.68(m, 2H), 2.95-3.05(m, 2H), 3.23(s, 3H), 3.59(t, 2H, J = 7.6), 4.23(t, 2H, J = 7.6), 8.10(s, 1H), 9.85(s, 1H), 12.00(br, 1H)


 


XI-039




DMSO-d6 1.24-1.80(m, 8H), 2.67-2.77(m, 2H), 3.02-3.13(m, 2H), 3.24(s, 3H), 3.62(s, 2H), 3.67(t, 1H, J = 5.1), 4.36(t, 1H, J = 5.1), 7.02(s, 1H), 8.30 (s, 1H), 12.41(br s, 1H), 13.37(s, 1H)
















TABLE 25













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-047




DMSO-d6 1.15-1.80(m, 16H), 1.98-2.10(m, 2H), 2.60-2.70(m, 2H), 2.95-3.10(m, 2H), 3.24 (s, 3H), 3.63(t, 2H, J = 5.4), 4.30(t, 2H, J = 5.4), 8.09(s, 1H), 10.22(s, 1H), 12.20(br s, 1H)


 


XI-123




DMSO-d6 1.11-1.78(m, 16H), 2.14-2.28(m, 2H), 2.62-2.68(m, 2H), 2.78(s, 2H), 2.94-3.08(m, 2H), 3.23(s, 3H), 3.61(t, 2H, J = 5.4), 4.27(t, 2H, J = 5.4), 8.10(s, 1H), 9.89(s, 1H), 11.81(br, 1H)


 


XI-138




DMSO-d6 0.93(s, 9H), 1.30(m, 2H), 1.42(m, 2H), 1.57(m, 3H), 1.73(m, 3H), 2.65(m, 2H), 3.01(m, 2H), 3.23(s, 3H), 3.61(m, 2H), 4.28(m, 2H), 4.48(m, 1H), 8.13(s, 1H), 10.10(d, 1H, J = 6.0)


 


XI-139




DMSO-d6 0.90(s, 9H), 1.30(m, 2H), 1.43(m, 2H), 1.59(m, 2H), 1.70(m, 2H), 2.16(m, 1H), 2.62(m, 3H), 3.01(m, 2H), 3.24(s, 3H), 3.61(m, 2H), 4.28(m, 3H), 8.12(s, 1H), 9.93(d, 1H, J = 7.2)


 


XI-150




DMSO-d6 1.20-1.84(m, 8H), 2.65-2.80(m, 2H), 3.02-3.15(m, 2H), 3.24(s, 3H), 3.68(t, 1H, J = 5.1), 3.81(s, 2H), 4.38(d, 2H, J = 5.1), 8.34(s, 1H), 12.69 (br s, 1H), 13.78(s, 1H)


 


XI-158




DMSO-d6 1.24-1.82(m, 8H), 2.65-2.80(m, 2H), 3.02-3.15(m, 2H), 3.24(s, 3H), 3.67(t, 2H, J = 5.4), 3.82(s, 2H), 4.30-4.45(m, 2H), 7.31(s, 1H), 8.30(s, 1H), 12.65(br s, 1H), 13.30(s, 1H)


 


XI-160




DMSO-d6 0.86(t, 6H, J = 6.0), 1.14-1.80(m, 13H), 2.21(t, 2H, J = 7.7), 2.65(t, 2H, J = 5.7), 3.01(t, 2H, J = 6.2), 3.23(s, 3H), 3.60(t, 2H, J = 5.7), 4.04(m, 1H), 4.27(t, 2H, J = 5.4), 8.12(s, 1H), 9.51(d, 1H, J = 9.0), 12.00(br s, 1H)
















TABLE 26













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-169




DMSO-d6 1.10-1.18(m, 16H), 2.20-3.10(m, 6H), 3.24(s, 3H), 3.63(t, 2H, J = 5.4), 4.20-4.40(m, 2H), 8.08(s, 1H), 10.39(s, 1H)


 


XI-173




DMSO-d6 1.22-1.52(m, 4H), 1.52-1.78(m, 4H), 2.62-2.72(m, 4H), 2.85 (dd, 1H, J = 4.8 and 16.5), 2.98-3.07(m, 2H), 3.23 (s, 3H), 3.61(t, 2H, J = 5.4), 4.29(t, 2H, J = 5.4), 5.18(m, 1H), 8.18(s, 1H), 10.37(d, 1H,


 


XI-177




DMSO-d6 0.88(s, 9H), 1.23-1.82(m, 12H), 2.19(t, 2H, J = 7.5), 2.60-2.69(m, 2H), 2.95- 3.04(m, 2H), 3.22(s, 3H), 3.60(t, 2H, J = 5.4), 4.10(m, 1H), 4.27(t, 2H, J = 5.4), 8.12(s, 1H), 9.85(d, 1H, J = 9.0), 12.00(brs, 1H)


 


XI-199




DMSO-d6 0.87(dd, 6H, J = 6.3 and 3.3), 1.24- 1.73(m, 11H), 2.44(t, 2H, J = 6.6), 2.64(t, 2H, J = 5.4), 3.00(t, 2H, J = 5.9), 3.23(s, 3H), 3.59(t, 2H, J = 5.3), 4.26(t, 2H, J = 5.3), 4.33(m, 1H), 8.12(s, 1H), 9.80(d, 1H, J = 8.7), 12.18(br s, 1H)


 


XI-224




DMSO-d6 1.24-1.49(m, 6H), 1.49-1.76(m, 4H), 1.76-1.95(m, 2H), 2.16-2.30(m, 4H), 2.59-2.76(m, 2H), 2.88(s, 2H), 2.94-3.06(m, 2H), 3.23(s, 3H), 3.60(t, 2H, J = 5.4), 8.09 (s, 1H), 10.03(s, 1H), 12.02(br, 1H)


 


XI-243




DMSO-d6 1.26-1.80(m, 18H), 2.25(s, 2H), 2.72 (t, 2H, J = 5.4), 3.09(t 2H, J = 6.5), 3.31(s, 3H), 3.49(d, 2H, J = 6.3), 3.70(t, 2H, J = 5.4), 4.39(t, 2H, J = 5.6), 8.34(s, 1H), 10.23(t, 1H, J = 6.0), 12.49(br s, 1H)


 


XI-252




DMSO-d6 1.24-1.80(m, 8H), 2.65-2.75(m, 2H), 3.00-3.10(m, 2H), 3.60 (s, 2H), 3.67(t, 1H, J = 5.1), 4.30-4.40(m, 2H), 7.72(dd, 1H, J = 2.1, 8.7), 8.19-8.26 (m, 2H), 8.29(s, 1H), 12.40(br s, 1H), 12.52(s, 1H)
















TABLE 27













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-267




DMSO-d6 0.86(s, 3H), 0.90(s, 3H), 1.15- 1.52(m, 8H), 1.53-1.78(m, 6H), 2.02-2.18(m, 2H), 2.60-2.71(m, 2H), 2.81(s, 2H), 2.92- 3.16(m, 2H), 3.23(s, 3H), 3.61(t, 2H, J = 7.5), 4.27(t, 2H, J = 5.4), 8.10(s, 1H), 9.89(s, 1H), 11.95(br, 1H)


 


XI-279




DMSO-d6 1.25-1.80(m, 8H), 2.67-2.77(m, 2H), 3.00-3.12(m, 2H), 3.25(s, 3H), 3.67(t, 1H, J = 5.1), 4.30-4.40(m, 2H), 6.58(d, 1H, J = 16.2), 7.59(d, 1H, J = 15.9), 8.22(dd, 1H, J = 2.1, 8.7), 8.31(d, 1H, J = 8.7), 8.31(s, 1H), 8.62(d, 1H, J = 1.8), 12.44(br s, 1H), 12.73 (s, 1H)


 


XI-290




DMSO-d6 1.25-1.80(m, 8H), 2.65-2.77(m, 2H), 3.00-3.10(m, 2H), 3.25(s, 3H), 3.67(t, 1H, J = 5.1), 4.30-4.40(m, 2H), 6.73(d, 1H, J = 16.5), 7.57(d, 1H, J = 16.2), 8.27(s, 1H), 9.03(s, 2H), 12.96(s, 1H)


 


XI-297




1.34-1.71(m, 3H, J = 6.6), 2.19-2.41(m, 6H), 2.63-2.67(m, 2H), 3.02-3.07(m, 2H), 3.33(s, 3H), 3.71(t, 2H, J = 5.1), 4.36(t, 2H, J = 5.4), 8.34(s, 1H), 10.01(1H, s)


 


XI-305




0.93(s, 3H), 0.96(s, 3H), 1.36-1.80(m, 12H), 2.05-2.24(m, 2H), 2.66(m, 2H), 3.08(m, 2H), 3.30(s, 3H), 3.70(2H, t, J = 5.1), 4.37(t, 2H, J = 5.1), 8.31(s, 1H), 10.67(s, 1H)
















TABLE 28













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-001




1.02-1.96(m, 19H), 1.65(s, 6H), 2.73(s, 3H), 2.61(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 4.00(br, 2H), 8.29(s, 1H), 10.45(s, 1H)


 


I-002




1.00-1.98(m, 25H), 2.63(t, 2H, J = 5.7), 2.92(t, 2H, J = 5.7), 4.03(br, 2H), 5.23(br, 1H), 6.97(br, 1H), 8.28(s, 1H), 10.38(br, 1H)


 


I-003




1.00-1.98(m, 26H), 2.65(t, 2H, J = 6.0), 2.95(t, 2H, J = 6.0), 3.29(s, 3H), 4.09(br, 2H), 8.27(s, 1H), 10.56(d, 1H, J = 5.7)


 


I-005




1.00-1.90(m, 26H), 2.62(t, 2H, J = 5.7), 2.92(t, 2H, J = 6.3), 3.98(br, 2H), 4.48(d, 2H, J = 6.0), 7.18-7.40(m, 5H), 8.26(s, 1H), 10.35(br s, 1H)


 


I-006




1.00-1.90(m, 26H), 2.65(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 4.00(br, 2H), 7.03(m, 1H), 7.24-7.30(m, 2H), 7.56-7.62(m, 2H), 8.31(s, 1H), 10.53(br s, 1H)


 


I-007




1.00-1.90(m, 25H), 2.63(t, 2H, J = 6.0), 2.80(d, 3H, J = 4.5), 2.92(t, 2H, J = 6.0), 4.00(br, 2H), 7.09(br s, 1H), 8.27(s, 1H), 10.35(br s, 1H)


 


I-008




1.00-1.90(m, 25H), 2.63(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.0), 3.03(s, 6H), 4.02(br, 2H), 8.29(s, 1H), 10.29(br s, 1H)


 


I-009




1.02-1.90(m, 19H), 1.66(s, 6H), 2.63(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3), 3.73(s, 3H), 4.02(br, 2H), 4.06(d, 2H, J = 5.4), 7.52(brt, 1H), 8.28(s, 1H), 10.40(s, 1H)


 


I-010




1.00-1.96(m, 18H), 1.62(s, 6H), 2.63(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3), 3.37(q, 2H, J = 6.0), 3.73(t, 2H, J = 5.4), 3.98(br, 2H), 6.76(brt, 1H), 8.25(s, 1H), 10.49(s, 1H)
















TABLE 29













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-011




1.02-1.90(m, 19H), 1.63(s, 6H), 2.64(t, 2H, J = 5.7),  2.95(t, 2H, J =  6.0), 4.00(br, 2H),  4.09(d, 2H, J =  5.7), 7.06(t, 1H,  J = 6.0), 8.26(s, 1H), 10.59(s, 1H)


 


I-012




1.00-2.00(m, 19H),  1.63(s, 6H), 2.19(s, 6H), 2.42(t, 2H, J = 6.3), 2.63(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.34(q, 2H, J = 6.3), 4.00(br, 2H), 7.08(brt, 1H), 8.26(s, 1H),  10.30(s, 1H)


 


I-013




1.02-1.97(m, 19H), 1.63(s, 6H), 2.62(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3),  3.75(m, 1H),  3.86(dd, 2H, J =  3.3, 11.7), 3.98(dd,  1H, J = 3.3, 11.7),  6.83(d, 1H, J =  7.2), 8.20(s, 1H),  10.59(s, 1H)


 


I-014




1.03-1.93(m, 19H), 1.62(s, 6H), 2.63(t, 2H, J = 6.0), 2.94(t, 2H, J = 6.3), 3.30- 3.50(m, 2H), 3.54- 3.69(m, 2H), 3.80- 4.17(m, 3H),  6.90(brt, 1H),  8.24(s, 1H),  10.50(s, 1H)


 


I-015




1.03-1.91(m, 19H),  1.63(s, 6H),  2.41(brs, 4H),  2.48(t, 2H, J = 6.0),  2.63(t, 2H, J = 6.0),  2.93(t, 2H, J = 6.3),  3.34(q, 2H, J =  6.0), 3.53(brt, 4H),  4.03(br, 2H), 7.19(brt, 1H), 8.26(s, 1H),  10.32(s, 1H)


 


I-016




1.01-1.92(m, 19H),  1.65(s, 6H), 2.62(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3), 3.75(s, 6H), 4.00(br, 2H), 4.40(br, 3H),  7.28(s, 1H), 8.16(s,  1H), 10.68(s, 1H)


 


I-017




1.02-1.89(m, 19H),  1.63(s, 6H), 2.63(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3), 3.12(s, 3H), 3.34-3.70(m, 4H), 4.01(br, 2H), 4.07-4.16(m, 2H), 8.27(s, 1H),  10.48(s, 1H)


 


I-018




1.03-1.88(m, 19H),  1.65(s, 6H), 2.63(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3),  3.62(br, 4H), 3.62- 4.20(m, 4H),  8.22(s, 1H),  10.51(s, 1H)
















TABLE 30













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-019




1.02-1.90(m, 19H), 1.66(s, 6H), 2.62(t, 2H, J = 6.0), 2.92(t, 2H, J =  6.3), 3.17(br, 2H),  3.71(br, 2H),  4.09(br, 2H), 8.28(s, 1H),  10.34(s, 1H)


 


I-020




1.02-1.89(m, 19H), 1.63(s, 6H), 2.63(t, 2H, J = 6.0),  2.93(t, 2H, J = 6.3), 3.09(s, 3H), 3.53(t, 2H, J = 4.5), 3.82(t, 2H, J =  4.8), 4.01(br, 2H), 8.27(s, 1H), 10.47(s, 1H)


 


I-021




1.03-1.97(m, 19H), 1.64(s, 6H), 2.65(t, 2H, J = 6.0), 2.88- 2.98(m, 6H),  3.81(t, 4H, J = 4.8), 4.05(br, 2H),  8.26(s, 1H), 8.33(s, 1H), 10.34(s, 1H)


 


I-022




1.02-1.90(m, 19H), 1.66(s, 6H), 2.65(t, 2H, J = 6.0), 2.95(t, 2H, J =  6.3), 3.13(s, 3H), 4.00(br, 2H), 4.24(s, 2H), 8.28(s, 1H), 10.76(s, 1H)


 


I-023




1.07-1.83(m, 19H), 2.65(t, 2H, J =  6.9), 2.94(t, 2H, J = 6.3), 3.41-3.43(m, 2H), 3.70-3.74(m, 2H), 3.91-4.20(m, 4H), 8.30(s, 1H), 10.52(s, 1H)


 


I-024




1.00-1.94(m, 25H), 2.62(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0), 3.19(s, 3H), 3.51(s, 3H), 4.02(br, 2H), 8.30(s, 1H),  10.34(br s, 1H) 


 


I-025




1.00-1.92(m, 21H), 1.65(s, 6H), 2.64(t, 2H, J = 6.0), 2.94(t-like, 2H), 3.43(q-like, 3H), 3.63(t-like, 2H), 4.00(br, 2H), 7.23(br, 1H),  8.28(s, 1H), 10.39(brs, 1H)


 


I-026




1.02-1.94(m, 23H), 1.64(s, 6H), 2.64(t-like, 2H), 2.93(t, 2H, J =  6.3), 3.29-3.31(m, 2H), 3.63-3.67(m, 2H), 3.99(br, 2H), 7.15(br, 1H),  8.26(s, 1H), 10.34(brs, 1H)
















TABLE 31













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





I-031




0.87(d, 1H, J = 10.2), 0.94(s, 3H), 1.18(s, 3H), 1.01-2.31(m, 25H), 1.57(s, 3H), 1.64(s, 3H), 2.55-3.01(m, 6H), 3.61(m, 1H), 3.78(m, 1H), 4.00(br, 2H), 4.11(m, 1H), 6.53(brd, 1H, J = 8.4), 8.22(s, 1H), 10.46(brs, 1H)


 


I-032




1.00-1.94(m, 25H), 2.64(t, 2H, J = 6.0), 2.75(t, 2H, J = 7.2), 2.91(t, 2H, J = 6.0), 3.44(q, 2H, J = 6.6), 3.98(br, 2H), 6.69(d, 2H, J = 8.4), 7.02(d, 2H, J = 8.4), 7.08(m. 1H), 8.26(s, 1H), 10.31(br s, 1H)


 


I-033




1.00-1.94(m, 25H), 2.64(t, 2H, J = 6.0), 2.75(t, 2H, J = 7.2), 2.91(t, 2H, J = 6.0), 3.44(q, 2H, J = 6.6), 3.74(s, 3H), 3.98(br, 2H), 6.69(d, 2H, J = 8.4), 7.05-7.15(m, 3H), 8.26(s, 1H), 10.29(br s, 1H)


 


I-036




1.02-1.94(m, 19H), 1.63(s, 6H), 2.38-2.47(m, 4H), 2.51(t, 2H, J = 5.4), 2.61-2.65(m, 2H), 2.77(br, 1H), 2.90-2.95(m, 2H), 3.58(t, 2H, J = 5.4), 3.66-3.80(m, 4H), 3.86-4.20(br, 2H), 8.26(s, 1H), 10.26(s, 1H)


 


I-037




1.02-1.94(m, 19H), 1.58(s, 6H) 1.83(s, 3H) 2.60-2.73(m, 2H), 2.88-3.01(m, 2H), 3.50- 3.78(m, 4H), 3.85-4.36(m, 11H), 8.19(s, 1H), 10.45(s, 1H)


 


I-040




1.01-1.92(m, 23H), 1.63(s, 6H), 2.17(brs, 2H), 2.64(t-like, 2H), 2.93(t-like, 2H), 3.27(q-like, 2H), 3.62(t, 2H, J = 6.0), 4.00(br, 2H), 7.08(brt, 1H), 8.26(s, 1H), 10.35(brs, 1H)


 


I-041




1.01-1.92(m, 27H), 1.64(s, 6H), 2.64(t-like, 2H), 2.93(t-like, 2H), 3.26(q-like, 2H), 3.62(t, 2H, J = 6.3), 3.99(br, 2H), 7.18(brt, 1H), 8.28(s, 1H), 10.34(brs, 1H)


 


I-042




1.00-1.91(m, 19H), 1.65(s, 6H), 2.65(t-like, 2H), 2.93(t-like, 2H), 3.45(q-like, 2H), 3.56- 3.61(m, 4H), 3.68-3.70(m, 2H, 3.99(br, 2H), 7.81(brt, 1H), 8.28(s, 1H), 10.48(brs, 1H)
















TABLE 32













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-043




1.00-2.08(m, 19H),  1.62(s, 6H), 2.64(t- like, 2H), 2.93(t-like, 2H), 3.47(s, 9H), 3.84(brs, 4H), 4.00(br, 2H), 7.71(brt, 1H), 8.15(s, 1H),  10.39(s, 1H)


 


I-044




0.86(s, 6H), 1.01- 1.92(m, 19H), 1.65(s, 6H), 2.64(t-like, 2H), 2.94(t-like, 2H),  3.09(d, 2H, J = 6.6), 3.17(s, 2H), 3.99(br, 2H), 7.55(brt, 1H), 8.27(s, 1H),  10.37(brs, 1H)


 


I-045




1.02-1.90(m, 24H),  1.63(S, 6H), 2.61- 2.65(m, 2H), 2.90- 2.94(m, 2H), 3.14- 3.30(m, 2H), 3.70- 4.30(br, 2H), 3.80(m, 1H), 4.12-4.36(m, 2H), 8.26(s, 1H), 10.30(s, 1H)


 


I-046




1.02-1.93(m, 19H),  1.74(s, 6H), 2.62- 2.66(m, 2H), 2.93- 2.97(m, 2H), 3.75- 4.18(br, 2H), 8.27(s, 1H), 10.68(s, 1H), 11.29(s, 1H), 13.29(brs, 1H)


 


I-047




1.02-2.00(m, 19H),  1.64(s, 6H), 2.24(s, 3H), 2.28-2.38(m, 4H), 2.61-2.65(m, 2H), 2.90-2.94(m, 2H), 3.66-3.78(m, 4H), 3.80-4.20(br, 2H), 8.26(s, 1H), 10.25(s, 1H)


 


I-048




1.02-1.94(m, 19H), 1.59(s, 6H), 2.64- 2.68(m, 2H), 2.94- 2.98(m, 2H), 3.50- 3.66(m, 4H), 3.60(s, 6H), 3.86-4.16(br, 2H), 4.04-4.14(m, 4H), 8.18(s, 1H), 10.46(s, 1H)


 


I-049




1.02-1.94(m, 19H), 1.59(s, 6H), 2.64- 2.68(m, 2H), 2.94- 2.98(m, 2H), 3.50- 3.66(m, 4H), 3.60(s, 6H), 3.86-4.16(br, 2H), 4.04-4.14(m, 4H), 8.18(s, 1H), 10.46(s, 1H)


 


I-050




1.00-1.92(m, 19H), 1.65(s, 6H), 2.45- 2.90(br, 2H), 2.62- 2.71(m, 2H), 2.91- 2.95(m, 2H), 3.75- 4.25(br, 2H), 8.25(br, 1H), 8.26(s, 1H), 10.38(s, 1H)
















TABLE 33













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-051




1.02-1.94(m, 19H),  1.22(d, 6H, J = 6.0), 1.62(s, 6H), 2.62- 2.66(m, 2H), 2.93- 2.97(m, 2H), 3.80- 4.15(br, 2H), 3.97(m, 1H), 5.91(brs, 1H), 6.46(d, 1H, J = 7.8), 7.79(s, 1H), 8.23(s, 1H), 10.52(s, 1H)


 


I-052




1.02-1.94(m, 19H, 1.65(s, 6H), 2.62- 2.66(m, 2H), 2.92- 2.96(m, 2H), 3.06(s, 3H), 3.75-4.18(br, 2H), 6.93(d, 1H, J =  5.4), 8.24(s, 1H), 8.86(d, 1H, J = 5.4), 10.46(s. 1H)


 


I-053




1.02-1.90(m, 19H), 1.62(S, 6H), 2.33(m, 1H), 2.61-2.65(m,  2H), 2.76-2.96(m, 4H), 2.90-2.94(m,  2H), 3.75-4.25(br, 2H), 4.45-4.65(m, 4H), 5.35(brs, 1H), 5.64(brs, 1H), 8.24(s, 1H), 10.31(s, 1H)


 


I-054




1.02-1.95(m, 19H), 1.62(s, 6H), 2.63- 2.67(m, 2H), 2.93- 2.97(m, 2H), 3.75- 4.15(br, 2H), 3.95(d, 2H, J = 6.6), 5.37(brs, 1H), 6.65(t, 1H, J = 6.6), 7.66(brs, 1H), 8.20(s, 1H), 10.55(s, 1H)


 


I-055




1.01-1.92(m, 19H), 1.65(s, 6H), 2.63- 2.67(m, 2H), 2.92- 2.96(m, 2H), 3.80- 4.20(br, 2H), 4.17(d, 2H, J = 6.0), 8.25(s, 1H), 8.30(t, 1H, J = 6.0), 10.50(s, 1H)


 


I-056




1.01-1.94(m, 19H),  1.66(s, 6H), 2.66- 2.70(m, 2H), 2.93- 2.98(m, 2H), 3.80- 4.20(br, 2H), 4.86(d, 2H, J = 6.0), 6.74(t, 1H, J = 6.0), 8.33(s, 1H), 10.86(s, 1H)


 


I-057




1.03-1.90(m, 19H),  1.43(s, 9H), 1.63(s, 6H), 2.61-2.65(m,  2H), 2.90-2.95(m,  2H), 3.27-3.38(m, 4H), 3.60-3.70(m, 4H), 3.80-4.20(br, 2H), 8.24(s, 1H), 10.28(s, 1H)
















TABLE 34













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-058




1.02-1.90(m, 19H), 1.62(S, 6H), 2.61- 2.65(m, 2H), 2.69(s, 3H), 2.92- 2.96(m, 2H), 3.04- 3.17(m, 4H), 3.75- 3.87(m, 4H), 3.80- 4.20(br, 2H),  8.23(s, 1H), 10.28(s, 1H)


 


I-059




1.02-1.90(m, 19H), 1.28(d, 6H, J =  6.9), 1.62(S, 6H), 2.61-2.65(m, 2H), 2.91-2.95(m, 2H), 3.14(m, 1H), 3.20- 3.30(m, 4H), 3.68- 3.82(m, 4H), 3.80- 4.20(br, 2H), 8.24(s, 1H), 10.27(s, 1H)


 


I-060




1.02-1.94(m, 19H), 1.46(d, 6H, J =  6.6), 1.64(s, 6H), 2.62-2.66(m, 2H), 2.92-2.96(m, 2H), 3.41(m, 1H),  3.80-4.20(br, 2H), 6.85(d, 1H, J =  5.4), 8.24(s, 1H), 8.95(d, 1H, J = 5.4), 10.44(s, 1H)


 


I-061




DMSO-d6 1.01- 1.86(m, 19H),  1.31(s, 6H), 2.60- 2.70(m, 2H), 2.89- 3.01(m, 2H), 3.80- 4.16(br, 2H), 7.47- 7.65(m, 3H), 7.78- 7.84(m, 2H), 8.05(s, 1H), 9.67(s, 1H), 10.00(s, 1H), 10.12(s, 1H)


 


I-062




1.00-1.90(m, 25H), 2.67(t, 2H, J =  6.0), 2.95(t, 2H, J = 6.0), 4.01(br, 2H), 7.47-7.66(m, 3H), 8.06-8.11(m, 2H), 8.32(s, 1H), 10.59(br, 1H), 11.68(br, 1H)


 


I-072




1.02-1.92(m, 19H), 2.41(m, 1H), 2.64(t, 2H, J =  6.0), 2.74(m, 1H), 2.93(t, 2H, J = 6.3), 4.01(br, 2H), 4.31(ddd, 1H, J = 6.6 and 9.3 and  10.5), 4.52(dt, 1H, J = 1.8 and 9.0), 4.73(ddd, 1H, J =  7.2 and 9.0 and  11.1), 8.28(s, 1H), 10.54(d, 1H,  J = 7.2)


 


I-081




1.12-1.87(m, 19H), 2.64(t, 2H, J =  5.7), 2.92(t, 2H, J = 6.6), 3.77(s, 3H), 4.08(m, 2H), 4.22(d, 2H, J =  5.7), 8.29(s, 1H), 10.40(t, 1H,  J = 5.7)
















TABLE 35













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-082




1.02(d, 3H, J = 6.9), 1.04(d, 3H, J =  6.9), 1.11-1.84(m, 19H), 2.30 (m, 1H), 2.63(t, 2H, J = 5.7), 2.91(t, 2H, J = 6.6), 3.75(s, 3H), 4.12(m, 2H), 4.66(dd, 1H, J = 5.4, 2.7), 8.27(s, 1H), 10.45(d, 1H, J = 8.1)


 


I-083




1.02(d, 3H, J = 6.9), 1.04(d, 3H, J = 6.9), 1.11-1.84(m, 19H), 2.30 (m, 1H), 2.63(t, 2H, J = 5.7), 2.91(t,  2H, J = 6.6), 3.75(s, 3H), 4.12(m, 2H), 4.66(dd, 1H, J = 5.4, 2.7), 8.27(s, 1H), 10.45(d, 1H, J = 8.1)


 


I-084




1.05-1.83(m, 19H), 1.62(s, 6H), 2.62(t, 2H, J = 5.7), 2.91(t, 2H, J = 6.0), 3.76(s, 3H), 3.90-4.16(m, 2H), 8.26(s, 1H), 10.31(s, 1H)


 


I-104




1.11-2.22(m, 29H), 2.61(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.6), 3.98- 4.16(m, 2H), 8.25(s, 1H), 10.40(s, 1H)


 


I-105




1.15-1.69(m, 19H), 2.62(t, 2H, J = 6.0), 2.90(t, 2H, J = 6.3), 3.16- 3.23(m, 2H), 3.93-4.14(m, 2H), 4.96(m, 1H), 7.20-7.27(m, 5H), 8.23(s, 1H), 10.50(d, 1H, J = 7.5)


 


I-130




1.09-2.32(m, 27H), 2.61(t, 2H, J =  6.0), 2.91(t, 2H, J = 6.0), 3.74(s, 3H), 3.98-4.16(m, 2H), 8.26(s, 1H), 10.31(s, 1H)


 


I-131




0.93-2.05(m, 31H), 0.99(s, 9H), 2.62(t, 2H, J = 6.3), 2.91(t, 2H, J = 6.0), 3.73(s, 3H), 3.91-4.13(m, 2H), 4.76(m, 1H), 8.27(s, 1H), 10.28(d, 1H, J = 7.8)
















TABLE 36













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-132




1.01-1.72(m, 19H),  1.09(s, 9H), 2.62(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.3), 3.74(s, 3H), 3.92- 4.16(m, 2H), 4.54(d, 1H, J = 8.1), 8.26(s, 1H), 10.61(d, 1H, J = 7.8)


 


I-146




1.01-1.93(m, 22H), 2.63(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 3.78(s, 3H), 4.00(br, 2H), 4.74(m, 1H), 8.28(s, 1H), 10.36(br, 1H)


 


I-157




1.01-1.93(m, 30H),  2.63(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 3.74(s, 3H), 4.05(br, 2H), 4.66(m, 1H),  8.27(s, 1H), 10.42(br, 1H)


 


I-159




1.01-1.93(m, 30H),  2.63(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 3.74(s, 3H), 4.05(br, 2H), 4.66(m, 1H), 8.27(s, 1H), 10.42(br, 1H)


 


I-184




DMSO-d6 1.00- 1.84(m, 19H),  2.66(brm, 2H),  2.96(brm, 2H), 3.99(br, 2H), 5.75(d, 1H, J =  6.6), 7.03(dd, 1H, J = 3.6 and 5.1), 7.13(m, 1H), 7.51(dd, 1H, J =  1.5 and 5.1), 8.13(s, 1H), 10.70(d, 1H, J =  6.6), 13.30(br, 1H)


 


I-185




DMSO-d6 1.00-1.82(m, 23H), 1.46(s, 6H), 2.38(m, 1H), 2.60- 2.69(m, 2H), 2.72- 3.00(m, 4H), 3.85- 4.10(br, 2H), 4.13- 4.25(m, 2H), 8.07(s, 1H), 10.28(s, 1H), 12.16(brs, 1H)


 


I-190




DMSO-d6 1.01-1.93(m, 22H), 2.65(br, 2H),  2.95(br, 2H), 4.00(br, 2H), 4.41(m, 1H), 8.11(s, 1H), 10.19(d, 1H, J = 7.2), 12.78(br, 1H)
















TABLE 37













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-191




DMSO-d6 1.01-1.93(m, 30H), 2.65(br, 2H), 2.96(br, 2H), 3.97(br, 2H), 4.38(m, 1H), 8.12(s, 1H), 10.24(d, 1H, J = 8.4), 12.72(br, 1H)


 


I-195




DMSO-d6 1.01-1.93(m, 30H), 2.65(br, 2H), 2.96(br, 2H), 3.97(br, 2H), 4.38(m, 1H), 8.12(s, 1H), 10.24(d, 1H, J = 8.4), 12.72(br, 1H)


 


I-209




1.00-1.90(m, 19H), 2.63(t, 2H, J =  6.0), 2.93(t, 2H, J = 6.3), 3.73(s, 3H), 4.06(br, 2H), 5.60(d, 1H, J = 6.6), 6.67(d, 2H, J = 8.4), 7.25(d, 2H, J = 8.4), 8.28(s, 1H), 10.81(d, 1H, J = 6.6)


 


I-210




1.00-1.92(m, 19H), 2.59(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.75(s, 3H), 4.02(br, 2H), 5.72(d, 1H, J = 6.6), 7.31-7.45(m, 4H), 8.28(s, 1H), 10.96(d, 1H, J = 6.0)


 


I-235




1.17-1.72(m, 23H), 2.61-2.65(m,  2H), 2.90-2.94(m, 2H), 3.69(s, 3H), 3.81-4.08(m, 2H), 8.31(s, 1H), 10.34(s, 1H)


 


I-244




DMSO-d6 1.01-1.93(m, 22H),  2.65(br, 2H), 2.95(br, 2H), 4.00(br, 2H), 4.41(m, 1H), 8.11(s, 1H), 10.19(d, 1H, J = 7.2), 12.78(br, 1H)
















TABLE 38













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-259




1.00-1.92(m, 19H), 2.62(t, 2H, J = 6.0),  2.92(t, 2H, J = 6.3), 3.80(s, 3H),  4.00(br, 2H),  6.02(d, 1H, J =  6.9), 6.98(dd, 1H,  J = 3.6 and 5.1),  7.16(m, 1H),  7.26(dd, 1H,  J = 1.2 and 5.1), 8.28(s, 1H),  10.88(d, 1H, J = 6.9)


 


I-260




1.00-1.94(m, 19H), 2.62(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.77(s, 3H),  4.00(br, 2H),  5.87(d, 1H, J = 6.9), 7.02(dd, 1H, J = 1.2 and 5.1),  7.29(dd, 1H, J = 3.0 and 5.1), 7.38(m, 1H), 8.28(s, 1H), 10.82(d, 1H,  J = 6.9)


 


I-264




1.00-1.94(m, 19H),  2.62(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.6), 3.79(s, 3H),  4.00(br, 2H),  5.94(d, 1H, J = 7.2), 6.35(dd, 1H, J = 1.8 and 3.3), 6.43(m, 1H),  7.40(dd, 1H, J = 0.9 and 1.8),  8.28(s, 1H),  10.82(d, 1H,  J = 7.2)


 


I-265




1.09-1.89(m, 19H), 1.35(s, 3H), 1.48(s, 3H), 2.63(t, 2H, J =  5.7), 2.92(t, 2H, J = 6.3), 3.78(s, 3H), 3.95-4.12(m, 4H), 4.33-4.40(m, 2H), 4.55(m, 1H),  5.19(d, 1H, 7.5),  8.29(s, 1H),  10.45(t, 1H, J =  5.4)


 


I-268




1.02-1.97(m, 23H), 1.33(d, 6H, J =  6.9), 1.61(s, 6H),  2.62-2.66(m, 2H),  2.80-3.00(m, 4H),  3.07(m, 1H),  3.41(m, 1H), 3.80-4.20(br, 2H),  4.00(d, 1H, J =  9.0), 4.40-4.56(m,  2H), 8.24(s, 1H),  10.31(s, 1H)


 


I-269




1.00-1.96(m, 19H), 2.62(brt, 2H), 2.90(brt, 2H),  3.44(dd, 1H, J = 7.2  and 14.7), 3.52(dd, 1H, J = 5.4 and  14.7), 3.74(s, 3H), 3.98(br, 2H), 5.12(td, 1H, J =  5.7 and 7.2), 7.15(d, 1H, J =  2.1), 8.24(s, 1H),  8.75(d, 1H, J =  2.1), 10.53(d, 1H,  J = 7.2)
















TABLE 39













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-274




0.95-1.88(m, 19H), 2.61(t-like, 2H), 2.89(t-like, 2H), 3.74(s, 3H), 3.95(br, 2H), 6.56(d, 1H, J = 7.2), 7.45- 7.64(m, 5H), 7.85(t, 2H, J = 8.4), 8.29(s, 1H), 8.31(d, 1H, J = 8.4), 10.93(d, 1H, J = 7.2)


 


I-275




0.98-1.93(m, 19H), 2.59-2.63(m, 2H), 2.89-2.93(m, 2H), 3.74(s, 3H), 3.79(s, 3H), 3.80-4.20(br, 2H), 5.66(d, 1H, J = 6.3), 6.89(d, 2H, J = 9.0), 7.42(d, 2H, J = 9.0), 8.26(s, 1H), 10.81(d, 1H, J = 6.3)


 


I-276




1.00-1.94(m, 19H), 2.60-2.63(m,  2H), 2.89-2.94(m, 2H), 3.75(s, 3H), 3.80-4.20(br, 2H), 5.72(d, 1H, J = 6.3), 7.05(t, 2H, J = 8.7), 7.47(dd, 2H, J = 5.1 and 8.7), 8.25(s, 1H), 10.92(d, 1H, J = 6.3)    


 


I-277




0.98-1.90(m, 19H), 2.60(t, 2H, J = 6.0), 2.89(t, 2H, J = 6.3), 3.72(s, 3H), 3.89(s, 3H), 3.98(br, 2H), 6.07(d, 1H, J = 7.5), 6.91(d-like, 1H), 6.95(td, 1H, J = 7.5 and 0.9), 7.28(m, 1H), 7.44(dd, 1H, J = 7.5 and 1.8), 8.27(s, 1H), 10.82(d, 1H, J = 7.5)


 


I-284




1.00-1.94(m, 19H), 2.61-2.65(m, 2H), 2.90-2.94(m, 2H), 3.82(s, 3H), 3.86-4.22(br, 2H), 6.10(d, 1H, J =  6.9), 7.26-7.36(m, 2H), 7.39(s, 1H), 7.70-7.81(m, 2H), 8.28(s, 1H), 11.02(d, 1H, J = 6.9)
















TABLE 40













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-291




0.99-1.92(m, 19H),  2.61(t-like, 2H),  2.91(t-like, 2H),  3.74(s, 3H), 4.00(br,  2H), 5.74(d, 1H,  J = 6.6), 7.27- 7.52(m, 5H),  8.26(s, 1H), 10.89(d, 1H, J = 6.6)


 


I-296




1.00-1.94(m, 19H),  2.60-2.64(m, 2H),  2.90-2.94(m, 2H),  3.78(s, 3H), 3.80- 4.20(br, 2H), 5.79(d, 1H, J = 6.6), 7.34(m, 1H), 7.40- 7.47(m, 2H) 7.54- 7.62(m, 6H), 8.27(s, 1H), 10.95(d, 1H,  J = 6.6)


 


I-297




1.00-1.95(m, 19H),  2.61-2.65(m, 2H),  2.90-2.94(m, 2H), 3.81(s, 3H), 3.82- 4.18(br, 2H),  6.09(d, 1H, J = 7.5), 6.82(s, 1H), 7.17- 7.31(m, 2H), 7.46- 7.56(m, 2H), 8.28(s,  1H), 10.99(d, 1H,  J = 7.5)


 


I-300




1.00-1.90(m, 22H),  2.61(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0), 3.95(br, 2H), 4.22(q, 2H, J = 6.9), 8.27(s, 1H), 10.30(s, 1H)


 


I-301




1.03-1.95(m, 25H),  2.61(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.3), 4.00(br, 2H), 5.09(m, 1H), 8.26(s, 1H), 10.31(s, 1H)


 


I-302




1.00-1.96(m, 20H),  1.59(s, 3H), 1.70(s,  3H), 2.59(t, 2H, J =  6.0), 2.91(t, 2H, J =  6.6), 3.97(br, 2H),  4.15(d, 2H, J = 12.0), 4.32(d, 2H, J = 12.0), 4.78(t, 1H, J = 1.5), 5.52(s, 1H), 7.30- 7.47(m, 5H), 8.24(s, 1H), 10.31(s, 1H)
















TABLE 41













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-303




1.04-1.96(m, 31H), 2.61(t, 2H, J = 6.0),  2.92(t, 2H, J = 6.3), 3.78-4.34(m, 7H), 8.24(s, 1H), 10.29(s, 1H)


 


I-304




1.10-1.90(m, 25H),  2.62(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.76(dd, 2H, J = 5.7 and 12.6), 3.91(dd, 2H, J = 3.3 and 12.6), 3.98(br, 2H), 4.98(m, 1H), 8.21(s, 1H), 10.56(s, 1H)


 


I-305




1.05-1.90(m, 25H), 2.63(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3), 3.56(dd, 2H, J = 5.4 and 11.4), 3.66(dd, 2H, J = 4.2 and 11.4), 3.80-4.10(m, 3H), 4.27-4.32(m, 2H),  8.23(s, 1H), 10.56(s, 1H)


 


I-306




1.04-1.90(m, 19H),  1.61(s, 3H), 1.65(s, 3H), 2.61(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.47(s, 3H), 4.00(br, 2H), 5.32(s, 2H), 8.25(s, 1H)


 


I-307




1.02-1.96(m, 19H),  1.75(s, 6H), 2.63(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 4.00(br, 2H), 7.14-7.36(m,  5H), 8.30(s, 1H), 10.37(s, 1H)


 


I-308




1.01-1.96(m, 19H), 1.59(s, 6H), 2.19(s, 3H), 2.62(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 4.00(br, 2H), 4.89(s, 2H), 8.21(s, 1H), 10.28(s, 1H)


 


I-309




1.02-1.96(m, 19H), 1.61(s, 6H), 2.62(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.3), 4.02(br, 2H), 4.49(dd, 1H,  J = 2.1 and 10.2), 4.60(dd, 1H, J = 5.4 and 10.4), 6.73(dd, 1H, J = 2.1 and 5.4), 8.19(s, 1H), 10.34(s, 1H)
















TABLE 42













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-310




1.10-1.87(m, 19H), 1.31(t, 6H, J = 6.9), 2.62(t, 2H, J = 5.7), 2.91(t, 2H, J = 6.3), 3.92-4.18(m, 2H), 4.19-4.34(m, 4H), 5.36(d, 1H, J =  6.6), 8.25(s, 1H),  10.95(d, 1H, J = 6.3)


 


I-311




1.06-1.71(m, 19H), 2.64(t, 2H, J = 6.0), 2.92(t, 2H, J = 5.7), 3.94-4.18(m, 2H), 4.26(d, 2H, J =  5.7), 4.38-4.69(m,  4H), 8.29(s, 1H),  10.43(t, 1H, J =  2.4)


 


I-312




1.06-2.05(m, 19H),  2.64(t, 2H, J = 6.3), 2.93(t, 2H, J = 6.3), 3.91-4.18(m, 2H), 4.30(d, 2H, J =  5.7), 4.54(q, 2H,  J = 8.4), 8.29(s, 1H), 10.46(t, 1H,  J = 5.1)


 


I-313




1.16-1.71(m, 19H), 2.15(s, 3H), 2.64(t, 2H, J = 6.0), 2.75(t, 2H, J = 6.9), 2.92(t, 2H, J = 6.0), 3.84- 4.13(m, 2H),  4.22(d, 2H, J =  5.7), 4.34(t, 2H,  J = 6.9), 8.29(s, 1H), 10.41(t, 1H,  J = 5.1)


 


I-314




1.02-1.88(m, 21H), 2.60-2.78(m, 6H),  2.79(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.0), 3.79-4.12(m, 2H), 4.19-4.34(m, 4H), 8.28(s, 1H),  10.39(t, 1H, J =  5.4)


 


I-315




1.10-1.75(m, 19H), 2.52(t, 2H, J = 4.8), 2.61-2.68(m, 4H), 2.92(t, 2H, J = 6.9), 3.68-3.77(m, 4H), 3.82-4.12(m, 2H), 4.22(d, 2H, J =  5.4), 4.31(t, 2H,  J = 6.0), 8.29(s,  1H), 10.43(t, 1H,  J = 5.4)


 


I-316




1.03-1.85(m, 19H), 1.96-2.07(m, 2H), 2.38(t, 2H, J = 8.1), 2.64(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.9), 3.43-3.58(m, 4H), 3.82(m, 2H), 4.20(d, 2H, J =  5.4), 4.31(t, 2H, J = 5.7), 8.28(s, 1H), 10.41(t, 1H,  J = 5.7)


 


I-317




1.07-1.83(m, 19H), 1.45(s, 9H), 2.64(t, 2H, J = 5.7), 2.93(t, 2H, J = 6.3), 3.41- 3.44(m, 2H), 3.81- 4.25(m, 4H),  5.17(br, 1H),  8.29(s, 1H),  10.47(t, 1H, J =  5.4)
















TABLE 43













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-318




1.02-2.00(m,  31H), 2.61(t,  2H, J = 6.0),  2.91(t, 3H, J = 6.0), 4.04(br, 2H), 4.17- 4.30(m, 2H),  6.80(q, 1H,  J = 5.4), 8.24(s, 1H), 10.25(br, 1H)


 


I-320




1.06-1.80(m,  19H), 2.01(s,  3H), 2.65(t, 2H,  J = 6.0), 2.94(t,  2H, J = 6.0),  3.56(dd, 2H, J = 5.7, 10.8),  3.97-4.18(m,  2H), 4.17(d,  2H, J = 5.4),  4.27(m, 2H), 6.55(br, 1H), 8.27(s, 1H),  10.49(t, 1H, J = 5.4)


 


I-322




1.06-1.86(m,  19H), 2.64(t,  2H, J = 5.7),  2.92(t, 2H, J =  5.7), 3.15(t, 2H,  J = 6.9), 3.95- 4.09(m, 2H),  4.17(d, 2H, J =  5.7), 4.56(t, 2H, J = 6.6), 7.13- 7.22(m, 2H),  7.47(m, 1H), 8.28(s, 1H), 8.55(d, 1H, J =  5.1), 10.38(t,  1H, J = 5.4)


 


I-324




1.06-1.72(m,  19H), 1.22(s,  9H), 2.64(t, 2H,  J = 6.3), 2.92(t,  2H, J = 6.3),  3.98-4.15(m,  2H), 4.25(d, 2H  J = 5.7), 5.82(s,  2H), 8.28(s, 1H), 10.42(t, 1H, J =  4.8)


 


I-325




1.00-1.94(m,  26H), 2.28(s,  6H), 2.55- 2.70(m, 2H),  2.85-2.97(m,  2H), 3.98(br,  2H), 4.29(t,  2H, J = 5.4),  8.25(s, 1H), 10.32(br s, 1H)


 


I-326




1.00-1.94(m,  25H), 2.55- 2.70(m, 2H), 2.87-2.99(m,  2H), 3.52(s,  9H), 4.05(br,  2H), 4.05- 4.08(m, 2H), 4.58-4.70(m,  2H), 8.11(s,  1H), 10.41(br s,  1H)


 


I-328




1.06-1.86(m,  19H), 1.31(d,  6H, J = 6.3),  1.62(s, 6H),  2.61(t, 2H,  J = 6.0), 2.91(t,  2H, J = 6.0),  3.81-4.11(m,  2H), 4.89(m,  1H), 6.81(q, 1H,  J = 5.1), 8.24(s,  1H), 10.26(s,  1H)
















TABLE 44













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-329




0.88-1.94(m, 29H), 1.54(d, 3H, J = 6.0), 1.72(s, 6H), 2.63(t, 2H), J = 6.0), 2.92(t, 2H, J = 6.3), 3.75-4.23(m, 2H), 4.66(m, 1H), 6.83(q, 1H, J = 5.1), 8.24(s, 1H), 10.25(s, 1H)


 


I-331




0.94(t, 3H, J = 6.9), 1.06-1.85(m, 23H), 1.61(s, 6H), 2.35(t, 2H, J = 7.8), 2.61(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.3), 3.95-4.14(m, 2H), 5.81(s, 2H), 8.22(s, 1H), 10.27(s, 1H)


 


I-332




0.96-1.87(m, 29H), 1.62(s, 6H), 2.61(t, 2H, J = 5.7), 2.92(t, 2H), J = 6.0), 3.41-3.45(m, 4H), 3.83-4.16(m, 2H), 5.84(s, 2H), 8.23(s, 1H), 10.27(s, 1H)


 


I-333




1.02-1.89(m, 25H), 1.62(s, 6H), 2.61(t, 2H, J = 5.7), 2.94(t, 2H, J = 6.6), 3.22-3.34(m, 4H), 3.87-4.14(m, 2H), 5.85(s, 2H), 8.23(s, 1H), 10.28(s, 1H)


 


I-334




0.91(t, 3H, J = 7.5), 1.09-1.73(m, 23H), 1.61(s, 6H), 2.61(t, 2H, J = 5.1), 2.92(t, 2H, J = 5.1), 3.15-3.22(m, 2H), 3.79-4.18(m, 2H), 4.91(m, 1H), 8.23(s, 1H), 10.28(s, 1H)


 


I-335




0.90(d, 6H, J = 6.6), 1.01-1.86(m, 20H), 1.61(s, 6H), 2.63(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.97-4.09(m, 2H), 4.98(t, 1H, J = 6.0), 5.79(s, 2H), 8.22(s, 1H), 10.27(s, 1H)


 


I-336




1.11-1.85(m, 25H), 1.52(d, 3H, J = 5.4), 1.63(s, 6H), 2.61(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.6), 3.21-3.28(m, 4H), 3.81-4.18(m, 2H), 6.87(q, 1H, J = 5.4), 8.25(s, 1H), 10.27(s, 1H)


 


I-337




0.90(t, 3H, J = 7.2), 1.09-1.92(m, 23H), 1.62(s, 6H), 2.61(t, 2H, J = 5.7), 2.91(t, 2H, J = 6.3), 3.15-3.19(m, 2H), 3.72-4.13(m, 2H), 4.78(m, 1H), 6.83(q, 1H, J = 5.7), 8.24(s, 1H), 10.26(s, 1H)
















TABLE 45













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-338




0.88-1.74(m, 19H), 1.63(s, 6H), 2.39(t, 2H, J = 5.7), 2.87(t, 2H, J = 6.3), 3.95-4.15(m, 2H), 5.86(s, 2H), 6.83(s, 1H), 7.02-7.40(m, 5H), 8.09(s, 1H), 10.33(s, 1H)


 


I-339




1.00-1.94(m, 26H), 2.21(s, 6H), 2.36(t, 2H, J = 7.8), 2.60(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0), 3.98(br, 2H), 4.20(t, 2H, J = 5.4), 8.25(s, 1H), 10.29(br s, 1H)


 


I-340




1.00-1.94(m, 25H), 2.18-2.30(m, 2H), 2.63(t, 2H, J = 6.0), 2.94(t, 2H, J = 6.0), 3.45(s, 9H), 3.70-3.80(m, 2H), 4.00(br, 2H), 4.35-4.40(m, 2H), 8.01(s, 1H), 10.41(br s, 1H)


 


I-341




1.00-1.94(m, 25H), 2.55-2.70(m, 2H), 2.87- 2.99(m, 2H), 3.34(s, 6H), 4.00(br, 2H), 4.05- 4.08(m, 2H), 4.58-4.70(m, 2H), 5.06(s, 2H), 7.40-7.52(m, 3H), 7.66-7.70(m, 2H), 8.08(s, 1H), 10.41(br s, 1H)


 


I-342




1.00-1.94(m, 32H), 2.58-2.70(m, 2H), 2.87- 2.99(m, 2H), 3.49(s, 6H), 3.67-3.73(m, 2H), 3.78-4.20(m, 4H),4.60-4.70(m, 2H), 8.11(s, 1H), 10.41(br s, 1H)


 


I-343




0.88(t, 6H, J = 7.2), 1.00-1.94(m, 33H), 2.38- 2.50(m, 4H), 2.55-2.70(m, 2H), 2.72-2.80(m , 2H), 2.88-2.97(m, 2H), 3.98(br, 2H), 4.22(t, 2H, J = 5.4), 8.25(s, 1H), 10.30(br s, 1H)


 


I-344




1.00(t, 6H, J = 7.2), 1.00-1.94(m, 33H), 2.58- 2.68(m, 2H), 2.89-3.00(m, 2H), 3.35(s, 3H), 3.47-3.70(m, 4H), 3.80-4.12(m, 4H), 4.60- 4.69(m, 2H), 8.11(s, 1H), 10.38(br s, 1H)
















TABLE 46













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-345




1.00-1.94(m, 29H), 2.21(s, 6H), 2.29(t, 2H, J = 7.2), 2.61(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0), 3.98(br, 2H), 4.17(q, 2H, J = 6.3), 8.25(s, 1H), 10.29(br s, 1H)


 


I-346




1.00-1.94(m, 29H), 2.64(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.43(s, 9H), 3.64-3.76(m, 2H), 3.96(br, 2H), 4.27(t, 2H, J = 6.3), 8.05(s, 1H), 10.36(br s, 1H)


 


I-355




DMSO-d6 1.11-1.67(m, 19H), 2.66(t, 2H, J = 6.0), 2.95(t, 2H, J = 6.0), 4.00(m, 2H), 4.03(m, 2H), 8.12(s, 1H), 10.10(t 1H, J = 5.4), 12.67(s, 1H)


 


I-356




DMSO-d6 0.92(d, 3H, J = 6.9), 1.03(d, 3H, J = 6.0), 1.03-2.51(m, 19H), 2.16(m, 1H), 2.66(t, 2H, J = 5.7), 2.96(t, 2H, J = 6.0), 4.03(m, 2H), 4.39(m, 1H), 8.12(s, 1H), 10.28(d, 1H, J = 8.1), 12.76(s, 1H)


 


I-357




DMSO-d6 0.92(d, 3H, J = 6.9), 1.03(d, 3H, J = 6.0), 1.03-2.51(m, 19H), 2.16(m, 1H), 2.66(t, 2H, J = 5.7), 2.96(t, 2H, J = 6.0), 4.03(m, 2H), 4.39(m, 1H), 8.12(s, 1H), 10.28(d, 1H, J = 8.1), 12.76(s, 1H)


 


I-358




DMSO-d6 1.11-1.83(m, 19H), 1.48(s, 6H), 2.66(t, 2H, J = 4.8), 2.95(t, 2H, J = 6.0), 3.97- 4.07(m, 2H), 8.09(s, 1H), 10.22(s, 1H), 12.42(s, 1H)


 


I-379




DMSO-d6 1.13-2.05(m, 29H), 2.65(t, 2H, J = 5.1), 2.96(t, 2H, J = 6.0), 3.98-4.11(m, 2H), 8.08(s, 1H), 10.27(s, 1H), 12.18(s, 1H)
















TABLE 47













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-380




DMSO-d6 1.13-1.75(m, 19H), 2.62-3.18(m, 6H), 3.96-4.06(m, 2H), 4.70(m, 1H), 7.18- 7.27(m, 5H), 8.08(s, 1H), 10.25(d, 1H, J = 7.8), 12.88(s, 1H)


 


I-402




1.04-1.82(m, 19H), 2.60-2.69(m, 2H), 2.89- 3.00(m, 2H), 3.98-4.13(m, 2H), 5.71(d, 1H, J = 6.3), 7.25-7.54(m, 5H), 8.27(s, 1H), 11.00(d, 1H, J = 6.0)


 


I-403




1.06-1.86(m, 23H), 2.11-2.19(m, 2H), 2.44- 2.66(m, 2H), 2.65(t, 2H, J = 6.0), 2.95(t, 2H, J = 5.7), 3.95-4.14(m, 2H), 8.29(s, 1H), 10.80(s, 1H)


 


I-404




0.98(s, 9H), 1.06-1.90(m, 20H), 2.15(dd, 1H, J = 3.6, 14.7), 2.65(t, 2H, J = 5.7), 2.93(t, 2H, J = 6.0), 3.92-4.16(m, 2H), 4.53(m, 1H), 8.28(s, 1H), 10.63(d, 1H, J = 6.3)


 


I-405




1.06-1.93(m, 19H), 1.15(s, 9H), 2.64(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.6), 4.02-4.16(m, 2H), 4.47(d, 2H, J = 7.8), 8.28(s, 1H), 10.76(d, 1H, J = 7.8)


 


I-419




1.01-1.93(m, 25H), 2.64(t, 2H, J = 6.0), 2.77(t, 2H, J = 8.01), 2.93(t, 2H, J = 6.0), 2.99(s, 3H), 3.42-3.55(m, 2H), 3.83(s, 3H), 3.86(s, 3H), 4.00(br, 2H), 6.74-6.75(m, 3H), 8.26(s, 1H), 10.32(br, 1H)


 


I-421




1.01-1.93(m, 25H), 2.64(t, 2H, J = 6.0), 2.77(t, 2H, J = 8.01) 2.93(t, 2H, J = 6.0) 3.42-3.55(m, 2H), 3.86(S, 3H), 4.00(br, 2H), 5.43(br, 1H), 6.63-6.74(m, 3H), 7.13(br, 1H), 8.24(s, 1H), 10.30(br, 1H)
















TABLE 48













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-430




1.01-1.91(m, 21H), 1.62(s, 6H), 1.96-2.07(m, 2H), 2.62-2.66(m, 2H), 2.77(s, 3H), 2.82- 2.98(m, 4H), 3.58-3.69(m, 2H), 3.80-4.20(br, 3H), 7.42(d, 1H, J = 7.5), 8.24(s, 1H), 10.34(s, 1H)


 


I-432




1.01-1.93(m, 19H), 1.67(s, 6H), 2.03(s, 3H), 2.61-2.65(m, 2H), 2.91-2.95(m, 2H), 3.75- 4.20(br, 2H), 8.27(s, 1H), 8.28(brs, 1H), 9.58(d, 1H, J = 6.6), 10.46(brs, 1H)


 


I-454




1.02-1.94(m, 19H), 1.62(s, 6H), 2.63-2.67(m, 2H), 2.93-2.97(m, 2H), 3.75-4.20(br, 2H), 5.40-6.20(br, 2H), 6.18(brs, 1H), 7.99(brs, 1H), 8.22(s, 1H), 10.58(s, 1H)


 


I-455




1.01-1.93(m, 25H), 2.66(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 4.00(br, 2H), 7.42-7.60(m, 3H), 8.02(d, 2H, J = 7.2), 8.03(s, 1H), 10.67(br, 1H), 11.69(br, 1H)


 


I-456




1.01-1.93(m, 25H), 2.49(s, 3H), 2.66(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 4.00(br, 2H), 8.26(s, 1H), 9.16(d, 1H, J = 2.1), 10.45(br, 1H)


 


I-461




1.02-1.90(m, 19H), 1.09(d, 6H, J = 6.6), 1.63(s, 6H), 2.61-2.65(m, 2H), 2.72(m, 1H), 2.91-2.96(m, 2H), 3.37-3.54(m, 4H), 3.60- 3.77(m, 4H), 3.80-4.20(br, 2H), 8.23(s, 1H), 10.32(s, 1H)


 


I-462




1.01-1.93(m, 25H), 2.66(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 4.00(br, 2H), 4.49-4.64(m, 4H), 7.18-7.28(m, 2H), 7.40-7.52(m, 4H), 8.06(d, 2H, J = 7.8), 8.24(s, 1H), 10.27(br, 1H)
















TABLE 49













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-465




1.01-1.93(m, 34H), 2.66(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 3.44-3.60(m, 6H), 3.87(t, 2H, J = 5.1), 4.00(br, 2H), 4.59(t, 2H, J = 5.1), 8.13(s, 1H), 10.39(br, 1H)


 


I-481




1.03-1.92(m, 19H), 2.59-3.00(m, 4H), 3.75(s, 3H), 4.06(br, 2H), 5.56(s, 1H), 6.80(d, 2H, J = 8.4), 7.34(d, 2H, J = 8.4), 8.23(s, 1H)


 


I-482




1.00-1.90(m, 19H), 2.62(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.40(br, 2H), 5.69(d, 1H, J = 6.3), 7.32-7.49(m, 4H), 8.25(s, 1H), 11.03(d, 1H, J = 6.3)


 


I-501




1.05-1.73(m, 23H), 2.63-2.69(m, 2H), 2.91- 2.96(m, 2H), 4.00-4.18(m, 2H), 8.32(s, 1H), 10.61(s, 1H)


 


I-510




1.02-1.96(m, 19H), 1.68(s, 6H), 2.61-2.65(m, 2H), 2.91-2.95(m, 2H), 3.80-4.20(br, 2H), 7.40-7.56(m, 3H), 7.78-7.85(m, 2H), 8.31(s, 1H), 8.83(d, 1H, J = 5.7), 10.03(d, 1H, J = 5.7), 10.53(s, 1H)


 


I-525




DMSO-d6 1.00-1.84(m, 19H), 2.66(brm, 2H), 2.96(brm, 2H), 3.99(br, 2H), 5.75(d, 1H, J = 6.6), 7.03(dd, 1H, J = 3.6 and 5.1), 7.13 (m, 1H), 7.51(dd, 1H, J = 1.5 and 5.1), 8.13 (s, 1H), 10.70(d, 1H, J = 6.6), 13.30(br, 1H)
















TABLE 50













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-526




DMSO-d6 1.00-1.84(m, 19H), 2.65(brm, 2H), 2.96(brm, 2H), 4.00(br, 2H), 5.58(d, 1H, J = 6.9), 7.12(dd, 1H, J = 1.2 and 5.1), 7.51(m, 1H), 7.58(dd, 1H, J = 3.0 and 5.1), 8.13(s, 1H), 10.60(d, 1H, J = 6.9), 13.07(br, 1H)


 


I-530




DMSO-d6 1.00-1.85(m, 19H), 2.62(brm, 2H), 2.96(brm, 2H), 3.99(br, 2H), 5.65(d, 1H, J = 7.5), 6.45-6.48(m, 2H), 7.68(dd, 1H, J = 0.9 and 1.8), 8.13(s, 1H), 10.64(d, 1H, J = 7.2), 13.27(br, 1H)


 


I-533




1.02-1.92(m, 19H), 1.73(s, 6H), 2.64-2.68(m, 2H), 2.90-2.96(m, 2H), 2.94(s, 3H), 3.75- 4.25(br, 2H), 6.58(s, 1H), 7.16(d, 2H, J = 8.7), 7.56(d, 2H, J = 8.7), 8.31(s, 1H), 9.98(s, 1H), 10.56(s, 1H)


 


I-534




DMSO-d6 1.00-1.80(m, 19H), 2.64(brt, 2H), 2.93(brt, 2H), 3.22-3.33(m, 2H), 3.99(br, 2H), 4.81(m, 1H), 7.38(d, 1H, J = 1.8), 8.08(s, 1H), 9.01(d, 1H, J = 1.8), 10.21(d, 1H, J = 7.8), 12.83(br, 1H)


 


I-539




DMSO-d6 0.96-1.80(m, 19H), 2.63(brt, 2H), 2.93(brt, 2H), 3.94(br, 2H), 6.27(d, 1H, J = 7.2), 7.53-7.64(m, 4H), 7.92-8.01(m, 2H), 8.12(s, 1H), 8.21(d, 1H, J = 8.4), 10.82(d, 1H, J = 7.2), 13.16(br, 1H)


 


I-540




DMSO-d6 1.00-1.84(m, 19H), 2.66-2.70(m, 2H), 2.90-3.00(m, 2H), 3.75(s, 3H), 3.80- 4.15(br, 2H), 5.37(d, 1H, J = 6.6), 6.96(d, 2H, J = 9.0), 7.32(d, 2H, J = 9.0), 8.10(s, 1H), 10.61(d, 1H, J-6.6), 12.94(brs, 1H)
















TABLE 51













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-541




DMSO-d6 1.00-1.84(m, 19H), 2.60-2.70(m, 2H), 2.90-3.02(m, 2H), 3.85-4.20(br, 2H), 5.50(d, 1H, J = 6.9), 7.23(t, 2H, J = 9.0), 7.44(dd, 2H, J = 5.4 and 9.0), 8.10(s, 1H), 10.72(d, 1H, J = 6.9), 13.19(brs, 1H)


 


I-542




DMSO-d6 0.98-1.82(m, 19H), 2.60(brt, 2H), 2.94(brt, 2H), 3.82(s, 3H), 3.97(br, 2H), 5.77(d, 1H, J = 7.8), 6.96(td, 1H, J = 7.5 and 0.9), 7.06(d, 1H, J = 7.5), 7.27-7.35(m, 2H), 8.10(s, 1H), 10.55(d, 1H, J = 7.8), 12.72(br, 1H)


 


I-549




DMSO-d6 1.00-1.86(m, 19H), 2.60-2.71(m, 2H), 2.90-3.02(m, 2H), 3.85-4.15(br, 2H), 5.87(d, 1H, J = 6.9), 7.32-7.42(m, 2H), 7.47(s, 1H), 7.84(m, 1H), 7.93(m, 1H), 8.13(s, 1H), 10.85(d, 1H, J = 6.9), 13.52(brs, 1H)


 


I-556




1.02-2.10(m, 19H), 1.71(s, 6H), 2.61-2.65(m, 2H), 2.91-2.95(m, 2H), 3.80-4.20(br, 2H), 7.34(brs, 1H), 8.21(d, 1H, J = 7.8), 8.29(s, 1H), 8.75(brs, 1H), 9.09(bes, 1H), 9.33(brs, 1H), 10.05(s, 1H), 10.56(s, 1H)


 


I-561




DMSO-d6 1.00-1.86(m, 19H), 2.59-2.70(m, 2H), 2.89-3.02(m, 2H), 3.80-4.20(br, 2H), 5.53(d, 1H, J = 6.9), 7.34-7.53(m, 5H), 7.64- 7.74(m, 4H), 8.11(s, 1H), 10.77(d, 1H, J = 6.9), 13.15(brs, 1H)


 


I-562




DMSO-d6 1.00-1.86(m, 19H), 2.60-2.70(m, 2H), 2.90-3.01(m, 2H), 3.85-4.05(br, 2H), 5.86(d, 1H, J = 7.2), 6.95(s, 1H), 7.23-7.36(m, 2H), 7.57-7.67(m, 2H), 8.13(s, 1H), 10.80(d, 1H, J = 7.2), 13.48(br, 1H)
















TABLE 52













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-565




1.01-1.93(m, 25H), 2.64(t, 2H, J = 6.0), 2.77(t, 2H, J = 8.01), 2.93(t, 2H, J = 6.0), 3.42-3.55(m, 2H), 3.83(s, 3H), 3.86(s, 3H), 4.00(br, 2H), 6.74-6.75(m, 3H), 7.19(br, 1H), 8.26(s, 1H), 10.32(br, 1H)


 


I-566




1.01-1.93(m, 25H), 2.64(t, 2H, J = 6.0), 2.77(t, 2H, J = 8.01), 2.93(t, 2H, J = 6.0), 3.42-3.55(m, 2H), 4.00(br, 2H), 5.87(s, 2H), 6.62(s, 2H), 6.69(s, 1H), 7.11(br, 1H), 8.27(s, 1H), 10.30(br, 1H)


 


I-567




1.01-1.93(m, 25H), 2.64(t, 2H, J = 6.0), 2.77(t, 2H, J = 8.01), 2.93(t, 2H, J = 6.0), 3.42-3.55(m, 2H), 4.00(br, 2H), 5.08(s, 2H), 5.13(s, 2H), 6.68-6.84(m, 3H), 7.12(t, 1H, J = 5.4), 7.24- 7.48(m, 10H), 8.25(s, 1H), 10.31(br, 1H)


 


I-568




1.01-1.90(m, 21H), 1.32(d, 6H, J = 6.6), 1.62(s, 6H), 1.92-2.03(m, 2H), 2.63-2.66(m, 2H), 2.92-2.96(m, 2H), 2.98-3.10(m, 2H), 3.16(m, 1H), 3.66-3.78(m, 2H), 3.83-4.15(m, 3H), 7.34(d, 1H, J = 7.5), 8.25(s, 1H), 10.33(s, 1H)


 


I-569




1.02-1.95(m, 19H), 1.68(s, 6H), 2.61-2.65(m, 2H), 2.91-2.95(m, 2H), 3.80-4.40(br, 2H), 7.08(dd, 1H, J = 3.6 and 4.8), 7.50(dd, 1H, J = 0.9 and 4.8), 7.61(d, 1H, J = 3.6), 8.30(s, 1H), 8.69(brs, 1H), 9.86(brs, 1H), 10.52(s, 1H)


 


I-570




1.01-1.92(m, 24H), 1.41(s, 9H), 1.62(s, 6H), 2.62-2.66(m, 2H), 2.83-3.03(m, 4H), 3.58(m, 1H), 3.75-4.20(br, 2H), 4.32-4.52(m, 2H), 8.25(s, 1H), 10.28(s, 1H)


 


I-571




CDCl3 1.01-1.93(m, 25H), 2.66(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 4.00(br, 2H), 7.44(m, 1H), 8.33(s, 1H), 8.36(t, 1H, J = 2.1), 8.77(dd, 1H, J = 2.1 and 3.6), 9.23(d, 1H, J = 2.1), 10.74(br, 1H), 11.96(br, 1H)
















TABLE 53













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-572




1.02-1.98(m, 23H), 1.61(s, 6H), 2.62-2.66(m, 2H), 2.86-3.02(m, 4H), 2.94(s, 3H), 3.45(m, 1H), 3.70-4.20(br, 2H), 4.38(d, 1H, J = 7.5), 4.40-4.56(m, 2H), 8.24(s, 1H), 10.31(s, 1H)


 


I-574




1.01-1.93(m, 35H), 2.66(t, 2H, J = 6.0), 2.79(br, 2H), 2.96(t, 2H, J = 6.0), 4.00(br, 2H), 4.26(br, 2H), 8.24(s, 1H), 10.27(br, 1H)


 


I-575




0.99-1.90(m, 23H), 1.30(d, 6H, J = 6.9), 1.63(s, 6H), 2.60-2.64(m, 2H), 2.66-2.98(br, 2H), 2.67(s, 3H), 2.91-2.95(m, 2H), 3.10(m, 1H), 3.76(m, 1H), 3.80-4.20(br, 2H), 4.45- 4.80(br, 2H), 8.24(s, 1H), 10.29(s, 1H)


 


I-576




1.02-1.90(m, 19H), 1.74(s, 6H), 2.64-2.68(m, 2H), 2.92-2.96(m, 2H), 3.70-4.20(br, 2H), 5.30-6.30(br, 2H), 7.68(d, 2H, J = 9.0), 7.77(d, 2H, J = 9.0), 8.31(s, 1H), 10.45(s, 1H), 10.60(s, 1H)


 


I-577




1.02-1.96(m, 19H), 1.72(s, 6H), 2.53-2.68(m, 2H), 2.85-2.98(m, 2H), 3.70-4.20(br, 2H), 5.50-6.40(br, 2H), 8.11(dd, 1H, J = 2.1 and 8.7), 8.30(s, 1H), 8.37(d, 1H, J = 8.7), 8.74(brs, 1H), 9.78(s, 1H), 10.56(s, 1H)


 


I-578




1.02-1.90(m, 23H), 1.22(t, 3H, J = 7.2), 1.63(s, 6H), 2.43(m, 1H), 2.61-2.65(m, 2H), 2.90- 2.94(m, 2H), 2.95-3.08(m, 2H), 3.80-4.15(br, 2H), 4.09(q, 2H, J = 7.2), 4.30-4.43(m, 2H), 8.26(s, 1H), 10.30(s, 1H)


 


I-579




1.03-1.90(m, 19H), 1.63(s, 6H), 2.06(s, 3H), 2.61-2.65(m, 2H), 2.91-2.95(m, 2H), 3.34- 3.52(m, 4H), 3.62-3.76(m, 4H), 3.80-4.20(br, 2H), 8.23(s, 1H), 10.30(s, 1H)
















TABLE 54













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-580




1.02-1.88(m, 23H), 1.61(s, 6H), 2.04(m, 1H), 2.46(m, 1H), 2.62-2.66(m, 2H), 2.91-2.95(m, 2H), 3.40-4.30(m, 5H), 5.34(brs, 1H), 6.82(br, 1H), 8.23(s, 1H), 10.30(s, 1H)


 


I-581




0.88(t, 3H, J = 7.2), 1.02-1.88(m, 25H), 1.63(s, 6H), 2.25(m, 1H), 2.60-2.64(m, 2H), 2.72- 2.80(m, 2H), 2.90-2.94(m, 2H), 3.17(q, 2H, J = 7.2), 3.75-4.20(br, 2H), 4.46-4.64(m, 2H), 5.58(m, 1H), 8.24(s, 1H), 10.33(s, 1H)


 


I-582




1.01-1.93(m, 25H), 2.60-2.74(m, 4H), 2.96(t, 2H, J = 6.0), 3.38-3.47(q, 2H, J = 6.0), 4.00(br, 2H), 5.77(br, 1H), 6.55(d, 1H, J = 8.4), 6.69- 6.83(m, 3H), 8.23(s, 1H), 10.33(br, 1H)


 


I-583




1.02-1.91(m, 21H), 1.56(s, 6H), 1.92-2.03(m, 2H), 2.37-2.48(m, 2H), 2.63-2.67(m, 2H), 2.92-2.96(m, 2H), 3.60-3.76(m, 3H), 3.80- 4.20(br, 2H), 7.21(d, 1H, J = 8.1), 7.49- 7.63(m, 3H), 7.73-7.78(m, 2H), 8.23(s, 1H), 10.28(s, 1H)


 


I-584




1.01-1.93(m, 25H), 2.65(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 4.00(br, 2H), 7.32-7.40(m, 3H), 7.44-7.50(m, 2H), 8.30(s, 1H), 10.62(br, 1H), 11.68(br, 1H)


 


I-585




1.01-1.93(m, 25H), 2.65(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 4.00(br, 2H), 7.37(m, 1H), 8.10(d, 1H, J = 6.9), 8.31(s, 1H), 8.66(dd, 1H, J = 2.1 and 4.8), 8.92(d, 1H, J = 2.4), 10.66(br, 1H), 11.76(br, 1H)


 


I-586




1.01-1.93(m, 25H), 2.65(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 3.00(s, 3H), 4.00(br, 2H), 8.30(s, 1H), 10.50(br, 1H), 10.92(br, 1H)
















TABLE 55













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-587




1.01-1.93(m, 22H), 2.63(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 3.78(s, 3H), 4.00(br, 2H), 4.74(m, 1H), 8.28(s, 1H), 10.36(br, 1H)


 


I-588




1.02-1.96(m, 19H), 1.60(s, 6H), 2.46-2.50(m, 2H), 2.61-2.65(m, 2H), 2.92-2.96(m, 2H), 3.51-3.57(m, 2H), 3.80-4.20(br, 2H), 5.34(brs, 1H), 6.71(brs, 1H), 6.87(m, 1H), 8.18(s, 1H), 10.39(s, 1H)


 


I-589




1.03-1.96(m, 19H), 1.61(s, 6H), 1.95(s, 3H), 2.61-2.65(m, 2H), 2.93-2.97(m, 2H), 3.32- 3.48(m, 4H), 3.80-4.20(br, 2H), 6.59(t, 1H, J = 5.7), 6.89(m, 1H), 8.23(s, 1H), 10.46(s, 1H)


 


I-590




1.02-1.94(m, 19H), 1.62(s, 6H), 2.63-2.67(m, 2H), 2.82(d, 3H, J = 4.8), 2.93-2.97(m, 2H), 3.80-4.20(br, 2H), 3.96(d, 2H, J = 6.6), 6.56(t, 1H, J = 6.6), 7.58(m, 1H), 8.21(s, 1H), 10.54(s, 1H)


 


I-592




1.02-1.90(m, 22H), 1.20(t, 3H, J = 7.2), 1.63(s, 6H), 2.01(m, 1H), 2.43(m, 1H), 2.61-2.65(m, 2H), 2.72-2.96(m, 2H), 2.90-2.94(m, 2H), 3.75-4.20(br, 2H), 4.07(q, 2H, J = 7.2), 4.44(m, 1H), 4.73(m, 1H), 8.26(s, 1H), 10.32(s, 1H)


 


I-593




DMSO-d6 1.00-1.92(m, 23H), 1.47(s, 6H), 2.12(m, 1H), 2.58-2.83(m, 4H), 2.88-3.00(m, 2H), 3.75-4.30(m, 3H), 4.43(m, 1H), 8.08(s, 1H), 10.35(s, 1H), 12.23(br, 1H)


 


I-594




0.91(t, 3H, J = 7.5), 1.02-1.88(m, 26H), 1.63(s, 6H), 2.04(brs, 1H), 2.37(brs, 1H), 2.61- 2.65(m, 2H), 2.90-2.95(m, 2H), 3.12-3.26(m, 2H), 3.40-4.25(m, 4H), 6.62(brs, 1H), 8.23(s, 1H), 10.29(s, 1H)
















TABLE 56













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-595




1.02-1.88(m, 27H), 1.63(s, 6H), 2.04(brs, 1H), 2.37(brs, 1H), 2.61-2.65(m, 2H), 2.90- 2.94(m, 2H), 3.20-3.34(m, 2H), 3.40-4.25(m, 4H), 6.64(brs, 1H), 8.23(s, 1H), 10.29(s, 1H)


 


I-596




1.02-1.94(m, 19H), 1.45(t, 3H, J = 7.5), 1.64(s, 6H), 2.62-2.66(m, 2H), 2.92-2.96(m, 2H), 3.18(q, 2H, J = 7.5), 3.80-4.20(br, 2H), 6.92(d, 1H, J = 5.4), 8.24(s, 1H), 8.90(d, 1H, J = 5.4), 10.45(s, 1H)


 


I-597




1.01-1.93(m, 25H), 2.60-2.74(m, 4H), 2.96(m, 2H), 3.30-3.47(m, 2H), 4.00(br, 2H), 5.30(s, 1H), 6.39(s, 1H), 6.52(s, 1H), 7.19(br, 1H), 8.28(s, 1H), 10.28(br, 1H)


 


I-598




1.01-1.93(m, 25H), 2.61(t, 2H, J = 6.0), 2.70(br, 4H), 2.91(t, 2H, J = 6.0), 3.81(t, 2H, J = 5.4), 3.98(br, 2H), 4.37(t, 2H, J = 5.4), 8.22(s, 1H), 10.23(br, 1H)


 


I-599




1.01-1.93(m, 25H), 1.11(d, 6H, J = 6.3), 1.61(s, 6H), 2.61-2.65(m, 2H), 2.88-3.08(m, 4H), 3.68-3.86(m, 2H), 3.80-4.20(br, 2H), 4.28-4.50(m, 2H), 8.21(s, 1H), 10.35(s, 1H)


 


I-600




1.02-1.98(m, 23H), 1.14(d, 6H, J = 6.3), 1.62(s, 6H), 2.62-2.66(m, 2H), 2.89-3.01(m, 4H), 3.71-3.82(m, 2H), 3.80-4.20(br, 2H), 3.84-4.00(m, 2H), 4.23(m, 1H), 7.22(d, 1H, J = 8.1), 8.25(s, 1H), 10.32(s, 1H)


 


I-601




1.02-1.90(m, 28H), 1.63(s, 6H), 2.57-2.68(m, 4H), 2.80-2.98(m, 4H), 3.33-3.56(m, 4H), 3.80-4.20(br, 2H), 4.46-4.62(m, 2H), 8.27(s, 1H), 10.30(s, 1H)
















TABLE 57













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-602




1.02-1.90(m, 24H), 1.62(s, 6H), 2.26(m, 1H), 2.61-2.64(m, 2H), 2.77(d, 3H, J = 4.8), 2.83(m, 1H), 2.90-2.94(m, 2H), 3.75-4.20(br, 2H), 4.46-4.64(m, 2H), 5.61(m, 1H), 8.24(s, 1H), 10.32(s, 1H)


 


I-603




DMSO-d6 1.02-1.86(m, 19H), 1.51(s, 6H), 2.58-2.68(m, 2H), 2.90-3.00(m, 2H), 3.84- 4.12(br, 2H), 6.85-7.10(br, 2H), 8.07(s, 1H), 8.71(brs, 1H), 9.22(brs, 1H), 9.46(brs, 1H), 10.42(s, 1H)


 


I-604




1.02-1.90(m, 19H), 1.12(d, 6H, J = 6.3), 1.62(s, 6H), 2.61-2.65(m, 2H), 2.90-2.95(m, 2H), 3.21-3.32(m, 4H), 3.64-3.76(m, 4H), 3.85-4.22(m, 4H), 8.23(s, 1H), 10.31(s, 1H)


 


I-605




1.02-1.90(m, 23H), 1.62(s, 6H), 2.20-2.56(m, 3H), 2.62-2.65(m, 2H), 2.75-2.98(m, 4H), 3.75-4.20(br, 2H), 4.44-4.64(m, 2H), 8.25(s, 1H), 10.35(s, 1H)


 


I-606




1.02-1.90(m, 23H), 1.61(s, 6H), 2.51(m, 1H), 2.60-2.69(m, 2H), 2.78-3.00(m, 4H), 2.92(s, 3H), 3.80-4.20(br, 2H), 4.44-4.64(m, 2H), 7.14(d, 1H, J = 4.5), 8.25(s, 1H), 8.87(d, 1H, J = 4.5), 10.41(s, 1H)


 


I-607




1.02-1.86(m, 23H), 1.62(s, 6H), 1.96(brs, 1H), 2.34(m, 1H), 2.61-2.65(m, 2H), 2.74- 2.98(m, 4H), 3.38(q, 2H, J = 4.8), 3.68(t, 2H, J = 4.8), 3.80-4.20(br, 2H), 4.46-4.64(m, 2H), 6.46(m, 1H), 8.22(s, 1H), 10.39(s, 1H)


 


I-608




0.92(t, 3H, J = 7.2), 1.02-1.88(m, 28H), 1.63(s, 6H), 2.01(brs, 1H), 2.36(brs, 1H), 2.61- 2.65(m, 2H), 2.90-2.94(m, 2H), 3.14-3.28(m, 2H), 3.38-4.25(m, 4H), 6.60(br, 1H), 8.23(s, 1H), 10.29(s, 1H)
















TABLE 58













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-609




1.01-1.93(m, 25H), 2.61(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 4.03(br, 2H), 7.41(m, 1H), 7.84(m, 1H), 8.24(s, 1H), 8.25(m, 1H), 8.37(m, 1H), 10.41(br, 1H), 11.57(br, 1H)


 


I-610




1.01-1.93(m, 25H), 2.61(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 4.03(br, 2H), 7.92(br, 2H), 8.30(br, 1H), 8.82(br, 2H), 10.74(br, 1H), 12.01(br, 1H)


 


I-611




1.02-1.93(m, 19H), 1.62(s, 6H), 2.63-2.67(m, 2H), 2.93-2.97(m, 2H), 3.80-4.20(br, 2H), 5.51(s, 2H), 8.21(s, 1H), 10.13(s, 1H), 10.56(s, 1H)


 


I-612




1.02-1.96(m, 24H), 1.61(s, 6H), 2.55(m, 1H), 2.62-2.66(m, 2H), 2.80-3.02(m, 3H), 3.23(s, 3H), 3.80-4.20(br, 2H), 4.43-4.62(m, 2H), 8.23(s, 1H), 9.57(brs, 1H), 10.46(s, 1H)


 


I-613




1.02-1.90(m, 24H), 1.58(s, 6H), 2.62-2.66(m, 2H), 2.88(m, 1H), 2.91-2.95(m, 2H), 3.28(m, 1H), 3.75-4.15(br, 2H), 4.24-4.42(m, 2H), 4.64(d, 1H, J = 8.1), 7.45-7.60(m, 3H), 7.81- 7.87(m, 2H), 8.24(s, 1H), 10.28(s, 1H)


 


I-614




1.00-1.90(m, 24H), 1.57(s, 6H), 2.56-2.72(m, 3H), 2.80-3.10(m, 3H), 3.75-4.20(br, 2H), 4.36-4.60(m, 2H), 6.06(brs, 2H), 8.26(s, 1H), 10.51(s, 1H), 10.56(s, 1H)


 


I-615




1.02-1.88(m, 23H), 1.59(s, 6H), 2.24(brs, 1H), 2.56(brs, 1H), 2.62-2.66(m, 2H), 2.86- 2.98(m, 2H), 3.02-3.32(m, 2H), 3.60-4.40(m, 7H), 4.64(brs, 1H), 7.54(brs, 1H), 8.15(s, 1H), 10.39(brs, 1H)
















TABLE 59













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





I-616




0.89(t, 3H, J = 6.9), 1.02-1.88(m, 30H), 1.60(s, 6H), 2.01(brs, 1H), 2.36(brs, 1H), 2.61- 2.65(m, 2H), 2.90-2.94(m, 2H), 3.14-3.28(m, 2H), 3.40-4.20(m, 4H), 6.60(brs, 1H), 8.23(s, 1H), 10.29(s, 1H)


 


I-617




1.02-1.88(m, 22H), 1.66(s, 6H), 2.53-2.67(m, 4H), 2.80-2.98(m, 4H), 3.40-3.50(m, 2H), 3.54-3.69(m, 6H), 3.75-4.20(br, 2H), 4.46- 4.62(m, 2H), 8.26(s, 1H), 10.29(s, 1H)


 


I-618




1.01-1.93(m, 25H), 2.65(t, 2H, J = 6.0), 2.95(t, 2H, J = 6.0), 4.00(br, 2H), 4.25(s, 2H), 7.31(d, 2H, J = 4.5), 8.24(s, 1H), 8.56(d, 2H, J = 4.5), 9.44(br, 1H), 10.49(br, 1H)


 


I-619




1.01-1.93(m, 25H), 2.65(t, 2H, J = 6.0), 2.95(t, 2H, J = 6.0), 3.18(s, 6H), 4.02(br, 2H), 8.26(s, 1H), 10.38(br, 1H), 10.55(br, 1H)


 


I-620




1.01-1.93(m, 25H), 2.42-2.59(br, 4H), 2.63(t, 2H, J = 6.0), 2.95(t, 2H, J = 6.0), 3.23-3.47(br, 2H), 3.48-3.60(br, 4H), 4.00(br, 2H), 8.26(s, 1H), 10.14(br, 1H), 10.44(br, 1H)


 


II-002




1.09-1.92(m, 19H), 2.63(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.3), 3.00(dd, 2H, J = 2.1, 5.1), 3.71(s, 3H), 3.78(s, 3H), 4.02(m, 2H), 5.09(m, 1H), 8.26(s, 1H), 10.70(d, 1H, J = 7.8)


 


II-006




1.17-1.72(m, 19H), 2.67(t, 2H, J = 5.7), 2.94(t, 2H, J = 7.5), 3.99(s, 3H), 4.05-4.16(m, 2H), 7.12(dd, 1H, J = 7.2, 8.7), 7.54(dd, 1H, J = 6.9, 8.7), 8.01(d, 1H, J = 7.2), 8.35(s, 1H), 8.62(d, 1H, J = 6.9), 12.98(s, 1H)
















TABLE 60













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





II-014




1.6-1.88(m, 19H), 2.61- 2.69(m, 4H), 2.89-2.99(m, 2H), 3.67-3.77(m, 2H), 3.71(s, 3H), 3.94-4.07(m, 2H), 8.29(s, 1H), 10.16(s, 1H)


 


II-015




1.05-1.83(m, 19H), 1.27(t,  3H, J = 5.7), 2.61-2.67(m, 4H), 2.91(t, 2H, J = 6.3), 3.71(q, 2H, J = 6.6), 3.81- 3.99(m, 2H), 4.16(q, 2H, J = 7.2), 8.28(s, 1H), 10.17(br, 1H)


 


II-016




1.00-2.05(m, 28H), 2.62(t,  2H, J = 5.7), 2.80(m, 1H), 3.89(t, 2H, J = 6.3), 3.77- 4.09(m, 2H), 4.06-4.17(m, 2H), 4.53(m, 1H),  8.25(1H, s), 10.43(d, 1H, J = 8.7)


 


II-017




1.15-1.92(m, 19H), 1.33(t, 3H, J = 7.2), 2.46-2.65(m, 6H), 2.92(t, 2H, J = 5.7), 3.31(t, 2H, J = 7.5), 4.11- 4.20(m, 2H), 4.32(q, 2H, J = 7.2), 8.25(1H, s), 12.94(s, 1H)


 


II-034




DMOS-d6 1.12-1.91(m, 19H), 2.65(t, 2H, J = 5.4), 2.71-2.95(m, 2H), 3.33(t, 2H, J = 6.0), 3.92-4.06(m, 2H), 4.76(m, 1H), 8.13(s, 1H), 12.21-12.91(m, 2H)


 


II-035




1.05-1.83(m, 19H), 2.64(t, 2H, J = 5.7), 2.72(t, 2H, J = 6.3), 2.92(t, 2H, J = 6.0), 3.68-3.74(m, 2H), 3.78-4.17(m, 2H), 8.31(s, 1H), 10.27(t, 1H, J = 5.7)


 


II-038




DMSO-d6 1.12-1.83(m,  21H), 2.43(t, 2H, J = 6.9), 2.65(t, 2H, J = 6.3), 2.95(t, 2H, J = 6.0), 3.16(t, 2H, J = 7.2), 3.99-4.04(m, 2H), 8.14(s, 1H), 12.10(s, 1H), 12.75(s, 1H)
















TABLE 61













 









Comp. 




No.
Q
1H-NMR(CDCl3/TMS) δ





II-039




DMSO-d6 1.13-1.81(m, 25H),  2.62-2.66(m, 3H), 2.91-2.95(m, 2H), 3.95-4.05(m, 2H), 4.41(m, 1H),  8.10(s, 1H), 10.23(d, 1H, J = 8.7), 12.14(s, 1H)


 


II-042




1.17-1.73(m, 19H), 2.66(t, 2H, J =  5.1), 2.94(t, 2H, J = 6.6), 3.94- 4.22(m, 2H), 7.13(dd, 1H, J =  7.2, 8.1), 7.58(dd, 1H, J = 8.4, 7.2), 8.09(d, 1H, J = 8.1),  8.37(s, 1H), 8.73(d,  1H, J = 8.4), 13.15(s, 1H)


 


II-064




DMSO-d6 1.00-1.95(m, 19H), 2.60- 2.65(m, 2H), 2.90-3.00(m, 2H), 3.90-4.15(br, 2H), 7.81(d, 1H, J = 5.4), 8.20(d, 1H, J = 5.7), 8.23(s, 1H), 13.02(s,1H)


 


II-065




1.04-1.96(m, 23H), 2.60-2.74(m, 4H), 2.85-3.00(m, 4H), 3.90- 4.30(br, 2H), 8.35(s, 1H), 14.11(s, 1H)


 


II-066




DMSO-d6 1.02-1.90(m, 19H),  2.08(d, 3H, J = 0.9), 2.63-2.75(m, 2H), 2.92-3.03(m, 2H), 3.90- 4.15(br, 2H), 7.48(s, 1H), 8.21(s, 1H), 12.01(s, 1H)


 


II-068




DMSO-d6 1.00-1.84(m, 19H), 2.64(brt, 2H), 2.77-2.97(m, 4H),  3.98(br, 2H), 5.40(q-like, 1H), 7.23-7.40(m, 5H), 8.11(s, 1H), 10.42(d, 1H, J = 8.1), 12.26(br, 1H)
















TABLE 62













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





II-069




0.94(t, 6H, J = 6.3), 1.06- 1.73(m, 18H), 2.63-2.72(m,  4H), 2.91-2.95(m, 2H),  4.00(br, 2H), 4.37(m, 1H), 8.29(s, 1H), 10.43(d, 1H, J = 7.8)


 


II-070




1.08-1.71(m, 24H), 2.64(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0), 3.65(d, 2H, J = 6.0), 4.11(br, 2H), 8.31(s, 1H), 10.29(t 1H, J = 6.0)


 


II-071




1.07-1.73(m, 19H), 2.62(t, 3H, J = 6.0), 2.70(d, 2H, J = 6.0), 2.92(t, 2H, J = 6.0), 3.03(d, 2H, J = 6.0), 4.17(2H, br),  4.61-4.67(m, 1H), 7.16- 7.28(m, 5H), 8.26(s, 1H), 10.47(d, 1H, J = 6.0)


 


II-072




1.00-1.86(m, 19H), 2.57- 2.67(m, 2H), 2.88-2.98(m, 2H), 3.80-4.20(br, 2H), 7.33-7.47(m, 3H), 7.52-7.58(m, 2H), 8.13(s, 1H), 8.25(s, 1H), 12.79(s, 1H)


 


II-073




1.04-1.88(m, 26H), 2.15- 2.17(m, 2H), 2.64(t, 3H, J = 6.0), 2.93(t, 2H, J =  6.0), 2.98(s, 1H), 4.00(br, 2H), 8.28(s, 1H),  10.77(s, 1H)


 


II-074




1.08-1.88(m, 30H), 2.60- 2.79(m, 4H), 2.93(t, 2H,  J = 6.9), 3.77-4.12(m, 3H), 8.29(s, 1H), 10.60(d, 1H, J = 6.0)
















TABLE 63













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





II-075




1.06-1.84(m, 21H), 2.62-2.99(m, 6H), 4.00(bs(, 2H), 4.88- 4.95(m, 1H), 5.57- 5.81(m, 2H), 8.30(s, 1H), 10.39(d, 1H, J = 7.5)


 


II-076




1.05-1.85(m, 19H), 2.64(t, 2H, J = 5.4), 2.74-2.95(m, 6H), 4.00(br, 2H),  5.35(m, 1H), 8.32(s, 1H), 10.61(d, 1H, J = 9.6)


 


II-077




1.09-2.17(m, 25H),  2.62(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0), 3.65(m, 2H),  4.00(br, 2H), 8.28(s, 1H), 10.21(t, 1H, J = 6.0)


 


II-081




1.02-1.83(m, 25H), 2.09-2.27(m, 2H), 2.39-2.43(m, 2H), 2.62(t, 2H, J = 6.3), 2.91(t, 2H, J = 6.3), 3.97(br, 2H), 8.28(s, 1H), 10.00(s, 1H)


 


II-082




DMSO-d6 1.00- 1.84(m, 19H), 1.20(d, 3H, J = 6.6), 2.41(dd, 1H, J = 6.9 and 15.6), 2.55(dd, 1H, J = 5.7 and  15.6), 2.64(brt, 2H), 2.94(brt, 2H),  3.96(br, 2H), 4.27(m, 1H), 8.11(s, 1H), 9.90(d, 1H, J = 8.7), 12.25(br, 1H)


 


III-001




1.06-1.86(m, 19H),  2.65(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.73-4.35(m, 6H), 6.91(s, 1H), 7.05(t, 1H, J = 7.2), 7.27- 7.38(m, 5H), 8.32(s, 1H), 10.20(d, 1H, J = 5.7)


 


III-005




1.09-1.88(m, 19H),  1.93-1.98(m, 2H), 2.42(t, 2H, J = 7.5), 2.62-2.66(m, 2H), 2.89-2.96(m, 2H), 3.44-3.48(m, 2H), 3.67(s, 3H), 3.85- 4.12(m, 2H), 8.29(d, 1H, J = 4.2),  10.00(s, 1H)
















TABLE 64













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





III-008




1.18-1.74(m, 19H),  1.41(t, 3H, J = 7.2), 2.68(t, 2H, J = 6.3), 2.96(t, 2H, J = 6.6), 3.95-4.18(m, 1H), 4.38(q, 2H, J = 7.2), 7.42(dd, 1H, J = 7.8, 8.1), 7.78(d, 1H, J = 7.8), 8.12(d, 1H, J = 8.1), 8.30(s, 1H), 8.41(s, 1H), 12.32(s, 1H)


 


III-011




1.15-1.75(m, 19H), 2.69(t, 2H, J = 5.7), 2.97(t, 2H, J = 6.6), 3.84-4.15(m, 2H), 7.46(dd, 1H, J = 5.7, 4.8), 7.84(d, 1H, J = 5.7), 8.24(d, 1H, J = 4.8), 8.34(s, 1H), 8.42(s, 1H), 12.37(s, 1H)


 


III-013




1.07-1.85(m, 19H),  1.90-2.05(m, 2H), 2.43(t, 2H, J = 6.3), 2.68(t, 2H, J = 6.0), 2.94(t, 2H, J = 5.7), 3.52-3.56(m, 2H),  3.82-4.08(m, 2H), 8.32(s, 1H), 10.39(s, 1H)


 


III-014




DMSO-d6 1.00- 1.90(m, 19H), 2.65- 2.77(m, 2H), 2.93- 3.05(m, 2H), 4.06(br, 2H), 6.49(d, 1H, J = 3.6), 7.25(d, 1H, J = 3.6), 8.26(s, 1H), 12.84(br, 1H),  13.20(s, 1H)


 


III-015




1.02-1.90(m, 19H),  2.63-2.73(m, 2H), 2.69(s, 3H), 2.92- 3.00(m, 2H), 3.90- 4.20(br, 2H), 8.36(s, 1H), 13.66(s, 1H)


 


III-016




1.04-1.90(m, 19H), 1.36(t, 3H, J = 7.2), 2.62-2.73(m, 2H), 2.67(s, 3H), 2.90- 3.00(br, 2H), 4.31(q, 2H, J = 7.2), 8.34(s, 1H), 13.60(s, 1H)


 


III-017




1.06-2.05(m, 27H), 2.64(t, 2H, J = 6.3), 2.91(t, 2H, J = 6.3), 3.44-3.51(m, 2H), 4.00(br, 2H), 8.30(s, 1H), 9.97(m 1H)
















TABLE 65













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





III-018




1.05-2.09(m, 27H), 2.37(d, 2H, J = 12.3), 2.50(t, 2H, J = 12.3), 2.64(t, 2H, J = 5.1), 2.92(t, 2H, J = 5.1), 3.95-3.99(m, 2H), 8.32(s, 1H), 10.21(t, 1H, J = 7.6)


 


III-019




1.04-1.94(m, 19H), 2.63- 2.74(m, 2H), 2.91-3.02(m, 2H), 3.90-4.20(br, 2H), 7.94(s, 1H), 8.36(s, 1H), 13.66(s, 1H)


 


III-020




1.04-1.94(m, 19H), 2.63- 2.74(m, 2H), 2.92-3.03(m, 2H), 3.90-4.25(br, 2H), 5.61(br, 1H), 7.15(br, 1H), 7.82(s, 1H), 8.38(s, 1H), 13.50(s, 1H)


 


III-021




DMSO-d6 1.00-1.95(m,  19H), 2.64-2.80(m, 2H), 2.94-3.08(m, 2H), 3.94- 4.20(br, 2H), 8.09(s, 1H), 8.33(s, 1H), 12.80- 13.50(br, 1H), 13.75(s, 1H)


 


III-022




DMSO-d6 1.15-1.90(m,  19H), 2.63-2.80(m, 2H), 2.93-3.08(m, 2H), 3.95- 4.15(br, 2H), 8.27(s, 1H), 8.54(s, 1H), 13.29(s, 1H)


 


III-023







 


IV-002




1.05-2.33(m, 27H), 2.64(t, 2H, J = 6.0), 2.89(t, 2H, J = 5.7), 3.68(s, 3H), 3.92-4.13(m, 3H), 8.29(s, 1H), 9.86(d, 1H, J = 7.5)
















TABLE 66













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





IV-003




1.14-1.74(m, 19H), 2.68(t, 2H, J = 5.7), 2.95(t, 2H, J = 5.4), 3.90(s, 3H), 3.95- 4.18(m, 2H), 7.85(d, 2H, J = 5.7), 8.02(d, 2H, J = 6.6), 8.39(s, 1H), 12.48(s, 1H)


 


IV-008




1.09-1.85(m, 23H), 2.36(t, 2H, J = 7.2), 2.62-2.66(m, 2H), 2.88-2.96(m, 2H), 3.43-3.63(m, 2H), 3.66(s, 3H), 3.89- 3.98(m, 2H), 8.30(s, 1H), 9.96(s, 1H)


 


IV-009




1.15-1.71(m, 19H), 2.64(t, 2H, J = 6.3), 2.91(t, 2H, J = 6.6), 3.66(s, 3H), 3.66- 3.71(m, 4H), 3.82- 4.14(m, 2H), 4.67(s, 2H), 8.31(s, 1H), 10.21(s, 1H)


 


IV-010




1.17-1.73(m, 19H),  2.64(t, 2H, J = 6.0), 2.91-2.95(m, 4H),  3.42-3.57(m, 4H),  3.68(s, 3H), 3.90(s, 2H), 3.91-4.18(m, 2H), 7.23-7.43(m, 5H), 8.28(s, 1H), 10.10(s, 1H)


 


IV-011




1.06-1.87(m, 20H), 2.64(t, 2H, J = 5.7), 2.87-2.94(m, 4H), 3.49(s, 2H), 3.56- 3.60(m, 2H), 3.73(s, 3H), 3.82-4.18(m, 2H), 8.30(s, 1H), 10.10(m, 1H)


 


IV-012




1.09-2.19(m, 28H),  2.62-2.65(m, 2H), 2.91(t, 2H, J = 6.3), 3.89-4.00(m, 2H), 8.30(s, 1H), 9.90(d, 1H, J = 4.8)


 


IV-013




1.09-1.86(m, 19H), 2.69(t, 2H, J = 5.4), 2.96(t, 2H, J = 6.0), 3.84-4.21(m, 2H), 7.88(d, 2H, J = 8.7), 8.09(d, 2H, J = 9.0), 8.40(s, 1H), 12.54(s, 1H)
















TABLE 67













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





IV-018




1.05-1.80(m, 23H), 2.41(t, 2H, J = 7.2), 2.64(t, 2H, J = 5.7), 2.92(t, 2H, J = 6.6), 3.43-3.47(m, 2H), 3.81-4.12(m, 2H), 8.31(s, 1H), 10.04(s, 1H)


 


IV-019




1.11-1.73(m, 19H),  2.65-3.04(m, 6H), 3.65(m, 4H), 4.03- 4.14(m, 4H), 7.25- 7.40(m, 5H), 8.31(s, 1H)


 


IV-020




0.88-1.70(m, 19H),  2.60-2.69(m, 2H), 2.88- 3.10(m, 2H), 3.33- 4.16(m, 10H), 8.27(s, 1H), 10.35(m, 1H)


 


IV-021




1.04-1.90(m, 19H),  1.44(t, 3H, J = 7.2), 2.64-2.73(m, 2H), 2.92-3.01(m, 2H), 3.95-4.15(br, 2H), 4.46(q, 2H, J = 7.2), 8.27(s, 1H), 8.35(s, 1H), 13.57(s, 1H)


 


IV-022




1.04-1.90(m, 19H), 2.60-2.74(m, 2H), 2.94-3.02(m, 2H), 3.90-4.20(br, 2H), 8.36(s, 1H), 8.55(d, 1H, J = 0.9), 13.89(s, 1H)


 


IV-023




1.04-1.92(m, 19H),  2.65-2.73(m, 2H), 2.93- 3.02(m, 2H), 3.79(s, 2H), 3.95-4.15(br, 2H), 6.71(s, 1H), 8.36(s, 1H), 13.63(s, 1H)


 


IV-024




DMSO-d6 1.04-1.90(m,  19H), 1.20(t, 3H, J =  7.2), 2.65-2.77(m, 2H), 2.95-3.07(m, 2H), 3.07(s, 2H), 3.92- 4.16(br, 2H), 4.10(q, 2H, J = 7.2), 7.05(s, 1H), 8.29(s, 1H), 13.48(s, 1H)
















TABLE 68













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





IV-025




DMSO-d6 1.03-1.89(m, 19H), 2.70(brt, 2H), 2.99(brt, 2H), 3.58(s, 2H), 4.05(br, 2H), 6.99(d, 1H, J = 7.8), 7.29(t, 1H, J = 7.8), 7.52(s, 1H), 7.69(d, 1H, J = 7.8), 8.25(s, 1H), 12.30(s, 1H), 12.34(br, 1H)


 


IV-026




1.00-1.90(m, 19H), 2.62-2.73(m, 2H), 2.90- 3.00(m, 2H), 3.90-4.20(br, 2H), 5.68(br, 1H), 7.46(br, 1H), 8.35(s, 1H), 8.91(s, 1H), 13.64(s, 1H)


 


IV-027




DMSO-d6 1.05-1.90(m, 19H), 2.66-2.77(m, 2H), 2.93-3.05(m, 2H), 3.44(s, 2H), 3.95- 4.20(br, 2H), 6.96(br, 2H), 7.39(s, 1H), 8.29(s, 1H), 13.47(s, 1H)


 


IV-029




DMSO-d6 1.04-1.88(m, 19H), 2.70(brt, 2H), 2.99(brt, 2H), 3.49(s, 2H), 4.05(br, 2H), 6.78- 6.79(m, 2H), 8.23(s, 1H), 12.88(s, 1H)


 


V-001




1.01-2.05(m, 17H), 2.26(m, 1H), 2.64(t, 2H, J = 6.0), 2.92(t, 2H, J = 6.3), 3.30(m, 2H), 3.65(s, 3H), 3.97-4.13(m, 2H), 8.30(s, 1H), 10.01(t, 1H, J = 5.4)


 


V-005




1.16-1.71(m, 19H), 1.09(s, 9H), 2.62(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.3), 3.74(s, 3H), 3.92- 4.16(m, 2H), 4.54(d, 1H, J = 8.1), 8.26(s, 1H), 10.61(d, 1H, J = 7.8)


 


V-006




1.09-1.72(m, 25H), 2.31(t, 2H, J = 7.5), 2.61- 2.66(m, 2H), 2.89-2.94(m, 2H), 3.66(s, 3H), 3.88-4.18(m, 2H), 8.30(s, 1H), 9.94(m, 1H)


 


V-007




1.03-2.07(m, 28H), 2.29(m, 1H), 2.64(t, 2H, J = 6.3), 2.91(t, 2H, J = 5.7), 3.31(m, 2H), 3.91- 4.09(m, 2H), 8.31(s, 1H), 10.03(t, 1H, J = 5.7)
















TABLE 69













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





V-011




1.05-1.82(m, 19H), 2.66(t, 2H, J = 5.7), 2.93(t, 2H, J = 5.7), 3.85-4.18(m, 2H), 4.71(d 2H, J = 5.7), 7.44(d, 2H, J = 8.1), 8.01(d, 2H, J = 8.1), 8.35(s, 1H), 10.46(d, 1H, J = 6.0)


 


V-012




1.09-1.79(m, 23H), 2.37(t, 2H, J = 7.8), 2.62- 2.66(m, 2H), 2.89-2.91(m, 2H), 3.43(dd, 2H, J = 6.9, 13.2), 3.86-4.14(m, 2H), 8.31(s, 1H), 9.97(s, 1H)


 


V-013




DMSO-d6 1.04-1.90(m, 19H), 2.70(brt, 2H), 2.99(brt, 2H), 3.54(s, 2H), 4.05(br, 2H), 7.23(d, 2H, J = 8.4), 7.64(d, 2H, J = 8.4), 8.25(s, 1H), 12.24(s, 1H), 12.29(br, 1H)


 


X-1




DMSO-d6 1.00-1.90(m, 19H), 2.65-2.80(m, 2H), 2.95-3.10(m, 2H), 3.95-4.20(br, 2H), 8.34(s, 1H), 13.96(s, 1H)


 


X-2




DMSO-d6 1.00-1.90(m, 19H), 2.65-2.80(m, 2H), 2.95-3.10(m, 2H), 3.89(d, 2H, J = 6.0), 3.95-4.18(br, 2H), 7.87(s, 1H), 8.33(s, 1H), 8.66(t, 1H, J = 6.0), 12.20-13.00(br, 1H), 13.70(s, 1H)


 


X-3




DMSO-d6 1.00-1.90(m, 19H), 2.65-2.80(m, 2H), 2.95-3.07(m, 2H), 3.40-3.55(m, 2H), 3.95-4.25(br, 2H), 7.83(s, 1H), 8.32(s, 1H), 8.44(t, 1H, J = 6.0), 11.80-12.80(br, 1H), 13.62(s, 1H)


 


X-4




DMSO-d6 1.02-1.90(m, 19H), 2.65-2.80(m, 2H), 2.94-3.09(m, 2H), 3.91(d, 2H, J = 6.0), 3.95-4.18(br, 2H), 8.15(s, 1H), 8.32(s, 1H), 8.91(t, 1H, J = 6.0), 12.40-13.00(br, 1H), 13.68(s, 1H)
















TABLE 70













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





X-5




1.02-1.94(m, 19H), 1.61(s, 6H), 2.64-2.68(m, 21H), 2.92-2.67(m, 2H), 2.97(s, 3H), 3.80- 4.15(br, 2H), 4.09(d, 2H, J = 6.6), 6.61(t, 1H, J = 6.6), 6.86(d, 1H, J = 5.1), 8.41(s, 1H), 10.33(d, J = 5.1, 1H), 10.67(s, 1H)


 


X-6




1.01-1.96(m, 25H), 1.65(s, 6H), 2.59-2.63(m, 2H), 2.89-2.94(m, 2H), 3.31-3.35(m, 2H), 3.52-3.55(m, 2H), 3.80-4.15(br, 2H), 4.08(d, 2H, J = 3.6), 7.37(m, 1H), 8.26(s, 1H), 10.37(s, 1H)


 


X-7




1.06-2.20(m, 31H), 2.64(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0)3.47(td, 2H, J = 6.0 and 16.2), 3.98(br, 2H), 8.30(s, 1H), 9.92(t, 1H, J = 6.0)


 


X-8




DMSO-d6 1.00-1.95(m, 19H), 2.62-2.78(m, 2H), 2.90-3.08(m, 2H), 3.54(s, 2H), 3.78(d, 2H, J = 6.0), 3.95-4.20(br, 2H), 6.70(s, 1H), 8.20-8.35(m, 2H), 12.20-12.90(br, 1H), 13.46(s, 1H)


 


X-9




1.07-1.83(m, 27H), 2.08-2.29(m, 4H), 2.35- 2.41(m, 2H), 2.62(t, 2H, J = 5.4), 2.91(t, 2H, J = 5.4), 4.00(br, 2H), 8.28(s, 1H), 10.07(s, 1H)


 


 X-11




1.02-1.88(m, 24H), 1.62(s, 6H), 2.05(brs, 1H), 2.41(brs, 1H), 2.61-2.65(m, 2H), 2.80(d, 3H, J = 4.2), 2.91-2.95(m, 2H), 3.30-4.20(m, 4H), 6.66(br, 1H), 8.21(s, 1H), 10.29(brs, 1H)


 


 X-12




0.9-2.0(m, 31H), 2.64(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.00(s, 2H), 4.01(bs, 1H), 8.29(s, 1H), 10.6(s, 1H)


 


 X-13




1.0-1.9(m, 27H), 2.64(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.01(s, 2H), 4.01(bs, 1H), 8.29(s, 1H), 10.6(s, 1H)
















TABLE 71













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





X-14




DMSO-d6 1.02-1.86(m, 19H), 2.71(t-like, 2H), 3.00(t-like, 2H), 3.93(s, 2H), 4.05(br, 2H), 6.94(s, 1H), 8.27(s, 1H), 12.78(s, 1H), 12.88(br, 1H)


 


X-15




CDCl3 1.01-1.94(m, 31H), 2.64(t, 2H, J = 6.0), 2.96(t, 2H, J = 6.0), 3.51(m, 4H), 4.00(br, 2H), 4.84(s, 1H), 8.28(s, 1H), 10.24(br, 1H), 10.42(br, 1H)


 


X-16




CDCl3 1.01-1.93(m, 25H), 2.64(t, 2H, J = 6.0), 2.94(t, 2H, J = 6.0), 3.29(s, 1H), 4.00(br, 2H), 8.28(s, 1H), 10.45(br, 1H), 10.53(br, 1H)


 


X-17




CDCl3 1.01-1.90(m, 25H), 2.65(t, 2H, J = 6.0) 2.94(t, 2H, J = 6.0) 3.02(s, 6H) 4.00(br, 2H), 6.91(br, 1H), 7.26-7.44(m, 3H), 8.28(s, 1H), 10.64(br, 1H), 11.59(br, 1H)


 


X-18




CDCl3 1.01-1.90(m, 25H), 2.74(t, 2H, J = 6.0) 2.94(t, 2H, J = 6.0), 3.81-4.14(m, 11H), 7.79(t, 1H, J = 8.1), 8.16(d, 1H, J = 8.1), 8.19(s, 1H), 8.28(dd, 1H, J = 2.4 and 8.1) 8.52(m, 1H), 10.82(br, 1H), 11.08(br, 1H)


 


X-19




1.02-1.88(m, 24H), 1.19(dd, 6H, J = 3.9 and 6.6), 1.60(s, 6H), 2.55-2.75(m, 3H), 2.85- 3.03(m, 3H), 3.65-4.04(m, 4H), 4.29(m, 1H), 4.69(m, 1H), 5.88(m, 1H), 8.17(s, 1H), 10.59(s, 1H)


 


X-20




1.02-1.92(m, 23H), 1.59(s, 6H), 2.56-2.80(m, 3H), 2.84-3.04(m, 3H), 3.09(s, 3H), 3.60- 4.45(br, 2H), 3.72(m, 1H), 4.31(m, 1H), 4.72(m, 1H), 6.55(m, 1H), 8.41(s, 1H), 10.53(s, 1H)


 


X-21




DMSO-d6 1.0-1.8(m, 19H), 2.72(br-s, 2H), 3.01(br-s, 2H), 3.81(s, 2H), 4.07(br-s, 2H), 8.33(s, 1H), 12.6(br-s, 1H), 13.8(br-s, 1H)
















TABLE 72













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





X-23




1.0-1.9(m, 21H), 2.65(t, 2H, J = 6.0), 2.94(t, 2H, J = 6.0), 3.70-3.81(m, 1H), 3.86-4.16(m, 3H), 4.38(t, 1H, J = 3.3), 8.27(s, 1H), 10.7(s, 1H)


 


X-25




CDCl3 1.01-1.94(m, 31H), 2.64(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 4.00(br, 2H), 8.32(s, 1H), 10.35(br, 1H)


 


X-27




DMSO-d6 1.0-1.8(m, 22H), 2.20-2.28(m, 2H), 2.72(br-s, 2H), 3.01(br-s, 2H), 4.03(br-s, 2H), 6.90(t, 1H, J = 7.2 Hz), 8.28(s, 1H), 13.4(br-s, 1H)


 


X-28




1.00-1.90(m, 21H), 2.66(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 4.01(bs, 1H), 4.33(d, 2H, J = 5.4), 8.30(s, 1H), 10.3(t, 1H, J = 5.4)


 


X-29




1.02-1.93(m, 24H), 1.14(dd, 6H, J = 6.6 and 9.0), 1.62(s, 6H), 2.61-2.65(m, 2H), 2.91- 2.95(m, 2H), 3.08(dd, 1H, J = 7.5 and 13.5), 3.22(m, 1H), 3.42-3.60(m, 2H), 3.70-4.20(m, 3H), 4.81(br, 1H), 7.26(m, 1H), 8.24(s, 1H), 10.34(s, 1H)


 


X-30




1.02-1.94(m, 22H), 1.64(s, 6H), 2.62-2.66(m, 2H), 2.78(s, 3H), 2.91-2.95(m, 2H), 3.07(dd, 1H, J = 6.9 and 12.0), 3.14-3.23(m, 2H), 3.39(dd, 1H, J = 3.3 and 12.0), 3.75-4.20(m, 4H), 7.63(d, 1H, J = 8.1), 8.25(s, 1H), 10.36(s, 1H)


 


X-31




1.01-1.91(m, 24H), 1.10(t, 3H, J = 7.5), 1.62(s, 6H), 2.14(q, 2H, J = 7.5), 2.61-2.65(m, 2H), 2.82-3.02(m, 3H), 3.75-4.20(br, 2H), 3.93(m, 1H), 4.36-4.58(m, 2H), 5.38(d, 1H, J = 7.8), 8.24(s, 1H), 10.30(s, 1H)













TABLE 73













 









Comp. No.
Q
1H-NMR(CDCl3/TMS) δ





X-32




1.02-1.86(m, 23H), 1.20(t, 3H, J = 7.5), 1.60(s, 6H), 2.30-2.50(m, 2H), 2.56-2.66(m, 2H), 2.71(m, 1H), 2.85-3.04(m, 3H), 3.60-4.45(m, 2H), 4.16(m, 1H), 4.34(m, 1H), 4.69(m, 1H), 7.18(m, 1H), 8.20(s, 1H), 10.48(s, 1H)


 


X-33




1.02-1.96(m, 19H), 1.11(t, 3H, J = 7.2), 1.19(t, 3H, J = 7.2), 1.66(s, 6H), 2.59-2.63(m, 2H), 2.90-2.94(m, 2H), 3.27(q, 2H, J = 7.2), 3.38(q, 2H, J = 7.2), 3.80-4.15(br, 2H), 4.09(d, 2H, J = 3.6), 7.34(m, 1H), 8.27(s, 1H), 10.37(s, 1H)


 


X-34




1.02-1.98(m, 24H), 1.61(s, 6H), 2.39(s, 6H), 2.52-2.72(m, 4H), 2.90-2.94(m, 2H), 3.24- 3.60(m, 4H), 3.74-4.30(m, 4H), 6.89(brs, 1H), 8.24(s, 1H), 10.31(s, 1H)


 


X-37




DMSO-d6 0.91(t, 3H, J = 7.2 Hz), 1.0-1.96(m, 26H), 2.71(br-s, 2H), 3.01(br-s, 2H), 3.63(t, 1H, J = 7.5 Hz), 4.03(br-s, 2H), 7.0(s, 1H), 8.28(s, 1H), 12.3(br-s, 1H), 13.5(br-s, 1H)


 


X-38




0.94(t, 6H, J = 7.2), 1.05-1.88(m, 25H), 2.64(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.00(s, 2H), 4.01(bs, 1H), 8.28(s, 1H), 10.7(t, 1H, J = 5.4)


 


X-39




1.00-1.90(m, 27H), 1.94-2.07(m, 1H), 2.58- 2.79(rn 4H), 2.93(t, 2H, J = 6.0), 3.90-4.18(m, 2H), 8.30(s, 1H), 10.6(bs, 1H)


 


X-40




0.85-1.86(m, 32H), 2.60-2.74(m, 4H), 2.93(t, 2H, J = 6H), 4.00(bs, 1H), 4.30-4.39(m, 1H), 8.30(s, 1H), 10.6(d, 1H, J = 7.5)
















TABLE 74













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-41




DMSO-d6 1.02-1.80(m, 21H), 2.65(t, 2H, J = 6), 2.93(t, 2H, J = 6H), 3.66-3.85(m, 3H), 4.00(bs, 1H), 8.12(s, 1H), 10.2(bs, 1H)


 


X-42




1.00-1.90(m, 24H), 2.65(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.59(dd, 1H, J = 9.9 and 4.8, 3.70(dd, 1H, J = 9.9 and 6.9), 4.00(bs, 1H), 4.14-4.25(m, 2H), 4.37-4.52(m, 1H), 8.31(s, 1H), 10.2(d, 1H, J = 7.8)


 


X-43




DMSO-d6 0.92-1.80(m, 24H), 1.48(s, 6H), 2.04(m, H), 2.55-2.75(m, 2H), 2.88-2.99(m, 2H), 3.07(m, 1H), 3.70-4.44(m, 3H), 5.07(m, 1H), 8.08(s, 1H), 10.33(s, 1H), 12.62(brs, 1H)


 


X-44




1.02-1.92(m, 24H), 1.14(t, 3H, J = 7.5), 1.62(s, 6H), 2.53(m, 1H), 2.59-2.68(m, 2H), 2.77(m, 1H), 2.92-2.96(m, 2H), 3.12-3.44(m, 2H), 3.75-4.20(br, 2H), 4.31(m, 1H), 5.48(m, 1H), 7.65(m, 1H), 8.22(s, 1H), 10.51(s, 1H)


 


X-46




DMSO-d6 1.03-1.90(m, 19H), 2.70(t-like, 2H), 2.99(t-like, 2H), 3.71(s, 2H), 4.05(br, 2H), 6.70(d, 1H, J = 3.9), 6.73(d, 1H, J = 3.9), 8.23(s, 1H), 12,45(brs, 1H), 12.83(s, 1H)


 


X-47




DMSO-d6 1.04-1.90(m, 19H), 2.71(t-like, 2H), 3.00(t-like, 2H), 3.71(s, 2H), 4.05(br, 2H), 5.99(d, 1H, J = 15.6), 6.98(d, 2H, J = 3.9), 7.33(d, 1H, J = 3.9), 7.67(d, 1H, J = 15.6), 8.25(s, 1H), 12.15(brs, 1H), 13.14(s, 1H)


 


X-49




DMSO-d6 1.02-1.88(m, 19H), 2.56(t, 2H, J = 7.2), 2.70(t-like, 2H), 2.94(t, 2H, J = 7.2), 2.99(t-like, 2H), 4.04(br, 2H), 6.62(d, 1H, J = 3.9), 6.70(d, 1H, J = 3.9), 8.22(s, 1H), 12.23(br, 1H), 12,80(s, 1H)
















TABLE 75













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-51




0.95-1.88(m, 27H), 1.90-2.02(m, 1H), 2.67(t, 2H, J = 6.0), 2.94(t, 2H, J = 6.0), 3.65(dd, 1H, J = 9.9 and 3.9), 3.79(t, 1H, J = 9.9), 4.06- 4.23(m, 4H), 8.36(s, 1H), 10.5(s, 1H)


 


X-52




1.00-1.90(m, 23H), 1.59(s, 6H), 2.10(m, 1H), 2.54-2.68(m, 3H), 2.91-2.95(m, 2H), 3.56- 3.38(m, 2H), 3.80-4.30(br, 2H), 4.03(d, 2H, J = 5.1), 4.47(br, 1H), 5.51(brs, 1H), 7.09(brs, 1H), 7.61(brs, 1H), 8.14(s, 1H), 10.39(s, 1H)


 


X-53




1.02-1.92(m, 22H), 1.60(s, 6H), 2.03(s, 3H), 2.27(m, 1H), 2.55(brs, 1H), 2.62-2.66(m, 2H), 2.86-2.97(m, 2H), 2.99-3.20(m, 2H), 3.25-3.45(m, 2H), 3.46-3.68(m, 2H), 3.70- 4.20(br, 2H), 4.32(m, 1H), 4.64(m, 1H), 7.31-7.52(m, 2H), 8.12(s, 1H), 10.39(s, 1H)


 


X-56




DMSO-d6 1.01-1.92(m, 19H), 2.60-2.78(br, 2H), 2.89(d, 2H, J = 2.4), 2.94-3.10(br, 2H), 3.78(s, 2H), 4.00(br, 2H), 4.73(q, 1H, J = 5.1 and 12.9), 7.20-7.32(m, 5H), 8.14(s, 1H), 10.46(d, 1H, J = 7.8), 13.12(br, 1H)


 


X-57




DMSO-d6 1.01-1.92(m, 19H), 2.08(s, 3H), 2.60-2.77(m, 2H), 2.94-3.10(m, 4H), 4.00(br, 2H), 4.69(q, 1H, J = 5.1), 8.12(s, 1H), 10.37(d, 1H, J = 7.5), 13.01(br, 1H) 


 


X-58




DMSO-d6 0.81-1.82(m, 19H), 1.72(s, 3H), 2.50-2.70(m, 2H), 2.81-3.00(m, 2H), 4.02(br, 2H), 4.86(s, 1H), 8.11(br, 1H), 13.00(br, 1H)


 


X-59




DMSO-d6 0.81-1.82(m, 19H), 2.62-2.75(m, 2H), 2.91-3.04(m, 2H), 4.04(br, 2H), 6.25(s, 1H), 8.18(s, 1H), 12.42(br, 1H) 
















TABLE 76













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-60




DMSO-d6 0.80-1.82(m, 19H), 2.57-2.80(m, 2H), 2.80-3.04(m, 4H), 3.97(br, 2H), 5.66(q, 1H, J = 6.9 and 14.7), 6.97(m, 1H), 7.05(d, 1H, J = 3.3), 7.39(m, 1H), 8.14(s, 1H), 10.42(d, 1H, J = 8.4)


 


X-61




DMSO-d6 0.80-1.82(m, 19H), 2.57-2.80(m, 2H), 2.80-2.90(m, 2H), 2.90-3.00(m, 2H), 3.97(br, 2H), 5.49(q, 1H, J = 6.9 and 14.7), 6.29(m, 1H), 7.60(m, 1H), 7.67(m, 1H), 8.14(s, 1H), 10.29(d, 1H, J = 8.4), 12.50(br, 1H)


 


X-62




DMSO-d6 1.0-2.1(m, 23H), 2.69-2.70(m, 4H), 2.98(br-s, 2H), 3.57(t, 1H, J = 6.9 Hz), 4.07(br-s, 2H), 8.26(s, 1H), 13.8(br-s, 1H)


 


X-64




DMSO-d6 1.04-1.88(m, 19H), 2.60(t, 2H, J = 7.5), 2.71(t-like, 2H), 2.84(t, 2H, J = 7.5), 3.00(t-like, 2H), 4.07(brd, 2H), 6.86(s, 1H), 8.28(s, 1H), 12.15(br, 1H), 13.43(s, 1H)


 


X-65




DMSO-d6 1.05-1.90(m, 19H), 2.72(t-like, 2H), 3.01(t-like, 2H), 4.08(brd, 2H), 6.46(d, 1H, J = 16.6), 7.49(d, 1H, J = 15.6), 7.68(s, 1H), 8.30(s, 1H), 12.39(br, 1H), 13.59(s, 1H)


 


X-66




0.94(t, 3H, J = 7.2), 1.05-1.88(m, 25H), 2.60- 2.82(m, 4H), 2.93(t, 2H, J = 6.0), 4.00(bs, 1H), 4.31(bs, 1H), 8.33(s, 1H), 10.4(s, 1H)


 


X-67




0.90(t, 3H, J = 6.9), 1.00-1.90(m, 27H), 2.60- 2.80(m, 4H), 2.93(t, 2H, J = 6.0), 4.00(bs, 1H), 4.25-4.37(m, 1H), 8.33(s, 1H), 10.4(s, 1H)
















TABLE 77













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-68




DMSO-d6 1.01-1.92(m, 19H), 2.60-2.78(br, 2H), 2.94-3.00(br, 2H), 3.69(d, 2H, J = 2.4), 4.00(br, 2H), 4.50(s, 2H), 4.97(q, 1H, J = 5.1 and 12.9), 7.36(s, 5H), 8.14(s, 1H), 10.48(d, 1H, J = 7.8), 13.12(br, 1H)


 


X-69




DMSO-d6 1.01-1.92(m, 19H), 2.60-2.78(br, 2H), 2.94-3.05(br, 2H), 3.20-2.38(m, 2H), 3.80-4.20(m, 4H), 4.45(m, 1H), 4.97-5.30(m, 1H), 7.20-7.48(m, 5H), 8.32(m, 1H), 11.02(m, 1H)


 


X-70




1.02-1.88(m, 31H), 1.65(s, 6H), 2.61-2.65(m, 2H), 2.89-2.93(m, 2H), 3.34-3.56(m, 4H), 3.67(m, 1H), 3.75-4.25(br, 2H), 4.29(m, 1H), 5.47(m, 1H), 8.25(s, 1H), 10.33(s, 1H)


 


X-71




1.00-1.90(m, 23H), 1.64(s, 6H), 2.14-2.38(m, 2H), 2.84-2.89(m, 2H), 3.07(m, 1H), 3.34(dd, 1H, J = 2.4 and 13.5), 3.58-3.79(m, 2H), 3.75- 4.20(br, 2H), 4.15(m, 1H), 6.96(t, 1H, J = 7.5), 7.11(d, 1H, J = 8.1), 7.21-7.29(m, 2H), 7.54(d, 2H, J = 7.5), 7.62(s, 1H), 8.06(s, 1H), 10.42(s, 1H)


 


X-72




DMSO-d6 1.00-1.93(m, 19H), 2.60-2.74(br, 2H), 2.92-3.05(br, 2H), 4.00(br, 2H), 5.56(m, 1H), 5.71(s, 1H), 6.23(s, 1H), 8.15(s, 1H), 12.03(br, 1H)


 


X-73




DMSO-d6 0.81-1.82(m, 19H), 2.62-2.75(m, 2H), 2.91-3.04(m, 2H), 4.04(br, 2H), 6.25(s, 1H), 8.18(s, 1H), 12.42(br, 1H)
















TABLE 78













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-74




0.90(t, 3H, J = 7.5), 1.02-1.94(m, 25H), 1.62(s, 6H), 2.61-2.65(m, 2H), 2.91-2.95(m, 2H), 3.05-3.33(m, 4H), 3.42-3.55(m, 2H), 3.80- 4.20(br, 2H), 3.90(m, 1H), 5.10(br, 1H), 7.23(d, 1H, J = 7.5, 8.22(s, 1H), 10.34(s, 1H)


 


X-75




1.02-1.88(m, 21H), 1.61(s, 6H), 1.94-2.16(m, 3H), 2.36-2.60(m, 3H), 2.63-2.67(m, 2H), 2.91-2.95(m, 2H), 3.36-3.70(m, 4H), 3.75- 4.25(br, 3H), 5.66(brs, 1H), 6.75-7.22(m, 2H), 8.20(s, 1H), 10.35(s, 1H)


 


X-76




0.96(s, 91), 1.00-1.82(m, 23H), 2.60-2.82(m, 4H), 2.92(t, 2H, J = 6.0), 4.00(bs, 1H), 4.46(bs, 1H), 8.34(s, 1H), 10.4(s, 1H)


 


X-77




1.06(s, 9H), 1.00-1.82(m, 21H), 2.51(dd, 1H, J = 16.0 and 6.3), 2.65(t, 2H, J = 6), 2.83(dd, 1H, J = 16.0 and 3.6), 2.93(t, 2H, J = 6.9), 3.90-4.10(m, 2H), 8.31(s, 1H), 10.8(s, 1H)


 


X-78




1.00-1.86(m, 27H), 2.65(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.17-3.30(m, 1H), 3.57-4.15(m, 3H), 4.30-4.40(m, 1H), 5.82(d, 1H, J = 7.2), 8.30(s, 1H), 10.6(t, 1H, J = 6.0)


 


X-79




DMSO-d6 1.00-1.84(m, 19H), 2.41(d, 3H, J = 0.9), 2.65(t-like, 2H), 2.95(t-like, 2H), 3.98(brd, 2H), 5.64(d, 1H, J = 6.9), 6.69(m, 1H), 6.90(d, 1H, J = 3.3), 8.12(s, 1H), 10.61(d, 1H, J = 6.9), 13.21(br, 1H)


 


X-80




DMSO-d6 1.00-1.86(m, 19H), 2.65(t-like, 2H), 2.96(t-like, 2H), 4.00(brd, 2H), 5.70(dd, 1H, J = 0.6 and 6.9), 6.97(dd, 1H, J = 0.6 and 3.9), 7.02(d, 1H, J = 3.9), 8.12(s, 1H), 10.73(d, 1H, J = 6.9), 13.49(br, 1H)
















TABLE 79













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-81




DMSO-d6 1.00-1.82(m, 19H), 2.72(br, 2H), 3.00(br, 2H), 4.07(br, 2H), 8.28-8.38(m, 3H), 8.84(m, 1H), 12.96(s, 1H), 13.23(br, 1H)


 


X-82




DMSO-d6 1.00-1.93(m, 25H), 2.58-2.72(br, 2H), 2.90-3.02(br, 2H), 3.38(d, 2H, J = 6.0), 3.69(d, 2H, J = 6.0), 4.02(br, 2H), 6.15(t, 2H, J = 6.0), 8.12(s, 1H), 9.82(s, 1H), 12.45(br, 1H)


 


X-83




DMSO-d6 1.00-1.93(m, 25H), 2.58-2.72(br, 2H), 2.90-3.02(br, 2H), 3.49(d, 2H, J = 6.0), 4.02(br, 2H), 6.24(t, 1H, J = 6.0), 7.31(t, 1H, J = 7.8), 7.46(dd, 1H, J = 1.2 and 7.8), 7.55(dd, 1H, J = 1.2 and 8.1), 8.03(s, 1H), 8.14(s, 1H), 8.72(s, 1H), 9.92(s, 1H), 12.79(br, 1H)


 


X-84




DMSO-d6 1.00-1.93(m, 22H), 2.48-2.72(m, 3H), 2.90-3.02(br, 2H), 3.36-3.48(m, 2H), 4.03(br, 2H), 8.11(s, 1H), 9.99(t, 1H, J = 5.7), 12.40(br, 1H)


 


X-86




DMSO-d6 1.0-1.8(m, 19H), 1.47(s, 6H), 2.72(br-s, 2H), 3.01(br-s, 2H), 4.07(br-s, 2H), 6.99(s, 1H), 8.29(s, 1H), 12.2(br-s, 1H), 13.4(br-s, 1H)


 


X-88




1.00-1.96(m, 23H), 2.29(d, 2H, J = 13.5), 2.63(t, 2H, J = 6.0), 2.93(t, 2H, J = 6.0), 3.03(s, 2H), 3.67-3.88(m, 4H), 4.00(bs, 1H), 8.25(s, 1H), 10.6(s, 1H)


 


X-90




DMSO-d6 1.03-1.88(m, 19H), 2.72(t-like, 2H), 3.00(t-like, 2H), 3.82(d, 2H, J = 0.6), 4.07(brd, 2H), 7.31(t, 1H, J = 0.6), 8.29(s, 1H), 12.62(br, 1H), 13.39(s, 1H)


 


X-91




1.02-1.96(m, 23H), 2.12(br, 1H), 2.65-2.75 (brm, 3H), 2.96(br, 2H), 3.24(br, 1H), 3.00- 4.80(brm, 4H), 7.55(s, 1H), 8.37(s, 1H), 13.41(brs, 1H)
















TABLE 80













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-92




DMSO-d6 1.00-1.80(m, 19H), 2.69(br, 2H), 2.97(br, 2H), 3.61(s, 2H), 4.04(br, 2H), 6,53(s, 1H), 8.23(s, 1H), 12.30(s, 1H), 12.39(br, 1H)


 


X-93




0.88(br, 3H), 1.04-4.20(brm, H), 2.69(t, 2H, J = 6.3), 2.97(t, 2H, J = 6.0), 6.50-7.20 (brm, 1H), 7.57(brs, 1H), 8.37(s, 1H), 13.36-13.68(brm, 1H)


 


X-95




DMSO-d6 1.04-1.90(m, 19H), 2.71(t-like, 2H), 3.00(t-like, 2H), 4.06(brd, 2H), 6.03(d, 1H, J = 15.6), 6.51(d, 1H, J = 3.6), 6.97(d, 1H, J = 3.6), 7.32(d, 1H, J = 15.6), 8.25(s, 1H), 12.19(br, 1H), 13.10(s, 1H)


 


X-97




DMSO-d6 1.00-1.93(m, 25H), 2.32(t, 2H, J = 6.6), 2.58-2.72(br, 2H), 2.90-3.02(br, 2H), 3.18(q, 2H, J = 6.0), 3.35(m, 2H), 3.97(br, 2H), 5.98(t, 2H, J = 6.0), 8.11(s, 1H), 9.80(s, 1H), 12.15(br, 1H)


 


X-98




DMSO-d6 1.00-1.93(m, 27H), 2.17(t, 2H, J = 7.5), 2.58-2.72(br, 2H), 2.90-3.02(m, 4H), 3.35(m, 2H), 3.98(br, 2H), 5.82(t, 1H, J = 6.0), 5.94(t, 1H, J = 6.0), 8.11(s, 1H), 9.82(s, 1H), 12.10(br, 1H)


 


X-99




DMSO-d6 1.00-1.93(m, 25H), 2.58-2.72(br, 2H), 2.90-3.02(br, 2H), 3.35(m, 2H), 3.98(br, 2H), 7.52(br, 1H), 7.80(d, 2H, J = 8.7), 8.09(d, 2H, J = 8.7), 8.20(br, 1H), 8.90(s, 1H), 10.62(br, 1H), 12.63(br, 1H)


 


X-104




DMSO-d6 1.06-1.84(m, 25H), 2.64(bs, 2H), 2.83-3.06(m, 6H), 3.17-3.26(m, 2H), 4.00(bs, 1H), 4.28-4.37(m, 1H), 8.10(s, 1H), 10.2(d, 1H, J = 5.4)two protons overlap with water
















TABLE 81













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-105




DMSO-d6 1.08-1.86(m, 19H), 2.71(br, 2H), 3.00(br, 2H), 4.06(br, 2H), 6.59(d, 1H, J = 16.2), 7.59(d, 1H, J = 15.9), 8.21(dd, 1H, J = 2.1 and 9.0), 8.29(s, 1H), 8.31(d, 1H, J = 9.0), 8.61(d, 1H, J = 2.1), 12.82(s, 1H)


 


X-108




DMSO-d6 1.00-1.93(m, 25H), 2.58-2.72(br, 2H), 2.90-3.02(br, 2H), 3.35(m, 2H), 3.98(br, 2H), 4.37(s, 2H), 7.16(t, 2H, J = 7.5), 7.65(td, 1H, J = 1.5 and 7.5), 7.86(dd, 1H, J = 1.5 and 8.1), 8.08(s, 1H), 9.90(s, 1H), 11.37(br, 1H)


 


X-114




1.00-1.90(m, 19H), 2.38(s, 3H), 2.60-2.70(m, 2H), 2.90-3.00(m, 2H), 3.90-4.20(br, 2H), 6.53(s, 1H), 8.34(s, 1H), 13.50(s, 1H)


 


X-119




DMSO-d6 1.0-1.8(m, 23H), 1.99-2.08(m, 2H), 2.24-2.29(m, 2H), 2.70(br-s, 2H), 2.98(br-s, 2H), 4.04(br-s, 2H), 6.99(s, 1H), 8.26(s, 1H), 13.4(br-s, 1H)


 


X-126




DMSO-d6 1.00-1.82(m, 23H), 2.20-2.36(br, 2H), 2.54-2.70(br, 2H), 2.76-2.84(br, 2H), 2.84-3.00(br, 2H), 4.00(br, 2H), 8.09(s, 1H), 12.24(br, 1H), 12.60(s, 1H)


 


X-127




DMSO-d6 1.08-1.84(m, 19H), 2.56(t, 2H, J = 7.5), 2.70(t, 2H, J = 5.4), 2.80(t, 2H, J = 7.5), 2.98(br, 2H), 4.04(br, 2H), 7.70(dd, 1H, J = 2.4 and 8.4), 8.18(d, 1H, J = 8.7), 8.20(d, 1H, J = 2.4), 8.27(s, 1H), 12.22(br, 1H), 12.57(s, 1H)


 


X-130




DMSO-d6 1.0-1.8(m, 19H), 2.62-2.74(m, 3H), 2.93-3.02(m, 3H), 4.04(br-s, 2H), 5.72(q, 1H, J = 7.5 Hz), 7.49-7.63(m, 3H), 7.99(d, 1H, J = 7.5 Hz), 8.10(s, 1H), 10.49(d, 1H, J = 8.4 Hz), 12.42(br-s, 1H)
















TABLE 82













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ












X-134




DMSO-d6 1.04-1.90(m, 19H), 2.68-2.78(m, 2H), 2.95-3.07(m, 2H), 3.88(s, 2H), 3.98- 4.15(br, 2H), 7.35-7.51(m, 3H), 7.59-7.65(m, 2H), 8.31(s, 1H), 12.79(brs, 1H), 13.51(s, 1H)


 


X-137




DMSO-d6 0.79(t, 3H, J = 7.2), 0.98-1.72(m, 23H), 2.55(t, 2H, J = 5.7), 2.85(br, 2H), 3.90(br, 2H), 4.34(m, 1H), 8.01(s, 1H), 10.10 (d, 1H, J = 7.8)


 


X-148




DMSO-d6 0.90(dd, 6H, J = 6.0 and 10.5), 1.02-1.86(m, 22H), 2.60-2.69(m, 2H), 2.90- 3.00(m, 2H), 3.80-4.15(br, 2H), 4.46(m, 1H), 8.12(s, 1H), 10.15(d, 1H, J = 7.8), 12.73(brs, 1H)


 


X-151




DMSO-d6 1.00-1.90(m, 19H), 2.65-2.78(m, 2H), 2.93-3.07(m, 2H), 3.98(s, 2H), 4.00- 4.20(br, 2H), 8.32(s, 1H), 12.20-13.40(m, 2H), 13.74(s, 1H)


 


X-154




DMSO-d6 0.82-0.92(m, 6H), 1.02-1.86(m, 24H), 2.20(t, 2H, J = 7.2), 2.59-2.69(m, 2H), 2.89-2.99(m, 2H), 3.80-4.12(m, 3H), 8.11(s, 1H), 9.69(d, 1H, J = 9.0), 12.03(brs, 1H)


 


X-156




DMSO-d6 1.04-1.82(m, 19H), 2.64-2.67(m, 4H), 2.95(br, 2H), 3.96(br, 2H), 4.71(m, 1H), 7.13(s, 1H), 7.46(s, 1H), 8.11(s, 1H), 10.23(d, 1H, J = 8.1)


 


X-159




DMSO-d6 1.05-1.90(m, 19H), 2.65-2.80(m, 2H), 2.90-3.07(m, 2H), 3.61(s, 2H), 3.95- 4.15(br, 2H), 8.29(s, 1H), 12.20-13.00(br, 1H), 13.62(s, 1H)
















TABLE 83













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-160




DMSO-d6 1.00-1.90(m, 19H), 2.65-2.77(m, 2H), 2.93-3.07(m, 2H), 3.61(s, 2H), 3.95- 4.15(br, 2H), 8.29(s, 1H), 12.20-13.00(br, 1H), 13.64(s, 1H)


 


X-166




1.00-1.89(m, 19H), 2.67(t, 2H, J = 6.0 Hz), 2.93(t, 2H, J = 6.0 Hz), 3.69(m, 2H), 3.91(s, 3H), 3.91-4.02(br-s, 2H), 5.04(t, 1H, J = 6.0 Hz), 7.49(d, 2H, J = 8.1 Hz), 8.01(d, 2H, J = 8.1 Hz), 8.36(br-s, 1H), 10.46(br-s, 1H)


 


X-167




DMSO-d6 1.0-1.8(m, 19H), 2.62(br-s, 2H), 2.92(br-s, 2H), 3.56(m, 1H), 4.00(br-s, 2H), 4.77(br-s, 1H), 5.75(br-s, 1H), 7.48(d, 2H, J = 8.1 Hz), 7.87(d, 2H, J = 8.1 Hz), 8.08(s, 1H), 10.1(br-s, 1H)


 


X-177




DMSO-d6 1.04-1.90(m, 19H), 2.65-2.80(m, 2H), 2.95-3.05(m, 2H), 3.61(s, 2H), 4.00- 4.20(br, 2H), 7.30-7.55(m, 5H), 8.30(s, 1H), 13.54(s, 1H)


 


X-181




DMSO-d6 1.08-1.86(m, 19H), 2.72(t, 2H, J = 5.2), 3.00(br, 2H), 4.05(br, 2H), 6.74(d, 1H, J = 15.9), 7.57(d, 1H, J = 16.2), 8.26(s, 1H), 9.03(s, 2H), 12.45(br, 1H), 13.05(s, 1H)


 


X-182




DMSO-d6 0.86(t, 3H, J = 6.9), 1.06-1.86(m, 25H), 2.65(t, 2H, J = 5.7), 2.95(br, 2H), 3.99(br, 2H), 4.43(m, 1H), 8.11(s, 1H), 10.21(d, 1H, J = 7.5), 12.78(br, 1H)


 


X-183




DMSO-d6 1.08-1.86(m, 19H), 2.61(t, 2H, J = 7.5), 2.71(br, 2H), 2.79(t, 2H, J = 7.5), 2.99(br, 2H), 4.05(br, 2H), 8.24(s, 1H), 8.58(s, 2H), 12.27(br, 1H), 12.78(s, 1H)
















TABLE 84













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-189




DMSO-d6 1.10-1.90(m, 19H), 2.60-2.80(m, 2H), 2.90-3.10(m, 2H), 3.67(s, 2H), 3.95- 4.20(br, 2H), 4.74(s, 1H), 8.30(s, 1H), 12.58(br s, 1H), 13.71(s, 1H)


 


X-191




DMSO-d6 1.02-1.90(m, 19H), 2.66-2.78(m, 2H), 2.95-3.07(m, 2H), 3.73(s, 2H), 3.95- 4.20(br, 2H), 7.16(dd, 1H, J = 3.6 and 5.1), 7.24(dd, 1H, J = 1.2 and 3.6), 7.64(dd, 1H, J = 0.9 and 5.1), 8.29(s, 1H), 12.56(br s, 1H), 13.58(s, 1H)


 


X-192




1.10-1.8(m, 22H), 2.65(t, 2H), 2.93(t, 2H), 4.00(brs, 2H), 4.42(q, 2H, J = 7.2), 4.97(d, 2H, J = 6.0), 8.10(s, 1H), 8.33(s, 1H), 10.69(t, 1H, J = 6.0 Hz)


 


X-195




DMSO-d6 1.04-1.90(m, 19H), 2.67-2.79(m, 2H), 2.96-3.08(m, 2H), 3.69(s, 2H), 3.95- 4.20(br, 2H), 7.73(d, 2H, J = 8.1), 7.84(d, 2H, J = 8.4), 8.30(s, 1H), 12.64(br s, 1H), 13.62(s, 1H)


 


X-200




DMSO-d6 1.10-1.8(19H, m), 2.66(brs, 2H), 2.96(brs, 2H), 3..33(brs, 2H), 4.00(brs, 2H), 4.81(d, 2H, J = 6.3), 8.17(s, 1H), 8.33(s, 1H), 10.53(t, 1H, J = 6.0), 12.98(brs, 1H)


 


X-201




DMSO-d6 1.11-1.7(19H, m), 2.62(brs, 2H), 2.92(brs, 2H), 3.61(s, 3H), 4.97(d, 2H, J = 6.0), 7.48(d, 2H, J = 8.1), 7.87(d, 2H, J = 8.4), 8.08(s, 1H), 10.09(t, 1H, J = 6.0)


 


X-212




DMSO-d6 1.04-1.89(m, 19H), 2.66-2.76(m, 2H), 2.95-3.04(m, 2H), 3.95-4.20(br, 2H), 6.44(d, 1H, J = 16.2), 7.55(d, 1H, J = 16.2), 7.68(d, 2H, J = 8.7), 7.76(d, 2H, J = 8.7), 8.27(s, 1H), 12.25(br, 1H), 12.44(s, 1H)
















TABLE 85













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





X-220




DMSO-d6 1.02-1.90(m, 19H), 2.64-2.75(m, 2H), 2.93-3.03(m, 2H), 3.90-4.20(br, 2H), 4.65(s, 2H), 6.90(d, 2H, J = 9.0), 7.61(d, 2H, J = 9.0), 8.24(s, 1H), 12.12(s, 1H), 12.98(brs, 1H)


 


X-228




DMSO-d6 1.00-1.90(m, 19H), 2.29(s, 3H), 2.65-2.77(m, 2H), 2.92-3.05(m, 2H), 3.55(s, 2H), 3.95-4.15(br, 2H), 8.27(s, 1H), 12.36(br s, 1H), 13.35(s, 1H)


 


X-229




DMSO-d6 1.02-1.86(m, 19H), 2.62-2.75(m, 2H), 2.92-3.05(m, 2H), 3.85-4.15(br, 2H), 5.43(m, 1H), 8.18(s, 1H), 10.83(d, 1H, J = 9.0), 14.22(brs, 1H)


 


X-240




DMSO-d6 1.02-1.86(m, 29H), 1.93-2.17(m, 4H), 2.58-2.68(m, 2H), 2.90-3.01(m, 2H), 3.85-4.15(br, 2H), 8.06(s, 1H), 10.13(s, 1H), 12.19(brs, 1H)


 


XI-002




DMSO-d6 1.02-1.90(m, 19H), 2.64-2.75(m, 2H), 2.93-3.05(m, 2H), 3.85-4.20(br, 2H), 4.68(s, 2H), 6.65(m, 1H), 7.14-7.29(m, 2H), 7.45(m, 1H), 8.26(s, 1H), 12.26(s, 1H), 13.01(brs, 1H)


 


XI-010




DMSO-d6 1.02-1.90(m, 19H), 2.52(t, 2H, J = 7.5), 2.65-2.74(m, 2H), 2.80(t, 2H, J = 7.5), 2.94-3.03(m, 2H), 3.85-4.20(br, 2H), 7.20(d, 2H, J = 8.4), 7.60(d, 2H, J = 8.4), 8.25(s, 1H), 12.11(brs, 1H), 12.20(s, 1H)


 


XI-020




DMSO-d6 1.04-1.90(m, 19H), 2.67-2.78(m, 2H), 2.97-3.08(m, 2H), 4.00-4.20(m, 2H), 4.13(s, 2H), 8.30(s, 1H), 13.00(br s, 1H), 13.82(s, 1H)
















TABLE 86













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





XI-021




DMSO-d6 1.02-1.92(m, 19H), 2.65-2.75(m, 2H), 2.93-3.05(m, 2H), 3.90-4.20(br, 2H), 4.80(s, 2H), 6.91(d, 1H, J = 8.7), 8.06(dd, 1H, J = 2.7 and 8.7), 8.26(s, 1H), 8.44(d, 1H, J = 2.7), 12.11(s, 1H), 12.82(brs, 1H)


 


XI-032




DMSO-d6 1.00-1.96(m, 35H), 2.04-2.20(m, 2H), 2.58-2.70(m, 2H), 2.89-3.00(m, 2H), 3.97(br, 2H), 8.07(s, 1H), 10.03(s, 1H), 12.21(br, 1H)


 


XI-036




DMSO-d6 1.00-1.84(m, 25H), 2.04-2.17(m, 2H), 2.60-2.68(m, 2H), 2.87(s, 2H), 2.95- 3.05(m, 2H), 3.95(br, 2H), 8.09(s, 1H), 9.90(s, 1H), 11.92(br, 1H)


 


XI-040




1.00-2.08(m, 23H), 2.23-2.45(m, 4H), 2.60- 2.68(m, 2H), 2.90-2.97(m, 2H), 3.09(s, 2H), 4.01(br, 2H), 8.28(s, 1H), 10.77(s, 1H)


 


XI-043




DMSO-d6 1.00-1.97(m, 20H), 2.64-2.67(m, 2H), 2.92-3.02(m, 2H), 3.27(s, 3H), 3.61(dd, 1H, J = 3.9 and 9.9), 3.77(dd, 1H, J = 3.9 and 9.9), 4.00(br, 2H), 4.61(m, 1H), 8.13(s, 1H), 10.31(d, 1H, J = 7.8)


 


XI-045




DMSO-d6 1.03-1.88(m, 19H), 2.65-2.75(m, 2H), 2.93-3.04(m, 2H), 3.60(s, 2H), 3.94- 4.15(br, 2H), 7.72(dd, 1H, J = 1.8 and 8.7), 8.18-8.24(m, 2H), 8.28(s, 1H), 12.45(brs, 1H), 12.61(s, 1H)


 


XI-050




DMSO-d6 1.01-1.92(m, 21H), 2.20-2.28(m, 2H), 2.18-2.26(m, 2H), 2.60-2.69(m, 2H), 2.90-2.99(m, 2H), 3.27(s, 3H), 3.30-3.45(m, 2H), 3.84-4.15(br, 2H), 4.12(m, 1H), 8.12(s, 1H), 9.86(d, 1H, J = 8.7), 12.07(brs, 1H)
















TABLE 87













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





XI-051




DMSO-d6 1.00-1.96(m, 25H), 2.60-2.68(m, 2H), 2.88-3.02(m, 2H), 3.46-3.48(m, 2H), 3.69-3.78(m, 2H), 3.97(br, 2H), 8.11(s, 1H), 10.06(t, 1H, J = 5.7), 12.57(br, 1H)


 


XI-056




DMSO-d6 1.02-1.88(m, 19H), 2.61-2.71(m, 2H), 2.91-3.02(m, 2H), 3.06-3.22(m, 2H), 3.85-4.15(br, 2H), 4.78(q, 1H, J = 6.0), 8.14(s, 1H), 10.51(d, 1H, J = 7.2), 13.32(brs, 1H)


 


XI-059




DMSO-d6 1.14-1.90(m, 19H), 2.65-2.80(m, 2H), 2.95-3.05(m, 2H), 3.90-4.20(m, 2H), 4.99(s, 2H), 6.43(d, 1H, 3.0), 7.29(dd, 1H, J = 2.1, 8.7), 7.33(d, 1H, J = 3.0), 7.35(d, 1H, J = 8.7), 8.06(s, 1H), 8.26(s, 1H), 12.19(s, 1H), 12.94(br s, 1H)


 


XI-071




DMSO-d6 1.04-1.90(m, 19H), 2.60-2.75(m, 2H), 2.90-3.05(m, 2H), 3.90-4.18(m, 2H), 4.85(s, 2H), 7.36(d, 1H, J = 1.5), 7.46(d, 1H, J = 1.2), 8.20(s, 1H), 12.13(s, 1H), 13.05(br s, 1H)


 


XI-074




DMSO-d6 1.10-1.89(m, 19H), 2.73(br s, 2H), 3.02(br s, 2H), 4.08(br s, 2H), 4.13(s, 2H), 8.32(s, 1H), 13.07(br s, 1H), 13.75(s, 1H)


 


XI-076




DMSO-d6 0.87(s, 9H), 1.00-1.82(m, 23H), 2.18(t, 2H, J = 7.5), 2.60-2.68(m, 2H), 2.87- 2.98(m, 2H), 3.80-4.15(br, 2H), 4.08(m, 1H), 8.11(s, 1H), 9.79(d, 1H, J = 9.0), 12.01(brs, 1H)


 


XI-078




DMSO-d6 1.08-1.84(m, 26H), 2.22(m, 1H), 2.46(m, 1H), 2.60-2.68(m, 3H), 2.90-3.00(m, 2H), 3.88-4.10(br, 2H), 8.06(s, 1H), 10.42(s, 1H), 12.08(br, 1H)
















TABLE 88













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS)δ





 









XI-080




DMSO-d6 1.00-1.86(m, 19H), 2.59(d, 2H, J = 15.9), 2.60-2.68(m, 2H), , 2.90-3.00(m, 2H), 3.02(d, 2H, J = 15.9), 3.80-4.10(br, 2H), 5.68(s, 2H), 8.08(s, 1H), 10.31(s, 1H), 12.42(brs, 1H)


 


XI-084




DMSO-d6 0.85(d, 6H, J = 6.6), 1.00-1.88(m, 24H), 2.60-2.70(m, 2H), 2.95-3.05(m, 2H), 3.85-4.10(br, 2H), 4.43(dd, 1H, J = 7.2 and 12.9), 8.11(s, 1H), 10.22(d, 1H, J = 7.8), 12.81(brs, 1H)


 


XI-086




DMSO-d6 1.04-1.84(m, 19H), 2.63-2.75(m, 2H), 2.90-3.05(m, 2H), 3.67(s, 2H), 3.95- 4.20(m, 2H), 7.09(m, 1H), 7.23-7.32(m, 2H), 8.06(d, 1H, J = 8.1), 8.24(s, 1H), 12.08(s, 1H), 12.37(br s, 1H)


 


XI-088




DMSO-d6 1.05-1.84(m, 19H), 2.63-2.77(m, 2H), 2.90-3.05(m, 2H), 3.69(s, 2H), 3.90- 4.20(m, 2H), 7.56(d, 1H, J = 9.0), 7.63(m, 1H), 8.20(d, 1H, J = 8.7), 8.27(s, 1H), 12.47(s, 1H)


 


XI-090




DMSO-d6 1.06-1.90(m, 19H), 2.60-2.75(m, 2H), 2.90-3.05(m, 2H), 3.90-4.20(m, 2H), 4.68(s, 2H), 6.06(m, 1H), 6.23(m, 1H), 7.23(m, 1H), 8.18(s, 1H), 11.81(s, 1H), 12.80(br s, 1H)


 


XI-092




DMSO-d6 1.05-1.90(m, 19H), 2.67-2.75(m, 2H), 2.92-3.04(m, 2H), 3.90-4.20(m, 2H), 4.80(s, 2H), 7.21(d, 1H, J = 3.0), 7.26(dd, 1H, J = 2.4, 9.0), 8.06(d, 1H, J = 9.0), 8.25(s, 1H), 12.27(s, 1H), 13.10(br, 1H) 
















TABLE 89













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-093




DMSO-d6 1.05-1.90(m, 19H), 2.63-2.76(m, 2H), 2.90-3.05(m, 2H), 3.90-4.20(m, 2H), 4.70(s, 2H), 6.79(m, 1H), 6.97(dd, 1H, J = 3.0, 12.9), 8.25(s, 1H), 8.28(m, 1H), 12.30(s, 1H), 13.06(br s, 1H)


 


XI-097




DMSO-d6 1.13-1.81(m, 18H), 2.09(s, 1H),  2.51(br s, 2H), 2.99(br s, 2H), 3.58(s, 2H), 4.08(br s, 2H), 7.28- 7.32(m, 2H), 7.78(d, 1H, J = 12.9), 8.26(s, 1H), 12.37(br s, 2H)


 


XI-101




DMSO-d6 1.00-1.94(m, 19H), 2.65-2.75(m, 2H), 2.92-3.05(m, 2H), 3.74(s, 2H), 3.90- 4.20(m, 2H), 7.47(d, 1H, J = 8.4), 7.79(dd,  1H, J = 1.8, 8.1), 8.24(d, 1H, J = 1.8), 8.27(s, 1H), 12.46(s, 1H)


 


XI-102




DMSO-d6 1.00- 1.90(m, 19H), 2.18(s, 3H), 2.65-2.78(m, 2H), 2.95-3.05(m, 2H), 3.71(s, 2H), 3.95-4.20(m, 2H), 8.27(s, 1H), 12.60(br s, 1H), 13.35(s, 1H)


 


XI-108




1.1-1.6(m, 18H),  1.44(dd, 6H, J = 10.8, 21.0), 2.26(ddd, 1H, J = 9.3, 24.6, 27.9), 2.49(ddd, 2H, J = 4.2, 15.3, 21.6), 2.65(t, 2H, J = 5.4), 2.93(t, 2H, J = 6.3), 3.7-4.3(br, 2H), 4.74(ddd, 1H, J = 4.2, 6.0, 9.3), 8.28(s, 1H), 10.77(d, 1H, J = 5.1)


 


XI-110




DMSO-d6 0.83(s, 3H), 0.89(s, 3H), 1.00- 1.78(m, 25H), 2.04- 2.14(m, 2H), 2.60- 2.68(q, 2H, J = 7.5), 2.81(s, 2H), 2.78- 2.84(m, 2H), 4.00(br, 2H), 8.08(s, 1H), 9.98(s, 1H)
















TABLE 90













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-117




DMSO-d6 1.0-2.0(m, 27H),  2.50-4.15(m, 10H), 8.10(s,  1H), 9.83(t, 1H, J = 5.7)


 


XI-120




DMSO-d6 1.0-1.8(m, 20H),  1.31(dd, 6H, J = 5.7, 21.6),  1.85(dd, 2H, J = 6.3, 20.4), 2.20(t, 2H, J = 8.1), 2.64(brt, 2H), 2.94(brt, 2H), 3.97(br, 2H), 4.17(br, 2H9, 8.11(s, 1H), 9.82(d, 1H, =8.7)


 


XI-129




DMSO-d6 1.02-1.90(m,  19H), 2.65-2.78(m, 2H), 2.90-3.0(m, 2H), 4.03(s, 2H), 3.90-4.20(m, 2H), 7.61(s, 1H), 8.26(s, 1H), 12.79(s, 1H), 12.86(br s, 1H)
















TABLE 91













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-253




1.01(d, 3H, J = 6.6), 1.02(d, 3H, J =  6.6), 1.34-1.56(m, 4H), 1.58-1.78(m, 4H), 2.27(m, 1H), 2.62(t, 2H, J = 6.0), 2.78(t, 2H, J = 6.0), 3.75(s, 3H), 4.66(dd, 1H, J = 5.1 and 8.1), 5.44(br, 2H), 6.98-7.10(m, 4H), 8.37(s, 1H), 10.32(d, 1H, J = 8.1)


 


I-254




1.34-1.54(m, 4H), 1.54-1.80(m, 4H), 2.61(t, 2H, J = 6.0), 2.78(t, 2H, J = 6.0), 3.75(s, 3H), 5.42(br, 2H), 5.72(d, 1H, J = 6.6), 6.92-7.12(m, 4H), 7.26-7.40(m, 3H), 7.48(d, 2H, J = 6.6), 8.36(s, 1H), 10.75(d, 1H, J = 6.9)


 


I-255




1.34-1.54(m, 4H), 1.61(s, 6H), 1.62- 1.78(m, 4H), 2.62(t, 2H, J = 6.0), 2.78(t, 2H, J = 6.0), 3.75(s, 3H), 5.42(br, 2H), 6.94-7.10(m, 4H), 8.37(s, 1H), 10.20(br s, 1H)


 


I-262




1.32-1.75(m, 8H), 2.63(brt, 2H),  2.79(brt, 2H), 3.79(s, 3H), 5.43(br, 2H), 6.00(d, 1H, J = 6.3), 6.95- 7.08(m, 5H), 7.15(m, 1H), 7.25(dd, 1H, J = 0.9 and 3.6), 8.37(s, 1H), 10.73(d, 1H, J = 6.3)


 


I-263




1.08(s, 9H), 1.32-1.74(m, 8H), 2.62(brt, 2H), 2.77(brt, 2H), 3.74(s, 3H), 4.54(d, 1H, J = 8.1), 5.45(br,  2H), 6.98-7.10(m, 4H), 8.36(s, 1H), 10.47(d, 1H, J = 8.1)


 


I-270




1.33-1.76(m, 8H), 2.63(brt, 2H),  2.79(brt, 2H), 3.79(s, 3H), 5.43(br, 2H), 5.92(d, 1H, J = 7.2), 6.33(dd, 1H, J = 1.8 and 3.3), 6.41(d, 1H, J = 3.3), 6.98-7.09(m, 4H), 7.38(d, 1H, J = 1.8), 8.37(s, 1H), 10.68(d, 1H, J = 7.2)
















TABLE 92













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-299




1.22-1.74(m, 14H), 1.82-1.92(m,  2H), 2.13-2.24(brm, 2H), 2.61(t, 2H, J = 6.0), 2.78(t, 2H, J = 6.3), 3.74(s, 3H), 5.43(br, 2H), 6.99-7.09(m, 4H), 8.35(s, 1H), 10.26(brs, 1H)


 


I-522




DMSO-d6 1.34-1.50(m, 4H), 1.47(s, 6H), 1.50-1.70(m, 4H), 2.66(t, 2H, J = 6.0), 2.83(t, 2H, J = 6.0), 5.42(br, 2H), 7.11-7.24(m, 4H), 8.18(s, 1H), 10.14(br s, 1H), 12.44(br, 1H)


 


I-528




DMSO-d6 1.24-1.68(m, 8H),  2.67(brm, 2H), 2.83(brm, 2H), 5.43(brs, 2H), 5.76(d, 1H, J = 7.2), 7.01(dd, 1H, J = 3.6 and 5.1), 7.10- 7.21(m, 5H), 7.49(dd, 1H, J = 1.2 and 5.1), 8.22(s, 1H), 10.62(d, 1H, J = 7.2), 13.32(br, 1H)


 


I-529




DMSO-d6 0.98(s, 9H), 1.22-1.70(m, 8H), 2.67(brm, 2H), 2.82(brm, 2H), 4.26(d, 1H, J = 8.4), 5.44(brm, 2H), 7.12-7.22(m, 4H), 8.22(s, 1H),  10.32(d, 1H, J = 8.4), 12.69(br, 1H)


 


I-535




DMSO-d6 1.22-1.68(m, 8H),  2.67(brt, 2H), 2.84(brt, 2H),  5.42(brs, 2H), 5.67(d, 1H, J = 7.5), 6.45(d-like, 2H), 7.11-7.21(m, 4H), 7.64(t-like, 1H), 8.23(s, 1H), 10.56(d, 1H, J = 7.5),  13.28(br, 1H)


 


I-564




DMSO-d6 1.15-1.18(m, 16H), 1.96- 2.08(brm, 2H), 2.66(brt, 2H),  2.83(brt, 2H), 5.44(brs, 2H), 7.11- 7.22(m, 4H), 8.18(s, 1H), 10.16(s, H), 12.20(br, 1H)


 


II-067




1.42-1.46(m, 4H), 1.69(bs, 4H), 2.65-2.74(m, 6H), 5.33-5.39(m, 3H), 6.99-7.26(m, 4H), 8.41(s, 1H), 10.47(d, 1H, J = 9.6)
















TABLE 93













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





II-078




0.92(d, 6H, J = 6.6), 1.24- 1.78(m, 8H), 2.59-2.82(m, 6H), 4.40(m, 1H), 5.41(br, 2H), 7.02-7.04(m, 4H),  8.39(s, 1H), 10.19(d, 1H, J = 6.6) 


 


II-079




1.41-1.45(m, 4H), 1.67- 1.69(m, 7H), 2.63-2.83(m, 6H), 4.93(m, 1H), 5.41(br, 2H), 5.58(dd, 1H, J = 4.8, 15.3), 7.01-7.05(m, 4H), 8.39(s, 1H), 10.25(d, 1H, J = 7.8)


 


II-080




1.32-1.71(m, 16H), 2.17- 2.19(m, 2H), 2.63-2.67(m, 2H), 2.78-2.82(m, 2H), 5.44(br, 2H), 7.02-7.09(m, 4H), 8.38(s, 1H), 10.51(s, 1H)


 


X-10




1.24-1.71(m, 18H), 2.33(s,  2H), 2.67(t, 2H, J = 6.0), 2.84(t, 2H, J = 6.0), 3.43(d, 2H, J = 6.9), 5.43(br, 2H), 7.03-7.05(m, 4H), 8.42(s, 1H), 10.53(t, 1H, J = 6.9)


 


X-85




DMSO-d6 1.20-1.50(m, 4H), 1.50-1.74(m, 4H), 2.65- 2.80(m, 2H), 2.83-2.97(m, 2H), 3.60(s, 2H), 5.49(br s, 2H), 7.03(s, 1H), 7.10- 7.30(m, 4H), 8.38(s, 1H), 12.20-12.50(br, 1H), 13.31(s, 1H)


 


X-87




DMSO-d6 1.30-1.43(m, 4H), 1.62-1.63(m, 4H), 2.73(br-s, 2H), 2.92(br-s, 2H), 3.80(s, 2H), 5.50(br-s, 2H), 7.13- 7.30(m, 4H), 8.41(s, 1H), 12.6(br-s, 1H), 13.66(br-s, 1H)


 


X-89




0.92(t, 6H, J = 7.2), 1.20- 1.91(m, 18H), 2.64(t, 2H, J = 6.0), 2.80(t, 2H, J = 6.0), 3.01(s, 2H), 5.42(bs, 1H), 6.98-7.06(m, 4H), 8.37(s, 1H), 10.4(s, 1H)


 


X-96




DMSO-d6 1.26-1.72(m, 8H), 2.73(t-like, 2H), 2.90(t-like, 2H), 3.82(d, 2H, J = 0.6), 5.49(brs, 2H), 7.14-7.24(m, 4H), 7.30(t, 1H, J = 0.6), 8.38(s, 1H), 12.63(br, 1H), 13.24(s, 1H)
















TABLE 94













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





X-100




1.36-1.76(m, 10H),  1.82-1.94(m, 2H), 2.27(d, 2H, J = 14), 2.64(t, 2H, J = 6.0), 2.80(t, 2H, J = 6.0), 3.05(s, 2H), 3.68- 3.86(m, 4H), 5.42(bs, 1H), 6.98-7.06(m,  4H), 8.36(s, 1H), 10.5(s, 1H)


 


X-101




0.89(t, 3H, J = 7.2),  1.32-1.76(m, 16H), 2.60-2.84(m, 6H), 4.22-4.36(m, 1H),  5.44(bs, 1H), 6.98- 7.06(m, 4H), 8.40(s, 1H), 10.3(d, 1H, J = 7.5)


 


X-120




DMSO-d6 1.28-1.49(m, 4H), 1.60-1.71(m, 8H), 2.01-2.07(m, 2H), 2.21-2.27(m, 2H), 2.71(br-s, 2H), 2.90(br-s, 2H),  5.47(br-s, 2H), 6.99-7.21(m, 5H), 8.36(s, 1H), 13.25(s, 1H)


 


X-122




DMSO-d6 1.00-1.75(m, 12H), 2.20-2.38(br, 2H), 2.56-2.70(br, 2H), 2.70-2.98(m, 4H), 5.40(br, 2H), 7.10- 7.29(m, 4H), 8.19(s, 1H), 12.23(br, 1H), 12.58(s, 1H)


 


X-149




DMSO-d6 1.22-1.46(m, 4H), 1.54-1.70(m, 4H), 1.80(t, 2H, J =  7.5), 2.42(t, 2H, J = 8.1), 2.62-2.70(br, 2H), 2.76-2.90(br, 2H), 3.18(t, 2H, J = 7.8), 5.42(br, 2H), 7.16(d, 4H, J = 7.5), 8.25(s, 1H), 12.10(br, 1H), 12.72(s, 1H)


 


X-168




DMSO-d6 1.28-1.70(m, 8H), 2.73(br, 2H), 2.90(br, 2H), 5.49(br, 2H), 6.58(d, 1H, J = 16.2), 7.15-7.22(m, 4H), 7.59(d, 1H, J = 15.9), 8.23(dd, 1H, J = 2.1 and 8.7), 8.32(d, 1H, J = 8.7), 8.39(s,  1H), 8.60(d, 1H, J =  2.1), 12.43(s, 1H), 12.68(s, 1H)


 


X-171




DMSO-d6 1.26-1.66(m, 8H), 2.56(t, 2H, J =  7.5), 2.72(br, 2H),  2.80(t, 2H, J = 7.5),  2.89(br, 2H), 5.48(br, 2H), 7.15-7.21(m, 4H), 7.71(dd, 1H, J = 2.1 and 8.7), 8.37(s, 1H), 12.18(s, 1H), 12.43 (s, 1H)
















TABLE 95













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





X-194




DMSO-d6 0.85(t, 3H,  J = 6.6), 1.20-1.83(m, 14H), 2.67(br, 2H), 2.83(br, 2H), 4.44(m, 1H), 5.43(brs, 2H), 7.10-7.21(m, 4H), 8.21(s, 1H), 10.12(d, 1H, J = 7.5), 12.79(br, 1H)


 


X-217




DMSO-d6 0.57(t, 6H, J = 7.2), 1.04-1.70(m, 12H), 2.40-2.62(m,  6H), 5.19(s, 2H), 6.86- 6.99(m, 4H), 7.97(s, 1H), 9.51(s, 1H), 11.78(brs, 1H)


 


X-219




DMSO-d6 0.86(dd, 6H, J = 2.4 and 6.6), 1.22-1.68(m, 12H), 1.78(m, 1H), 2.20(t, 2H, J = 7.5), 2.62- 2.71(m, 2H), 2.77- 2.87(m, 2H), 4.05(m, 1H), 5.41(brs, 2H), 7.09-7.23(m, 4H), 8.21(s, 1H), 9.56(d, 1H, J = 8.7), 12.03(brs, 1H)


 


X-226




DMSO-d6 1.26- 1.47(m, 4H), 1.54- 1.70(m, 4H), 2.67- 2.77(m, 2H), 2.82- 2.93(m, 2H), 5.49(brs, 2H), 6.44(d, 1H, J = 15.9), 7.16- 7.21(m, 4H), 7.54(d, 1H, J = 15.9), 7.67(d, 2H, J = 8.7), 7.74(d, 2H, J = 8.7), 8.36(s, 1H), 12.28(brs, 1H), 12.32(s, 1H)


 


XI-012




DMSO-d6 1.26- 1.48(m, 4H), 1.55- 1.70(m, 4H), 2.52(t, 2H, J = 7.5), 2.66- 2.75(m, 2H), 2.79(t, 2H, J = 7.5),  2.83-2.92(m, 2H), 5.48(brs, 2H), 7.16- 7.20(m, 4H), 7.19(d, 2H, J = 8.4), 7.59(d, 2H, J = 8.4), 8.34(s, 1H), 12.07(s, 1H), 12.12(brs, 1H)


 


XI-034




DMSO-d6 1.20- 1.68(m, 22H), 1.78- 1.94(m, 2H), 2.04- 2.20(m, 2H), 2.60-2.74(m, 2H), 2.78-2.88(m, 2H),  5.42(s, 2H), 7.10- 7.22(m, 4H), 8.17(s, 1H), 9.92(s, 1H), 12.23(br, 1H)


 


XI-125




DMSO-d6 1.32(m, 2H), 1.42(m, 2H), 1.63(m, 4H),  2.73(m, 2H), 2.89(m, 2H), 5.48(s, 2H), 6.73(d, 1H, J = 16.2), 7.14-7.21(m, 4H), 7.56(d, 1H, J = 16.2), 8.36(s, 1H), 9.02(s, 2H), 12.89(s, 1H)
















TABLE 96













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-136




DMSO-d6 0.92(s, 9H),  1.30(m, 2H), 1.40(m, 2H), 1.58(m, 5H), 1.77(m, 1H), 2.66(m, 2H), 2.83(m, 2H), 4.48(m, 1H), 5.43(m, 2H), 7.15(m, 4H), 8.22(s, 1H), 10.05(d, 1H, J = 6.0)


 


XI-137




DMSO-d6 0.88(s, 9H), 1.30(m, 2H), 1.40(m, 2H), 1.60(m, 4H), 2.16(m, 1H), 2.57(m, 1H), 2.66(m, 2H), 2.82(m, 2H), 4.28(m, 1H), 5.42(m, 2H), 7.16(m, 4H), 8.21(s, 1H), 9.88(d, 1H, J = 7.2)


 


XI-156




DMSO-d6 0.87(s, 9H), 1.22-1.82(m, 12H), 2.19(t, 2H, J = 7.5), 2.60- 2.70(m, 2H), 2.76-2.87(m, 2H), 4.09(m, 1H), 5.41(brs, 2H), 7.08- 7.21(m, 4H), 8.21(s, 1H), 9.66(d, 1H, J = 9.0), 11.97(brs, 1H)


 


XI-168




DMSO-d6 1.10-1.18(m,  16H), 2.20-2.95(m, 6H), 5.30-5.60(m, 2H), 7.10- 7.25(m, 4H), 8.16(s, 1H), 10.32(s, 1H)


 


XI-211




DMSO-d6 1.25-1.50(m,  4H), 1.57-1.70(m, 4H), 2.67-2.77(m, 2H), 2.85- 2.95(m, 2H), 3.60(s, 2H), 5.48(s, 2H), 7.12-7.26(m, 4H), 7.72(dd, 1H, J = 2.4, 8.4), 8.19(d, 1H, J = 2.1), 8.23(d, 1H, J = 8.4), 8.38(s, 1H), 12.47(s, 1H)


 


XI-215




1.44(m, 2H), 1.69-1.88(m, 10H), 2.18-2.22(m, 2H), 2.63-2.67(m, 2H), 2.78- 2.83(m, 2H), 5.41(s, 2H), 7.02-7.05(m, 4H), 8.39(s, 1H), 10.49(s, 1H)


 


XI-225




DMSO-d6 1.22-1.46(m, 4H), 1.52-1.68(m, 4H), 1.77-1.92(m, 2H), 2.22(t, 3H, J = 7.5), 2.59-2.71(m, 2H), 2.76-2.87(m, 2H), 2.88(s, 3H), 5.40(br, 2H), 7.08-7.22(m, 4H), 8.18(s, 1H), 9.99(s, IH), 12.02(br, 1H)
















TABLE 97













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-008




DMSO-d6 1.28-1.50(m, 4H), 1.57-1.73(m, 4H), 2.70-2.80(m, 2H), 2.87-2.99(m, 2H), 3.60(s, 2H), 5.45(s, 2H), 6.88-7.10(m, 3H), 7.34(m, 1H), 8.39(s, 1H), 12.38(br s, 1H), 13.21(s, 1H)


 


XI-018




DMSO-d6 1.10-1.80(m, 16H),  1.94-2.10(m, 2H), 2.63-2.74(m, 2H), 2.78-2.88(m, 2H), 5.40(s, 2H), 6.78(m, 1H), 7.03(m, 1H), 7.34(m, 1H), 8.19(s, 1H), 10.06(s, 1H), 12.23(br s, 1H)
















TABLE 98













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-112




DMSO-d6 1.27-1.49(m, 4H),  1.55-1.72(m, 4H), 2.67- 2.80(m, 2H), 2.85-2.97(m, 2H), 3.60(s, 2H), 5.48(br s, 2H),  6.96-7.04(m, 1H), 7.03(s, 1H), 7.30-7.46(m, 2H), 8.38(s, 1H), 12.39(br s, 1H), 13.26(s, 1H)


 


XI-017




DMSO-d6 1.14-1.78(m, 16H), 1.96-2.08(m, 2H), 2.60- 2.75(m, 2H), 2.75-2.90(m, 2H), 5.43(s, 2H), 6.86(m, 1H), 7.28(m, 1H), 7.40(m, 1H), 8.18(s, 1H), 10.12(s, 1H), 12.23(br s, 1H)


 


XI-124




DMSO-d6 1.10-1.68(m, 16H),  2.14-2.28(m, 2H), 2.62-2.68(m, 2H), 2.72-2.88(m, 4H), 5.41(br, 2H), 6.84-6.90(m, 1H), 7.19-7.29(m, 1H), 7.34- 7.47(m, 1H), 8.20(s, 1H), 9.80(s, 1H), 11.83(br, 1H)


 


XI-127




DMSO-d6 1.25-1.48(m, 4H),  1.55-1.73(m, 4H), 2.68-2.80(m, 2H), 2.85-2.97(m, 2H), 3.81(s, 2H), 5.49(s, 2H), 7.02(m, 1H), 7.30-7.48(m, 2H), 8.42(s, 1H), 12.66(br s, 1H), 13.61(s, 1H)


 


XI-128




DMSO-d6 1.20-1.50(m, 4H), 1.54-1.74(m, 4H), 2.67- 2.80(m, 2H), 2.83-2.97(m, 2H), 3.82(s, 2H), 5.48(s, 2H), 6.98(m, 1H), 7.28-7.50(m, 2H), 7.30(s, 1H), 8.38(s, 1H), 12.65(br s, 1H), 13.19(s, 1H)


 


XI-144




DMSO-d6 0.92(s, 9H), 1.31(m,  2H), 1.41(m, 2H), 1.59(m, 5H), 1.76(m, 1H), 2.67(m, 2H), 2.84(m, 2H), 4.49(m, 1H),  5.42(m, 2H), 6.87(m, 1H), 7.24(m, 1H), 7.40(m, 1H), 8.22(s, 1H), 10.20(d, 1H, J = 6.0)


 


XI-145




DMSO-d6 0.88(s, 9H), 1.31(m, 2H), 1.41(m, 2H), 1.60(m, 4H), 2.16(m, 1H), 2.58(m, 1H), 2.67(m, 2H), 2.82(m, 2H), 4.29(m, 1H), 5.42(m, 2H), 6.88(m, 1H), 7.24(m, 1H), 7.40(m, 1H), 8.22(s, 1H), 9.85(d, 1H, J = 7.2)
















TABLE 99













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-147




DMSO-d6 1.25- 1.50(m, 4H), 1.55- 1.75(m, 4H), 2.60- 2.80(m, 2H), 2.80- 3.00(m, 2H), 5.47(s, 2H), 6.58(d, 1H, J = 16.2), 6.96(m, 1H), 7.26-7.48(m, 2H), 7.58(d, 1H, J = 15.9), 8.22(dd, 1H, J = 2.1,  8.7), 8.31(d, 1H, J = 2.1), 8.39(s, 1H), 8.59(d, 1H, J = 1.8), 12.63(s, 1H)


 


XI-159




DMSO-d6 0.86(dd, 6H, J = 6.6 and 2.4), 1.25- 1.41(m, 6H), 1.48- 1.74(m, 7H), 2.20(t, 2H, J = 7.5), 2.67(br s, 2H), 2.82(br s, 2H), 4.05(m, 1H), 5.39(br s, 2H), 6.88(m, 1H), 7.26(m, 1H), 7.39(dt, 1H, J = 10.8 and 8.4), 8.21(s, 1H), 9.51(d, 1H, J = 9.0), 12.09(br s, 1H)


 


XI-172




DMSO-d6 1.05- 2.00(m, 16H), 2.20- 2.95(m, 6H), 5.30- 5.55(m, 2H), 6.80- 7.46(m, 3H), 8.16(s, 1H), 10.28(s, 1H)  


 


XI-175




DMSO-d6 1.24- 1.47(m, 4H), 1.50- 1.72(m, 4H), 2.59- 2.76(m, 3H), 2.77- 2.85(m, 3H), 5.16(m, 1H), 5.40(br s, 2H), 6.88(m, 1H), 7.26(m, 1H), 7.39(m, 1H),  8.27(s, 1H), 10.27(d, 1H, J = 9.0), 12.74(br, 1H)


 


XI-180




DMSO-d6 0.87(s, 9H), 1.23-1.82(m, 12H), 2.19(t, 2H, J = 7.5), 2.60-2.70(m, 2H), 2.77-2.87(m, 2H), 4.08(m, 1H), 5.40(brs, 2H), 6.87(m, 1H), 7.22(m, 1H), 7.40(m, 1H), 8.22(s, 1H), 9.62(d, 1H, J = 9.0), 11.98(brs, 1H)


 


XI-200




DMSO-d6 0.86(d, 6H,  J = 6.6), 1.25-1.68(m, 11H), 2.44(t, 2H, J = 6.8), 2.66(t, 2H, J = 6.0), 2.81(br s, 2H), 4.33(m, 1H), 5.38(br s, 2H), 6.86(m, 1H),  7.24(ddd, 1H, J = 11.6, 7.8 and 2.0), 7.39(dt,  1H, J = 10.8 and 8.4), 8.21(s, 1H), 9.71(d, 1H, J = 8.4), 12.14(br s, 1H)
















TABLE 100













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-206




DMSO-d6 1.26- 1.68(m, 18H), 2.17(s, 2H), 2.67(br s, 2H), 2.81(br s, 2H), 3.40(d, 2H, J = 6.3), 5.41(br s, 2H), 6.86(m, 1H), 7.25(ddd, 1H, J = 11.9, 7.7 and 2.3), 7.39(dt, 1H, J = 10.8 and 8.4), 8.23(s, 1H), 9.89(t, 1H, J = 6.0), 12.06(br s, 1H)


 


XI-213




DMSO-d6 1.34(m,  2H), 1.43(m, 2H),  1.63(m, 4H), 2.73(m, 2H), 2.89(m, 2H), 5.47(s, 2H), 6.73(d,  1H, 16.2), 6.97(m, 1H), 7.30-7.45(m, 2H), 7.55(d, 1H, J = 16.2), 8.36(s, 1H), 9.02(s, 2H), 12.84(s, 1H)


 


XI-214




1.45(m, 2H), 1.69- 1.90(m, 10H), 2.17- 2.22(m, 2H), 2.64- 2.68(m, 2H), 2.77- 2.81(m, 2H), 5.40(s, 2H), 6.80(m, 1H), 6.87-6.93(m, 1H), 7.09-7.18(m, 1H), 8.39(s, 1H), 10.37(s, 1H)


 


XI-222




DMSO-d6 1.23- 1.52(m, 4H), 1.52- 1.68(m, 4H), 1.78- 1.92(m, 2H), 2.21(t, 4H, J = 7.8), 2.62- 2.71(m, 2H), 2.76- 2.86(m, 2H), 2.88(s, 2H), 5.39(br, 2H), 6.87(m, 1H), 7.25(m, 1H), 7.39(m, 1H), 8.18(s, 1H), 9.95(s,  1H), 11.86(br, 1H)


 


XI-249




DMSO-d6 1.26- 1.50(m, 4H), 1.55- 1.73(m, 4H), 2.66- 2.78(m, 2H), 2.83- 2.95(m, 2H), 3.60(s, 2H), 5.46(s, 2H), 6.96(m, 1H), 7.26- 7.48(m, 2H), 7.72(dd, 1H, J = 2.4, 8.4), 8.19(d, 1H, J = 2.4), 8.23(d, 1H, J = 8.4), 8.37(s, 1H), 12.43(s, 1H), 12.44(br s, 1H)


 


XI-285




DMSO-d6 1.20- 2.20(m, 12H), 2.60- 2.95(m, 4H), 2.86(s, 2H), 3.48(t, 2H, J = 10.5), 3.60-3.75(m, 2H), 5.30-5.55(m, 2H), 6.82-7.48(m, 2H), 8.20(s, 1H), 9.98(s, 1H)
















TABLE 101













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-004




0.98(t, 3H, J = 7.2), 1.36- 1.81(m, 12H), 2.64(br, 2H), 2.85(t, 2H, J = 6.0), 3.15(dd, 1H, J = 8.7 and 13.8), 3.30(dd, 1H, J = 5.7 and 13.8), 3.89(dd, 1H, J = 4.2 and 18.3), 3.94(br, 2H), 4.25(dd, 1H, J = 6.3 and 15.3), 4.80(m, 1H), 6.91(brt, 1H), 7.20- 7.37(m, 5H), 10.79(d, 1H, J = 7.5), 15.38(s, 1H)


 


I-071




0.95(t, 3H, J = 7.2), 1.37- 2.20(m, 18H), 2.65(br, 2H), 2.85(t, 2H, J = 6.0), 3.20- 3.42(m, 2H), 3.90-4.20(m, 2H), 4.73(dd, 1H, J = 6.6 and 10.8), 6.02(brt, 1H), 11.18(d, 1H, J = 7.2), 15.77(s, 1H)


 


I-150




0.96(t, 3H, J = 7.2), 1.37- 1.81(m, 12H), 2.65(br, 2H), 2.85(t, 2H, J = 6.0), 3.75(s, 3H), 4.00(br, 2H), 5.68(d, 1H, J = 6.9), 7.30-7.70(m, 5H), 11.37(d, 1H, J = 6.3), 15.42(s, 1H)


 


I-202




0.98(t, 3H, J = 7.2), 1.23- 2.12(m, 22H), 2.65(br, 2H), 2.86(t, 2H, J = 6.0), 3.72(s, 3H), 3.99(br, 2H), 10.86(s, 1H), 15.63(s, 1H)


 


I-423




0.97(t, 3H, J = 7.2), 1.18- 1.80(m, 12H), 2.64(br, 2H), 2.86(t, 2H, J = 6.0), 4.00(br, 2H), 5.64(d, 1H, J = 6.9),  7.26-7.53(m, 5), 11.37(d, 1H, J = 6.9), 15.59(s, 1H)


 


I-438




0.97(t, 3H, J = 7.2), 1.08- 2.00(m, 22H), 2.66(br, 2H), 2.88(t, 2H, J = 6.0), 3.75(s, 3H), 3.99(br, 2H), 4.59(dd, 1H, J = 5.7 and 8.1), 10.89(d, 1H, J = 8.1), 15.69(s, 1H)
















TABLE 102













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-443




0.97(t, 3H, J = 7.2), 1.08- 2.05(m, 22H), 2.66(br, 2H), 2.86(t, 2H, J = 6.0), 4.01(br, 2H), 4.60(dd, 1H, J = 5.7 and 8.4), 10.90(d, 1H, J = 8.1), 15.55(s, 1H)


 


I-474




0.97(t, 3H, J = 7.2), 1.23- 1.80(m, 18H), 1.88-1.96(m, 2H), 2.23-2.32(m, 2H), 2.66(br, 2H), 2.87(t, 2H, J = 6.0), 3.99(br, 2H), 11.03(s, 1H), 15.02(s, 1H)


 


II-009




0.97(t, 3H, J = 7.2), 1.39- 1.80(m, 12H), 2.65(br, 2H), 2.83-2.92(m, 3H), 3.01(dd, 1H, J = 7.2, 15.3), 3.64(s, 3H),  3.98(br, 2H), 5.60(q, 1H, J = 7.8), 7.25-7.42(m, 5H), 11.12(d, 1H, J = 8.1), 15.80(s, 1H)


 


II-025




0.94(t, 3H, J = 7.2), 1.23(t, 3H,  J = 7.2), 1.31-2.05(m, 21H), 2.64(br, 2H), 2.76(m, 1H), 2.84(t, 2H, J = 6.6), 3.98(br, 2H), 4.10-4.19(m, 2H), 4.51(m, 1H), 10.91(d, 1H, J = 8.7), 16.17(s, 1H)


 


II-050




0.96(t, 3H, J = 7.2), 1.29- 1.80(m, 12H), 2.65(br, 2H), 2.85(t, 2H, J = 6.0), 2.92(dd, 1H, J = 6.6 and 9.6), 3.08(dd, 1H, J = 7.5 and 16.2), 5.59(q, 1H, J = 7.8), 7.22-7.48(m, 5H), 11.07(d, 1H, J = 7.8), 15.75(s, 1H)


 


II-051




0.93(t, 3H, J = 7.2), 1.31- 2.08(m, 21H), 2.64(br, 2H), 2.76(m, 1H), 2.84(t, 2H, J = 6.6), 3.85-4.10(m, 2H), 4.50(m, 1H), 10.91(d, 1H, J = 8.7), 16.04(s, 1H) 
















TABLE 103













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-145




1.00-1.80(m, 25H), 2.30(m, 1H), 2.65(brs, 2H), 2.89(t, 2H, J = 6.3), 3.76(s, 3H), 4.57(dd, 1H, J = 5.1 and 8.1), 10.94(d, 1H, J = 8.1), 15.71(s, 1H)


 


I-149




1.08-2.21(m, 29H), 2.65(m, 2H), 2.89(t, 2H, J = 6.3), 3.73(s, 3H), 3.7-4.1(br, 2H), 10.88(s, 1H), 15.67(s, 1H)


 


I-418




DMSO-d6 0.93-1.81(m, 25H),  2.20(m, 1H), 2.60(m, 1H), 2.95(m, 2H), 4.38(dd, 1H, J = 4.5 and 8.1), 10.84(d, 1H, J = 8.1), 15.96(s, 1H)


 


I-422




1.03-2.30(m, 29H), 2.50-2.90(br,  2H), 2.90(t, 2H, J = 6.0), 3.7- 4.2(br, 2H), 11.08(s, 1H), 15.00(s, 1H)


 


II-023




1.05-2.08(m, 35H), 2.45-2.80(m,  5H), 4.14(q, 2H, J = 7.2), 4.50(m, 1H), 10.92(d, 1H, J = 8.7), 16.22(s, 1H)


 


II-048




1.02-2.10(m, 27H), 2.3-3.2(m,  5H), 3.7-4.3(br, 2H), 4.98(m, 1H), 10.93(d, 1H, J = 9.0), 16.07(s, 1H)
















TABLE 104













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-135




0.98-1.08(m, 8H), 1.22(t, 3H, 6.6), 1.40-1.52(m, 2H), 1.65-1.78 (m, 3H), 2.18(s, 3H), 2.28(m, 1H), 2.74(q, 2H, J = 7.2), 3.74(s, 3H), 4.02-4.18(m, 2H), 4.64(dd, 1H, J = 4.8 and 8.7), 8.28 (s, 1H), 10.42(d, 1H, J = 7.8)


 


I-136




0.99(t, 3H, J = 7.2), 1.22(t, 3H, 7.5), 1.40-1.94(m, 10H), 2.15-2.24(m, 5H), 2.28(m, 1H), 2.73(q, 2H, J = 7.8), 3.71(s, 3H), 4.05- 4.16(m, 2H), 8.26(s, 1H), 10.35(br, 1H)


 


I-156




0.98(t, 3H, J = 7.2), 1.21(t, 3H, J = 7.2), 1.38-1.55(m, 2H), 1.58-1.80(m, 3H), 2.16(s, 3H), 2.72(q, 2H, J = 7.5), 4.00-4.20(m, 2H), 5.73(d, 1H, J = 7.2), 7.20-7.40(m, 3H), 7.45-7.52(m, 2H), 8.27(s, 1H), 10.87(d, 1H, J = 7.5)


 


I-408




DMSO-d6 0.90-1.00(m, 9H), 1.16(t, 4H, 7.8), 1.35-1.47 (m, 2H), 1.53-1.66(m, 2H), 2.17(s, 3H), 2.76(q, 2H, J = 7.5), 3.95-4.20(m, 2H), 4.40(dd, 1H, J = 4.8 and 8.7), 8.13(s, 1H), 10.27(d, 1H, J = 8.4), 12.90(br, 1H)


 


I-409




DMSO-d6 0.94(t, 3H, J = 7.5), 1.16(t, 3H, 7.5), 1.40-1.78(m, 12H), 1.97-2.10(m, 2H), 2.17(s, 3H), 2.76(q, 2H, J = 7.2), 4.02-4.13(m, 2H), 8.08(s, 1H), 10.26(br, 1H), 12.14(br, 1H)


 


I-429







 


X-206




DMSO-d6 0.95(t, 3H, J = 7.5), 1.19(t, 3H, J = 7.5), 1.34-1.50(m, 2H), 1.56-1.72(m, 2H), 2.23(s, 3H), 2.82(q, 2H, J = 7.5), 3.61(s, 2H), 4.10-4.20(m, 2H), 7.02(s, 1H), 8.29(s, 1H), 12.38(br s, 1H), 13.47(s, 1H)
















TABLE 105













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-106




DMSO-d6 0.98(d, 6H), 1.21(t, 3H, J = 7.5), 1.48-1.62(m, 2H), 1.75(m, 1H), 2.23(s, 3H), 2.80(q, 2H, J = 7.2), 3.61(s, 2H), 3.80-4.21(m, 2H), 7.02(s, 1H), 8.29(s, 1H), 12.40(br s, 1H), 13.46(s, 1H)


 


XI-113




DMSO-d6 0.97(d, 6H, J = 6.6), 1.18(s, 3H, J = 7.5), 1.26-1.78(m, 8H), 2.16(s, 3H), 2.75(q, 2H, J = 7.5), 4.09(m, 2H), 8.09(s, 1H), 10.24(s, 3H)
















TABLE 106













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-030




0.98-1.30(m, 14H), 1.54-2.30(m, 8H), 2.15 and 2.17(s, total 3H), 2.75(q, 2H, J = 7.5), 3.00 and 3.28(s, total 3H), 3.24-4.18(m, 6H), 4.79(m, 1H), 8.23 and 8.24(s, total 1H), 10.46 and 10.55(brd, total 1H)


 


I-034




1.00-1.30(m, 8H), 1.14(s, 9H), 1.53-1.90(m, 6H), 2.09(br, 1H), 2.18(s, 3H), 2.76(q, 2H, J = 7.5), 3.40(q, 2H, J = 5.4), 3.62-3.78(m, 2H), 3.80-4.20(br, 2H), 4.19(d, 1H, J = 6.9), 6.54(m, 1H), 8.25(s, 1H), 10.71(d, 1H, J = 6.9)


 


I-035




1.00-1.40(m, 18H), 1.52-1.92(m, 6H), 2.14- 2.17(m, 3H), 2.33(br, 1H), 2.76(q, 2H, J = 7.5), 2.98-4.23(m, 7H), 3.33(s, 3H), 4.98(m, 1H), 8.24(m 1H), 10.66 and 10.88(m, total 1H)


 


I-038




1.01-1.30(m, 5H), 1.15(s, 9H), 1.16(t, 3H, J = 7.5), 1.54-1.92(m, 6H), 2.18(s, 3H), 2.77(q, 2H, J = 7.5), 3.70-4.20(br, 2H), 3.77-3.94(m, 5H), 4.13(d, 1H, J = 6.0), 6.89(m, 1H), 8.22(s, 1H), 10.83(d, 1H, J = 6.0)


 


I-039




1.00-1.30(m, 5H), 1.14(t, 3H, J = 7.5), 1.17(s, 9H), 1.52-1.90(m, 6H), 2.16(s, 3H), 2.75(q, 2H, J = 7.5), 3.26-3.50(m, 2H), 3.66-4.00(m, 5H), 3.80-4.20(m, 2H), 4.20(m, 1H), 4.85(d, 1H, J = 6.6), 8.22(s, 1H), 10.86(d, 1H, J = 6.6)


 


I-129




1.00-1.31(m, 5H), 1.15(t, 3H, J = 7.5), 1.57-1.96(m, 6H), 1.61(s, 6H), 2.17(s, 3H), 2.76(q, 2H, J = 7.5), 3.74(s, 3H), 3.80-4.20(br, 2H), 8.27(s, 1H), 10.26(s, 1H)


 


I-134




0.94-1.28(m, 14H), 1.57-1.94(m, 6H), 2.18(s, 3H), 2.27(m, 1H), 2.73(q, 2H, 7.2), 3.74(s, 3H), 3.98(br, 2H), 4.62(dd, 1H, J = 4.8 and 8.1), 8.28(s, 1H), 10.42(d, 1H, J = 7.8)


 


I-137




0.99-1.47(m, 9H), 1.48-1.95(m, 13H), 2.14- 2.26(m, 5H), 2.75(q, 2H, J = 7.5), 3.72(s, 3H), 4.02(br, 2H), 8.27(s, 1H), 10.35(br, 1H)
















TABLE 107













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-180




0.99-1.35(m, 9H), 1.52-1.96(m, 5H), 2.17(s, 3H), 2.75(q, 2H, J = 7.5), 3.74(s, 3H), 4.01(br, 2H), 5.73(d, 1H, J = 6.9), 7.29-7.39(m, 3H), 7.47-7.53(m, 2H), 8.27(s, 1H), 10.86(d, 1H, J = 8.4)


 


I-182




DMSO-d6 1.00-1.22(m, 5H), 1.10(t, 3H, J = 7.5), 1.44-1.85(m, 6H), 1.47(s, 6H), 2.17(s, 3H), 2.78(q, 2H, J = 7.5), 3.80-4.10(br, 2H), 8.10(s, 1H), 10.20(s, 1H), 12.41(brs, 1H)


 


I-252




1.00-1.30(m, 5H), 1.08(s, 9H), 1.15(s, 3H), 1.55-1.83(m, 6H), 2.17(s, 3H), 2.76(q, 2H, J = 7.5), 3.73(s, 3H), 3.75-4.30(br, 2H), 4.54(d, 1H, J = 8.1), 8.27(S, 1H), 10.57(d, 1H, J = 8.1)


 


I-321




1.02-1.30(m, 5H), 1.14(s, 9H), 1.17(t, 3H, J = 7.5), 1.55-1.88(m, 6H), 2.19(s, 3H), 2.77(q, 2H, J = 7.5), 3.60-4.30(br, 2H), 3.76-3.95(m, 4H), 4.34(d, 1H, J = 6.0), 4.99(m, 1H), 8.25(s, 1H), 10.74(d. 1H, J = 6.0)


 


I-327




1.02-1.30(m, 11H), 1.17(t, 3H, J = 7.5), 1.66- 1.88(m, 6H), 2.19(s, 3H), 2.30(m, 1H), 2.97(q, 2H, J = 7.5), 3.76-4.18(m, 6H), 4.41(t, 1H, J = 6.0), 4.99(m, 1H), 8.26(s, 1H), 10.60(d, 1H, J = 6.0)


 


I-407




DMSO-d6 0.91(d, 6H, 6.9), 1.04-1.30(m, 8H), 1.47-1.87(m, 6H), 2.10-2.21(m, 4H), 2.70- 2.88(m, 2H), 4.02(br, 2H), 4.40(dd, 1H, J = 4.5 and 7.5), 8.14(s, 1H), 10.25(d, 1H, J = 8.4)


 


I-410




DMSO-d6 1.03-1.47(m, 9H), 1.47-1.85(m, 13H), 1.95-2.10(m, 2H), 2.17(s, 3H), 2.79(q, 2H, J = 7.5), 4.02(br, 2H), 8.09(s, 1H), 10.24(br, 1H), 12.13(br, 1H)
















TABLE 108













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-519




DMSO-d6 0.90-1.23(m, 5H), 0.98(s, 9H), 1.11(t, 3H, J = 7.5), 1.46-1.85(m, 6H), 2.18(s, 3H), 2.79(q, 2H, J = 7.5), 3.80-4.20(br, 2H), 4.26(d, 1H, J = 8.7), 8.14(s, 1H), 10.40(d, 1H, J = 8.7), 12.65(brs, 1H)


 


I-573




1.02-1.33(m, 5H), 1.17(t, 3H, J = 7.5), 1.57- 1.94(m, 6H), 1.64(s, 6H), 2.20(s, 3H), 2.79(q, 2H, J = 7.5), 3.07(s, 3H), 3.80-4.20(br, 2H), 6.94(d, 1H, J = 5.7), 8.26(s, 1H), 8.85(d, 1H, J = 5.7), 10.43(s, 1H)


 


X-22




DMSO-d6 1.04-1.86(m, 14H), 2.23(s, 3H), 2.83(q, 2H, J = 7.5), 3.92(s, 2H), 4.05(br, 2H), 6.94(s, 1H), 8.28(s, 1H), 12.77(s, 1H), 12.87(br, 1H)


 


X-24




DMSO-d6 1.05-1.25(m, 8H), 1.45-1.90(m, 6H), 2.24(s, 3H), 2.83(q, 2H, J = 7.8), 3.62(s, 2H), 3.95-4.20(br, 2H), 7.02(s, 1H), 8.31(s, 1H), 12.40(s, 1H), 13.48(s, 1H)


 


X-48




DMSO-d6 1.03-1.88(m, 14H), 2.22(s, 3H), 2.82(q, 2H, J = 7.5), 3.71(s, 2H), 4.05(br, 2H), 6.68(d, 1H, J = 3.9), 6.72(d, 1H, J = 3.9), 8.25(s, 1H), 12.45(brs, 1H), 12.83(s, 1H)


 


X-109




DMSO-d6 1.00-1.20(m, 7H), 1.40-1.80(m, 7H), 2.16(s, 3H), 2.62-2.88(m, 4H), 3.97(brs, 2H), 5.10(brs, 1H), 8.17(s, 1H), 10.40(d, 1H, J = 9.6)


 


X-132




DMSO-d6 1.16(t, 3H, J = 7.5 Hz), 1.51- 18.9(m, 11H), 2.16(s, 3H), 2.76-2.80(m, 2H), 3.43-3.51(m, 2H), 3.73-3.77(m, 2H), 3.99(br-s, 2H), 8.09(s, 1H), 10.40(s, 1H), 12.43(br-s, 1H)
















TABLE 109













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-133




DMSO-d6 1.16(t, 3H, J = 7.5 Hz), 1.51- 18.9(m, 11H), 2.24(s, 3H), 2.85(q, 2H, J = 7.5 Hz), 3.81(s, 2H), 4.08(br-s, 2H), 8.34(s, 1H), 12.65(br-s, 1H), 13.84(s, 1H)


 


X-144




DMSO-d6 1.00-1.25(m, 8H), 1.40-1.82(m, 10H), 2.16(s, 3H), 2.22-2.36(br, 2H), 2.64- 2.84(br, 4H), 3.97(br, 2H), 8.11(s, 1H), 12.11(br, 1H), 12.58(s, 1H)


 


X-162




DMSO-d6 1.02-1.82(m, 19H), 1.10(t, 3H, J = 7.5), 2.13-2.26(m, 2H), 2.17(s, 3H), 2.77(q, 2H, J = 7.5), 2.78(s, 2H), 3.85-4.10(br, 2H), 8.11(s, 1H), 9.92(s, 1H), 11.88(brs, 1H)


 


X-173




DMSO-d6 0.90(dd, 6H, J = 5.4 and 10.8), 1.02-1.22(m, 5H), 1.10(t, 3H, J = 7.5), 1.46- 1.84(m, 9H), 2.18(s, 3H), 2.79(q, 2H, J = 7.5), 3.80-4.20(br, 2H), 4.46(m, 1H), 8.14(s, 1H), 10.14(d, 1H, J = 8.1), 12.73(brs, 1H)


 


X-179




DMSO-d6 0.86(t, 6H, J = 6.3), 1.01-1.85(m, 16H), 1.10(t, 3H, J = 7.5), 2.17(s, 3H), 2.20(t, 2H, J = 7.5), 2.78(q, 2H, J = 7.5), 3.80-4.22(m, 3H), 8.13(s, 1H), 9.65(d, 1H, J = 9.0), 12.02(brs, 1H)


 


X-184




DMSO-d6 0.89(t, 6H, J = 6.3), 1.01-1.20(m, 5H), 1.11(t, 3H, J = 7.5), 1.44-1.84(m, 9H), 2.18(s, 3H), 2.79(q, 2H, J = 7.5), 3.85-4.15(br, 2H), 4.70(m, 1H), 5.76(dd, 1H, J = 1.5 and 15.6), 6.82(dd, 1H, J = 5.4 and 15.6), 8.14(s, 1H), 9.99(d, 1H, J = 8.4), 12.32(brs, 1H)


 


X-203




DMSO-d6 0.86(d, 3H, J = 6.3), 0.87(d, 3H, J = 6.3), 1.00-1.24(m, 5H), 1.10(t, 3H, J = 7.5), 1.33(m, 1H), 1.45-1.82(m, 8H), 2.17(s, 3H), 2.36-2.52(m, 2H), 2.77(q, 2H, J = 7.5), 3.70- 4.10(br, 2H), 4.32(m, 1H), 8.13(s, 1H), 9.83(d, 1H, J = 8.7), 12.11(brs, 1H)
















TABLE 110













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-213




DMSO-d6 1.02-1.24(m, 4H), 1.14(t, 3H, J = 7.5), 1.48-1.90(m, 7H), 2.23(s, 3H), 2.83(q, 2H, J = 7.5), 3.90-4.20(br, 2H), 6.45(d, 1H, J = 15.9), 7.55(d, 1H, J = 15.9), 7.68(d, 2H, J = 8.7), 7.76(d, 2H, J = 8.7), 8.29(s, 1H), 12.29(brs, 1H), 12.45(s, 1H)


 


X-218




DMSO-d6 0.57(t, 6H, J = 7.2), 0.80-0.98(m, 8H), 1.24-1.72(m, 10H), 1.94(s, 3H), 2.48- 2.60(m, 4H), 3.73(brs, 2H), 7.88(s, 1H), 9.58(s, 1H), 11.76(brs, 1H)


 


X-221




DMSO-d6 1.04-1.27(m, 5H), 1.13(t, 3H, J = 7.2), 1.48-1.88(m, 6H), 2.22(s, 3H), 2.82(q, 2H, J = 7.2), 3.90-4.20(br 2H), 4.65(s, 2H), 6.90(d, 2H, J = 9.0), 7.61(d, 2H, J = 9.0), 8.26(s, 1H), 12.12(s, 1H), 12.99(brs, 1H)


 


XI-003




DMSO-d6 1.04-1.27(m, 5H), 1.13(t, 3H, J = 7.2), 1.48-1.88(m, 6H), 2.22(s, 3H), 2.82(q, 2H, J = 7.2), 3.90-4.15(br, 2H), 4.68(s, 2H), 6.65(m, 1H), 7.14-7.29(m, 2H), 7.45(m, 1H), 8.28(s, 1H), 12.26(s, 1H), 13.01(brs, 1H)


 


XI-011




DMSO-d6 1.04-1.25(m, 5H), 1.13(t, 3H, J = 7.5), 1.48-1.88(m, 6H), 2.22(s, 3H), 2.47- 2.56(m, 2H), 2.75-2.87(m, 4H), 3.90-4.20(br, 2H), 7.20(d, 2H, J = 8.4), 7.60(d, 2H, J = 8.4), 8.27(s, 1H), 12.11(brs, 1H), 12.19(s, 1H)


 


XI-033




DMSO-d6 1.00-1.24(m, 7H), 1.30-2.20(m, 23H), 2.16(s, 3H), 2.58-2.70(m, 2H), 2.76(m, 2H), 3.97(br, 2H), 8.08(s, 1H), 10.00(s, 1H), 12.19(br, 1H)


 


XI-126




DMSO-d6 1.14(t, 3H, J = 7.5), 1.15(m, 5H), 1.57-1.79(m, 6H), 2.83(t, 3H, J = 7.5), 4.06(s, 2H), 6.73(d, 1H, J = 16.2), 7.56(d, 1H, 16.2), 8.29(s, 1H), 9.02(s, 2H), 13.04(s, 1H)
















TABLE 111













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-134




DMSO-d6 0.92(s, 9H), 1.11(m, 8H), 1.43-1.81 (m, 8H), 2.17(s, 3H), 2.78(m, 2H), 4.01(m, 2H), 4.49(m, 1H), 8.13(s, 1H), 10.16(d, 1H, J = 5.7)


 


XI-135




DMSO-d6 0.88(s, 9H), 1.10(m, 8H), 1.43-1.80 (m, 6H), 2.15(m, 1H), 2.17(s, 3H), 2.57(m, 1H), 2.77(m, 2H), 3.99(m, 2H), 4.26(m, 1H), 8.11(s, 1H), 9.96(d, 1H, J = 9.6)


 


XI-155




DMSO-d6 0.86(s, 9H), 1.00-1.18(m, 8H), 1.38-1.82(m, 10H), 2.17(s, 3H), 2.18(t, 2H, J = 7.5), 2.71-2.83(m, 2H), 3.80-4.16(m, 3H), 8.13(s, 1H), 9.76(d, 1H, J = 9.3), 11.98(brs, 1H)


 


XI-157




DMSO-d6 1.04-1.30(m, 8H), 1.48-1.90(m, 6H), 2.24(s, 3H), 2.84(q, 2H, J = 7.8), 3.82(s, 2H), 3.90-4.20(m, 2H), 7.31(s, 1H), 8.31(s, 1H), 12.63(br s, 1H), 13.39(s, 1H)


 


XI-190




DMSO-d6 1.11(t, 3H, J = 7.5), 1.03-1.80(m, 20H), 2.17(s, 3H), 2.14-2.24(br, 2H), 2.77(q, 2H, J = 7.5), 3.40(d, 2H, J = 5.7), 4.00(br, 2H), 8.11(s, 1H), 10.01(t, 1H, J = 6.0)


 


XI-191




DMSO-d6 1.00-1.85(m, 20H), 1.10(t, 3H, J = 7.8), 2.17(s, 2H), 2.10-2.70(m, 2H), 2.79(q, 2H, J = 7.2), 3.80-4.20(m, 2H), 8.08 (s, 1H), 10.04(s, 1H)


 


XI-194




DMSO-d6 1.00-1.82(m, 12H), 1.11(t, 3H, J = 7.5), 2.10-2.30(m, 2H), 2.17(s, 2H), 2.78(q, 2H, J = 7.5), 2.84(s, 2H), 3.20-4.20(m, 6H), 8.11(s, 1H), 10.10(s, 1H)
















TABLE 112













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-216




1.17(t, 3H, J = 7.5), 1.06-1.26(m, 4H), 1.58- 1.88(m, 11H), 2.17(m, 2H), 2.20(s, 3H), 2.78(q, 2H, J = 7.5), 3.04(s, 2H), 4.00(s, 2H), 8.31(s, 1H), 10.67(s, 1H)


 


XI-220




DMSO-d6 1.07-1.24(m, 8H), 1.46-1.92(m, 8H), 2.16(s, 3H), 2.17-2.30(m, 4H), 2.74- 2.84(q, 2H, J = 7.5), 2.87(s, 2H), 3.96(br, 2H), 8.09(s, 1H), 10.06(s, 1H), 12.01(br, 1H)


 


XI-231




DMSO-d6 1.00-1.22(m, 5H), 1.10(t, 3H, J = 7.5), 1.46-1.82(m, 8H), 2.00-2.18(m, 6H), 2.17(s, 3H), 2.78(q, 2H, J = 7.5), 3.40-3.52(m, 2H), 3.62-3.74(m, 2H), 3.85-4.15(br, 2H), 8.11(s, 1H), 9.97(s, 1H), 12.08(brs, 1H)


 


XI-246




DMSO-d6 1.05-1.25(m, 8H), 1.47-1.77(m, 6H), 2.23(s, 3H), 2.82(q, 2H, J = 6.9), 3.60(s, 2H), 3.90-4.20(m, 2H), 7.72(dd, 1H, J = 2.4, 8.7), 8.19-8.25(m, 2H), 8.30(s, 1H), 12.49(br s, 1H), 12.61(s, 1H)


 


XI-280




DMSO-d6 1.04-1.26(m, 8H), 1.50-1.90(m, 6H), 2.23(s, 3H), 2.83(q, 2H, J = 7.5), 3.95- 4.20(m, 2H), 6.58(d, 1H, J = 16.2), 7.59(d, 1H, J = 15.9), 8.22(dd, 1H, J = 2.2, 8.4), 8.30(d, 1H, J = 8.1), 8.31(s, 1H), 8.61(d, 1H, J = 2.1), 12.36(br s, 1H), 12.82(s, 1H)
















TABLE 113













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-26




DMSO-d6 1.06(t, 3H, J = 7.5 Hz), 2.24(s, 3H), 2.75(q, 2H, J = 7.5 Hz), 3.79(s, 2H), 5.49(br-s, 2H), 7.13-7.28(m, 4H), 8.42(s, 1H), 13.65(s, 1H)


 


X-45




DMSO-d6 0.85(t, 3H, J = 7.2 Hz), 1.05(t, 3H, J = 7.2 Hz), 1.18-1.25(m, 2H), 1.70-1.95(m, 2H), 2.22(s, 3H), 2.31(m, 2H), 3.60(t, 1H, J = 7.8 Hz), 5.47(br-s, 2H), 6.98(s, 1H), 7.13- 7.28(m, 4H), 8.37(s, 1H), 13.28(br-s, 1H)


 


X-63




DMSO-d6 1.05(t, 3H, J = 7.2 Hz), 1.63- 2.05(m, 4H), 2.22(s, 3H), 2.69-2.76(m, 4H), 3.55(t, 1H, J = 6.0 Hz), 5.45-5.48(m, 2H), 7.12- 7.24(m, 4H), 8.36(s, 1H), 13.19(s, 1H)


 


X-121




DMSO-d6 1.04(t, 3H, J = 7.5 Hz), 2.17(s, 3H), 2.66(q, 2H, J = 7.5 Hz), 3.43-3.51(m, 2H), 3.71-3.76(m, 2H), 5.44(br-s, 2H), 7.17(d, 4H, J = 8.1 Hz), 8.19(s, 1H), 10.31(s, 1H), 12.50(br-s, 1H)


 


X-124




DMSO-d6 1.04(t, 3H, J = 7.5), 1.50-1.67(m, 4H), 2.17(s, 3H), 2.20-2.36(br, 2H), 2.60- 2.76(br, 2H), 2.76-2.84(br, 2H), 5.40(br, 2H), 7.18(d, 4H, J = 7.5), 8.20(s, 1H), 12.22(br, 1H), 12.56(s, 1H)


 


X-135




DMSO-d6 1.07(t, 3H, J = 7.2), 2.24(s, 3H), 2.74(q, 2H, J = 7.2), 5.48(s, 2H), 6.63(d, 1H, J = 16.2), 7.15-7.26(m, 4H), 7.59(d, 1H, J = 16.2), 8.22(dd, 1H, J = 2.1 and 8.7), 8.31 (d, 1H, J = 8.7), 8.40(s, 1H), 8.60(d, 1H, J = 1.8), 12.42(br, 1H), 12.68(s, 1H)


 


X-136




DMSO-d6 1.07(t, 3H, J = 7.2), 2.23(s, 3H), 2.55(t, 2H, J = 7.5), 2.71-2.82(m, 4H), 5.47 (s, 2H), 7.15-7.25(m, 4H), 7.71(d, 1H, J = 9.0), 8.16-8.20(m, 2H), 8.38(s, 1H), 12.25 (br, 1H), 12.43(s, 1H)
















TABLE 114













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-150




DMSO-d6 1.04(t, 3H, J = 7.5), 1.72-1.90(m, 2H), 2.18(s, 3H), 1.80(t, 2H, J = 7.5), 2.42(t, 2H, J = 8.1), 2.62-2.76(br, 2H), 3.18(t, 2H, J = 7.8), 5.42(br, 2H), 7.17(d, 4H, J = 7.5), 8.27(s, 1H), 12.10(br, 1H), 12.72(s, 1H)


 


X-163




DMSO-d6 1.04(t, 3H, J = 7.5), 1.10-1.58(m, 8H), 2.14-2.25 (m, 2H), 2.18(s, 3H), 2.65(q, 2H, J = 7.5), 2.79(s, 2H), 5.42(brs, 2H), 7.10-7.23(m, 4H), 8.21(s, 1H), 9.82(s, 1H), 11.88(brs, 1H)


 


X-164




DMSO-d6 0.87(t, 3H, J = 7.5), 1.05(t, 3H, J = 7.5), 1.25-1.37 (m, 2H), 1.60-1.82(m, 2H), 2.19(s, 3H), 2.67(q, 2H, J = 7.5), 4.44(m, 1H), 5.41 (br, 2H), 7.14-7.22(m, 4H), 8.23(s, 1H), 10.10(d, 1H, J = 7.8)


 


X-165




DMSO-d6 1.06(t, 3H, J = 7.5), 2.24(s, 3H), 2.73(q, 2H, J = 7.8), 3.81(s, 2H), 5.48 (s, 2H), 7.14-7.25(m, 4H), 7.29(s, 1H), 8.39(s, 1H), 13.24(s, 1H)


 


X-172




DMSO-d6 0.85-0.94(m, 6H), 1.05(t, 3H, J = 7.5), 1.54-1.70 (m, 3H), 2.19(s, 3H), 2.58- 2.75(m, 2H), 4.47(m, 1H), 5.29-5.55(m, 2H), 7.11-7.23(m, 4H), 8.23(s, 1H), 10.05(d, 1H, J = 7.8), 12.74(brs, 1H)


 


X-180




DMSO-d6 0.85(dd, 6H, J = 3.3 and 6.6), 1.04 (t, 3H, J = 7.5), 1.22-1.45 (m, 2H), 1.48-1.64(m, 2H), 1.77(m, 1H), 2.18(s, 3H), 2.20(t, 2H, J = 7.5), 2.66 (q, 2H, J = 7.5), 4.05(m, 1H), 5.41(brs, 2H), 7.11-7.22 (m, 4H), 8.23(s, 1H), 9.54(d, 1H, J = 9.0), 12.02(brs, 1H)
















TABLE 115













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-185




DMSO-d6 0.88(dd, 6H, J = 3.6 and 6.3), 1.05(t, 3H, J = 7.5), 1.43-1.53(m, 2H), 1.61(m, 1H), 2.19(s, 3H), 2.67(q, 2H, J = 7.5), 4.71(m, 1H), 5.306-5.45(m, 2H), 5.76(dd, 1H, J = 1.5 and 15.6), 6.81(dd, 1H, J = 5.7 and 15.6), 7.12-7.23(m, 4H), 8.24(s, 1H), 9.88(d, 1H, J = 8.1), 12.33(brs, 1H)


 


X-187




1.20(t, 3H, J = 7.5 Hz), 1.68-1.74(m, 4H), 2.14- 2.23(m, 2H), 2.25(s, 3H), 2.32-2.44(m, 2H), 2.73(q, 2H, J = 7.5 Hz), 3.67(s, 3H), 5.46(br-s, 2H), 6.69(s, 1H), 7.00-7.18(m, 4H), 8.46(s, 1H), 13.06(s, 1H)


 


X-188




DMSO-d6 1.06(t, 3H, J = 7.5 Hz), 1.60- 1.73(m, 4H), 1.90-2.10(m, 2H), 2.22(s, 3H), 2.23-2.29(m, 2H), 2.75(q, 2H, J = 7.5 Hz), 5.48(br-s, 2H), 7.00(s, 1H), 7.13-7.27(m, 4H), 8.37(s, 1H), 12.21(br-s, 1H), 13.26(s, 1H)


 


X-193




DMSO-d6 0.84(t, 3H, J = 6.6), 1.05(t, 3H, J = 7.2), 1.27(br, 4H), 1.60-1.90(brm, 2H), 2.19(s, 3H), 2.60-2.78(brm, 2H), 4.44(m, 1H), 5.30-5.50(m, 2H), 7.10-7.21(m, 4H), 8.23(s, 1H), 10.11(d, 1H, J = 7.8), 12.78(br, 1H)


 


X-197




DMSO-d6 1.04(t, 3H, J = 7.5), 1.22-1.58(m, 10H), 2.17(s, 2H), 2.18(s, 3H), 2.65(q, 2H, J = 7.5), 3.40(d, 2H, J = 6.3), 5.43(brs, 2H), 7.11-7.21(m, 4H), 8.25(s, 1H), 9.94(t, 1H, J = 5.7), 12.15(brs, 1H)


 


X-204




DMSO-d6 0.86(d, 6H, J = 6.3), 1.04(t, 3H, J = 7.5), 1.33(m, 1H), 1.46-1.66(m, 2H), 2.18(s, 3H), 2.36-2.53(m, 2H), 2.66(q, 2H, J = 7.5), 4.34(m, 1H), 5.28-5.54(m, 2H), 7.10- 7.23(m, 4H), 8.23(s, 1H), 9.76(d, 1H, J = 8.7), 12.14(brs, 1H)
















TABLE 116













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-214




DMSO-d6 1.07(t, 3H, J = 7.5), 2.34(s, 3H), 2.71(q, 2H, J = 7.5), 5.49(brs, 2H), 6.44(d, 1H, J = 15.9), 7.14-7.24(m, 4H), 7.55(d, 1H, J = 15.9), 7.67(d, 2H, J = 9.0), 7.75(d, 2H, J = 9.0), 8.38(s, 1H), 12.29(brs, 1H), 12.33(s, 1H)


 


X-216




DMSO-d6 0.77(t, 6H, J = 6.9), 1.02(t, 3H, J = 7.5), 1.67-1.90(m, 4H), 2.16(s 3H), 2.62(m, 2H), 2.74(s, 2H), 5.38(s, 2H), 7.12- 7.20(m, 4H), 8.19(s, 1H), 9.69(s, 1H), 11.80(brs, 1H)


 


X-222




DMSO-d6 1.07(t, 3H, J = 7.5), 2.24(s, 3H), 2.75(q, 2H, J = 7.5), 3.60(s, 2H), 5.49(s, 2H), 7.02(s, 1H), 7.15-7.30(m, 4H), 8.39(s, 1H), 12.40(br s, 1H), 13.31(s, 1H)


 


X-224




DMSO-d6 1.04(t, 3H, J = 7.5), 1.60-1.78(m, 4H), 1.81-1.96(m, 2H), 2.06-2.24(m, 5H), 2.60-2.78(m, 2H), 5.42(br, 2H), 7.10-7.24(m, 4H), 8.19(s, 1H), 10.10(s, 1H), 12.32(br, 1H)


 


X-231




DMSO-d6 1.05(t, 3H, J = 7.5), 1.32-1.64(m, 14H), 1.79-1.96(m, 2H), 2.04-2.24(m, 5H), 2.60-2.78(m, 2H), 5.42(br, 2H), 7.10-7.24(m, 4H), 8.18(s, 1H), 9.91(s, 1H), 12.21(br, 1H)


 


X-234




DMSO-d6 1.04(t, 3H, J = 7.5), 1.54-1.84(m, 6H), 2.00-2.15(m, 2H), 2.18(s, 3H), 2.56- 2.72(m, 2H), 2.87(s, 2H), 5.40(br, 2H), 7.08- 7.24(m, 4H), 8.20(s, 1H), 9.82(s, 1H), 11.93(br, 1H)


 


X-238




DMSO-d6 1.05(t, 3H, J = 7.2), 2.20(s, 3H), 2.60-2.75(m, 3H), 2.86(dd, 1H, J = 5.1 and 17.1), 5.17(m, 1H), 5.42(br s, 2H), 7.10- 7.25(m, 4H), 10.31(d, 1H, J = 9.3), 12.68(br s, 1H)
















TABLE 117













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-239




DMSO-d6 1.05(t, 3H, J = 7.5), 1.37-1.63(m, 10H), 1.90-2.14(m, 4H), 2.18(s, 3H), 2.66(q, 2H, J = 7.5), 5.42(brs, 2H), 7.11-7.24(m, 4H), 8.17(s, 1H), 10.02(s, 1H), 12.19(brs, 1H)


 


XI-014




DMSO-d6 1.06(t, 3H, J = 7.5), 2.23(s, 3H), 2.70(q, 2H, J = 7.5), 4.65(s, 2H), 5.48(brs, 2H), 6.90(d, 2H, J = 9.0), 7.14-7.22(m, 4H), 7.61(d, 2H, J = 9.0), 8.36(s, 1H), 12.00(s, 1H), 12.98(brs, 1H)


 


XI-022




DMSO-d6 1.07(t, 3H, J = 7.5), 2.23(s, 3H), 2.71(q, 2H, J = 7.5), 4.79(s, 2H), 5.48(brs, 2H), 6.90(d, 1H, J = 9.0), 7.14-7.23(m, 4H), 8.07(dd, 1H, J = 2.7 and 9.0), 8.37(s, 1H), 8.43(d, 1H, J = 2.7), 12.00(s, 1H), 12.81(brs, 1H)


 


XI-023




DMSO-d6 1.07(t, 3H, J = 7.5), 2.25(s, 3H), 2.76(q, 2H, J = 7.8), 4.12(s, 2H), 5.50(s, 2H), 7.14-7.29(m, 4H), 8.41(s, 1H), 13.06(br s, 1H), 13.65(s, 1H)


 


XI-031




DMSO-d6 1.05(t, 3H, J = 7.2), 1.54(br, 6H), 2.15-2.25(m, 7H), 2.68(q, 2H, J = 7.5), 5.45(s, 2H), 7.14-7.24(m, 4H), 8.24(s, 1H), 11.14(s, 1H), 12.41(br s, 1H)


 


XI-041




1.16(t, 3H, J = 7.5), 1.86-2.18(m, 2H), 2.21(s, 3H), 2.34-2.39(m, 4H), 2.60-2.78(q, 2H, J = 7.5), 3.08(s, 2H), 5.41(s, 2H), 7.00-7.10(m, 4H), 8.38(s, 1H), 10.52(s, 1H)


 


XI-044




DMSO-d6 1.07(t, 3H, J = 7.5), 2.19(s, 3H), 2.60-2.67(m, 2H), 3.25(s, 3H), 3.61(dd, 1H, J = 3.9 and 9.9), 3.77(dd, 1H, J = 3.9 and 9.9), 4.62(m, 1H), 5.42(br, 2H), 7.12-7.22(m, 4H), 8.24(s, 1H), 10.22(d, 1H, J = 7.8)
















TABLE 118













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-046




DMSO-d6 1.07(t, 3H, J = 7.5), 2.24(s, 3H), 2.73(q, 2H, J = 7.5), 3.60(s, 2H), 5.48(brs, 2H), 7.13-7.26(m, 4H), 7.72(dd, 1H, J = 2.1 and 8.4), 8.19(d, 1H, J = 2.1), 8.22(d, 1H, J = 8.4), 8.39(s, 1H), 12.40(brs, 1H), 12.47(s, 1H)


 


XI-048




DMSO-d6 1.04(t, 3H, J = 7.5), 1.57-1.92(m, 2H), 2.19(s, 3H), 2.18-2.26(m, 2H), 2.66(q, 2H, J = 7.2), 3.25(s, 3H), 3.30-3.45(m, 2H), 4.11(m, 1H), 5.41(brs, 2H), 7.12-7.21(m, 4H), 8.23(s, 1H), 9.75(d, 1H, J = 8.7), 12.05(brs, 1H)


 


XI-052




DMSO-d6 1.04(t, 3H, J = 7.5), 1.40-1.49(m, 2H), 1.85-1.91(m, 2H), 2.18(s, 3H), 2.62- 2.70(m, 2H), 3.33-3.41(m, 2H), 3.52(d, 2H, J = 6.3), 3.70-3.74(m, 2H), 5.41(s, 2H), 7.11- 7.20(m, 4H), 8.23(s, 1H), 9.96(t, 1H, J = 6.3), 12.61(br, 1H)


 


XI-057




DMSO-d6 1.06(t, 3H, J = 7.5), 2.20(s, 3H), 2.69(q, 2H, J = 7.5), 3.06-3.23(m, 2H), 4.79(q, 1H, J = 6.0), 5.32-5.54(m, 2H), 7.13-7.23(m, 4H), 8.26(s, 1H), 10.41(d, 1H, J = 7.2), 13.47(brs, 1H)


 


XI-058




DMSO-d6 1.07(t, 3H, J = 7.5), 2.24(s, 3H), 2.71(q, 2H, J = 7.2), 4.99(s, 2H), 5.49(s, 2H), 6.42(d, 1H, J = 3.0), 7.13-7.38(m, 7H), 8.07(d, 1H, J = 1.8), 8.38(s, 1H), 12.06(s, 1H), 12.94(br s, 1H)


 


XI-070




DMSO-d6 0.91(s, 9H), 1.05(t, 3H, J = 7.5), 1.54(dd, 1H, J = 9.0 and 14.1), 1.76(dd, 1H, J = 3.0 and 14.1), 2.19(s, 3H), 2.67-2.76(m, 2H), 4.49(m, 1H), 5.28-5.56(m, 2H), 7.11- 7.23(m, 4H), 8.23(s, 1H), 10.04(d, 1H, J = 8.1), 12.65(brs, 1H)
















TABLE 119













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-072




DMSO-d6 1.07(t, 3H, J =  7.5), 2.25(s, 3H), 2.76(q, 2H, J = 7.5), 4.14(s, 2H), 5.51(br s, 2H), 7.15- 7.28(m, 4H), 8.43(s, 1H),  13.00(br s, 1H), 13.58(s, 1H)


 


XI-075




DMSO-d6 0.86(s, 9H),  1.04(t, 3H, J = 7.2), 1.33- 1.45(m, 2H), 1.50-1.81(m,  2H), 2.13-2.22(m, 2H),  2.18(s, 3H), 2.66(q, 2H, J = 7.2), 4.10(m, 1H),  5.41(brs, 2H), 7.10- 7.22(m, 4H), 8.23(s, 1H),  9.64(d, 1H, J = 9.0),  11.99(brs, 1H)


 


XI-077




DMSO-d6 1.06(t, 3H, J =  7.5), 2.22(s, 3H), 2.71(q, 2H, J = 7.5), 4.85(s, 2H), 5.47(s, 2H), 7.13-7.25(m, 4H), 7.37(d, 1H, J = 1.5), 7.45(d, 1H, J = 1.5),  8.32(s, 1H), 12.01(s, 1H), 13.10(br s, 1H)


 


XI-079




DMSO-d6 1.05(t, 3H, J =  6.6), 1.08-1.84(m, 10H), 2.22(m, 1H), 2.44(m, 1H), 2.60-2.78(m, 3H), 5.43(br s, 2H), 7.10-7.22(m, 4H), 8.17(s, 1H), 10.30(s, 1H), 12.13(br, 1H)


 


XI-081




DMSO-d6 1.04(t, 3H, J = 7.5), 2.18(s, 3H), 2.58(d, 2H, J = 15.6), 2.67(q, 2H, J = 7.5), 3.01(d, 2H, J =  15.6), 5.41(brs, 2H), 5.66(s, 2H), 7.10-7.22(m, 4H), 8.20(s, 1H), 10.21(s, 1H), 12.45(brs, 1H)


 


XI-083




DMSO-d6 1.04(t, 3H, J =  7.5), 1.04-1.60(m, 7H),  1.99-2.22(m, 6H), 2.18(s, 3H), 2.58-2.73(m, 3H),  5.43(s, 2H), 7.12-7.22(m, 4H), 8.22(s, 1H), 9.71(s, 1H), 11.95(br, 1H)


 


XI-085




DMSO-d6 0.83(d, 6H, J =  6.6), 1.05(t, 3H, J = 7.5), 1.10-1.28(m, 2H), 1.51(m, 1H), 1.61-1.88(m, 2H), 2.19(s, 3H), 2.59-2.75(m, 2H), 4.44(m, 1H), 5.30- 5.55(m, 2H), 7.11-7.22(m, 4H), 8.23(s, 1H), 10.12(d, 1H, J = 7.5), 12.78(brs, 1H)
















TABLE 120













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-087




DMSO-d6 1.06(t, 3H,  J = 7.5), 2.22(s, 3H), 2.70(q, 2H, J = 7.8), 3.65(s, 2H), 5.48(s, 2H), 7.06-7.33(m, 7H), 8.07(d, 1H, J = 8.1), 8.36(s, 1H), 11.95(s, 1H), 12.40(br s, 1H)


 


XI-089




DMSO-d6 1.07(t, 3H, J = 7.4), 2.24(s, 3H), 2.71(q, 2H, J = 7.5), 3.57(s, 2H), 5.49(br s, 2H), 7.09(d, 1H, J =  8.7), 7.17-7.23(m, 5H), 8.38(s, 1H), 8.39(t, 1H, J = 8.4), 12.37(br s, 2H)


 


XI-091




DMSO-d6 1.07(t, 3H, J = 7.5), 2.22(s, 3H), 2.70(q, 2H, J = 7.5), 4.80(s, 2H), 5.48(s, 2H), 7.16-7.23(m,  5H), 7.26(dd, 1H, J = 3.0, 9.0), 8.08(d, 1H, J = 9.0), 8.37(s, 1H), 12.15(s, 1H), 13.05(br, 1H)


 


XI-094




DMSO-d6 1.06(t, 3H,  J = 7.5), 2.23(s, 3H), 2.71(q, 2H, J = 7.5), 4.69(s, 2H), 5.48(s, 2H), 6.79(m, 1H), 6.96(dd, 1H, J = 2.7, 12.6), 7.13-7.22(m, 4H), 8.31(m, 1H), 8.37(s, 1H), 12.20(s, 1H), 13.04(br, 1H)


 


XI-095




DMSO-d6 1.04(t, 3H, J = 7.5), 1.17-1.66(m, 8H), 1.80-1.96(m, 2H), 2.18(s, 3H), 2.58- 2.74(m, 2H), 3.46(d, 2H, J = 6.0), 5.40(s, 2H), 7.11-7.20(m, 4H), 8.23(s, 1H),  9.92(t, 1H, J = 6.0), 12.35(br, 1H)


 


XI-096




DMSO-d6 1.07(t, 3H, J = 7.4), 2.49(s, 3H), 2.71(q, 2H, J = 7.4), 3.57(s, 2H), 5.48(br s, 2H), 7.17-7.28(m, 6H),  7.78(d, 1H, J = 12.9), 8.37(s, 1H), 12.25(br s, 2H)
















TABLE 121













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-098




DMSO-d6 1.07(t, 3H, J =  7.4), 2.22(s, 3H), 2.70(q, 2H, J = 7.8), 3.59(s, 2H), 5.46(br s, 2H), 7.15-7.29(m, 7H), 8.31(s, 1H), 11.36(s, 1H), 12.40(br s, 1H)


 


XI-099




DMSO-d6 1.06(t, 3H, J =  7.5), 2.22(s, 3H), 2.69(q, 2H, J = 7.4), 3.67(s, 2H), 5.47(br s, 2H), 7.10-7.25(m, 6H), 7.99(dd, 1H, J = 8.6 and 5.6), 8.35(s, 1H),  11.89(s, 1H), 12.48(br s, 1H)


 


XI-103




DMSO-d6 1.07(t, 3H, J =  7.5), 2.24(s, 3H), 2.72(q, 2H, J = 8.1), 3.74(s, 2H), 5.49(s, 2H), 7.12-7.28(m, 4H), 7.46(d, 1H, J = 8.4), 7.77(m, 1H), 8.25(m, 1H), 8.38(s, 1H), 12.33(s, 1H), 12.50(br s, 1H)


 


XI-104




DMSO-d6 1.07(t, 3H, J = 7.5), 2.17(s, 3H), 2.24(s, 3H), 2.74(q, 2H, J = 7.5), 3.71(s, 2H), 5.48(s, 2H), 7.15-7.28(m, 4H), 8.38(s, 1H), 12.50(br, 1H),  13.17(s, 1H)


 


XI-107




1.16(t, 3H, J = 7.5), 1.43(dd, 6H, J = 8.1, 21.3), 2.21(s, 3H), 2.43(ddd, 2H, 4.2, 15.3, 25.8), 2.67(ddd, 2H, 2.4, 7.2, 15.0), 4.76(ddd, 1H, J = 4.2, 6, 9.3), 5.42(br, 2H), 7.07-6.98(m, 4H), 8.40(s, 1H), 10.58(d, 1H, J = 5.4)


 


XI-111




DMSO-d6 0.83(s, 3H),  0.89(s, 3H), 1.04(t, 2H, J = 7.5), 1.15-1.18(m, 3H), 1.26-1.35(m, 2H), 1.61-1.68(m, 2H), 2.18(s, 3H), 2.20-2.14(m, 2H), 2.62-2.69(q, 2H, J = 7.5), 2.81(s, 2H), 5.42(br, 2H), 7.11-7.20(m, 4H), 8.20(s, 1H), 9.83(s, 1H),  11.87(br, 1H)
















TABLE 122













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-112




DMSO-d6 1.04(t, 3H,  J = 7.5), 1.72-1.84(m, 2H), 2.12-2.24(m, 5H), 2.62-2.74(q, 2H, J = 7.5), 2.84(s, 2H), 3.44- 3.52(m, 2H), 3.62- 3.73(m, 2H), 5.43(br, 2H), 7.12-7.22(m,  4H), 8.21(s, 1H),  9.99(s, 1H), 11.89(br,  1H)


 


XI-115




DMSO-d6 0.86(s, 3H), 0.90(s, 3H), 1.06(t, 3H, J = 7.5), 1.23- 1.37(m, 4H), 1.76- 2.00(m, 4H), 2.18(s, 3H), 2.67(q, 2H, J = 7.5), 5.44(brs, 2H), 7.11-7.23(m, 4H), 8.19(s, 1H), 10.15(s, 1H), 12.23(brs, 1H)


 


XI-116




DMSO-d6 1.04(t, 1H, J = 7.5), 1.40-2.00(m, 6H), 2.18(s, 3H), 2.67(q, 2H, J = 7.5), 3.20-3.75(m, 6H), 5.30-5.50(m, 2H), 7.10-7.20(m, 4H), 8.21(s, 1H), 9.70(t, 1H, J = 5.7)


 


XI-119




DMSO-d6 1.04(t, 3H, J = 7.2), 1.30(dd, 6H, J = 5.7, 21.6), 1.5- 1.7(m, 1H), 1.8-1.9(m, 1H), 1.84(dd, 2H), 1.84(dd, 2H, J = 6.3, 20.1), 2.18(s, 3H),  2.21(br, 2H),  2.66(brdd, 2H),  4.20(br, 1H), 5.41(s,  2H), 7.1-7.3(m, 4H), 8.22(s, 1H), 9.67(d, 1H, J = 8.7)


 


XI-146




DMSO-d6 0.88(s, 9H),  1.04(t, 3H, J = 5.4), 2.16(m, 1H), 2.18(s,  3H), 2.57(m, 1H), 2.65(m, 2H), 4.28(m,  1H), 5.42(m, 2H), 7.16(m, 4H), 8.22(s, 1H), 9.87(d, 1H, J =  7.2)


 


XI-209




DMSO-d6 1.07(t, 3H, J = 7.5), 2.24(s, 3H), 2.74(q, 2H, J = 7.5), 5.48(s, 2H), 6.73(d, 1H, J = 16.2), 7.14- 7.28(m, 4H), 7.56(d, 1H, J = 16.2), 8.38(s, 1H), 9.02(s, 2H), 12.54(br s, 1H), 12.90(s, 1H)
















TABLE 123













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-229




DMSO-d6 1.04(t, 3H, J =  7.5), 1.48-1.62(m, 2H), 1.98-2.20(m, 6H), 2.18(s, 3H), 2.66(q, 2H, J = 7.5), 3.40-3.52(m, 2H), 3.62- 3.72(m, 2H), 5.43(brs,  2H), 7.12-7.23(m, 4H), 8.21(s, 1H), 9.86(s, 1H), 12.06(brs, 1H)


 


XI-241




DMSO-d6 1.05(t, 3H, J = 7.5), 1.9-2.3(m, 8H),  2.67(brq, J = 7.5), 5.45(s, 2H), 7.1-7.2(m, 4H), 8.21(s, 1H), 10.27(s, 1H)


 


XI-277




DMSO-d6 1.07(t, 3H, J =  7.5), 2.23(s, 3H), 2.73(q, 2H, J = 7.5), 4.01(s, 2H), 5.47(s, 2H), 7.13-7.27(m, 4H), 7.63(s, 1H), 8.37(s, 1H), 12.64(s, 1H), 12.85(br s, 1H)
















TABLE 124













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-063




DMSO-d6 1.09(t, 3H, J = 7.4), 1.24-1.74(m, 8H), 2.01(d,  2H, J = 13.5), 2.21(s, 3H), 2.67(q, 2H, J = 7.3), 5.40(br s, 2H), 6.80(q, 1H, J = 8.0), 7.03(td, 1H, J = 8.6 and 2.6), 7.34(td, 1H, J = 8.5 and 2.6), 8.21(s, 1H), 10.04(s, 1H), 12.21(br s, 1H)


 


XI-164




DMSO-d6 0.84(dd, 6H, J =  6.5 and 2.6), 1.08(t, 3H, J = 7.5), 1.32(m, 2H), 1.55(m, 2H), 1.76(m, 1H), 2.18(t, 2H, J = 7.2), 2.20(s, 3H), 2.66(q, 2H, J = 7.3), 4.04(m, 1H), 5.36(br s, 2H), 6.79(q, 1H, J = 7.8), 7.01(td, 1H, J = 8.6 and 2.4), 7.32(td, 1H, J = 10.1 and 2.4), 8.24(s, 1H), 9.43(d, 1H, J = 9.0), 11.97(br s, 1H)


 


XI-183




DMSO-d6 1.12(t, 3H, J =  7.5), 2.28(s, 3H), 2.78(q, 2H, J = 7.5), 3.80(s, 2H), 5.46(s, 2H), 6.93-7.06(m, 2H), 7.34(m, 1H), 8.45(s, 1H), 12.62(br s, 1H), 13.55(s, 1H)


 


XI-184




DMSO-d6 1.11(t, 3H, J = 7.5), 2.27(s, 3H), 2.76(q, 2H, J = 8.1), 3.81(s, 2H), 5.45(s, 2H), 6.88-7.06(m, 2H), 7.29(s, 1H), 7.34(m, 1H), 8.42(s, 1H), 12.64(br s, 1H), 13.13(s, 1H)


 


XI-187




DMSO-d6 0.85(s, 9H), 1.08(t, 3H, J = 7.5), 1.31- 1.44(m, 2H), 1.50-1.80(m, 2H), 2.16(t, 2H, J = 7.5), 2.20(s, 3H), 2.66(q, 2H, J = 7.5), 4.07(m, 1H), 5.28-5.45(m, 2H), 6.78(m, 1H), 7.01(m, 1H), 7.33(m, 1H), 8.24(s, 1H), 9.54(d, 1H, J = 9.0), 12.01(brs, 1H) 


 


XI-193




DMSO-d6 1.00-1.75(m, 8H), 1.09(t, 3H, J = 7.5), 2,20(s, 3H), 2.30-2.65(m, 2H), 2.68(q, 2H, J = 7.5), 5.39(s, 2H), 6.75-7.40(m, 3H), 8.19(s, 1H), 10.21(s, 1H)
















TABLE 125













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-196




DMSO-d6 1.08(t, 3H, J = 7.5), 1.70-2.25(m, 4H), 2.20(s, 3H), 2.26(q, 2H, J = 7.5), 2.84(s, 2H), 3.46(t, 2H, J = 10.8), 3.60-3.75(m, 2H), 5.39(s, 2H), 6.74-7.40(m,  3H), 8.22(s, 1H), 9.89(s, 1H)


 


XI-203




DMSO-d6 0.85(d, 6H, J = 6.3), 1.08(t, 3H, J = 7.7), 1.31(m,  1H), 1.42-1.61(m, 2H), 2.20(s, 3H), 2.42(t, 2H,  J = 6.2), 2.66(q, 2H, J =  7.5), 4.33(m, 1H), 5.36(dd, 2H, J = 24.0 and 17.1),  6.77(td, 1H, J = 8.9 and 6.3), 7.02(td, 1H, J = 8.4 and 1.9), 7.33(ddd, 1H, J = 10.5,  8.9 and 2.2), 8.24(s, 1H), 9.64(d, 1H, J = 8.7), 12.16(br s, 1H)


 


XI-204




DMSO-d6 0.86(s, 9H), 1.08(t, 3H, J = 7.5), 2.13(dd, 1H, J = 15.0 and 9.9), 2.20(s, 3H), 2.55(dd, 1H, J = 15.2 and 4.1), 2.65(qd, 2H, J = 7.4 and 2.7), 4.27(td, 1H, J = 9.8 and 3.9), 5.38(dd, 2H, J = 24.8 and 16.4), 6.78(td, 1H, J = 8.7 and 6.4), 7.02(tdd, 1H, J = 8.6, 2.9 and 1.1), 7.33(ddd, 1H, J = 11.2, 8.7 and 2.0), 8.23(s, 1H), 9.75(d, 1H, J = 9.9), 12.02(br s, 1H) 


 


XI-208




DMSO-d6 1.08(t, 3H, J = 7.5),  1.24-1.58(m, 10H), 2.15(s,  2H), 2.20(s, 3H), 2.65(q, 2H, J = 7.3), 3.39(d, 2H, J = 6.3), 5.38(br s, 2H), 6.79(td, 1H, J = 8.9 and 6.4), 7.01(tdd, 1H, J = 8.5, 2.9 and 1.2), 7.33(ddd, 1H, J = 10.8, 9.2 and 2.6), 8.26(s, 1H), 9.83(t, 1H, J = 6.2), 12.15(br s, 1H)


 


XI-227




DMSO-d6 1.09(t, 3H, J = 7.5), 2.22(m, 3H), 2.60-2.75(m,  3H), 2.82(dd, 1H, J = 4.8 and 16.5), 5.15(m, 1H), 5.37(s, 2H), 6.80(m, 1H), 7.01(m, 1H), 7.33(m, 1H), 8.29(s, 1H), 10.18(d, 1H, J = 9.0), 10.17(d, 1H, J = 9.0)
















TABLE 126













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-232




DMSO-d6 1.08(t, 3H, J =  7.0), 1.15-1.54(m, 8H),  2.12-2.22(m, 2H), 2.20(s,  3H), 2.65(q, 2H, J = 7.0), 2.79(s, 2H), 5.38(s, 2H), 6.78(m, 1H), 7.03(m, 1H), 7.32(m, 1H), 8.23(s, 1H), 9.71(s, 1H), 11.9(m, 1H)


 


XI-233




DMSO-d6 1.07(t, 3H, J =  7.0), 1.52-1.65(m, 4H), 1.69-1.80(m, 2H), 1.98- 2.09(m, 2H), 2.19(s, 3H), 2.65(q, 2H, J = 7.0), 2.86(s, 2H), 5.35(s, 2H), 6.77(m, 1H), 7.02(m, 1H), 7.31(m, 1H), 8.21(s, 1H), 9.79(s, 1H)


 


XI-234




DMSO-d6 1.08(t, 3H, J =  7.0), 1.72-1.86(m, 2H), 2.13-2.24(m, 4H), 2.19(s, 3H), 2.66(q, 2H, J = 7.0), 2.81(s, 2H), 5.36(s, 2H), 6.80(m, 1H), 7.02(m, 1H), 7.32(m, 1H), 8.20(s, 1H), 9.85(s, 1H)


 


XI-254




DMSO-d6 1.16(t, 3H, J = 7.2), 2.26(s, 3H), 2.75(q, 2H, J = 7.2), 3.59(s, 2H), 5.44(s, 2H), 6.86-7.08(m, 2H), 7.34(m, 1H), 7.72(dd, 1H, J = 2.4, 8.7), 8.16- 8.26(m, 2H), 8.40(s, 1H), 12.36(s, 1H), 12.43(br s, 1H)


 


XI-262




0.97(d, 3H, J = 6.6), 1.19(t, 3H, J = 7.2), 1.61(m, 1H), 2.17(m, 1H), 2.22(3H, s), 2.72(q, 2H, J = 7.2), 4.54- 4.60(m, 1H), 5.32-5.53(m, 2H), 6.81-6.94(m, 3H), 8.41(s, 1H), 10.40(d, 1H, J = 6.3)


 


XI-265




DMSO-d6 0.83(s, 3H),  0.89(s, 3H), 1.06(t, 4H, J = 7.5), 1.10-1.36(m, 3H), 1.54-1.72(m, 2H), 2.02- 2.16(m, 2H), 2.20(s, 3H), 2.65(q, 2H, J = 7.8),  2.79(s, 2H), 4.02(q, 2H, J = 7.5), 5.38(br, 2H), 6.78(m, 1H), 7.00(m, 1H), 7.33(m, 1H), 8.22(s, 1H), 9.73(s, 1H), 11.95(br, 1H)
















TABLE 127













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-270




DMSO-d6 1.08(t, 3H,  J = 7.5), 1.48-1.62(m, 2H), 1.98-2.18(m, 6H), 2.20(s, 3H), 2.66(q, 2H, J = 7.5), 3.38-3.50(m, 2H), 3.60-3.72(m, 2H), 5.39(brs, 2H), 6.82(m, 1H), 7.03(m, 1H), 7.34(m, 1H), 8.23(s, 1H), 9.76(s, 1H), 12.00(brs, 1H)


 


XI-275




DMSO-d6 1.09(t, 3H, J = 7.8), 1.7-2.3(m, 8H), 2.12(s, 3H),  2.64-2.74(br, 2H), 5.41(s, 2H), 6.8- 6.9(m, 1H), 7.03(dt, 1H, J = 2.4, 8.4), 7.34(dt, 1H, J = 2.7, 9.3), 8.22(s, 1H), 10.17(s, 1H)


 


XI-278




DMSO-d6 1.12(t, 3H, J = 7.5), 2.26(s, 3H), 2.75(q, 2H, J = 7.8), 5.47(s, 2H), 6.57(d, 1H, J = 15.9), 6.92(m, 1H), 7.03(m, 1H), 7.34(m, 1H), 7.58(d, 1H, J = 15.9),  8.21(dd, 1H, J = 2.1, 8.7), 8.30(d, 1H, J =  8.7), 8.42(s, 1H), 8.59(d, 1H, J = 2.1), 12.40(br s, 1H), 12.57(s, 1H)


 


XI-293




DMSO-d6 1.12(t, 3H, J = 7.5), 2.27(s, 3H), 2.75(q, 2H, J = 7.8), 5.44(s, 2H), 6.72(d, 1H, J = 15.9), 6.92(m, 1H), 7.03(m, 1H), 7.34(m, 1H), 7.56(d, 1H, J = 15.9), 8.39(s, 1H), 9.01(s, 2H),  12.54(br s, 1H), 12.78(s, 1H)


 


XI-299




DMSO-d6 0.82- 0.92(br, 6H), 1.08(t, 3H, J = 7.2), 1.2- 1.3(br, 4H), 1.7- 1.9(m, 4H), 2.19(s, 3H), 2.6-2.7(br, 2H), 5.39(s, 2H), 6.75(m, 1H), 6.95-7.05(m, 1H), 7.28-7.36(m, 1H), 8.19(s, 1H), 10.04(s, 1H)


 


XI-303




DMSO-d6 1.19(t, 3H, J = 7.5), 1.62-2.36(m, 8H), 2.23(s, 3H), 2.65(q, 2H, J = 7.5), 4.79(d, 1H, 48), 5.44(s, 2H), 6.8- 6.9(m, 3H), 8.41(s, 1H), 10.54(s, 1H)
















TABLE 128













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-025




DMSO-d6 1.08(t, 3H, J = 7.5), 2.24(s, 3H), 2.74(q, 2H, J = 7.2), 3.60(s, 2H), 5.47(s, 2H), 7.02(m, 1H), 7.02(s, 1H), 7.30-7.47(m, 2H), 8.39(s, 1H), 12.40(br s, 1H), 13.25(s, 1H)


 


XI-027




DMSO-d6 1.06(t, 3H, J = 7.5), 1.25-1.74(m, 8H), 2.02(d, 2H, J = 13.2), 2.19(s, 3H), 2.67(q, 2H, J = 7.3), 5.43(br s, 2H), 6.89(m, 1H), 7.28(m, 1H), 7.41(m, 1H), 8.20(s, 1H), 10.10(s, 1H), 12.21(br s, 1H)


 


XI-122




DMSO-d6 1.05(t, 3H, J = 6.6), 1.10-1.58(m, 9H), 2.12- 2.28(m, 4H), 2.54-2.72(m, 2H), 2.78(s, 2H), 5.41(br, 2H), 6.87-6.90(m, 1H), 7.21- 7.32(m, 1H), 7.34-7.47(m, 1H), 8.21(s, 1H), 9.77(s, 1H), 11.86(br, 1H),


 


XI-142




DMSO-d6 0.91(s, 9H), 1.06(t, 3H, J = 5.7), 1.55(m, 1H), 1.76(m, 1H), 2.20(s, 3H), 2.68(m, 2H), 4.50(m, 1H), 5.41(m, 2H), 6.91(m, 1H), 7.25(m, 1H), 7.40(m, 1H), 8.24(s, 1H), 10.02(d, 1H, J = 6.0)


 


XI-143




DMSO-d6 0.88(s, 9H), 1.06(t, 3H, J = 5.4), 2.17(m, 1H), 2.19(s, 3H), 2.52-2.73(m,  3H), 4.28(m, 1H), 5.42(m, 2H), 6.90(m, 1H), 7.26(m, 1H), 7.41(m, 1H), 8.23(s, 1H), 9.83(d, 1H, J = 7.2)


 


XI-151




DMSO-d6 1.08(t, 3H, J = 7.5), 2.25(s, 3H), 2.74(q, 2H, J = 7.5), 3.82(s, 2H), 5.48(s, 2H), 7.00(m, 1H), 7.30(s, 1H), 7.30-7.48(m, 2H), 8.40(s, 1H), 12.62(br s, 1H), 13.19(s, 1H)


 


XI-152




DMSO-d6 1.08(t, 3H, J =  7.5), 2.25(s, 3H), 2.75(q, 2H, J = 7.8), 3.80(s, 2H), 5.49(s, 2H), 7.05(m, 1H), 7.30-7.50(m, 2H), 8.44(s, 1H), 12.63(br s, 1H), 13.61(s, 1H)
















TABLE 129













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-162




DMSO-d6 0.86(dd, 6H, J =  6.6 and 3.0), 1.05(t, 3H, J = 7.5), 1.33(m, 2H), 1.56(m, 2H), 1.77(m, 1H), 2.19(s, 3H), 2.19(t, 2H, J = 7.5), 2.65(q, 2H, J = 7.6), 4.05(m, 1H), 5.39(br s, 2H), 6.90(m, 1H), 7.26(m, 1H), 7.39(dt, 1H, J = 10.8 and 8.4), 8.23(s, 1H), 9.49(d, 1H, J = 9.0), 11.99(br s, 1H)


 


XI-165




DMSO-d6 0.86(d, 6H, J =  6.6), 1.05(t, 3H, J = 7.4), 1.34(m, 1H), 1.46-1.57(m, 2H), 2.18(s, 3H), 2.43(t, 2H, J = 6.8), 2.65(q, 2H, J = 7.5), 4.34(m, 1H), 5.38(d, 2H, J = 8.1), 6.89(m, 1H), 7.25(m, 1H), 7.39(dt, 1H, J = 10.5 and 8.6), 8.23(s, 1H), 9.70(d, 1H, J = 8.7), 12.13(br s, 1H)


 


XI-171




DMSO-d6 1.00-1.80(m, 8H), 1.06(t, 3H, J = 7.2), 2.19(s, 3H), 2.20-2.60(m, 2H), 2.67(q, 2H, J = 7.2), 5.25- 5.55(m, 2H), 6.85-7.47(m, 3H), 8.17(s, 1H), 10.26(s, 1H)


 


XI-174




DMSO-d6 1.06(t, 3H, J =  7.5), 2.21(s, 3H), 2.62- 2.75(m, 3H), 2.85(dd, 2H, J = 16.5 and 5.1), 5.14(m, 1H), 5.21(br, 2H), 6.90(m, 1H), 7.27(m, 1H), 7.40(m, 1H), 8.28(s, 1H), 10.25(d, 1H, J = 9.0), 12.70(br, 1H)


 


XI-179




DMSO-d6 0.86(s, 9H), 1.05(t, 3H, J = 7.5), 1.33-1.45(m, 2H), 1.51- 1.81(m, 2H), 2.18(t, 2H, J = 7.5), 2.19(s, 3H), 2.66(q, 2H, J = 7.2),4.08(m, 1H), 5.40(brs, 2H), 6.90(m, 1H), 7.24(m, 1H), 7.41(m, 1H), 8.23(s, 1H), 9.60(d, 1H,  J = 9.0), 11.98(brs, 1H)


 


XI-205




DMSO-d6 1.05(t, 3H, J =  7.5), 1.26-1.58(m, 10H), 2.17(s, 2H), 2.19(s, 3H), 2.65(q, 2H, J = 7.3), 3.40(d, 2H, J = 6.0), 5.41(br s, 2H), 6.89(m, 1H), 7.26(ddd, 1H, J = 11.7, 7.8 and 2.1), 7,39(dt, 1H, J = 10.7 and 8.5), 8.25(s, 1H), 9.89(t, 1H, J = 6.3), 12.18(br s, 1H)
















TABLE 130













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-218




1.15(t, 3H, J = 7.8), 1.75- 1.89(m, 8H), 2.21(s, 3H), 2.66(q, 2H, J = 7.8), 3.05(s, 2H), 5.42(s, 2H), 7.01-7.07(m, 3H), 8.40(s, 1H), 10.42(s, 1H)


 


XI-221




DMSO-d6 1.05(t, 3H, J =  7.5), 1.76-1.94(m, 2H), 2.14-2.30(m, 7H), 2.61- 2.69(q, 2H, J = 8.1), 2.87(s, 2H), 5.38(br s, 2H), 6.88(m, 1H), 7.24(m, 1H), 7.39(m, 1H), 8.20(s, 1H), 9.93(s, 1H), 12.06(br, 1H)


 


XI-250




DMSO-d6 1.08(t, 3H, J =  7.5), 2.24(s, 3H), 2.72(q, 2H, J = 7.5), 3.60(s, 2H), 5.46(s, 2H), 6.98(m, 1H), 7.28-7.48(m, 2H),  7.72(dd, 1H, J = 2.1, 8.4), 8.19(d, 1H, J = 2.4), 8.22(d, 1H, J = 9.0), 8.39(s, 1H), 12.43(br s, 1H), 12.43(s, 1H)


 


XI-264




DMSO-d6 0.83(s, 3H),  0.89(s, 3H), 1.05(t, 4H, J = 7.5), 1.10-1.36(m, 3H), 1.54-1.72(m, 2H), 2.02-2.16(m, 2H), 2.18(s, 3H), 2.65(q, 2H, J = 7.8), 2.82(s, 2H), 5.41(br, 2H), 6.93(m, 1H), 7.24(m, 1H), 7.40(m, 1H), 8.21(s, 1H), 9.80(s, 1H), 12.02(br, 1H)


 


XI-269




DMSO-d6 1.05(t, 3H, J = 7.5), 1.48-1.62(m, 2H), 1.99-2.18(m, 6H), 2.18(s, 3H), 2.65(q, 2H, J = 7.5), 3.40-3.52(m, 2H), 3.60-3.72(m, 2H), 5.42(brs, 2H), 6.92(m, 1H), 7.29(m, 1H), 7.40(m, 1H), 8.22(s, 1H), 9.82(s, 1H), 12.00(brs, 1H)
















TABLE 131













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-284




DMSO-d6 1.05(t, 3H, J = 7.5), 1.70-1.82(m, 2H), 2.10-2.22(m, 2H), 2.19(s, 3H), 2.66(q, 2H, J = 7.5), 2.85(s, 2H), 3.48(t, 2H, J =  11), 3.60-3.75(m,  2H), 5.30-5.50(m, 2H), 6.85-7.45(m,  3H), 8.22(s, 1H), 9.95(s, 1H)


 


XI-288




DMSO-d6 0.86(s, 3H), 0.90(s, 3H), 1.06(t, 3H, J = 7.5), 1.23- 1.35(m, 4H), 2.15- 2.30(m, 2H), 2.16(s, 3H), 2.74(q, 2H, J = 7.5), 2.84(s, 2H), 3.50(t, 2H, J = 11.1), 3.60-4.20(m, 4H), 8.11(s, 1H), 10.09(s, 1H)


 


XI-292




DMSO-d6 1.08(t, 3H, J = 7.5), 2.25(s, 3H), 2.73(q, 2H, J = 7.5), 5.47(s, 2H), 6.73(d, 1H, J = 16.2), 6.98(m, 1H), 7.28-7.48(m, 2H), 7.56(d, 1H, J = 16.2), 8.38(s, 1H), 9.02(s, 2H), 12.54(br s, 1H), 12.84(s, 1H)


 


XI-295




DMSO-d6 1.08(t, 3H, J = 7.2), 2.24(s, 3H), 2.73(q, 2H, J = 7.2), 5.47(s, 2H), 6.58(d, 1H, J = 15.9),  6.90(m, 1H), 7.28- 7.46(m, 2H), 7.58(d, 1H, J = 15.9), 8.22(dd, 1H, J = 2.1, 9.0), 8.31(d, 1H, J = 9.0), 8.40(s, 1H), 8.60(d, 1H, J = 2.1), 12.40(br s, 1H), 12.63(s, 1H)
















TABLE 132













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-042




1.00(t, 3H, J = 7.5), 1.10(t, 3H, J = 7.5), 1.20(t, 3H, J = 7.5), 1.40-1.78(m, 8H), 1.864- 2.18(m, 3H), 2.35-2.41(m, 4H), 2.44-2.56(q, 2H, J =  7.5), 2.64-2.73(m, 2H),  3.08(s, 2H), 4.06- 4.11(m, 2H), 8.33(s, 1H), 10.75(s, 1H)


 


XI-053




DMSO-d6 0.94(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 1.12(t, 3H, J = 7.5), 1.32- 1.66(m, 12H), 1.86-1.91(m, 2H), 2.66-2.71(m, 2H), 3.52(d, 2H, J = 6.3), 3.71- 3.75(m, 2H), 4.00-4.04(m, 2H), 8.16(s, 1H), 10.56(t, 1H, J = 5.7), 12.55(br, 1H)


 


XI-132




DMSO-d6 0.93(s, 9H), 0.94(t, 3H, J = 5.4), 1.03(t, 3H, J = 5.4), 1.12(t, 3H, J = 5.4), 1.39(m, 2H), 1.56(m, 5H), 1.77(m, 1H), 2.51(m, 2H), 2.70(m, 2H), 4.04(m, 2H), 4.49(m, 1H), 8.17(s, 1H), 10.16(d, 1H, J = 6.3)


 


XI-133




DMSO-d6 0.89(s, 9H), 0.94(t, 3H, J = 5.4), 1.03(t, 3H, J = 5.4), 1.12(t, 3H, J = 5.4), 1.41(m, 2H), 1.56(m, 4H), 1.77(m, 1H), 2.51(m, 2H), 2.70(m, 2H), 4.04(m, 2H), 4.49(m, 1H), 8.17(s, 1H), 10.16(d, 1H, J = 6.3)


 


XI-149




DMSO-d6 0.96(t, 3H, J =  7.2), 1.05(t, 3H, J = 7.2), 1.16(t, 3H, J = 7.5), 1.34- 1.50(m, 2H), 1.50-1.72(m, 4H), 2.48-2.53(m, 2H), 2.57(q, 2H, J = 7.5), 2.70- 2.80(m, 2H), 3.82(s, 2H), 4.06-4.18(m, 2H), 7.31(s, 1H), 8.32(s, 1H), 12.63(br s, 1H), 13.37(s, 1H)


 


XI-154




DMSO-d6 0.87(s, 9H), 0.91(t, 3H, J = 7.2), 1.03(t, 3H, J = 7.5), 1.12(t, 3H, J = 7.5), 1.32- 1.80(m, 10H), 2.18(t, 2H, J = 7.5), 2.44-2.55(m, 2H), 2.64-2.74(m, 2H), 3.96- 4.16(m, 3H), 8.16(s, 1H), 9.76(d, 1H, J = 9.3), 11.98(brs, 1H)
















TABLE 133













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





XI-163




DMSO-d6 0.86(t, 6H, J = 6.3), 0.94(t, 3H, J = 7.4),1.03(t, 3H, J = 7.2), 1.12(t, 3H, J = 7.5), 1.24-1.45(m, 6H), 1.50-1.62(m, 6H), 1.78(m, 1H), 2.20(t, 2H, J = 7.5), 2.69(t, 2H, J = 8.3), 4.03(m, 1H), 5.39(br s, 2H), 8.16(s, 1H), 9.66(d, 1H, J = 9.0), 12.03(br s, 1H)


 


XI-167




DMSO-d6 0.95(t, 3H, J = 7.2), 1.03(t, 3H, J = 7.2), 1.12(t, 3H, J = 7.5), 1.10-1.80(m, 14H), 2.20-2.80(m, 6H), 3.95-4.20(m, 2H), 8.11(s, 1H), 10.43(s, 1H)


 


XI-189




DMSO-d6 0.94(t, 3H, J = 7.2), 1.03(t, 3H, 7.2), 1.12(t, 3H, J = 7.5), 2.19(s, 2H), 2.51(q, 2H, J = 7.4), 2.69(t, 2H, J = 7.8), 4.04(br, 2H), 8.17(s, 1H), 10.02(t, 1H, J = 5.7)


 


XI-210




DMSO-d6 0.96(t, 3H, J = 7.2), 1.05(t, 3H, J = 7.2), 1.16(t, 3H, J = 7.2), 1.43(m, 1H), 1.50-1.72(m, 2H), 2.55(q, 2H, J = 7.5), 2.68-2.80(m, 2H), 3.60(s, 2H), 4.04- 4.17(m, 2H), 7.72(dd, 1H, J = 2.1, 8.4), 8.20- 8.26(m, 2H), 8.32(s, 1H), 12.52(br s, 1H), 12.60(s, 1H)


 


XI-212




DMSO-d6 0.93(t, 3H,  J = 7.2), 1.05(t, 3H, J = 7.2), 1.14(t, 3H,  J = 7.5), 1.45(m, 2H), 1.52-1.74(m, 4H), 2.50(m, 2H), 2.60- 2.80(m, 2H), 4.05(m, 2H), 6.71(d, 1H, J = 16.2), 7.53(d, 1H, J = 16.2), 8.33(s, 1H), 9.01(s, 2H), 12.95(s, 1H)
















TABLE 134













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-065




DMSO-d6 1.03 (t, 3H, J = 7.5), 1.12 (t, 3H, J = 7.5), 1.14-1.78 (m, 10H), 1.98-2.12 (m, 2H), 2.48-2.55 (m, 2H), 2.77-2.83 (m, 2H), 3.24 (s, 3H), 3.63 (t, 2H,  J = 5.4), 4.28 (t, 2H, J = 5.4), 8.16 (s, 1H), 10.20 (s, 1H), 12.19 (br, 1H)  


 


XI-066




DMSO-d6 1.04 (t, 3H, J = 7.5),  1.16 (t, 3H, J = 7.5), 1.53-1.60 (m, 2H), 2.54-2.59 (q, 2H, J = 7.5), 2.80-2.87 (m, 2H),  3.24 (s, 3H), 3.68 (t, 2H, J = 5.4),  4.34 (t, 2H, J = 5.4), 7.02 (s, 1H), 8.32 (s, 1H), 12.41 (br, 1H),  13.34 (s, 1H) 


 


XI-121




DMSO-d6 1.01 (t, 3H, J = 7.5),  1.12 (t, 3H, J = 7.5), 1.35-1.60 (m,  12H), 2.20-2.58 (m, 2H), 2.70- 2.85 (m, 4H), 3.24 (s, 3H),  3.61 (t, 2H, J = 5.4), 4.25 (t, 2H, J = 5.4), 8.17 (s, 1H), 9.88 (s, 1H), 11.88 (br, 1H) 


 


XI-197




DMSO-d6 1.02 (t, 3H, J = 7.2),  1.05-1.80 (m, 11H), 2.20-2.90 (m,  8H), 3.24 (s, 3H), 3.50-3.75 (m, 2H), 4.20-4.40 (m, 2H), 8.14 (s, 1H), 10.37 (s, 1H)     


 


XI-219




1.07 (t, 3H, J = 7.5), 1.20 (t, 3H,  J = 7.2), 1.26-1.60 (m, 10H),  2.19-2.27 (m, 4H), 2.33-2.40 (m, 2H), 2.50 (q, 2H, J = 7.5), 2.79-2.85 (m, 2H), 3.32 (s, 3H), 3.70 (t, 2H, J = 5.4), 4.32 (t, 2H, J = 5.1), 8.40 (s, 1H), 9.99 (s, 1H)
















TABLE 135













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





XI-067




DMSO-d6 0.94 (t, 3H, J = 7.5),  1.21-1.52 (m, 6H), 1.52-1.78 (m, 9H), 3.79 (s, 3H), 4.06-4.11 (m, 2H), 4.56 (s, 2H), 8.28 (s, 1H), 10.40 (s, 1H), 12.24 (br, 1H)


 


XI-068




DMSO-d6 0.95 (t, 3H, J = 7.5),  1.37-1.47 (q, 2H, J = 7.5),  1.65-1.75 (m, 2H), 3.62 (s, 3H), 3.85 (s, 3H), 4.12-4.17 (m, 2H), 4.60 (s, 2H), 7.06 (s, 1H), 8.45 (s, 1H), 12.35 (br, 1H), 13.58 (s, 1H)
















TABLE 136













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





X-186




DMSO-d6 0.94 (t, 3H, J = 7.5  Hz), 1.16 (t, 3H, J = 7.5 Hz), 1.38-1.46 (m, 2H), 2.57 (q, 2H, J = 7.5 Hz), 2.67-2.73 (m, 2H), 3.79 (s, 2H), 5.48 (s, 2H),  7.13-7.28 (m, 4H), 8.43 (s, 1H), 13.63 (s, 1H)


 


X-210




DMSO-d6 0.96 (t, 3H, J = 7.2),  1.17 (t, 3H, J = 7.2), 1.36-1.52 (m, 2H), 2.57 (q, 2H, J = 7.5), 2.65-2.77 (m, 2H), 5.48 (s, 2H), 7.03 (s, 1H), 7.13-7.30 (m, 4H), 8.42 (s, 1H), 12.39 (br s, 1H), 13.30 (s, 1H)
















TABLE 137













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-073




0.99 (t, 3H, J = 7.2), 1.40-1.52 (m,  2H), 1.52 (d, 3H, J = 7.2), 1.63- 1.74 (m, 2H), 2.17 (s, 3H), 2.41 (s, 3H), 3.75 (s, 3H), 4.10-4.15 (m, 2H), 4.73 (qd, 1H, J = 7.2 and 7.2), 8.28 (s, 1H), 10.34 (d, 1H, J = 7.2)


 


I-074




0.99 (t, 3H, J = 7.2 Hz), 1.39-1.51 (m, 2H), 1.62-1.72 (m, 2H), 2.15 (s, 3H), 2.39 (s, 3H), 3.11-3.28 (m, 2H), 3.68 (s, 3H), 4.09-4.14 (m, 2H), 4.97 (m, 1H), 7.17-7.29 (m, 5H), 8.24 (s, 1H), 10.45 (d, 1H, J = 7.5 Hz)


 


I-075




0.97-1.04 (m, 9H), 1.40-1.52 (m,  2H), 1.64-1.74 (m, 2H), 2.16 (s, 3H), 2.29 (m, 1H), 2.41 (s, 3H), 3.74 (s, 3H), 4.10-4.16 (m, 2H), 4.66 (m, 1H), 8.28 (s, 1H), 10.42 (d, 1H, J = 8.1 Hz)


 


I-076




0.94-1.02 (m, 9H), 1.40-1.52 (m,  2H), 1.63-1.81 (m, 5H), 2.16 (s, 3H), 2.41 (s, 3H), 3.73 (s, 3H), 4.08-4.15 (m, 2H), 4.75 (m, 1H), 8.28 (s, 1H), 10.26 (d, 1H, J = 7.5 Hz)


 


I-077




0.92-1.00 (m, 9H), 1.23-1.72 (m,  6H), 2.03 (m, 1H), 2.16 (s, 3H),  2.40 (s, 3H), 3.74 (s, 3H), 4.09- 4.16 (m, 2H), 4.72 (m, 1H),  8.28 (s, 1H), 10.41  (d, 1H, J = 7.5 Hz)


 


I-078




0.97-1.04 (m, 9H), 1.40-1.52 (m,  2H), 1.66-1.72 (m, 2H), 2.16 (s, 3H), 2.29 (m, 1H), 2.41 (s, 3H), 3.74 (s, 3H), 4.10-4.16 (m, 2H), 4.66 (m, 1H), 8.28 (s, 1H),  10.42 (d, 1H, J = 7.8 Hz)


 


I-079




1.00 (t, 3H, J = 7.5 Hz), 1.40-1.52  (m, 2H), 1.63-1.74 (m, 2H), 2.10 (s, 3H), 2.17 (s, 3H), 2.05-2.31 (m, 2H), 2.60 (t, 2H, J = 7.5 Hz),  3.76 (s, 3H), 4.88 (m, 1H), 8.28 (s, 1H), 10.43 (d, 1H, J = 7.5 Hz)
















TABLE 138













 









Comp.

1H-NMR


No.
Q
(CDCl3/TMS) δ





I-080




0.99 (t, 3H, J = 7.2),  1.40-1.52 (m, 2H), 1.63-1.73 (m, 2H), 2.18 (s, 3H), 2.42  (s, 3H), 3.76 (s, 3H), 4.13 (q-like, 2H), 4.22 (d, 2H, J = 5.7), 8.29 (s, 1H), 10.38 (brs, 1H)


 


IV-001




1.01 (t, 3H, J = 7.4),  1.26 (d, 6H, J = 6), 1.47 (m, 2H), 1.71  (m, 2H), 2.21 (s,  3H), 2.45 (s, 3H), 2.75 (s, 3H), 4.18  (m, 2H), 4.28 (m,  1H), 5.91 (d, 1H, J = 7.2), 7.55 (dd, 1H, J = 8.4, 2.4),  7.67 (d, 1H, J = 2.4), 8.48 (d, 1H, J = 8.4), 12.25 (brs, 1H)


 


IV-004




1.02 (t, 3H, J = 7.5),  1.42-1.56 (m, 2H), 1.64-1.77 (m, 2H), 2.22 (s, 3H), 2.45 (s, 3H), 3.90 (s, 3H), 4.14-4.19 (m, 2H), 7.84 (d, 2H, J = 9.0), 8.02 (d, 2H, J = 9.0), 8.39 (s, 1H), 12.46 (s, 1H)


 


IV-007




0.99 (t, 3H, J = 7.2),  1.23-1.74 (m, 8H), 1.98-2.20 (m, 4H), 2.17 (s, 3H), 2.28 (m, 1H), 2.40 (s, 3H), 3.67 (s, 3H), 3.93 (m, 1H), 4.07-4.12 (m, 2H), 8.30 (s, 1H), 9.83 (d, 1H, J = 7.8)


 


IV-014




DMSO-d6 0.95 (t,  3H, J = 7.5), 1.34- 1.48 (m, 2H),  1.55-1.69 (m, 2H), 2.19 (s, 3H), 2.48  (s, 3H), 4.14-4.19 (m, 2H), 7.81 (d, 2H, J = 9.0), 7.93  (d, 2H, J = 9.0),  8.26 (s, 1H), 12.59 (s, 1H), 12.74  (brs, 1H)


 


IV-017




DMSO-d6 0.93 (t,  3H, J = 7.2), 1.18- 1.63 (m, 8H), 1.86- 1.97 (m, 4H), 2.14  (s, 3H), 2.21 (m,  1H), 2.42 (s, 3H),  3.70 (m, 1H), 4.06- 4.11 (m, 2H), 8.11  (s, 1H), 9.84 (d, 1H, J = 7.8), 12.11 (br,  1H)


 


V-004




0.99 (t, 3H, J = 7.5), 1.38-1.52 (m, 2H),  1.60-1.74 (m, 2H), 2.19 (s, 3H), 2.42 (s, 3H), 3.90 (s, 3H), 4.08-4.14 (m, 2H), 4.69 (d, 2H, J = 6.0), 7.66 (d, 2H, J = 8.7), 7.98 (d, 2H, J = 8.7), 8.34 (s, 1H), 10.40  (m, 1H)
















TABLE 139













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





V-010




DMSO-d6 0.93 (t, 3H,  J = 7.3), 1.31-1.43 (m, 2H), 1.52-1.62 (m, 2H), 2.15 (s, 3H), 2.44 (s, 3H), 4.10 (m, 2H), 4.59 (d, 2H, J = 6.0), 7.41 (d, 2H, J = 8.4), 7.90 (d, 2H, J = 8.4), 8.16 (s, 1H), 10.33 (1H, t, J = 6), 12.88 (brs, 1H)
















TABLE 140













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-085




1.06-1.28 (m, 4H), 1.52 (d, 3H,  J = 7.2), 1.55-1.88 (m, 7H),  2.16 (s, 3H), 2.38 (s, 3H), 3.75 (s, 3H), 4.02 (br, 2H), 4.72 (m, 1H), 8.28 (s, 1H)


 


I-086




1.06-1.29 (m, 4H), 1.54-1.88  (m, 7H), 2.15 (s, 3H), 2.37  (s, 3H), 3.36-3.42 (m, 2H),  3.63 (s, 3H), 3.86-4.16 (m,  2H), 5.06 (m, 1H), 7.02- 7.18 (m, 3H), 7.31 (d, 1H, J = 8.1), 7.61 (d, 1H, J =  7.8), 8.04 (br, 1H), 8.27  (s, 1H), 10.49 (d, 1H, 7.2)


 


I-087




1.06-1.29 (m, 4H), 1.54-1.88  (m, 7H), 2.15 (s, 3H), 2.37  (s, 3H), 3.10-3.30 (m, 2H),  3.68 (s, 3H), 3.86-4.16 (m,  2H), 4.96 (dd, 1H, J = 7.5  and 13.8), 7.17-7.30 (m, 5H), 8.24 (s, 1H), 10.46 (d, 1H, 7.8)


 


I-088




1.00-1.32 (m, 4H), 1.54-  1.95 (m, 7H), 2.15 (s, 3H),  2.38 (s, 3H), 3.02 (dd, 1H,  J = 7.8 and 13.5), 3.16 (dd, 1H, J = 5.4 and 13.5), 3.69 (s, 3H), 4.02 (br, 2H), 5.08 (m, 1H), 5.83 (br s, 1H), 6.66 (d, 2H, J = 8.7), 7.04 (d, 2H, 8.7), 8.24 (s, 1H), 10.45 (d, 1H, J = 7.8)


 


I-089




0.92-1.38 (m, 10H), 1.47-2.10 (m, 10H), 2.16 (s, 3H), 2.38 (s, 3H), 3.74 (s, 3H), 4.02 (br, 2H), 4.70 (dd, 1H, J = 7.8 and 8.4), 8.28 (s, 1H), 10.40 (d, 1H,  J = 7.8)


 


I-090




1.02-1.30 (m, 4H), 1.58-1.94 (m, 7H), 2.19 (s, 3H), 2.42 (s, 3H), 3.79 (s, 3H), 3.80-4.20 (m, 4H), 4.81 (m, 1H), 8.28 (s, 1H)


 


I-091




1.02-1.30 (m, 4H), 1.57-1.94  (m, 7H), 2.17 (s, 3H), 2.39 (s,  3H), 3.76 (s, 3H), 4.02 (br, 2H), 4.21 (d, 2H, J = 5.7), 8.29 (s, 1H), 10.36 (m, 1H)
















TABLE 141













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-093




0.94-1.32 (m, 10H), 1.56- 1.96 (m, 10H), 2.16 (s,  3H), 2.38 (s, 3H), 3.73  (s, 3H), 4.00 (br, 2H),  4.72 (dd, 1H, J = 6.6 and 14.4), 8.29 (s, 1H), 10.23 (d, 1H, J = 7.5)


 


V-003




1.02-1.30 (m, 4H), 1.56- 1.90 (m, 7H), 2.18 (s, 3H), 2.40 (s, 3H), 3.89 (s, 3H), 4.01 (br, 2H), 4.68 (d, 2H, J = 6.0), 7.42 (d, 2H,  J = 8.4), 7.98 (d, 2H, J = 8.4), 8.35 (s, 1H), 10.40 (m, 1H)


 


V-009




DMSO-d6 1.02-1.30 (m,  4H), 1.56-1.90 (m, 7H), 2.16 (s, 3H), 2.42 (s, 3H), 3.92-4.10 (m, 2H), 4.58 (d, 2H, J = 6.0), 7.42 (d, 2H, J = 8.4), 7.99 (d, 2H,  J = 8.4), 8.17 (s, 1H), 10.31 (t, 1H, J = 6.0), 12.86 (br, 1H)
















TABLE 142













 









Comp.




No.
Q
1H-NMR(CDCl3/TMS) δ





I-094




1.01-1.03 (d, 6H, J = 6.9),  2.16 (s, 3H), 2.29 (s, 3H),  3.74 (s, 3H), 4.66 (dd, 1H,  J = 5.4 and 8.1), 5.38-5.56  (m, 2H), 6.99-7.15 (m,  5H), 8.37 (s, 1H), 10.31 (d, 1h, J = 8.1)


 


X-145




DMSO-d6 2.19 (s, 3H), 2.39 (s, 3H), 3.80 (s, 2H), 5.52  (br-s, 2H), 7.13-7.31 (m, 4H), 8.40 (s, 1H), 13.69 (s, 1H)


 


X-236




DMSO-d6 2.20 (s, 3H), 2.39  (s, 3H), 3.61 (s, 2H), 5.51  (s, 2H), 7.03 (s, 1H), 7.18 (t, 2H, J = 8.7), 7.28 (dd, 2H, J = 5.7 and 9.0), 12.42 (br s, 1H), 13.34 (s, 1H)



















TABLE 143







Comp. No.
Structure









I-063







 



I-064







 



I-065







 



I-066
























TABLE 144







Comp. No.
Structure









I-067







 



I-068







 



I-069







 



I-070
























TABLE 145







Comp. No.
Structure









I-092







 



I-095







 



I-096







 



I-097






















TABLE 146





Comp. No.
Structure







I-098






 


I-099






 


I-100






 


I-101























TABLE 147







Comp. No.
Structure









I-102







 



I-103







 



I-106







 



I-107






















TABLE 148





Comp. No.
Structure







I-108






 


I-109 






 


I-110






 


I-115





















TABLE 149





Comp. No.
Structure







I-116






 


I-117






 


I-118






 


I-120





















TABLE 150





Comp. No.
Structure







I-121






 


I-122






 


I-123






 


I-125





















TABLE 151





Comp. No.
Structure







I-126






 


I-127






 


I-128






 


I-133





















TABLE 152





Comp. No.
Structure







I-138






 


I-139






 


I-140






 


I-141





















TABLE 153





Comp. No.
Structure







I-142






 


I-143






 


I-144






 


I-147





















TABLE 154





Comp.



No.
Structure







I-148






 


I-154






 


I-155






 


I-158























TABLE 155







Comp. No.
Structure









I-160







 



I-161







 



I-162







 



I-163






















TABLE 156





Comp. No.
Structure







I-164






 


I-165






 


I-166






 


I-167





















TABLE 157





Comp. No.
Structure







I-168






 


I-169






 


I-170






 


I-171





















TABLE 158





Comp. No.
Structure







I-172






 


I-173






 


I-174






 


I-175





















TABLE 159





Comp.



No.
Structure







I-176






 


I-177






 


I-178






 


I-179





















TABLE 160





Comp.



No.
Structure







I-181






 


I-183






 


I-186






 


I-187























TABLE 161







Comp. No.
Structure









I-188







 



I-189







 



I-193







 



I-194






















TABLE 162





Comp.



No.
Structure







I-196






 


I-197






 


I-198






 


I-199





















TABLE 163





Comp.



No.
Structure







I-200






 


I-201






 


I-202






 


I-205





















TABLE 164





Comp.



No.
Structure







I-206






 


I-207






 


I-208






 


I-211





















TABLE 165





Comp. 



No.
Structure







I-212






 


I-213






 


I-214






 


I-215





















TABLE 166





Comp.



No.
Structure







I-216






 


I-217






 


I-218






 


I-219





















TABLE 167





Comp.



No.
Structure







I-220






 


I-221






 


I-222






 


I-223





















TABLE 168





Comp.



No.
Structure







I-224






 


I-225






 


I-226






 


I-227





















TABLE 169





Comp.



No.
Structure







I-228






 


I-229






 


I-230






 


I-231





















TABLE 170





Comp.



No.
Structure







I-232






 


I-233






 


I-234






 


I-236





















TABLE 171





Comp.



No.
Structure







I-237






 


I-238






 


I-239






 


I-240





















TABLE 172





Comp.



No.
Structure







I-241






 


I-242






 


I-245






 


I-246





















TABLE 173





Comp.



No.
Structure







I-247






 


I-249






 


I-250






 


I-251





















TABLE 174





Comp.



No.
Structure







I-256






 


I-257






 


I-258






 


I-261





















TABLE 175





Comp.



No.
Structure







I-266






 


I-267






 


I-271






 


I-272





















TABLE 176





Comp.



No.
Structure







I-273






 


I-278






 


I-279






 


I-280





















TABLE 177





Comp. 



No.
Structure







I-281






 


I-282






 


I-283






 


I-285





















TABLE 178





Comp.



No.
Structure







I-287






 


I-288






 


I-289






 


I-290





















TABLE 179





Comp. No.
Structure







I-292






 


I-293






 


I-294






 


I-295





















TABLE 180





Comp.



No.
Structure







I-298






 


I-330






 


I-347






 


I-348























TABLE 181







Comp. No.
Structure









I-349







 



I-350







 



I-351







 



I-352






















TABLE 182





Comp. No.
Structure







I-353






 


I-354






 


I-359






 


I-360





















TABLE 183





Comp. No.
Structure







I-361






 


I-362






 


I-365






 


I-366























TABLE 184







Comp. No.
Structure









I-367







 



I-368







 



I-369







 



I-370
























TABLE 185







Comp. No.
Structure









I-371







 



I-372







 



I-373







 



I-374
























TABLE 186







Comp. No.
Structure









I-375







 



I-376







 



I-377







 



I-378






















TABLE 187





Comp. No.
Structure







I-381






 


I-382






 


I-383






 


I-384























TABLE 188







Comp. No.
Structure









I-385







 



I-387







 



I-388







 



I-389
























TABLE 189







Comp. No.
Structure









I-390







 



I-391







 



I-393







 



I-394
























TABLE 190







Comp. No.
Structure









I-395







 



I-396







 



I-398







 



I-399






















TABLE 191





Comp. No.
Structure







I-400






 


I-401






 


I-406






 


I-408





















TABLE 192





Comp. No.
Structure







I-411






 


I-412






 


I-413






 


I-414























TABLE 193







Comp. No.
Structure









I-415







 



I-416







 



I-417







 



I-420
























TABLE 194







Comp. No.
Structure









I-427







 



I-428







 



I-431







 



I-433
























TABLE 195







Comp. No.
Structure









I-434







 



I-435







 



I-436







 



I-437
























TABLE 196







Comp. No.
Structure









I-439







 



I-440







 



I-441







 



I-442
























TABLE 197







Comp. No.
Structure









I-444







 



I-445 







 



I-446







 



I-447






















TABLE 198





Comp. No.
Structure







I-448






 


I-449






 


I-450






 


I-451





















TABLE 199





Comp. No.
Structure







I-452






 


I-453






 


I-457






 


I-458























TABLE 200







Comp. No.
Structure









I-459







 



I-460







 



I-464







 



I-466






















TABLE 201





Comp. No.
Structure







I-467






 


I-468






 


I-469






 


I-470





















TABLE 202





Comp. No.
Structure







I-471






 


I-472






 


I-473






 


I-477























TABLE 203







Comp. No.
Structure









I-478







 



I-479







 



I-480







 



I-483






















TABLE 204





Comp. No.
Structure







I-484






 


I-485






 


I-486






 


I-487





















TABLE 205





Comp. No.
Structure







I-488






 


I-489






 


I-490






 


I-491





















TABLE 206





Comp. No.
Structure







I-492






 


I-493






 


I-494






 


I-495





















TABLE 207





Comp. No.
Structure







I-496






 


I-497






 


I-498






 


I-499























TABLE 208







Comp. No.
Structure









I-500







 



I-502







 



I-503







 



I-504






















TABLE 209





Comp. No.
Structure







I-505






 


I-506






 


I-507






 


I-508





















TABLE 210





Comp. No.
Structure







I-511






 


I-512






 


I-513






 


I-514























TABLE 211







Comp. No.
Structure









I-516







 



I-517







 



I-518







 



I-520
























TABLE 212







Comp. No.
Structure









I-521







 



I-522







 



I-523







 



I-524
























TABLE 213







Comp. No.
Structure









I-527







 



I-531







 



I-532







 



I-536
























TABLE 214







Comp. No.
Structure









I-537







 



I-538







 



I-543







 



I-544
























TABLE 215







Comp. No.
Structure









I-545







 



I-546







 



I-547







 



I-548
























TABLE 216







Comp. No.
Structure









I-550







 



I-552







 



I-553







 



I-554
























TABLE 217







Comp. No.
Structure









I-555







 



I-557







 



I-558







 



I-559
























TABLE 218







Comp. No.
Structure









I-560







 



I-563







 



II-003







 



II-004






















TABLE 219





Comp. No.
Structure







II-005






 


II-006






 


II-007






 


II-008





















TABLE 220





Comp.



No.
Structure







II-011






 


II-012






 


II-013






 


II-018





















TABLE 221





Comp.



No.
Structure







II-019






 


II-020






 


II-021






 


II-022





















TABLE 222





Comp.



No.
Structure







II-024






 


II-027






 


II-028






 


II-029





















TABLE 223





Comp.



No.
Structure







 


II-030






 


II-031






 


II-032






 


II-033























TABLE 224







Comp. No.
Structure









II-036







 



II-037







 



II-040







 



II-041
























TABLE 225







Comp. No.
Structure









II-043







 



II-044







 



II-045







 



II-046
























TABLE 226







Comp. No.
Structure









II-047







 



II-049







 



II-053







 



II-054






















TABLE 227





Comp. No.
Structure







II-056






 


II-057






 


II-058






 


II-059























TABLE 228







Comp. No.
Structure









II-060







 



II-061







 



II-062







 



II-063






















TABLE 229





Comp. No.
Structure







III-002






 


III-003






 


III-006






 


III-007





















TABLE 230





Comp.



No.
Structure







III-009






 


III-010






 


IV-005






 


IV-006





















TABLE 231





Comp.



No.
Structure







IV-015






 


IV-016






 


IV-030






 


V-002





















TABLE 232





Comp. 



No.
Structure







V-008






 


X-35






 


X-50






 


X-94





















TABLE 233





Comp.



No.
Structure







X-107






 


X-111






 


X-113






 


X-118





















TABLE 234





Comp. 



No.
Structure







X-140






 


X-141






 


X-142






 


X-143





















TABLE 235





Comp.



No.
Structure







X-145






 


X-146






 


X-147






 


X-152





















TABLE 236





Comp.



No.
Structure







X-153






 


X-161






 


X-174






 


X-175





















TABLE 237





Comp.



No.
Structure







X-176






 


X-178






 


X-190






 


X-196





















TABLE 238





Comp.



No.
Structure







 


X-198






 


X-207






 


X-208






 


X-209





















TABLE 239





Comp. 



No.
Structure







X-211






 


X-215






 


X-223






 


X-227





















TABLE 240





Comp. No.
Structure







X-229






 


X-230






 


X-233






 


X-237





















TABLE 241





Comp. No.
Structure







X-241






 


XI-001






 


XI-005






 


XI-006





















TABLE 242





Comp.



No.
Structure







 


XI-007






 


XI-009






 


XI-015






 


XI-016





















TABLE 243





Comp.



No.
Structure







XI-019






 


XI-024






 


XI-026






 


XI-028





















TABLE 244





Comp.



No.
Structure







XI-029






 


XI-030






 


XI-037






 


XI-038





















TABLE 245





Comp. No.
Structure







XI-049






 


XI-060






 


XI-061






 


XI-062





















TABLE 246





Comp. No.
Structure







XI-064






 


XI-069






 


XI-238






 


XI-239





















TABLE 247





Comp.



No.
Structure







XI-240






 


XI-245






 


XI-248






 


XI-251





















TABLE 248





Comp.



No.
Structure







XI-255






 


XI-256






 


XI-257






 


XI-258





















TABLE 249





Comp. No.
Structure







XI-259






 


XI-268






 


XI-271






 


XI-272





















TABLE 250





Comp.



No.
Structure







XI-273






 


XI-274






 


XI-276






 


XI-281





















TABLE 251





Comp. No.
Structure







XI-282






 


XI-286






 


XI-294






 


XI-296





















TABLE 252





Comp. No.
Structure







XI-298






 


XI-300






 


XI-301






 


XI-302





















TABLE 253





Comp.



No.
Structure







XI-304






 


XI-306






 


XI-307





















TABLE 254





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-063
DMSO-d6 0.92 and 0.93(each t, total 3H, J = 7.2), 1.26-



1.42(m, 2H), 1.46-1.60(m, 2H), 1.75-2.00(m, 3H), 2.03 and 



2.07(each s, total 3H), 2.18(m, 1H), 2.34 and 2.36(each s, 



total 3H), 3.40-3.51(m, 2H), 3.96-4.12(m, 2H), 4.28 and



4.38(each m, total 1H), 7.25 and 7.29(each s, total 1H), 



12.47(br, 1H)


I-064
DMSO-d6 1.11-1.99(m, 23H), 2.16-2.57(m, 2H), 



2.86(m, 2H), 3.35-3.51m, 2H), 3.78-3.98(m, 2H), 



4.28(m, 1H), 7.30(s, 1H), 12.48(s, 1H)


I-065
DMSO-d6 0.98-1.27(m, 6H), 1.45-1.93(m, 8H), 2.03 and 



2.07(s, 3H), 2.20(m, 1H), 2.32-2.34(s, 3H), 3.42-



3.59(m, 2H), 3.84-4.50(m, 3H), 7.25 and 7.29(s, 1H), 



12.44(br, 1H)


I-066
DMSO-d6 0.98-1.27(m, 6H), 1.45-1.93(m, 8H), 2.03 and 



2.07(s, 3H), 2.20(m, 1H), 2.32-2.34(s, 3H), 3.42-



3.59(m, 2H), 3.84-4.50(m, 3H), 7.25 and 7.29(s, 1H), 



12.35(br, 1H)


I-067
0.97(t, 3H, J = 7.2), 1.39-1.49(m, 2H), 1.54-1.72(m, 2H), 



1.86-2.06(m, 3H), 2.09 and 2.10each s, total 3H), 



2.27(m, 1H), 2.34 and 2.35(each s, total 3H), 3.48(m, 1H), 



3.54 and 3.77(each s, total 3H), 3.74(m, 1H), 3.97-



4.19(m, 2H), 4.61-4.70(m, 1H), 7.36 and 7.45(each s, 



total 1H)


I-068
1.14-2.05(m, 23H), 2.27(m, 1H), 2.51-2.57(m, 2H), 2.85-



2.88m, 2H), 3.74-3.76(m, 2H), 3.77(s, 3H), 4.02(m, 2H), 



4.67(m, 1H), 7.45(s, 1H)


I-069
DMSO-d6 0.84(d, 3H, J = 4.5), 0.90(d, 3H, 4.5), 2.10-



2.25(m, 4H), 2.29(s, 3H), 4.38(dd, 1H, J = 4.5 and 8.4), 5.40-



5.64(m, 2H), 7.10(d, 2H, J = 5.4), 8.26(s, 1H), 8.53(d, 2H, J = 



5.4), 10.12(d, 1H, J = 8.4), 12.67(br, 1H)


I-070
0.98-1.27(m, 4H), 1.55-1.88(m, 8H), 1.88-2.10(m, 2H), 2.06 



and 2.09(s, 3H), 2.28(m, 1H), 2.31 and 2.33(s, 3H), 3.45(m, 



1H), 3.55 and 3.76(s, 3H), 3.72-4.18(m, 2H), 4,60-4.76(m, 



2H), 7.37 and 7.46(s, 1H)


I-092
1.02(d, 3H, J = 6.9), 1.02(d, 3H, J = 6.6), 2.17(s, 3H), 



2.29(m, 1H), 2.46(s, 3H), 2.56(brt, 4H), 2.67(t, 2H, J = 6.9), 



3.71(t, 4H, J = 4.5), 3.75(s, 3H), 4.28(br, 1H), 4.67(dd, 1H, 



J = 5.1 and 8.1), 8.29(s, 1H), 10.35(d, 1H, J = 8.1)


I-095
0.86-0.94(m, 3H), 1.00-1.04(dd, 6H, J = 2.7 and 6.6), 1.24-



1.48(m, 8H), 1.60-1.77(m, 2H), 2.16(s, 3H), 2.28(m, 1H), 



2.40(s, 3H), 3.74(s, 3H), 4.10-4.38(m, 2H), 4.66(m, 1H), 



8.28(s, 1H), 10.41(d, 1H, J = 7.8)


I-096
1.00-1.04(m, 12H), 1.52-1.84(m, 3H), 2.16(s, 3H), 2.29(m, 



1H), 2.40(s, 3H), 3.74(s, 3H), 4.10-4.26(m, 2H), 4.66(m, 



1H), 8.27(s, 1H), 10.41(d, 1H, J = 8.1)


I-097
1.00-1.04(dd, 6H, J = 2.7 and 6.6), 2.16(s, 3H), 2.25(m, 1H), 



2.26(s, 3H), 3.74(s, 3H), 4.66(dd, 1H, J = 5.1 and 8.1), 



5.47(br, 2H), 7.02(dd, 1H, J = 1.5 and 4.5), 8.41(s, 1H), 



8.57(dd, 1H, J = 1.5 and 4.5), 10.20(d, 1H, J = 8.1)


I-098
1.00-1.05(dd, 6H, J = 2.7 and 6.9), 1.00-1.34(m, 4H), 1.58-



1.98(m, 7H), 2.29(m, 1H), 2.41(s, 3H), 3.75(s, 3H), 3.78(s, 



3H), 4.00(br, 2H), 4.63(dd, 1H, J = 5.4 and 8.1), 8.37(s, 



1H), 10.52(d, 1H, J = 8.1)

















TABLE 255





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-099
DMSO-d6 0.92(d, 6H, J = 6.9), 1.00-1.34(m, 4H), 1.46-



1.94(m, 7H), 2.17(m, 1H), 2.42(s, 3H) 3.74(s, 3H), 3.90-



4.15(m, 2H), 4.39(dd, 1H, J = 5.1 and 8.4), 8.21(s, 1H), 



10.37(d, 1H, J = 8.4), 12.73(br, 1H)


I-100
1.02-1.30(m, 4H), 1.56-1.94(m, 7H), 2.04-2.36(m, 2H), 



2.10(s, 3H), 2.16(s, 3H), 2.39(s, 3H), 2.59(t, 2H, J = 7.8), 



3.76(s, 3H), 4.05(br, 2H), 4.87(m, 1H), 8.28(s, 1H), 



10.42(d, 1H, J = 7.5)


I-101
1.00t, 3H, J = 7.2 Hz), 1.40-1.52m, 2H), 1.62s, 6H), 



1.60-1.74m, 2H), 2.15s, 3H), 2.41s, 3H), 3.74s, 3H), 



4.08-4.14m, 2H) , 8.27s, 1H), 10.29s, 1H)


I-102
1.00t, 3H, J = 7.2 Hz), 1.24-2.21m, 15H), 2.15s, 3H), 



2.41s, 3H), 3.72s, 3H), 4.10-4.15m, 2H) , 8.26s, 1H), 



10.35s, 1H)


I-103
0.98t, 3H, J = 7.2 Hz), 1.36-1.48m, 2H), 1.59-1.69m, 



2H), 2.14s, 3H), 2.38s, 3H), 3.63s, 3H), 4.51-4.10m, 



2H) , 5.07m, 1H), 7.03-7.64m, 5H), 8.15s, 1H), 8.26s, 



1H), 10.50d, 1H, J = 7.2 Hz)


I-106
0.99(t, 3H, J = 7.2), 1.39-1.52(m, 2H), 1.63-1.74(m, 2H), 



2.18(s, 3H), 2.42(s, 3H), 3.80(s, 3H), 4.01(dd, 1H, J = 4.8 and 



11.1), 4.06(dd, 1H, J = 3.9 and 11.1), 4.06-4.20(m, 2H), 



4.83(m, 1H), 8.29(s, 1H), 10.77(d, 1H, J = 6.6)


I-107
DMSO-d6 1.00t, 3H, J = 7.2 Hz), 1.24-2.21m, 15H), 2.15 



(s, 3H), 2.41s, 3H), 3.72s, 3H), 4.10-4.15m, 2H) , 8.26 



(s, 1H), 10.35s, 1H)


I-108
1.02-1.30(m, 4H), 1.56-1.94(m, 7H), 2.04-2.36(m, 2H), 



2.10(s, 3H), 2.17(s, 3H), 2.39(s, 3H), 2.59(t, 2H, J = 7.8), 



3.76(s, 3H), 4.05(br, 2H), 4.87(m, 1H), 8.28(s, 1H), 



10.42(d, 1H, J = 7.5)


I-109
1.04-1.31(m, 4H), 1.54-1.88(m, 7H), 2.15(s, 3H), 2.37(s, 



3H), 3.10-3.27(m, 2H), 3.68(s, 3H), 3.86-4.20(m, 2H), 



4.96(dd, 1H, J = 7.5 and 13.8), 7.17-7.30(m, 5H), 



8.24(s, 1H), 10.46(d, 1H, 7.5)


I-110
0.97-1.10(m, 10H), 1.18(t, 2H, 7.5), 1.42-1.78(m, 9H), 



2.28(m, 1H), 2.48(q, 2H, J = 7.5), 2.61-2.65(m, 2H), 



3.74(s, 3H), 4.08(br, 2H), 4,65(dd, 1H, J = 5.4 and 8.1), 



8.32(s, 1H), 10.43(d, 1H, J = 8.1)


I-115
1.09-1.86(m, 19H), 2.69(t, 2H, J = 5.4), 2.96(t, 2H, J = 6.0), 



3.84-4.21(m, 2H), 7.88(d, 2H, J = 8.7), 8.09(d, 2H, J = 9.0), 



8.40(s, 1H), 12.54(s, 1H)


I-116
1.02(d, 3H, J = 6.9),1.04(d, 3H, J = 6.9), 1.36-1.75(m, 14H), 



2.28(m, 1H), 2.49-2.64(m, 8H), 2.96(t, 2H, J = 6.6), 3.75(s, 



3H), 4.29(m, 2H), 4.66(dd, 1H, J = 5.1, 7.8), 8.27(s, 1H), 



10.42(d, 1H, J = 7.8)


I-117
1.36-1.76(m, 14H), 2.51-2.65(m, 8H), 2.95(t, 2H, J = 6.3), 



3.76(s, 3H), 4.22(d, 2H, J = 5.7), 4.29(t, 2H, J = 7.2), 8.29(s, 



1H), 10.34(t, 1H, J = 8.7)


I-118
1.26-1.76(m, 20H), 2.51-2.63(m, 8H), 2.95(t, 2H, J = 6.6), 



3.75(s, 3H), 4.27(t, 2H, J = 7.2), 8.26(s, 1H), 10.28(s, 1H)


I-120
0.94-1.02m, 9H), 1.40-1.52m, 2H), 1.64-1.77m, 5H), 



2.16s, 3H), 2.41s, 3H), 3.73s, 3H), 4.08-4.15m, 2H) , 



4.76m,1H), 8.28s, 1H), 10.24d, 1H, J = 7.8 Hz)

















TABLE 256





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-121
0.99(t, 3H, J = 7.2), 1.39-1.51(m, 2H), 1.62-1.72(m, 2H), 



2.15(s, 3H), 2.39(s, 3H), 3.15(dd, 1H, J = 7.2 and 13.8), 



3.24(dd, 1H, J = 6.3 and 13.8), 3.68(s, 3H), 4.11(t-like, 2H), 



4.97(q-like, 1H), 7.17-7.29(m, 5H), 8.24(s, 1H), 10.45(d, 



1H, J = 7.8)


I-122
0.97(t, 3H, J = 7.2),1.02(d, 3H, J = 6.9), 1.03(d, 3H, J = 



6.9), 1.40(m, 2H), 1.6-1.9(m, 6H), 2.28(m, 1H), 2.50(t, 2H, 



J = 6.0), 2.67(t, 2H, J = 6.0), 3.75(s, 3H), 3.93 3.98(m, 2H), 



4.57(dd, 1H, J = 5.1 and 8.1), 10.86(d, 1H, J = 7.5), 



16.00(s, 1H)


I-123
1.01-1.33(m, 10H), 1.60-1.90(4H, m), 2.03(s, 3H), 2.28(m, 



1H), 2.36(s, 3H), 3.75(s, 3H), 3.93(brs, 1H), 4.57(dd, 1H, 



J = 5.4 and 8.1), 10.90(d, 1H, J = 7.8), 15.76(s, 1H)


I-125
0.89-1.14(m, 9H), 1.23-2.35(m, 13H), 2.62-2.66(m, 2H), 



2.96-3.38(m, 5H), 3.75(s, 3H), 3.79-3.92(m, 3H), 4.33(m, 



1H), 4.69(m, 1H), 8.28(s, 1H), 10.44(m, 1H)


I-126
0.89-1.14(m, 9H), 1.23-2.35(m, 13H), 2.62-2.66(m, 2H), 



2.96-3.38(m, 5H), 3.75(s, 3H), 3.79-3.92(m, 3H), 4.33(m, 



1H), 4.69(m, 1H), 8.28(s, 1H), 10.44(m, 1H)


I-127
0.91-2.29(m, 25H), 2.61-2.65(m, 2H), 2.95-3.36(m, 5H), 



3.73(s, 3H), 3.74-3.92(m, 3H), 4.33(m, 1H), 8.26(s, 1H), 



10.39(s, 1H)


I-128
0.78-1.97(m, 17H), 0.99(s, 9H), 2.06-2.41(m, 2H), 2.58-



2.69(m, 2H), 2.89-3.35(m, 5H), 3.73(s, 3H), 3.81-4.43(m, 



2H), 4.79(m,1H), 8.28(s, 1H), 10.27(s, 1H)


I-132
1.01-1.72(m, 19H), 1.09(s, 9H), 2.62(t, 2H, J = 6.0), 



2.91(t, 2H, J = 6.3), 3.74(s, 3H), 3.92-4.16(m, 2H), 4.54(d, 



1H, J = 8.1), 8.26(s, 1H), 10.61(d, 1H, J = 7.8)


I-133
1.00-1.31(m, 13H), 1.47-1.95(m, 12H), 2.28(m, 1H), 2.42-



2.55(m, 2H), 2.64-2.75(m, 2H), 3.74(s, 3H), 4.01(br, 2H), 



4.65(dd, 1H, J = 4.8 and 8.1), 8.33(s, 1H), 10.43(d, 1H, 



J = 7.8)


I-138
1.00(t, 3H, J = 7.2), 1.08(t, 3H, J = 7.2), 1.17(t, 3H, J = 7.5), 



1.40-1.86(m, 12H), 2.15-2.25(m, 8H), 2.45(q, 2H, J = 7.8), 



2.60-2.68(m, 2H), 3.72(s, 3H), 4.11(br, 2H), 8.31(s, 1H), 



10.37(br, 1H)


I-139
1.00-1.96(m, 21H), 2.15-2.25(m, 8H), 2.47(q, 2H, J = 7.2), 



2.62-2.74(m, 2H), 3.72(s, 3H), 3.97(br, 2H), 8.31(s, 1H), 



10.37(3r, 1H)


I-140
1.06-1.42(m, 6H), 1.51-1.94(m, 15H), 2.14(s, 3H), 2.38(s, 



3H), 3.72(s, 3H), 4.03(br, 2H), 8.26(s, 1H), 10.35(br, 1H)


I-141
1.01(d, 6H, J = 8.1), 1.21-2.38(m, 13H), 2.58-2.71(m, 2H), 



2.93-3.22(m, 2H), 3.67-3.98(m 3H), 3.72(s, 3H), 4.26(m, 



1H), 4.65-4.71(m, 2H), 8.29(s, 1H), 10.43(t, 1H, J = 7.8)


I-142
1.22-2.20(m, 12H), 1.65(s, 6W, 2.59-2.71(m, 2H), 2.90-



3.15(m, 2H), 3.68-3.92(m 3H), 3.75(s, 3H), 4.25(m, 1H), 



4.59(m, 1H), 8.28(s, 1H), 10.26(s, 1H)

















TABLE 257





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-143
1.16-2.28(m, 22H), 2.59-2.63(m, 2H), 2.92-3.21(m, 2H), 



3.73(s, 3H), 3.76(m 1H), 3.84-3.92(m, 2H), 4.26(m, 1H), 



4.60(dd, 1H, J = 3.3, 12.3), 8.27(s, 1H), 10.33(s, 1H)


I-144
1.09-2.26(m, 12H), 1.08(s, 9H), 2.62-2.65(m, 2H), 2.92-



3.27(m, 2H), 3.73(s 3H), 3.72-3.94(m, 3H), 4.28(m, 1H), 



4.50-4.69(m, 2H), 8.28(s, 1H), 10.58(t, 1H, J = 6.6)


I-147
0.98t, 3H, J = 7.2 Hz), 1.39-1.51m, 2H), 1.62-1.73m, 



2H), 2.15s, 3H), 2.40s, 3H), 3.74s, 3H), 4.09-4.15 



(m, 2H), 5.73d, 1H, J = 6.6Hz), 7.30-7.50m, 5H), 8.26 



(s, 1H), 10.87d, 1H, J = 6.3 Hz)


I-148
1.23-1.93(m, 16H), 2.14-2.24(m, 2H), 2.61(t-like, 2H), 



3.05(t-like, 2H), 3.73(s, 3H), 5.37(brs, 2H), 6.32(dd, 1H, 



J = 0.6 and 3.3), 6.34(dd, 1H, J = 1.8 and 3.3), 7.35(dd, 



1H, J = 0.9 and 1.8), 8.28(s, 1H), 10.27(brs, 1H)


I-154
0.95-1.08(m, 9H), 1.48(m, 1H), 1.56-1.74(m, 9H), 1.85(m, 



1H), 2.69(t, 2H, J = 5.4), 2.93(t, 2H, J = 5.4), 3.74(s, 3H), 



4.18(br, 2H), 4.66(dd, 1H, J = 5.4 and 8.1), 8.26(s, 1H), 



10.42(d, 1H, J = 7.5)


I-155
0.95-1.08(m, 9H), 1.48(m, 1H), 1.56-1.74(m, 7H), 1.85(m, 



1H), 2.69(t, 2H, J = 5.4), 2.93(t, 2H, J = 5.4), 3.74(s, 3H), 



4.18(br, 2H), 4.66(dd, 1H, J = 5.4 and 8.1), 8.26(s, 1H), 



10.42(d, 1H, J = 7.5)


I-158
0.98(t, 3H, J = 7.5), 1.07(t, 3H, J = 7.5), 1.16(t, 3H, J = 7.5), 



1.38-1.78(m, 8H), 2.47(q, 2H, J = 7.5), 2.62-2.70(m, 2H), 



3.74(s, 3H), 3.98-4.20(m, 2H), 5.73(d, 1H, J = 7.2), 7.26-



7.38(m, 3H), 7.46-7.53(m, 2H), 8.31(s, 1H), 10.89(d, 1H, 



J = 6.9)


I-160
0.99-1.04m, 9H), 1.38-1.51m, 2H), 1.63-1.73m, 4H), 



1.82-1.91m, 2H), 2.29m, 1H), 2.60t, J = 6.0 Hz, 2H), 



2.74t, J = 6.0 Hz, 2H), 3.74s, 3H), 4.01-4.10m, 2H), 



4.66m, 1H), 8.21s, 1H), 10.43d, 1H, J = 8.4 Hz)


I-161
1.00-1.04m, 6H), 1.09-1.90m, 15H), 2.29m, 1H), 2.61 



(t, 2H, J = 6.0 Hz), 2.73t, 2H, J = 6.0 Hz), 3.75s, 3H), 



3.84-4.06m, 2H), 4.65m, 1H), 8.21s, 1H), 10.44d, 1H, 



J = 7.8 Hz)


I-162
0.94-1.01m, 9H), 1.39-1.51m, 2H), 1.62-1.79m, 7H), 



1.83-1.91m, 2H), 2.29m,1H), 2.60t, 2H, J = 6.0 Hz), 2.74 



(t, 2H, J = 6.0 Hz), 3.74s, 3H), 3.98-4.10m, 2H), 4.76m, 



1H), 8.21s, 1H), 10.27d, 1H, J = 7.2 Hz)


I-163
0.94-0.98m, 6H), 1.00-1.25m, 6H), 1.58-190m, 12H), 2.61 



(t, 2H, J = 6.0 Hz), 2.71t, 2H, J = 6.0 Hz), 3.74s, 3H), 3.82-



4.12m, 2H), 4.75m, 1H), 8.22s, 1H), 10.26d, 1H, J = 



7.2 Hz)


I-164
1.03(d, 6H, J = 6.6), 1.36-1.79(m, 8H), 2.28(m, 1H), 2.64(t, 



2H, J = 6.3), 2.86(t, 2H, J = 6.3), 3.74(s, 3H), 4.65(m, 1H), 



4.85(br, 2H), 4.96(d, 1H, J = 17.1), 5.21(d, 1H, J = 13.5), 



5.98(m, 1H), 8.32(s, 1H), 10.35(d, 1H, J = 7.8)

















TABLE 258





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-165
1.03(d, 3H, J = 6.9), 1.04(d, 3H, J = 6.9), 1.30-1.79(m, 9H), 



2.00-2.39(m, 2H), 2.63(t, 2H, J = 6.0), 2.99-3.16(m, 2H), 



3.75(s, 3H), 3.70-3.82(m, 2H), 4.03-4.37(m, 4H), 4.67(dd, 



1H, J = 5.4 and 7.8), 4.99(t, 1H, J = 5.4), 8.29(s, 1H), 



10.33(d, 1H, J = 7.8)


I-166
1.00(d, 3H, J = 6.9), 1.01(d, 3H, J = 6.9), 1.36-1.77(m, 8H), 



2.27(m, 1H), 2.63-2.76(m, 4H), 3.74(s, 3H), 4.66(dd, 1H, 



J = 5.1 and 8.1), 4.98(ABq, 2H, J = 17.7), 8.36(s, 1H), 



9.70(s, 1H), 10.08(d, 1H, J = 7.8)


I-167
0.99t, 3H, J = 7.2 Hz), 1.38-1.50m, 2H), 1.60-1.76m, 



4H), 1.83-1.90m, 2H), 2.59t, 2H, J = 6.0 Hz), 2.73(t, 



2H, J = 6.0 Hz), 3.11-3.27m, 2H), 3.68s, 3H), 4.06-



4.01m, 2H), 4.97m, 1H), 7.18-7.29m, 5H), 8.17s, 



1H), 10.48d, 1H, J = 7.5 Hz)


I-168
1.00-1.30m, 6H), 1.58-1.89m, 9H), 2.62t, 2H, J = 



6.0 Hz), 2.70t, 2H, J = 6.0 Hz), 3.11-3.27m,2H), 



3.69s, 3H), 3.78-4.14m, 2H), 4.96m, 1H), 7.16-



7.28m, 5H), 8.17s, 1H), 10.48d, 1H, J = 7.8 Hz)


I-169
0.92-1.03m, 9H), 1.23-1.91m, 10H), 2.04m, 1H), 



2.60t, 2H, J = 6.0 Hz), 2.74t, 2H, J = 6.0 Hz), 3.74 



(s, 3H), 4.00-4.08m, 2H), 4.72m, 1H), 8.21s, 1H), 



10.43d, 1H, J = 8.1 Hz)


I-170
0.92-1.00m, 6H), 1.02-1.94m, 17H), 2.04m,1H), 



2.61t, 2H, J = 6.0 Hz), 2.71t, 2H, J = 6.0 Hz), 3.74 



(s, 3H), 3.80-4.17m, 2H), 4.72m, 1H), 8.21s, 1H), 



10.43d, 1H, J = 8.1 Hz)


I-171
1.02(d, 6H, J = 6.6), 1.30-1.779(m, 8H), 2.28(m, 1H), 



2.64(t, 2H, J = 6.0), 3.06(t, 2H, J = 6.3), 3.74(s, 3H), 



3.86-4.05(m, 4H), 4.40(br, 2H), 4.66(dd, 1H, J = 5.4



and 7.8), 5.21(t, 1H, J = 4.5), 8.31(s, 1H), 10.32(d, 



1H, J = 8.4)


I-172
1.01(d, 3H, J = 6.6), 1.03(d, 3H, J = 6.6), 1.05-1.30(m, 



4H), 1.50-1.90(m, 11H), 2.30(m, 1H), 2.67-2.71(m, 



2H), 2.91-2.95(m, 2H), 3.74(s, 3H), 3.98(br, 2H), 



4.65(dd, 1H, J = 5.4 and 8.4), 8.26(s, 1H), 10.43(d, 1H, 



J = 8.4)


I-173
1.00-1.30(m, 6H), 1.50-1.97(m, 11H), 2.66-2.70(m, 2H), 



2.89-2.95(m, 2H), 3.74(s, 3H), 4.22(br, 2H), 5.76(d, 1H, 



J = 8.4), 7.32-7.40(m, 3H), 7.47-7.53(m, 2H), 8.25(s, 1H), 



10.88(d, 1H, J = 6.6)


I-174
0.99(t, 3H, J = 8.4), 1.20-2.32(m, 20H), 2.60-2.77(m, 2H), 



2.85-3.00(m, 2H), 3.71(s, 3H), 4.18(br, 2H), 8.25(s, 1H), 



10.36(br s, 1H)


I-175
0.99-1.95(m, 25H), 2.10-2.23(m, 2H), 2.60-2.75(m, 2H), 



2.85-2.96(m, 2H), 3.72(s, 3H), 4.13(br, 2H), 8.25(s, 1H), 



10.37(br s, 1H)


I-179
0.97(t, 3H, J = 7.5), 1.20-1.90(m, 16H), 2.70(brt, 2H), 



2.93(brt, 2H), 3.75(s, 3H), 4.13(br, 2H), 5.74(d, 1H, J = 



6.9), 7.28-7.51(m, 5H), 8.31(s, 1H), 10.93(d, 1H, J = 6.9)


I-177
0.98(t, 3H, J = 7.5), 1.03(d, 3H, J = 6.9), 1.04(d, 3H, J = 



6.9), 1.22-1.90(m, 16H), 2.30(m, 1H), 2.71(brt, 2H), 



2.94(brt, 2H), 3.75(s, 3H), 4.16(br, 2H), 4.66(dd, 1H, J = 



5.1 and 8.1), 8.31(s, 1H), 10.48(d, 1H, J = 8.1)

















TABLE 259





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-178
0.98(t, 3H, J = 7.2), 1.02(d, 3H, J = 6.9), 1.03(d, 3H, J = 6.9), 



1.36-1.48(m, 2H), 1.67-1.78(m, 2H), 2.13-2.34(m, 3H), 2.83(t, 



2H, J = 7.5), 3.00(t, 2H, J = 7.5), 3.74(s, 3H), 3.93-4.09(m, 2H), 



4.66(dd, 1H, J = 5.1 and 8.1), 8.37(s, 1H), 10.43(d, 1H, J = 8.1)


I-179
0.99(t, 3H, J = 7.2), 1.02(d, 3H, J = 7.2), 1.03(d, 3H, J = 7.2), 



1.39-1.51(m, 2H), 1.63-1.75(m, 2H), 2.29(m, 1H), 2.82(brt, 2H), 



3.75(s, 3H), 3.98-4.08(m, 4H), 4.58(s, 2H), 4.66(dd, 1H, J = 5.1 



and 8.1), 8.15(s, 1H), 10.35(d, 1H, J = 8.1)


I-181
1.00-1.30(m, 10H), 1.45-1.93(m, 9H), 2.48(q, 2H, J = 7.5), 



2.67(t, 2H, J = 8.1), 3.74(s, 3H), 3.99(br, 2H), 5.72(d, 1H, J = 



6.9), 7.25-7.40(m, 3H), 7.47-7.53(m, 2H), 8.32(s, 1H), 



10.88(d, 1H, J = 6.6)


I-183
DMSO-d6 1.17-1.80(m, 16H), 2.00-2.10(br, 2H), 2.67(brt, 



2H), 3.05(brt, 2H), 5.41(brs, 2H), 6.35(d, 1H, J = 3.3), 6.43(dd, 



1H, J = 1.8 and 3.3), 7.61(dd, 1H, J = 0.9 and 1.8), 8.13(s, 1H), 



10.16(s, 1H), 12.21(brs, 1H)


I-186
0.99t, 3H, J = 7.2 Hz), 1.34-1.51m, 2H), 1.62s, 6H), 1.83-



1.91m, 2H),2.59t, 2H, J = 6.0 Hz), 2.74t, 2H, J = 6.0 Hz), 



3.74s, 3H), 4.01-4.06m, 2H), 8.20s, 1H), 10.30s,1H)


I-187
1.00-1.30m, 6H), 1.62s, 6H), 1.60-1.92m, 9H), 2.60t, 2H, 



J = 6.3 Hz), 2.71t, 2H, J = 6.3 Hz), 3.74s, 3H), 3.80-4.00m, 



2H), 8.20s, 1H), 10.28s, 1H)


I-188
0.98t, 3H, J = 7.2 Hz), 1.37-1.61m, 2H), 1.61-1.76m, 4H), 



1.83-1.91m, 2H), 2.59t, 2H, J = 6.0 Hz), 2.74t, 2H, J = 6.0 



Hz), 3.74s, 3H), 4.02-4.07m, 2H), 5.73d, 1H, J = 6.6 Hz), 



7.30-7.52m, 5H), 8.19s, 1H), 10.90d, 1H, J = 6.9 Hz)


I-189
1.00-1.30m, 6H), 1.54-1.94m, 9H), 2.60t, 2H, J = 6.3 Hz), 



2.71t, 2H, J = 6.3 Hz), 3.74s, 3H), 3.80-4.05m, 2H), 5.73 



(d, 1H, J = 6.3 Hz), 7.28-7.53m, 5H), 8.20s, 1H), 10.88d, 



1H, J = 6.6 Hz)


I-193
2.15(s, 3H), 2.29(s, 3H), 3.74(s, 3H), 5.45-5.50(br, 2H), 5.73(d, 



1H, J = 6.6), 6.98-7.14(m, 4H), 7.26-7.40(m, 3H), 7.46-7.52(m, 



2H), 8.36(s, 1H), 10.76(d, 1H, J = 6.6)


I-194
1.20-1.40(m, 2H), 1.40-1.76(m, 7H), 1.80-1.96(m, 2H), 2.14-



2.25(m, 4H), 2.29(s, 3H), 3.74(s, 3H), 5.44(br s, 2H), 7.00-



7.18(m, 4H), 8.36(s, 1H), 10.26(br s, 1H)


I-196
1.02(d, 6H, J = 6.6), 1.14(t, 3H, J = 7.5), 2.18(s, 3H), 2.25(m, 



1H), 2.64(q, 2H, J = 7.5), 3.74(s, 3H), 4.65(dd, 1H, J = 5.1 



and 8.1), 5.64(br, 2H), 6.96-7.16(m, 4H), 8.38(s, 1H), 



10.30(d, 1H, J = 8.1)


I-197
0.98-1.06(m, 6H), 1.19(t, 3H, J = 7.5), 1.45-1.60(m, 2H), 



2.28(m, 1H), 2.44-2.60(m, 5H), 3.74(s, 3H), 4.65(dd, 1H, 



J = 5.4 and 8.1), 5.42(br, 2H), 6.96-7.12(m, 4H), 8.43(s, 



1H), 10.31(d, 1H, J = 8.1)


I-198
1.00t, 3H, J = 7.2 Hz), 1.24-1.96m, 16H), 2.17-2.21m, 



2H), 2.59t, 2H, J = 6.0 Hz), 2.74t, 2H, J = 6.0 Hz), 



3.71s, 3H), 4.02-4.08m, 2H), 8.19s, 1H), 10.37s, 1H)

















TABLE 260





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-199
1.01-1.40 (m, 6H), 1.50-1.96 (m, 17H), 2.16-2.20 (m, 2H), 



2.59 (t, 2H, J = 6.0 Hz), 2.69 (t, 2H, J = 6.0 Hz), 3.72 (s, 3H), 



3.80-4.05 (m, 2H), 8.19 (s, 1H), 10.38(s, 1H)


I-200
0.96 (t, 3H, J = 7.2 Hz), 1.37-1.42 (m, 2H), 1.62-1.80 (m, 4H), 



1.83-1.93 (m, 2H), 2.60 (t, 2H, J = 6.0 Hz), 2.75 (t, 2H, J = 



6.0 Hz), 3.18 (s, 3H), 4.03-4.09 (m, 2H), 5.58 (d, 1H, J = 6.3 



Hz), 6.61-7.25 (m, 4H), 8.21 (s, 1H), 10.84 (d, 1H, J = 6.6 Hz)


I-201
DMSO-d6 0.90-1.20 (m, 6H), 1.44-1.84 (m, 9H), 2.58 (t, 2H, 



m, J = 5.7 Hz), 2.78 (t, 2H, J = 5.7 Hz), 3.62 (s, 3H), 3.75-4.02 



(m, 2H), 5.40 (d, 1H, J = 6.3 Hz), 6.76-7.22 (m, 4H), 8.04 (s, 



1H), 9.66 (br, 1H), 10.53 (d, 1H, J = 6.6 Hz)


I-205
1.00(t, 3H, J = 7.5), 1.08(t, 3H, J = 7.5), 1.18(t, 3H, J = 7.5), 



1.39-1.76(m, 6H), 1.61(s, 6H), 2.47(q, 2H, J = 7.5), 2.60-



2.69(m, 2H), 3.74(s, 3H), 4.00-4.13(m, 2H), 8.32(s, 1H), 



10.31(s, 1H)


I-206
1.05(t, 3H, J = 7.5), 1.18(t, 3H, J = 7.5), 1.00-1.31(m, 4H), 



1.45-1.94(m, 9H), 1.61(s, 6H), 2.48(q, 2H, J = 7.5), 2.63-



2.73(m, 2H), 3.75(s, 3H), 3.98(br, 2H), 8.32(s, 1H), 



10.28(s, 1H)


I-207
0.96 (m, 9H), 1.38-1.63 (m, 2H), 1.62-1.92 (m, 4H), 1.82-



1.93 (m, 2H, 2.29 (m,1H), 2.60 (t, 2H, J = 6.0 Hz), 2.72 (t, 



2H, J = 6.0 Hz), 3.74 (s, 3H), 4.00-4.13 (m, 2H), 4.66 (m,



1H), 8.21 (s, 1H), 10.44 (d, 1H, J = 8.1 Hz)


I-208
1.00-1.04 (m, 6H), 1.05-1.30 (m, 6H), 1.56-1.93 (m, 9H), 



2.29 (m,1H), H), 2.61 (t, 2H, J = 6.0 Hz), 2.71 (t, 2H, J = 



6.0 Hz), 3.74 (s, 3H), 3.80-4.08 (m, 2H), 4.65 (m, 1H), 



8.21 (s, 1H), 10.44 (d, 1H, J = 7.8 Hz)


I-211
1.00(t, 3H, J = 7.5), 1.08(s, 9H), 1.08(t, 3H, J = 7.5), 1.17(t, 



3H, J = 7.5), 1.38-1.78(m, 6H), 2.48(q, 2H, J = 7.5), 2.60-



2.69(m, 2H), 3.73(s, 3H), 4.01-4.15(m, 2H), 4.54(d, 1H, J = 



8.4), 8.32(s, 1H), 10.58(d, 1H, J = 8.4)


I-212
0.98-1.31(m, 4H), 1.05(t, 3H, J = 7.5), 1.08(s, 9H), 1.18(t, 3H, 



J = 7.5), 1.45-1.90(m, 9H), 2.48(q, 2H, J = 7.5), 2.62-2.73(m, 



2H), 3.73(s, 3H), 3.98(br, 2H), 4.53(d, 1H, J = 8.1), 8.32(s, 



1H), 10.58(d, 1H, J = 8.1)


I-213
1.01 (t, 3H, J = 7.2 Hz), 1.18 (t, 3H, J = 7.5 Hz), 1.45-1.56 (m, 



2H), 2.45-2.60 (m, 4H), 3.73 (s, 3H), 5.25-5.58 (m, 2H), 



5.72 (d, 1H, J = 6.3 Hz), 6.98-7.50 (m, 9H), 8.42 (s, 1H), 



10.75 (d, 1H, J = 6.6 Hz)


I-214
1.14 (t, 3H, J = 7.5 Hz), 2.18 (s, 3H), 2.64 (dd, 2H, J = 7.5 



and 17.1 Hz), 3.73 (s, 3H), 5.25-5.56 (m, 2H), 5.72 (d, 1H, 



J = 6.6 Hz), 6.98-7.50 (m, 9H), 8.37 (s, 1H), 10.74 (d, 1H, 



J = 6.6 Hz)


I-215
2.17 (s, 3H), 2.28 (s, 3H), 3.74 (s, 3H), 5.40-5.70 (m, 2H), 



5.72 (d, 1H, J = 6.6 Hz), 7.20-7.60 (m, 9H), 8.39 (s, 1H), 



10.71 (d, 1H, J = 6.9 Hz)


I-216
1.37-1.81(m, 8H), 1.61(s, 6H), 2.62(t, 2H, J = 6.0), 2.85(t, 



2H, J = 6.3), 3.75(s, 3H), 4.82(br, 2H), 4.93(, d, 1H, J = 



17.1), 5.22(d, 1H, J = 10.5), 5.99(m, 1H), 8.31(s, 1H), 



10.24(s, 1H)

















TABLE 261





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-217
1.22-1.84(m, 8H), 1.62(s, 6H), 2.66(t, 2H, J = 6.0), 2.99(brt, 



2H), 3.54(dd, 1H, J = 3.6 and 11.7), 3.68(dd, 1H, J = 4.2 and 



12.0), 3.75(s, 3H), 3.96(m, 1H), 4.21(dd, 1H, J = 6.6 and 14.4), 



4.44(dd, 1H, J = 6.0 and 14.4), 8.33(s, 1H), 10.06(s, 1H)


I-218
1.40-1.90(m, 8H), 1.63(s, 6H), 2.58-3.10(m, 4H), 3.76(s, 



3H),4.26(dd, 1H, J = 6.9 and 14.4), 4.35(dd, 1H, J = 7.5 and 



9.3), 4.58(dd, 1H, J = 3.0 and 14.4), 4.74(dd, 1H, J = 8.1 and 



9.0), 5.09(m, 1H), 8.34(s, 1H), 10.03(s, 1H)


I-219
0.92-1.00(m, 6H), 1.00(t, 3H, J = 7.2), 1.08(t, 3H, J = 7.2), 



1.18(t, 3H, J = 7.5), 1.39-1.85(m, 9H), 2.48(q, 2H, J = 7.5), 



2.60-2.70(m, 2H), 3.73(s, 3H), 3.96-4.18(m, 2H), 4.75(q, 1H, 



J = 7.2), 8.33(s, 1H), 10.27(d, 1H, J = 7.5)


I-220
1.00(t, 3H, J = 7.5, 1.08(t, 3H, J = 7.5), 1.17(t, 3H, J = 7.5), 



1.38-1.76(m, 6H), 2.47(q, 2H, J = 7.5), 2.60-2.68(m, 2H), 



3.10-3.17(m, 2H), 3.68(s, 1H), 3.98-4.13(m, 2H), 4.96(q, 2H, 



J = 7.2), 7.17-7.31(m, 5H), 8.29(s, 1H), 10.48(d, 1H, J = 7.5)


I-221
1.36-2.04(m, 10H), 1.62(8,6H), 2.62(t, 2H, J = 6.0), 2.91(t, 



2H, J = 6.3), 3.46(t, 2H, J = 6.3), 3.75(s, 3H), 4.20(brt, 2H), 



8.28(s, 1H), 10.26(s, 1H)


I-222
0.91-1.05(m, 9H), 1.08(t, 3H, J = 7.5), 1.18(t, 3H, J = 7.5), 



1.22-1.78(m, 8H), 2.04(m, 1H), 2.48(q, 2H, J = 7.5), 2.61-



2.69(m, 2H), 3.74(s, 3H), 4.00-4.18(m, 2H), 4.72(dd, 1H, 



J = 5.4 and 8.1), 8.33(s, 1H), 10.43(d, 1H, J = 7.5)


I-223
2.14 (s, 3H), 2.30 (s, 3H), 3.74 (s, 3H), 5.33-5.50 (m, 2H), 



5.73 (d, 1H, J = 6.9 Hz), 6.82-7.51 (m, 9H), 8.35 (s, 1H), 



10.82 (d, 1H, J = 6.3 Hz)


I-224
1.14 (t, 3H, J = 7.8 Hz), 1.23-2.24 (m, 10H), 2.17 (s, 3H), 



2.63 (dd, 2H, J = 7.5 and 15 Hz), 3.73 (s, 3H), 5.30-5.55 



(m, 2H), 6.99-7.10 (m, 4H), 8.37 (s, 1H), 10.24 (s, 1H)


I-225
1.01 (t, 3H, J = 7.5 Hz), 1.19 (t, 3H, J = 7.5 Hz), 1.23-



1.70 (m, 8H), 1.80-1.93 (m, 2H), 2.14-2.23 (m, 2H), 



2.44-2.59 (m,4H), 3.74 (s, 3H), 5.42 (br, 2H), 7.00-7.10 



(m, 4H), 8.42 (s, 1H), 10.26 (s, 1H)


I-226
1.32-1.96(m, 10H), 1.46(s, 9H), 1.62(s, 6H), 2.61(t, 2H, 



J = 6.0), 2.88(t, 2H, J = 6.3), 3.20(brq, 2H), 3.75(s, 3H), 



4.18(brt, 2H), 5.15(br, 1H), 8.27(s, 1H), 10.27(s, 1H)


I-227
1.32-2.00(m, 10H), 1.64(s, 6H), 2.05(s, 3H), 2.62(t, 2H, 



J = 6.0), 2.89(t, 2H, J = 6.3), 3.27(brq, 2H), 3.76(s, 3H), 



4.21(brt, 2H), 6.65(br, 1H), 8.30(s, 1H), 10.27(s, 1H)


I-228
1.35(t, 3H, J = 7.2), 1.40-1.92(m, 10H), 1.61(s, 6H), 



2.59(t, 2H, J-6.9), 2.84(t, 2H, J = 6.3), 3.00(brq, 2H), 



3.60(br, 1H), 3.75(s, 3H9, 4.02-4.30(m, 4H), 7.40-



7.85(m, 5H), 8.26(s, 1H), 10.25(s, 1H)


I-229
0.92-1.31(m, 4H), 0.97(t, 6H, J = 6.0), 1.06(t, 3H, J = 



7.5), 1.18(t, 3H, J = 7.5), 1.46-1.93(m, 12H), 2.49(q, 2H, 



J = 7.5), 2.63-2.73(m, 2H), 3.74(s, 3H), 3.78-4.15(br, 2H), 



4.75(q, 1H, J = 7.5), 8.34(8, 1H), 10.26(d, 1H, J = 7.2)

















TABLE 262





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-230
1.02-1.31(m, 4H), 1.06(t, 3H, J = 7.5), 1.18(t, 3H, J = 7.5), 



1.45-1.88(m, 9H), 2.47(q, 2H, J = 7.5), 2.58-2.74(m, 2H), 



3.10-3.28(m, 2H), 3.68(s, 3H), 3.70-4.20(br, 2H), 4.96(q, 



1H, J = 7.5), 7.15-7.30(m, 5H), 8.29(s,1H), 10.49(d, 1H, 



J = 7.5)


I-231
2.15 (s, 3H), 2.28 (s, 3H), 3.74 (s, 3H), 5.43 (br, 2H), 5.72 



(d, 1H, J = 6.6 Hz), 7.02-7.51 (m, 9H), 8.37 (s, 1H), 10.75 



(d, 1H, J = 6.3 Hz)


I-232
2.17 (s, 3H), 2.28 (s, 3H), 3.74 (s, 3H), 5.45 (br, 2H), 5.73 



(d, 1H, J = 6.3 Hz), 6.90-7.52 (m, 9H), 8.38 (s, 1H), 10.37 



(d, 1H, J = 6.0 Hz)


I-233
0.98-1.30 (m, 6H), 1.55-1.96 (m, 9H), 2.59 (t, J = 6.0 Hz, 



2H), 2.70 (t, J = 6.0 Hz, 2H), 3.73 (s, 3H), 3.79 (s, 3H), 



3.85-4.05 (m, 2H), 5.65 (d, J = 6.6 Hz, 1H), 6.88-7.45 (m, 



4H), 8.19 (s, 1H), 10.80 (d, J = 6.9 Hz, 1H)


I-234
2.18 (s, 3H), 2.23(s, 3H), 3.73 (s, 3H), 5.46-5.58 (m, 2H), 



5.72 (d, 1H, J = 6.6 Hz), 6.62-7.50 (m, 9H), 8.41 (s, 1H), 



10.71 (d, 1H, J = 6.6 Hz)


I-236
1.02(d, 3H, J = 6.9), 1.03(d, 3H, J = 6.9), 1.34-1.56(m, 



4H), 1.64-1.83(m, 4H), 2.29(m, 1H), 2.65(t, 2H, J = 6.0), 



2.91-3.03(m, 4H), 3.75(s, 3H), 4.42(t, 2H, J = 6.6), 4.67(dd, 



1H, J = 5.1 and 8.1), 8.33(s, 1H), 10.18(d, 1H, J = 8.1)


I-237
1.32-1.56(m, 4H), 1.56-1.84(m, 4H), 2.64(t, 2H, J = 6.0), 2.90-



3.06(m, 4H), 3.75(s, 3H), 4.41(t, 2H, J = 6.6), 5.74(d, 1H, J = 



6.9), 7.28-7.44(m, 3H), 7.45-7.53(m, 2H), 8.32(s, 1H), 



10.66(d, 1H, J = 6.9)


I-238
1.02(dd, 6H, J = 1.5 and 6.9), 1.30-1.54(m, 4H), 1.64-



1.84(m, 4H), 1.95-2.07(m,2H), 2.29(m, 1H), 2.64(t, 2H,J = 



6.3), 2.84-2.95(m, 2H), 2.96(s, 3H), 3.00-3.22(m, 2H), 



3.75(s, 3H), 4.16-4.50(m, 2H), 4.67(dd, 1H, J = 5.1 and 



8.1), 5.92(t, 1H, J = 6.0), 8.32(s, 1H), 10.29(d, 1H, J = 8.1)


I-239
1.32-1.54(m, 4H), 1.58-1.84(m, 4H), 1.94-2.06(m,2H), 



2.63(t, 2H, J = 5.7), 2.84-2.96(m, 2H), 2.90(s, 3H), 3.00-



3.16(m, 2H), 3.74(s, 3H), 4.18-4.42(m, 2H), 5.75(d, 1H, 



J = 7.2), 5.83(m, 1H), 7.28-7.50(m, 5H), 8.31(s, 1H), 



10.78(d, 1H, J = 7.2)


I-240
1.32-1.54(m, 4H), 1.60-1.84(m, 4H), 1.62(s, 6H), 1.95-



2.06(m,2H), 2.62(t, 2H,J = 6.0), 2.86-2.94(m, 2H), 



2.97(s, 3H), 3.06-3.18(m, 2H), 3.76(s, 3H), 4.24-4.36(m, 



2H), 5.74(t, 1H, J = 6.0), 8.30(s, 1H), 10.17(s, 1H)


I-241
0.93-1.04 (m, 15H), 1.40-1.78 (m, 10H), 2.28 (m, 1H), 



2.38-2.46 (m, 2H), 2.62-2.71 (m, 2H), 3.74 (s, 3H), 



4.00-4.16 (m, 2H), 4.66 (m, 1H), 8.29 (s, 1H), 10.43 



(d, 1H, J = 7.8 Hz)


I-242
0.93-1.04 (m, 9H), 1.38-1.78 (m, 10H), 2.38-2.46 (m, 



2H), 2.62-2.72 (m, 2H), 3.74 (s, 3H), 4.04-4.16 (m, 



2H), 5.74 (d, 1H, J = 6.6 Hz), 7.25-7.55 (m, 5H), 8.28 



(s, 1H), 10.89 (d, 1H, J = 6.9 Hz)


I-245
0.93-1.02 (m, 9H), 1.61 (s, 6H), 1.40-1.77 (m, 10H), 



2.38-2.45 (m, 2H), 2.62-2.72 (m, 2H), 3.74 (s, 3H), 4.04-



4.16 (m, 2H), 8.28 (s, 1H), 10.30 (s, H)


I-246
0.93-1.03 (m, 9H), 1.22-1.78 (m, 16H), 1.82-1.94 (m, 2H), 



2.14-2.26 (m, 2H), 2.36-2.45 (m, 2H), 2.62-2.70 (m, 2H), 



3.72 (s, 3H), 4.02-4.16 (m, 2H), 8.27 (s, 1H), 10.37 (s, 1H)

















TABLE 263





Comp.
1H-NMR(CDCL3/TMS)


No.
δ







I-247
1.32-1.54(m, 4H), 1.61-1.82(m, 4H), 1.85-1.96(m,2H), 



2.01(s, 3H), 2.58-2.66(m, 2H), 2.85-2.94(m, 2H), 3.21-



3.33(m, 2H), 3.75(s, 3H), 4.16-4.32(m, 2H), 5.74(d, 1H, 



J = 6.9), 6.82(m, 1H), 7.28-7.53(m, 5H), 8.30(s, 1H), 



10.85(d, 1H, J = 6.9)


I-249
1.00(d, 3H, J = 6.9), 1.01(d, 3H, J = 6.9), 1.36-1.56(m, 



4H), 1.62-1.78(m, 4H), 2.27(m, 1H), 2.65(t, 2H, J = 6.0), 



2.73(t, 2H, J = 6.0), 3.75(s, 3H), 4.66(dd, 1H, J = 5.1 and 



8.1), 5.52(br, 2H), 7.20(d, 2H, J = 8.4), 7.63(d, 2H, J = 



8.4), 8.40(s, 1H), 10.20(d, 1H, J = 8.1)


I-250
1.45-1.56(m, 4H), 1.58-1.78(m, 4H), 2.65(t, 2H, J = 6.0), 



2.73(t, 2H, J = 6.0), 3.75(s, 3H), 5.48(br, 2H), 5.72(d, 



1H, J = 6.9), 7.18(d, 2H, J = 8.1), 7.26-7.40(m, 3H), 7.42-



7.51(m, 2H), 7.61(d, 2H, J = 8.1), 8.38(s, 1H), 10.65(d, 



1H, J = 6.6)


I-251
1.32-1.53(m, 4H), 1.60-1.80(m, 4H), 1.63(s, 6H), 1.86-



1.97(m, 2H), 2.57-2.95(m, 2H), 2.84-2.93(m, 2H), 3.18-



3.29(m, 2H), 3.69(s, 3H), 3.76(s, 3H), 4.15-4.27(m, 2H), 



5.50(m, 1H), 8.28(s, 1H), 10.24(s,1H)


I-256
1.02(d, 3H, J = 6.9), 1.03(d, 3H, J = 6.9), 1.06-1.30(m, 5H), 



1.57-1.91(m, 6H), 2.29(m, 1H), 2.94(brt, 2H), 3.02(brt, 2H), 



3.66(s, 2H), 3.75(s, 3H), 4.01(br, 2H), 4.66(dd, 1H, J = 5.4 



and 8.1), 8.24(s, 1H), 10.34(d, 1H, J = 8.1)


I-257
1.01(d, 3H, J = 6.9), 1.02(d, 3H, J = 6.9), 1.06-1.31(m, 5H), 



1.56-1.90(m, 6H), 2.29(m, 1H), 3.31(brt, 2H), 3.45(brt, 2H), 



3.76(s, 3H), 4.03(br, 2H), 4.11(d, 1H, J = 18.0), 4.17(d, 1H, 



J = 18.0), 4.65(dd, 1H, J = 5.1 and 8.1), 8.15(s, 1H), 10.13(d, 



1H, J = 8.1)


I-258
1.00-1.32(m, 11H), 1.58-1.94(m, 6H), 2.29(m, 1H), 2.87(m, 



1H), 3.08(m, 1H), 3.29(m, 1H), 3.45(m, 1H), 3.75(s, 3H), 



3.84(m, 2H), 4.06(m, 2H), 4.65(dd, 1H, J = 5.1 and 8.1), 



8.22(s, 1H), 10.20(brm, 1H)


I-261
1.34-1.54(m, 4H), 1.60(s, 6H), 1.62-1.78(m, 4H), 2.63(t, 



2H, J = 6.0), 2.73(t, 2H, J = 6.0), 3.75(s, 3H), 5.42(br, 2H), 



7.18(d, 2H, J = 8.4), 7.64(d, 2H, J = 8.4), 8.37(s, 1H), 



10.08(br s, 1H)


I-266
1.02(d, 6H, J = 6.9), 1.34-1.56(m, 4H), 1.62-1.85(m, 4H), 



2.05-2.17(m, 2H), 2.28(m, 1H), 2.53(t, 2H, J = 6.9), 



2.63(t, 2H, J = 6.0), 2.91(t, 2H, J = 6.0), 3.75(s, 3H), 



4.26(t, 2H, J = 7.5), 4.67(dd, 1H, J = 5.1 and 8.1), 8.03(s, 



1H), 10.30(d, 1H, J = 8.1)


I-267
1.34-1.56(m, 4H), 1.62-1.85(m, 4H), 2.05-2.17(m, 2H), 



2.53(t, 2H, J = 6.9), 2.63(t, 2H, J = 6.0), 2.91(t, 2H, J = 



6.0), 3.75(s, 3H), 4.26(t, 2H, J = 7.5), 5.74(d, 1H, J = 6.9), 



7.20-7.39(m, 3H), 7.45-7.53(m, 2H), 8.03(s, 1H), 10.78(d, 



1H, J = 8.1)


I-271
1.02(d, 6H, J = 7.2), 1.32-1.58(m, 4H), 1.60-1.96(m, 10H), 



2.28(m, 1H), 2.46(t, 2H, J = 6.9), 2.58-2.68(m, 2H), 



2.89-3.00(m, 2H), 3.75(s, 3H), 4.10-4.24(m, 2H), 4.67(dd, 



1H, J = 5.1 and 8.1), 8.28(s, 1H), 10.35(d, 1H, J = 8.1)

















TABLE 264





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-272
1.32-1.58(m, 4H), 1.60-1.96(m, 10H), 2.46(t, 2H, J = 6.9), 



2.62(t, 2H, J = 6.6), 2.89(t, 2H, J = 6.6), 3.75(s, 3H), 4.10-



4.24(m, 2H), 5.74(d, 1H, J = 6.6), 7.60-7.41(m, 3H), 7.46-



7.53(m, 2H), 8.27(s, 1H), 10.82(d, 1H, J = 6.9)


I-273
1.14(t, 3H, J = 7.5), 2.19(s, 3H), 2.65(q, 2H, J = 7.5), 



3.75(s, 3H), 5.43(br, 2H), 5.99(d, 1H, J = 6.9), 6.96(dd, 



1H, J = 3.6 and 5.1), 6.98-7.09(m, 4H), 7.14(m, 1H), 



7.24(dd, 1H, J = 1.2 and 5.1), 8.38(s, 1H), 10.72(d, 1H, 



J = 6.9)


I-278
1.34-1.80(m, 8H), 2.62(t-like, 2H), 3.06(t-like, 2H), 



3.74(s, 3H), 5.32(d, 1H, J = 15.9), 5.42(d, 1H, J = 



15.9), 5.72(d, 1H, J = 6.9), 6.31-6.33(m, 2H), 7.28-



7.39(m, 4H), 7.47-7.51(m, 2H), 8.29(s, 1H), 10.76(d, 1H, 



J = 6.9)


I-279
1.28-1.74(m, 8H), 2.59(t-like, 2H), 2.72(t-like, 2H), 



2.99(t-like, 2H), 3.76(s, 3H), 4.31(t-like, 2H), 5.77(d, 



1H, J = 6.9), 6.95-7.03(m, 2H), 7.14-7.21(m, 2H), 7.29-



7.41(m, 3H), 7.49-7.53(m, 2H), 8.29(s, 1H), 10.91(d, 1H, 



J = 6.9)


I-280
1.02(d, 3H, J = 6.6), 1.03(d, 3H, J = 6.6), 1.32-1.52(m, 4H), 



1.60-1.76(m, 4H), 2.28(m, 1H), 2.63(t, 2H, J = 6.0), 2.78(t, 



2H, J = 6.0), 3.74(t, 3H), 4.66(dd, 1H, J = 5.1 and 8.1), 



5.49(br, 2H), 7.07(d, 2H, J = 6.6), 7.23-7.37(m, 3H), 



8.37(s, 1H), 10.37(d, 1H, J = 8.1)


I-281
1.32-1.52(m, 41), 1.60-1.76(m, 4H), 2.63(t, 2H, J = 6.0), 



2.78(t, 2H, J = 6.0), 3.74(t, 3H), 5.49(br, 2H), 5.72(d, 



1H, J = 6.3), 7.05(d, 2H, J = 6.9), 7.21-7.39(m, 6H), 7.45-



7.52(m, 2H), 8.37(s, 1H), 10.37(d, 1H, J = 8.1)


I-282
1.02(d, 6H, J = 6.9), 1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 



2.28(m, 1H), 2.62(t, 2H, J = 6.0), 2.81(t, 2H, J = 6.0), 



3.75(s, 3H), 3.78(s, 3H), 4.66(dd, 1H, J = 5.4 and 7.8), 



5.42(br, 2H), 6.85(d, 2H, J = 8.7), 7.03(d, 2H, J = 8.7), 



8.36(s, 1H), 10.39(d, 1H, J = 8.1)


I-283
1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 2.62(t, 2H, J = 6.0), 



2.81(t, 2H, J = 6.0), 3.73(s, 3H), 3.77(s, 3H), 5.40(br, 2H), 



5.72(d, 1H, J = 6.6), 6.81-6.86(m, 2H), 7.01(d, 2H, J = 8.7), 



7.25-7.39(m, 3H), 7.46-7.52(m, 2H), 8.35(s, 1H), 10.80(d, 



1H, J = 8.1)


I-285
1.34-1.76(m, 8H), 2.64(t-like, 2H), 2.82(t-like, 2H), 



3.74(s, 3H), 5.52(br, 2H), 5.73(d, 1H, J = 6.6), 7.13(d, 



2H, J = 8.1), 7.27-7.56(m, 12H), 8.38(s, 1H), 10.79(d, 



1H, J = 6.6)


I-287
1.01(d, 3H, J = 6.9), 1.02(d, 3H, J = 6.9), 1.32-1.52(m, 



4H), 1.60-1.76(m, 4H), 2.28(m, 1H), 2.64(t, 2H, J = 6.0), 



2.74(t, 2H, J = 6.0), 3.74(s, 3H), 4.66(dd, 1H, J = 5.1 and 



8.1), 5.52(br, 2H), 7.19(d, 2H, J = 8.1), 7.59(d, 2H, J = 8.1),



8.40(s, 1H), 10.26(d, 1H, J = 8.1)


I-288
1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 2.64(t, 2H, J = 6.0), 



2.74(t, 2H, J = 6.0), 3.74(s, 3H), 5.53(br, 2H), 5.72(d, 



1H, J = 6.6), 7.17(d, 2H, J = 6.9), 7.25-7.38(m, 3H), 7.48-



7.52(m, 2H), 7.57(d, 2H, J = 8.1), 8.38(s, 1H), 10.69(d,



1H, J = 6.3)

















TABLE 265





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-289
1.02(d, 6H, J = 6.9), 1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 



2.28(m, 1H), 2.62(t, 2H, J = 6.0), 2.80(t, 2H, J = 6.0), 



3.74(s, 3H), 4.65(dd, 1H, J = 5.1 and 8.1), 5.38(br, 2H), 



5.94(s, 2H), 6.53-6.60(m, 2H), 6.75(d, 1H, J = 8.1),



8.35(s, 1H), 10.33(d, 1H, J = 8.1)


I-290
1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 2.62(t, 2H, J = 6.0), 



2.80(t, 2H, J = 6.0), 3.74(s, 3H), 5.38(br, 2H), 5.72(d, 



1H, J = 6.9), 5.93(s, 2H), 6.48-6.60(m, 2H), 6.75(d, 1H, J = 



8.1), 7.20-7.40(m, 3H), 7.48(d, 2H, J = 6.9), 8.35(s, 1H),



10.77(d, 1H, J = 8.1)


I-292
1.02(d, 6H, J = 6.9), 1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 



2.26(m, 1H), 2.31(s, 3H), 2.62(t, 2H, J = 6.0), 2.80(t, 2H, 



J = 6.0), 3.74(s, 3H), 4.65(dd, 1H, J = 5.1 and 8.1), 5.45(br, 



2H), 6.96(d, 2H, J = 8.1), 7.12(d, 2H, J = 8.1), 8.36(s,



1H), 10.35(d, 1H, J = 8.1)


I-293
1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 2.31(s, 3H), 2.62(t, 2H, 



J = 6.0), 2.80(t, 2H, J = 6.0), 3.74(s, 3H), 5.45(br, 2H), 



5.72(d, 1H, J = 6.6), 6.94(d, 2H, J = 8.1), 7.11(d, 2H, J = 



8.1), 7.26-7.39(m, 3H), 7.44-7.52(m, 2H), 8.35(s, 1H),



10.79(d, 1H, J = 6.9)


I-294
1.02(d, 6H, J = 6.9), 1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 



2.26(m, 1H), 2.63(t, 2H, J = 6.0), 2.77(t, 2H, J = 6.0), 



3.74(s, 3H), 4.65(dd, 1H, J = 5.1 and 8.1), 5.43(br, 2H), 



7.02(d, 2H, J = 8.1), 7.29(t, 2H, J = 8.1), 8.38(s, 1H), 



10.30(d, 1H, J = 8.1)


I-295
1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 2.63(t, 2H, J = 6.0), 



2.77(t, 2H, J = 6.0), 3.74(s, 3H), 5.40(br, 2H), 5.73(d, 1H, 



6.9), 7.00(d, 2H, J = 8.1), 7.25-7.37(m, 5H), 7.45-7.50(m, 



2H), 8.36(s, 1H), 10.73(d, 1H, J = 6.6)


I-298
0.94(d, 3H, J = 6.9), 0.95(d, 3H, J = 6.9), 1.24-1.75(m, 8H), 



2.22(m, 1H), 2.62(t, 2H, J = 6.0), 2.91(t-like, 2H), 3.74(s, 3H), 



4.00(br, 2H), 5.75(d, 1H, J = 6.6), 7.27-7.39(m, 3H), 7.47-



7.51(m, 2H), 8.27(s, 1H), 10.90(d, 1H, J = 6.6)


I-320
1.06-1.80(m, 19H), 2.01(s, 3H), 2.65(t, 2H, J = 6.0), 2.94(t, 



2H, J = 6.0), 3.56(dd, 2H, J = 5.7, 10.8), 3.97-4.18(m, 2H), 



4.17(d, 2H, J = 5.4), 4.27(m, 2H), 6.55(br, 1H), 8.27(s, 1H), 



10.49(t, 1H, J = 5.4)


I-330
1.00(t, 3H, J = 7.5), 1.09(t, 3H, J = 7.5), 1.14(s, 9H), 1.18(t, 



3H, J = 7.5), 1.39-1.75(m, 6H), 2.49(q, 2H, J = 7.5), 2.62-



2.72(m, 2H), 3.77-3.95(m, 4H), 3.96-4.20(m, 2H), 4.36(d, 



1H, J = 6.6), 4.99(m, 1H), 8.29(s, 1H), 10.75(d, 1H,



J = 6.6)


I-347
0.99(t, 3H, J = 7.2), 1.40-1.52(m, 2H), 1.52(d, 3H, J = 7.2), 



1.63-1.74(m, 2H), 2.17(s, 3H), 2.41(s, 3H), 3.75(s, 3H), 



4.10-4.15(m, 2H), 4.73(qd, 1H, J = 7.2 and 7.2), 8.28(s, 



1H), 10.34(d, 1H, J = 7.2)


I-348
DMSO-d6 0.94(t, 3H, J = 7.2), 1.31-1.43(m, 2H), 1.51-



1.61(m, 2H), 2.12(s, 3H), 2.42(s, 3H), 3.02(dd, 1H, J = 



7.2 and 13.8), 3.16(dd, 1H, J = 5.7 and 13.8), 4.00-



4.17(m, 2H), 4.71(m, 1H), 7.15-7.30(m, 5H), 8.09(s, 1H),



10.23(d, 1H, J = 7.8), 12.91(br, 1H)

















TABLE 266





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-349
DMSO-d6 0.92(d, 6H, J = 6.6), 0.95(t, 3H, J = 7.2), 1.33-



1.45(m, 2H), 1.53-1.64(m, 2H), 2.15(s, 3H), 2.16(m, 1H), 



2.44(s, 3H), 4.02-4.20(m, 2H), 4.40(dd, 1H, J = 4.5 and 8.4), 



8.12(s, 1H), 10.28(d, 1H, J = 8.4), 12.75(br, 1H)


I-350
DMSO-d6 0.88-0.97(m, 9H), 1.35-1.45(m, 2H), 1.53-



1.69(m, 2H), 2.14(s, 3H), 2.44(s, 3H), 4.02-4.18(m, 2H), 



4.47(m, 1H), 8.12(s, 1H), 10.16(d, 1H, J = 7.8), 12.73(br, 1H)


I-351
DMSO-d6 0.87-0.97 (m, 9H), 1.19 (m, 1H), 1.33-1.63 (m, 4H), 



1.89 (m, 1H), 2.14 (s, 3H), 2.50 (s, 3H), 4.02-4-19 (m, 2H), 



4.45 (dd, 1H, J = 5.1, 8.4), 8.12 (s, 1H), 10.28 (d, 1H, J = 8.4), 



12.75 (brs, 1H)


I-352
DMSO-d6 0.94(t, 3H, J = 7.2), 1.33-1.45(m, 2H), 1.53-1.63(m, 



2H), 1.89-2.13(m, 2H), 2.04(s, 3H), 2.15(s, 3H), 2.44(s, 3H), 



2.48(t, 2H, J = 7.2), 4.04-4.18(m, 2H), 4.58(m, 1H), 8.12(s, 1H), 



10.25(d, 1H, J = 7.8), 12.90(br, 1H)


I-353
DMSO-d6 0.94(t, 3H, J = 7.2), 1.33-1.45(m, 2H), 1.53-1.63(m, 



2H), 1.89-2.13(m, 2H), 2.04(s, 3H), 2.15(s, 3H), 2.44(s, 3H), 



2.48(t, 2H, J = 7.2), 4.04-4.18(m, 2H), 4.58(m, 1H), 8.12(s, 1H), 



10.25(d, 1H, J = 7.8), 12.90(br, 1H)


I-354
DMSO-d6 0.94(t, 3H, J = 7.2), 1.32-1.44(m, 2H), 1.53-1.63(m, 



2H), 2.15(s, 3H), 2.44(s, 3H), 4.02(d, 2H, J = 5.4), 4.11(t-like, 



2H), 8.12(s, 1H), 10.12(t, 1H, J = 5.4), 12.65(br, 1H)


I-359
DMSO-d6 1.02-1.26(m, 4H), 1.37(d, 3H, J = 7.2), 1.46-1.86(m, 



7H), 2.15(s, 3H), 2.42(s, 3H), 3.90-4.16(m, 2H), 4.41(m, 1H), 



8.12(s, 1H), 10.21(d, 1H, J = 6.9)


I-360
DMSO-d6 0.96-1.20(m, 4H), 1.42-1.80(m, 7H), 2.14(s, 3H), 



2.41(s, 3H), 3.14-3.34(m, 2H), 3.90-4.07(m, 2H), 4.76(m, 1H), 



6.88(m, 1H), 7.03(m, 1H), 7.10(d, 1H, J = 2.7), 7.31(d, 1H, J = 



8.1), 7.48(d, 1H, J = 7.8), 8.12(s, 1H), 10.27(d, 1H, J = 8.1), 



10.85(Br, 1H)


I-361
DMSO-d6 1.00-1.326n, 4H), 1.42-1.82(m, 7H), 2.14(s, 3H), 



2.41(s, 3H), 2.90(dd, 1H, J = 7.2 and 13.8), 3.01(dd, 1H, J = 



5.4 and 13.8), 4.02(br, 2H), 4.60(m, 1H), 6.60(d, 2H, J = 8.4), 



6.93(d, 2H, 8.4), 8.09(s, 1H), 9.20(br s, 1H), 10.20(d, 1H, 



J = 7.8)


I-362
DMSO-d6 1.02-1.32(m, 4H), 1.42-1.85(m, 7H), 2.13(s, 3H), 



2.40(s, 3H), 3.01(dd, 1H, J = 7.5 and 13.5), 3.16(dd, 1H, J = 



5.4 and 13.5), 3.91-4.12(m, 2H), 4.67(m, 1H), 7.12-7.26(m, 5H), 



8.09(s, 1H), 10.23(d, 1H, J = 7.5)


I-365
DMSO-d6 0.92(d, 6H, J = 6.9), 2.15(s, 3H), 2.16(m, 1H), 2.47-



2.58(m, 6H), 3.57(t, 4H, J = 4.2), 4.26(br, 1H), 4.41(dd, 1H, J = 



4.8 and 8.4), 8.14(s,1H), 10.23(d, 1H, J = 8.7)


I-366
DMSO-d6 0.92(d, 6H, J = 6.9), 2.15(s, 3H), 2.16(m, 1H), 2.47-



2.58(m, 6H), 3.57(t, 4H, J = 4.2), 4.26(br, 1H), 4.41(dd, 1H, J = 



4.8 and 8.4), 8.14(s,1H), 10.23(d, 1H, J = 8.7)

















TABLE 267





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-367
DMSO-d6 0.85-1.97(m, 20H), 2.15(s, 3H), 2.42(s, 3H), 



4.02(br, 2H), 4.44(dd, 1H, J = 4.8 and 8.4), 8.12(s, 1H), 



10.26(d, 1H, J = 8.7), 12.72(br, 1H)


I-368
DMSO-d6 1.00-1.29(m, 4H), 1.48-1.88(m, 7H), 2.15(s, 



3H), 2.42(s, 3H), 3.93-4.10(m, 4H), 8.13(s, 1H), 10.10(t, 



1H, J = 5.4), 12.66(br s, 1H)


I-369
DMSO-d6 1.00-1.28(m, 4H), 1.47-1.89(m, 7H), 2.15(s, 



3H), 2.42(s, 3H), 3.67(dd, 1H, J = 3.6 and 10.8), 3.82(dd, 



1H, J = 3.9 and 10.5), 4.02(br, 2H), 4.70(dd, 1H, J = 7.8 



and 8.4), 8.28(s, 1H), 10.40(d, 1H, J = 7.8)


I-370
DMSO-d6 0.85-1.32(m, 10H), 1.46-1.85(m, 10H), 2.15(s, 



3H), 2.41(s, 3H), 4.04(br, 2H), 4.46(m, 1H), 8.13(s, 1H), 



10.15(d, 1H, J = 7.8), 12.72(br, 1H)


I-371
DMSO-d6 1.00-1.32(m, 4H), 1.46-2.20(m, 11H), 2.03(s, 



3H), 2.14(s, 3H), 2.47(s, 3H), 3.94-4.30(m, 2H), 4.56(m, 



1H), 8.12(s, 1H), 10.23(d, 1H, J = 7.5), 12.90(br, 1H)


I-372
DMSO-d6 0.89-0.95(dd, 6H, J = 2.7 and 6.9), 2.16(s, 



3H), 2.31(s, 3H), 4.40(dd, 1H, J = 4.8 and 8.4), 5.38-



5.56(m, 2H), 6.99-7.15(m, 4H), 8.22(s, 1H), 10.18(d, 



1 h, J = 8.1)


I-373
DMS-d6 0.84-0.96(m, 9H), 1.22-1.42(m, 8H), 1.54-



1.66(m, 2H), 2.12-2.24(m, 4H), 2.43(s, 3H), 4.00-



4.18(m, 2H), 4.40(dd, 1H, J = 4.8 and 8.4), 8.12(s, 



1H), 10.27(d, 1H, J = 8.4)


I-374
DMSO-d6 0.91(d, 6H, J = 6.9), 0.96(d, 6H, J = 6.6), 



1.44-1.55(m, 2H), 1.71(m, 1H), 2.08-2.24(m, 4H), 



2.43(s, 3H), 4.00-4.25(m, 2H), 4.40(m, 1H), 8.12(s, 



1H), 10.27(d, 1H, J = 8.1)


I-375
0.98-1.27(m, 4H), 1.55-1.88(m, 8H), 1.88-2.10(m, 



2H), 2.06 and 2.09(s, 3H), 2.28(m, 1H), 2.31 and 



2.33(s, 3H), 3.45(m, 1H), 3.55 and 3.76(s, 3H), 3.72-



4.18(m, 2H), 4.60-4.78(m, 2H), 7.37 and 7.46(s, 1H)


I-376
DMSO-d6 0.94 (t, 3H, J = 7.2), 1.32-1.45 (m, 2H), 



1.47 (s, 6H), 1.52-1.63 (m, 2H), 2.14 (s, 3H), 2.43 



(s, 3H), 4.09 (m, 2H), 8.08 (s, 1H), 10.23 (s, 1H), 



12.37 (brs, 1H)


I-377
DMSO-d6 0.95 (t, 3H, J = 7.2 Hz), 1.22-2.06 (m, 



15H), 2.14 (s, 3H), 2.44 (s, 3H), 4.09-4.14 (m, 2H) , 



8.07 (s, 1H), 10.27 (s, 1H)


I-378
DMSO-d6 0.93(t, 3H, J = 7.2), 1.30-1.42(m, 2H), 



1.49-1.60(m, 2H), 2.13(s, 3H), 2.42(s, 3H), 3.14-3.31(m, 



2), 4.06(t-like, 2H), 4.75(q-like, 1H), 6.91(td, 1H, J = 8.1 and 



1.2), 7.04(td, 1H, J = 8.1 and 1.2), 7.10(d, 1H, J = 2.4), 7.31(d,



1H, J = 8.1), 7.50(d, 1H, J = 8.1), 8.11(s, 1H), 10.86(s, 1H), 



12.82(br, 1H)


I-381
DMSO-d6 0.95(t, 3H, J = 7.2), 1.33-1.45(m, 2H), 1.53-



1.63(m, 2H), 2.14(s, 3H), 2.44(s, 3H), 3.68(dd, 1H, J = 



3.6 and 10.5), 3.83(dd, 1H, J = 3.6 and 10.5), 4.10(t-like, 



2H), 4.47(m, 1H), 8.12(s, 1H), 10.32(d, 1H, J = 7.5), 



12.57(br, 1H)

















TABLE 268





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-382
DMSO-d6 0.94(t, 3H, J = 7.2), 1.31-1.43(m, 2H), 1.51-1.61(m, 



2H), 2.13(s, 3H), 2.42(s, 3H), 2.90(dd, 1H, J = 6.6 and 13.8), 



3.05(dd, 1H, J = 5.1 and 13.8), 4.02-4.17(m, 2H), 4.62(q-like, 



1H), 6.62(d, 2H, J = 8.4), 6.95(d, 2H, J = 8.4), 8.09(s, 1H), 



9.23(br, 1H), 10.18(d, 1H, J = 7.5), 12.79(br, 1H)


I-383
DMSO-d6 1.00-1.32(m, 4H), 1.46-2.20(m, 11H), 2.03(s, 3H), 



2.15(s, 3H), 2.47(s, 3H), 3.94-4.30(m, 2H), 4.56(m, 1H), 



8.12(s, 1H), 10.23(d, 1H, J = 7.5), 12.80(br, 1H)


I-384
DMSO-d6 1.02-1.32(m, 4H), 1.42-1.85(m, 7H), 2.13(s, 3H), 



2.40(s, 3H), 3.01(dd, 1H, J = 7.5 and 13.5), 3.16(dd, 1H, J = 



5.4 and 13.5), 3.91-4.12(m, 2H), 4.67(m, 1H), 7.12-7.26(m, 



5H), 8.09(s, 1H), 10.23(d, 1H, J = 7.5), 12.8(br, 1H)


I-385
DMSO-d6 0.90-0.98(m, 9H), 1.03(t, 3H, J = 7.5), 1.12(t, 3H, 



7.5), 1.36-1.68(m, 6H), 2.18(m, 1H), 2.40-2.50(m, 2H), 2.66-



2.73(m, 2H), 3.94-4.14(m, 2H), 4.00(q, 1H, J = 8.4 and 4.8), 



8.17(s, 1H), 10.27(d, 1H, J = 8.7), 12.70(br, 1H)


I-387
0.93(t, 3H, J = 7.2), 1.22-1.78(m, 12H), 2.63(brt, 2H), 2.89(brt, 



2H), 3.03(dd, 1H, J = 7.8 and 13.8), 3.15(dd, 1H, J = 5.4 and 



13.8), 4.04(brt, 2H), 4.71(m, 1H), 7.16-7.29(m, 5H), 8.08(s, 



1H), 10.23(d, 1H, J = 7.5), 12.89(brs, 1H)


I-388
1.06(d, 6H, J = 6.9), 1.39-2.39(m, 15H), 2.59-2.63(m, 2H), 



2.81-2.85(m, 2H), 3.13-3.24(m, 4H), 3.66-3.76(m, 2H), 



4.59(dd, 1H, J = 5.4, 6.6), 4.72-4.78(m, 2H), 8.27(s, 1H), 



12.12(m, 1H)


I-389
1.05(d, 6H, J = 5.7), 1.26-3.18(m, 25H), 4.57(dd, 1H, J = 



8.1, 5.4), 4.61-4.69(m, 2H), 8.25(s, 1H), 10.18(d, 1H, 



J = 8.1)


I-390
1.24-1.86(m, 14H), 2.61-2.68(m, 2H), 2.95-3.05(m, 8H), 



4.12-4.14(m, 2H), 4.46-4.68(m, 2H), 8.28(s, 1H), 



10.13(s, 1H)


I-391
1.36-2.17(m, 14H), 1.67(s, 6H), 2.64(t, 2H, J = 5.4), 2.87-



3.38(m, 8H), 4.61-4.82(m, 2H), 8.31(s, 1H), 10.40(s, 1H)


I-393
DMSO-d6 0.88-0.97(m, 9H), 1.33-1.45(m, 2H), 1.53-



1.69(m, 2H), 2.14(s, 3H), 2.44(s, 3H), 4.02-4.18(m, 2H), 



4.47(m, 1H), 8.12(s, 1H), 10.17(d, 1H, J = 7.8), 12.73(br, 



1H)


I-394
DMSO-d6 0.94(t, 3H, J = 7.2), 1.31-1.42(m, 2H), 1.51-



1.61(m, 2H), 2.13(s, 3H), 2.42(s, 3H), 3.02(dd, 1H, J = 



7.2 and 13.8), 3.16(dd, 1H, J = 5.7 and 13.8), 4.00-



4.17(m, 2H), 4.71(m, 1H), 7.15-7.30(m, 5H), 8.09(s, 



1H), 10.22(d, 1H, J = 7.8), 12.91(br, 1H)


I-395
0.97(t, 3H, J = 7.2),1.05(d, 3H, J = 6.9), 1.07(d, 3H, J = 



6.9), 1.42(m, 2H), 1.56-1.9(m, 6H), 2.35(m, 1H), 



2.51(t, 2H, J = 6.0), 2.67(t, 2H, J = 6.0), 3.94-3.99(m, 



2H), 4.60(dd, 1H, J = 5.1 and 8.1), 10.88(d, 1H, J = 7.5)


I-396
1.03-1.80(17H, m), 2.04(s, 3H), 2.32(m, 1H), 2.33(s, 3H), 



3.75(s, 3H), 3.95(brs, 1H), 4.58(dd, 1H, J = 5.1 and 8.1), 



10.94(d, 1H, J = 8.1), 15.59(s, 1H)

















TABLE 269





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-398
1.05(d, 6H, J = 6.0), 1.22-3.40(m, 22H), 3.78-4.28(m, 3H), 



4.45-4.69(m, 2H), 4.70(m, 1H), 8.24(s, 1H), 10.30(d, 1H, 



J = 7.8)


I-399
1.05(d, 6H, J = 6.0), 1.22-3.40(m, 22H), 3.78-4.28(m, 3H), 



4.45-4.69(m, 2H), 4.70(m, 1H), 8.24(s, 1H), 10.30(d, 1H, 



J = 7.8)


I-400
1.22-2.37(m, 24H), 2.56-2.67(m, 2H), 3.14-3.38(m, 3H), 



3.75-4.02(m, 2H), 4.68-4.99(m, 2H), 8.33(s, 1H, 10.41(s, 



1H)


I-401
0.78-1.97(m, 17H), 0.99(s, 9H), 2.06-2.41(m, 2H), 2.58-



2.69(m, 2H), 2.89-3.35(m, 5H), 3.81-4.43(m, 2H), 4.79(m,



1H), 8.28(s, 1H), 10.27(s, 1H)


I-406
DMSO-d6 0.91(d, 6H, J = 6.9), 1.01(t, 3H, 7.5), 1.07-



1.32(m, 9H), 1.42-1.84(m, 9H), 2.17(m, 1H), 2.72(t, 2H, 



7.7), 4.00(br, 2H), 4.39(dd, 1H, J = 4.8 and 8.4), 8.15(s, 



1H), 10.25(d, 1H, J = 8.1), 12.35(br, 1H)


I-411
DMSO-d6 0.94(t, 3H, J = 7.8), 1.03(t, 3H, J = 7.5), 



1.12(t, 3H, J = 7.5), 1.30-1.79(m, 16H), 1.97-2.10(m, 



2H), 2.65-2.75(m, 2H), 4.00-4.11(m, 2H), 8.12(s, 



1H), 10.27(br, 1H), 12.16(br, 1H)


I-412
DMSO-d6 1.00-1.44(m, 13H), 1.44-2.04(m, 14H), 



2.24-2.39(m, 2H), 2.52(q, 2H, J = 7.5), 2.70(t, 2H, J = 



8.4), 4.03(br, 2H), 8.34(s, 1H), 10.76(br, 1H)


I-413
DMSO-d6 1.00-1.48(m, 8H), 1.48-1.88(m, 11H), 



2.14(s, 3H), 2.42(s, 3H), 4.02(br, 2H), 8.08(s, 1H), 



10.26(br, 1H)


I-414
1.09(d, 6H, J = 6.6), 1.08-2.73(m, 15H), 2.94-3.23(m, 



2H), 3.69-3.98(m, 3H), 4.23(m, 1H), 4.45(m, 1H), 



4.60(d, 1H, J = 13.5), 8.30(s, 1H), 10.60(d, 1H, J = 3.9)


I-415
1.14-2.25(m, 12H), 1.68(s, 6H), 2.64-2.69(m, 2H), 2.95-



3.24(m, 2H), 3.71(dd, 1H, J = 5.4, 13.8), 3.84-3.95(m, 



2H), 4.24(m, 1H), 4.57(dd, 1H, J = 2.7, 13.8), 8.31(s, 



1H), 10.68(s, 1H)


I-416
1.15-2.39(m, 22H), 2.58-2.76(m, 2H), 2.97-3.23(m, 2H), 



3.69-3.96(m, 3H), 4.24(m, 1H), 4.59(d, 1H, J = 15.6), 



8.30(s, 1H), 10.66(s, 1H)


I-417
1.05-2.18(m, 12H), 1.14(s, 9H), 2.64-3.21(m, 4H), 



3.69-3.90(m, 3H), 4.28(m, 1H), 4.50(d, 1H, J = 7.8), 



4.63(d, 1H, J = 14.4), 8.29(s, 1H), 10.66(t, 1H, J = 7.2)


I-420
DMSO-d6 0.94(t, 3H, J = 7.2), 1.32-1.45(m, 2H), 1.51-



1.65(m, 2H), 2.13(s, 3H), 2.43(s 3H), 4.08-4.13(m, 2H) 



5.48(d, 1H, J = 7.2) 7.30-7.43(m, 5H), 8.10(s, 1H), 



10.74(d, 1H, J = 7.2), 13.08(brs, 1H)


I-427
DMSO-d6 0.94-0.98(m, 9H), 1.34-1.88(m, 10H), 



2.17(m, 1H), 2.66-2.72(m, 2H), 2.93-3.03(m, 2H) 



4.04-4.34(m, 2H) 4.40(dd, 1H, J = 4.5 and 8.4),



8.10(s, 1H), 10.27(d, 1H, J = 8.4), 12.79(br, 1H)


I-428
DMSO-d6 0.93(t, 3H, J = 7.2), 1.32-1.86(m, 8H), 2.68-



2.71(m, 2H), 2.98-3.01(m, 2H), 4.18(br, 2H), 4.10-



4.28(m, 2H), 5.48(d, 1H, J = 6.9), 7.30-7.45(m, 5H), 



8.08(s, 1H), 10.74(d, 1H, J = 6.9)

















TABLE 270





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-431
DMSO-d6 0.94(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 



1.19(t, 3H, J = 7.5), 1.26-1.68(m, 8H), 2.64-2.74(m, 2H), 



4.01-4.07(m, 2H), 5.48(d, 1H, J = 6.9), 7.25-7.42(m, 5H), 



8.15(s, 1H), 10.73(d, 1H, J = 6.9), 13.00(br, 1H)


I-433
DMSO-d6 0.84-0.98(m, 9H), 1.31-1.46(m, 2H), 1.51-1.72(m, 



4H), 1.73-1.85(m, 2H), 2.17(m, 1H), 2.57(t, 2H, J = 5.7), 



2.82(t, 2H, J = 5.7), 3.94-4.13(m, 2H), 4.40(dd, 1H, J = 4.8 



and 8.4), 8.04(s, 1H), 10.28(d, 1H, J = 8.4), 12.76(br, 1H)


I-434
DMSO-d6 0.89-0.92 (m, 6H), 1.00-1.88 (m, 15H), 2.16 (m, 



1H), 2.58 (t, 2H, J = 6.0 Hz), 2.79 (t, 2H, J = 6.0 Hz), 3.86-



4.07 (m, 2H), 4.39 (m, 1H), 8.05 (s, 1H), 10.27 (d, 1H, J = 



8.4 Hz), 12.75 (br,1H)


I-435
DMSO-d6: 0.87-1.00 (m, 9H), 1.32-1.44 (m, 2H), 1.52-1.81 (m, 



9H), 2.57 (t, 2H, J = 6.0 Hz), 2.82 (t, 2H, J = 6.0 Hz), 3.94-4.10 



(m, 2H), 4.47 (m, 1H), 8.03 (s, 1H), 10.17 (d, 1H, J = 7.8 Hz), 



12.73 (br,1H)


I-436
DMSO-d6: 0.87-0.92 (m, 6H), 1.00-1.24 (m, 6H), 1.46-185 (m, 



12H), 2.58 (t, 2H, J = 6.0 Hz), 2.78 (t, 2H, J = 6.0 Hz), 3.84-



4.07 (m, 2H), 4.47 (m, 1H), 8.04 (s, 1H), 10.16 (d, 1H, J = 7.8 



Hz), 12.76 (br, 1H)


I-437
1.08(d, 6H, J = 6.9), 1.37-1.80(m, 8H), 2.41(m, 1H), 2.65(t, 



2H, J = 6.0), 2.87(t, 2H, J = 6.3), 4.50(dd, 1H, J = 5.4 and 



7.2), 4.84(br, 2H), 4.95(d, 1H, J = 17.1), 5.22(d, 1H, J = 10.5), 



5.97(m, 1H), 8.33(s, 1H), 10.53(d, 1H, J = 7.5)


I-439
DMSO-d6 0.93 (t, 3H, J = 7.5), 1.38 (m, 1H), 1.58-1.87 (m, 



5H), 2.56 (t, 2H, J = 6.0), 2.80 (t, 2H, J = 6.0), 3.02 (dd, 1H, 



J = 7.2 and 13.8), 3.16 (dd, 1H, J = 7.2 and 13.8), 3.91-4.08 



(m, 4H), 4.70 (dd, 1H, J = 6.9 and 12.6), 7.13-7.28 (m, 5H), 



8.01 (s, 1H), 10.22 (d, 1H, J = 7.5), 12.84 (br, 1H)


I-440
DMSO-d6: 0.98-1.22 (m, 6H), 1.40-1.82 (m, 9H), 2.57 (t, 2H, 



J = 6.0 Hz), 2.77 (t, 2H, J = 6.0 Hz), 2.98-3.19 (m,2H), 3.85-



4.06 (m, 2H), 4.70 (m, 1H), 7.13-7.26 (m, 5H), 8.14 (s, 1H), 



10.48 (d, 1H, J = 7.8 Hz), 12.82 (br, 1H)


I-441
DMSO-d6: 0.86-0.98 (m, 9H), 1.12-1.94 (m, 11H), 2.57 (t, 2H, 



J = 6.0 Hz), 2.82 (t, 2H, J = 6.0 Hz), 3.94-4.11 (m, 2H), 4.45 



(m, 1H), 8.03 (s, 1H), 10.28 (d, 1H, J = 8.7 Hz), 12.74 (s, 1H)


I-442
DMSO-d6 0.88-0.92 (m, 6H), 1.00-1.93 (m, 18H), 2.58 (t, 2H, 



J = 6.0 Hz), 2.79 (t, 2H, J = 6.0 Hz), 3.84-4.07 (m, 2H), 4.44 



(m, 1H), 8.04 (s, 1H), 10.27 (d, 1H, J = 8.1 Hz), 12.82 (br,1H)


I-444
1.02(d, 6H, J = 6.9), 1.30-1.79(m, 8H), 2.42(m, 1H), 2.66(t, 2H, 



J = 6.0), 3.05(t, 2H, J = 6.3) 3.82-4.03(m, 4H), 4.39(br, 2H), 



4.51(dd, 1H, J = 5.4 and 7.5), 5.19(t, 1H, J = 4.5), 8.31(s, 1H), 



10.49(d, 1H, J = 7.5)


I-445
DMSO-d6 0.91(d, 6H, J = 6.6), 1.00-1.23(m, 6H), 1.48-1.84(m, 



11H), 2.14(m, 1H), 2.65-2.75(m, 2H), 2.95-3.07(m, 2H), 



4.09(br, 2H), 4.37(dd, 1H, J = 5.4 and 8.4), 8.26(s, 1H), 10.27(d, 



1H, J = 8.4), 12.80(br, 1H)

















TABLE 271





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-446
DMSO-d6 0.91-1.25(m, 5H), 1.40-1.82(m, 12H), 2.65-2.75(m, 



2H), 2.93-3.07(m, 2H), 4.15(br, 2H), 5.44(d, 1H, J = 8.4), 7.30-



7.44(m, 5H), 8.08(s, 1H), 10.71(d, 1H, J = 8.4), 13.05(br, 1H)


I-447
DMSO-d6 0.93(t, 3H, J = 8.4), 1.17-1.90(m, 18H), 1.98-2.03(m, 



2H), 2.65-2.76(m, 2H), 2.98-3.05(m, 2H), 4.18(br s, 2H), 8.05(s, 



1H), 10.26(br s, 1H), 12.18(br, 1H)


I-448
DMSO-d6 0.99-1.85(m, 25H), 1.96-2.10(m, 2H), 2.65-2.75(m, 



2H), 2.95-3.06(m, 2H), 4.15(br, 2H), 8.05(s, 1H), 10.26(br s, 



1H), 12.14(br, 1H)


I-449
DMSO-d6 0.92(t, 3H, J = 7.2), 1.24-1.82(m, 16H), 2.73(br, 



2H), 2.98(br, 2H), 4.09(br, 2H), 5.49(d, 1H, J = 6.9), 7.31-



7.42(m, 5H), 8.12(s, 1H), 10.75(d, 1H, J = 6.9), 13.10(br, 1H)


I-450
DMSO-d6 0.91-0.95(m, 9H), 1.12-1.84(m, 16H), 2.17(m, 1H), 



2.74(br, 2H), 2.99(br, 2H), 4.10(br, 2H), 4.40(dd, 1H, J = 4.8 



and 8.1), 8.13(s, 1H), 10.29(d, 1H, J = 8.1), 12.77(br, 1H)


I-451
DMSO-d6 1.00-1.20(m, 9H), 1.45-1.82(m, 5H), 2.17(s, 3H), 



2.70-2.84(m, 2H), 4.01(br, 2H), 5.47(d, 1H, J = 6.6), 7.29-



7.39(m, 5H), 8.12(s, 1H), 10.69(d, 1H, J = 8.4), 13.07(br, 1H)


I-452
DNSO-d6 0.98-1.25(m, 12H), 1.40-1.83(m, 7H), 2.45-2.60(m, 



2H), 2.65-2.79(m, 2H), 4.00(br, 2H), 5.47(d, 1H, J = 6.9), 



7.32-7.43(m, 5H), 8.15(s, 1H), 10.69(d, 1H, J = 6.9), 



13.09(br s, 1H)


I-453
DMSO-d6 0.95(t, 3H, J = 7.5), 1.37-1.50(m, 2H), 1.51-



1.75(m, 7H), 1.78-1.90(m, 2H), 2.66-2.69(m, 2H), 2.91-



2.95(m, 2H), 4.17(br, 2H), 5.73(d, 1H, J = 6.6), 7.26-



7.40(m, 3H), 7.48-7.54(m, 2H), 8.25(s, 1H), 11.00(d, 1H,



J = 6.6)


I-457
DMSO-d6 0.93(t, 3H, J = 7.5), 1.30-1.84(m, 14H), 2.56(t, 



2H, J = 6.0), 2.80(t, 2H, J = 6.0), 4.01(t, 2H, J = 7.8), 8.00(s, 



1H), 10.24(s, 1H), 12.42(br, 1H)


I-458
DMSO-d6 0.98-1.22(m, 4H), 1.40-1.86(m, 18H), 2.57(t, 2H, 



J = 6.0), 2.78(t, 2H, J = 6.0), 3.92(br, 2H), 8.01(s, 1H), 



10.22(s, 1H), 12.48(br, 1H)


I-459
DMSO-d6 0.93 (t, 3H, J = 7.2 Hz), 1.32-1.44 (m, 2H), 



1.50-1.70 (m, 4H), 1.72-1.84 (m, 2H), 2.56 (t, 2H, J = 



6.0 Hz), 2.82 (t, 2H, J = 6.0 Hz), 4.00-4.05 (m, 2H), 5.48 



(d, 1H, J = 6.9 Hz), 7.25-7.42 (m, 5H), 8.02 (s, 1H), 10.75



(d, 1H, J = 7.2 Hz)


I-460
DMSO-d6 1.00-1.20 (m, 6H), 1.46-1.85 (m, 9H), 2.57 (t, 



2H, J = 6.3 Hz), 2.78 (t, 2H, J = 6.3 Hz), 3.88-4.04 (m, 



2H), 5.47 (d, 1H, J = 6.9 Hz), 7.30-7.42 (m, 5H), 8.02 



(s, 1H), 10.72 (d, 1H, J = 6.9 Hz)


I-464
DMSO-d6 2.14(s, 3H), 2.31(s, 3H), 5.45-5.51(m, 3H), 



7.14(d, 4H, J = 8.4), 7.26-7.45(m, 5H), 8.20(s, 1H), 



10.67(d, 1H, J = 6.6)


I-466
DMSO-d6 1.14-1.48(m, 4H), 1.48-1.80(m, 6H), 



2.15(s, 3H), 2.31(s, 3H), 5.43(br s, 2H), 7.18(d, 4H, J = 



7.5), 8.18(s, 1H), 10.17(s, 1H), 12.01(br, 1H)

















TABLE 272





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-467
DMSO-d6 0.89(d, 3H, J = 6.6), 0.90(d, 3H, J = 6.9), 1.05(t, 3H, 



J = 7.5), 2.10-2.22(m, 4H), 2.58-2.76(m, 2H), 4.00(dd, 1H, J = 



5.1 and 8.1), 5.30-5.60(m, 2H), 7.12-7.22(m, 4H), 8.23(s, 1H),



10.16(d, 1H, J = 8.1), 12.71(br, 1H)


I-468
DMSO-d6 0.84-1.00(m, 9H), 1.13(t, 3H, J = 7.5), 1.35-1.52(m, 



2H), 2.16(m, 1H), 2.50-2.68(m, 4H), 4.38(dd, 1H, J = 5.4 and 



8.1), 5.30-5.60(m, 2H), 7.12-7.22(m, 4H), 8.27(s, 1H), 10.15(d, 



1H, J = 8.1), 12.77(br, 1H)


I-469
DMSO-d6 0.91-0.96(m, 9H), 1.30-1.42(m, 2H), 1.57-1.68(m, 



2H), 2.04-2.22(m, 3H), 2.79(t, 2H, J = 7.5), 3.08(t, 2H, J = 7.5), 



3.90-4.08(m, 2H), 4.40(dd, 1H, J = 4.8 and 8.4), 8.22(s, 1H), 



10.29(d, 1H, J = 8.4), 12.74(br, 1H)


I-470
DMSO-d6 0.94 (t, 3H, J = 7.2 Hz), 1.20-1.8 6 (m, 16H), 2.00-



2.10 (m, 2H), 2.57 (t, 2H, J = 6.0 Hz), 2.82 (t, 2H, J = 6.0 Hz), 



4.01-4.08 (m, 2H), 7.99 (s, 1H), 10.27 (s, 1H), 12.17 (br, 1H)


I-471
DMSO-d6 1.00-1.88 (m, 23H), 1.98-2.10 (m, 2H), 2.16-2.20 



(m, 2H), 2.58 (t, 2H, J = 6.0 Hz), 2.77 (t, 2H, J = 6.0 Hz), 



3.90-4.04 (m, 2H), 8.00 (s, 1H), 10.26(s, 1H), 12.20 (br, 1H)


I-472
DMSO-d6 0.93(t, 3H, J = 7.5), 1.38(m, 1H), 1.58-1.87(m, 9H), 



2.56(t, 2H, J = 6.0), 2.81(t, 2H, J = 6.0), 4.01(t, 2H, J = 8.7), 



6.77(d, 2H, J = 8.7), 7.19(d, 2H, J = 8.7), 8.01(s, 1H), 10.57(d, 



1H, J = 7.5), 12.84(br, 1H)


I-473
DMSO-d6 0.96(m, 4H), 1.44-1.86(m, 10H), 2.56(t, 2H, J = 



6.0), 2.78(t, 2H, J = 6.0), 3.87-4.10(m, 2H), 5.32(d, 1H, J = 



6.9), 6.77(d, 2H, J = 8.4), 7.18(d, 2H, J = 8.4), 8.02(s, 1H), 



10.54(d, 1H, J = 6.9), 12.86(br, 1H)


I-477
DMSO-d6 0.94(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 1.12(t, 



3H, J = 7.5), 1.33-1.66(m, 6H), 1.47(s, 6H), 2.42-2.55(m, 



2H), 2.65-2.74(m, 2H), 3.99-4.08(m, 2H), 8.14(s, 1H), 



10.23(s, 1H), 12.40(brs, 1H)


I-478
DMSO-d6 1.01(t, 3H, J = 7,2), 1.06-1.21(m, 4H), 



1.12(t, 3H, J = 7.5), 1.40-1.83(m, 9H), 1.47(s, 6H), 2.45-



2.56(m, 2H), 2.67-2.77(m, 2H), 3.96(br, 2H), 8.14(s, 1H), 



10.20(s, 1H), 12.42(brs, 1H)


I-479
DMSO-d6 0.82-0.98(m, 9H), 1.30-1.48(m, 2H), 1.50-



1.72(m, 4H), 1.72-1.86(m, 2H), 2.16(m, 1H), 2.57(t, 



2H, J = 6.0), 2.82(t, 2H, J = 6.0), 3.91-4.14(m, 2H), 



4.40(dd, 1H, J = 4.8 and 8.4), 8.03(s, 1H), 10.27(d, 



1H, J = 8.4), 12.70(br, 1H)


I-480
DMSO-d6 0.91(d, 6H, J = 6.9), 1.00-1.24(m, 6H), 1.42-



1.86(m, 8H), 2.16(m, 1H), 2.58(t, 2H, J = 6.0), 2.79(t, 



2H, J = 6.0), 3.82-4.08(m, 2H), 4.40(dd, 1H, J = 4.8 and 



8.4), 8.05(s, 1H), 10.27(d, 1H, J = 8.4), 12.77(br, 1H)


I-483
DMSO-d6 0.95(t, 3H, J = 7.5), 0.99(s, 9H), 1.03(t, 3H, J = 



7.5), 1.12(t, 3H, J = 7.5), 1.34-1.67(m, 6H), 2.45-2.56(m, 



2H), 2.64-2.76(m, 2H), 3.93-4.17(m, 2H), 4.27(d, 1H, J = 



8.7), 8.16(s, 1H), 10.41(d, 1H, J = 8.7), 12.66(brs, 1H)

















TABLE 273





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-484
DMSO-d6 0.97-1.22(m, 4H), 0.99(s, 9H), 1.01(t, 3H, J = 



7,5), 1.15(t, 3H, J = 7.5), 1.42-1.83(m, 9H), 2.47-2.56(m, 



2H), 2.68-2.77(m, 2H), 3.98(br, 2H), 4.26(d, 1H, J = 8.1), 



8.17(s, 1H), 10.39(d, 1H, J = 8.1), 12.65(brs, 1H)


I-485
DMSO-d6 0.93 (t, 3H, J = 7.2 Hz), 1.18 (t, 3H, J = 7.5 Hz), 



1.35-1.50 (m, 2H), 2.46-2.68 (m, 4H), 5.45-5.50 (m, 2H), 



5.48 (d, 1H, J = 6.9 Hz), 7.12-7.44 (m, 9H), 8.25 (s, 1H), 



10.63 (d, 1H, J = 6.9 Hz), 13.09 (br, 1H)


I-486
DMSO-d6 1.04 (t, 3H, J = 7.5 Hz), 2.18 (s, 3H), 2.64 



(dd, 2H, J = 7.2 and 14.7 Hz), 5.35-5.53 (m, 2H), 5.49 



(d, 1H, J = 6.6 Hz), 7.05-7.45 (m, 9H), 8.22 (s, 1H), 



10.65 (d, 1H, J = 6.6 Hz), 13.13 (br,1H)


I-487
DMSO-d6 2.16(s, 3H), 2.30(s, 3H), 5.48(d, 1H, J = 



6.6), 5.57(br, 2H), 7.32(d, 2H, J = 8.1), 7.36-7.42(m, 



4H), 7.72(d, 2H, J = 8.1), 8.23(s, 1H), 10.61(d, 1H, J = 6.6), 



12.99(br, 1H)


I-488
DMSO-d6 1.40-1.84(m, 8H), 1.48(s, 6H), 2.65(br, 2H), 



2.95(m, 1H), 3.19-3.50(m, 5H), 3.83-3.95(m, 2H), 



4.38(m, 1H), 4.78(br, 1H), 5.00(s, 1H), 10.24(s, 1H), 



12.40(brs, 1H)


I-489
DMSO-d6 0.90(dd, 6H, J = 6.0 and 10.8), 0.95(t, 3H, 



J = 7,2), 1.03(t, 3H, J = 7.2), 1.12(t, 3H, J = 7.5), 1.33-



1.70(m, 9H), 2.43-2.56(m, 2H), 2.66-2.78(m, 2H), 3.91-



4.14(m, 2H), 4.47(m, 1H), 8.17(s, 1H), 10.16(d, 1H, 



J = 7.8), 12.75(brs, 1H)


I-490
DMSO-d6 0.94(t, 3H, J = 7.2), 1.03(t, 3H, J = 7,2), 



1.11(t, 3H, J = 7.5), 1.12(t, 3H, J = 7.5), 1.32-1.64(m, 6H), 



2.43-2.55(m, 2H), 2.62-2.77(m, 2H), 2.99-3.19(m, 2H), 3.91-



4.13(m, 2H), 4.71(m, 1H), 7.16-7.30(m, 5H), 8.14(s, 1H), 



10.22(d, 1H, J = 7.8), 12.90(brs, 1H)


I-491
DMSO-d6 0.86-0.94(m, 6H), 0.95(t, 3H, J = 7.5), 1.04(t, 3H, 



J = 7,2), 1.12(t, 3H, J = 7.5), 1.19(m, 1H), 1.34-1.68(m, 7H), 



1.89(m, 1H), 2.44-2.57(m, 2H), 2.64-2.77(m, 2H), 3.92-



4.17(m, 2H), 4.45(dd, 1H, J = 4.8 and 8.4), 8.16(s, 1H), 



10.27(d, 1H, J = 8.4), 12.77(brs, 1H)


I-492
DMSO-d6 2.16(s, 3H), 2.30(s, 3H), 3.71(s, 3H), 5.40(br, 



2H), 5.48(d, 1H, J = 6.6), 6.90(d, 2H, J = 8.7), 7.06(d, 



2H, J = 8.7), 7.30-7.44(m, 5H), 8.19(s, 1H), 10.70(d, 



1H, J = 6.6), 13.07(br, 1H)


I-493
DMSO-d6 1.05 (t, 3H, J = 7.8 Hz), 1.15-2.10 (m, 10H), 



2.19 (s, 3H), 2.67 (dd, 2H, J = 7.2 and 15 Hz), 5.42 (s, 



2H), 7.13-7.22 (m, 4H), 8.19 (s, 1H), 10.14 (s, 1H),



12.17 (br, 1H)


I-494
DMSO-d6 0.94 (t, 3H, J = 7.5 Hz), 1.14 (t, 3H, J = 



7.5 Hz), 1.18-2.14 (m, 10H), 1.98-2.08 (m, 2H), 



2.47-2.66 (m, 4H), 5.43 (br, 2H), 7.11-7.23 (m, 4H), 



8.24 (s, 1H), 10.15 (s, 1H), 12.25 (br, 1H)


I-495
DMSO-d6 0.90(dd, 6H, J = 6.0 and 11.4), 1.01(t, 3H, 



J = 7.5), 1.06-1.24(m, 4H), 1.12(t, 3H, J = 7,5), 1.40-



1.84(m, 12H), 2.40-2.57(m, 2H), 2.67-2.78(m, 2H),



3.75-4.15(br, 2H), 4.46(q, 1H, J = 7.5), 8.17(s, 1H), 



10.13(d, 1H, J = 7.5), 12.72(brs, 1H)

















TABLE 274





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-496
DMSO-d6 1.01(t, 3H, J = 7.2), 1.05-1.22(m, 4H), 



1.11(t, 3H, J = 7.5), 1.40-1.80(m, 9H), 2.43-2.55(m, 



2H), 2.64-2.76(m, 2H), 2.96-3.20(m, 2H), 3.80-4.20(br, 



2H), 4.70(m,1H), 7.15-7.28(m,5H), 8.14-8.19(s,1H), 



10.22(d, 1H, J = 7.5), 12.89(brs, 1H)


I-497
DMSO-d6 2.15 (s, 3H), 2.30 (s, 3H) , 5.05 (br, 2H), 



5.48 (d, 1H, J = 6.9 Hz), 7.12-7.43 (m, 9H), 8.21 (s, 



1H), 10.64 (d, 1H, J = 6.9 Hz)


I-498
DMSO-d6 2.16(s, 3H), 2.30(s, 3H), 5.47-5.49(m, 



4H), 7.03(m, 1H), 7.27-7.46(m, 8H), 8.21(s, 1H), 



10.63(d, 1H, J = 6.6)


I-499
DMSO-d6 0.98-1.22 (m, 6H), 1.44-1.85 (m, 9H), 



2.57 (t, 2H, J = 6.0 Hz), 2.77 (t, 2H, J = 6.0 Hz), 



3.74 (s, 3H), 3.88-4.04 (m, 2H), 5.39 (d, 1H, J = 6.6 



Hz), 6.94-7.35 (m, 4H), 8.03 (s, 1H), 10.61 (d, 1H, 



J = 6.9 Hz)


I-500
DMSO-d6 2.19(s, 3H), 2.28(s, 3H), 5.39-5.51(m, 



4H), 6.58(d, 1H, J = 7.5), 7.22-7.41(m, 7H), 



7.55(m, 1H), 8.25(s, 1H), 10.55(d, 1H, J = 6.6), 



13.10(br, 1H)


I-502
DMSO-d6 1.08(d, 3H, J = 6.9), 1.34-1.58(m, 



4H), 1.63-1.85(m, 4H), 2.40(m, 1H), 2.67(t, 2H, 



J = 6.0), 2.88-3.09(m, 4H), 4.42(t, 2H, J = 6.6), 



4.58(dd, 1H, J = 5.1 and 7.5), 8.35(s, 1H), 10.18(d, 



1H, J = 7.5)


I-503
DMSO-d6 1.20-1.50(m, 4H), 1.52-1.78(m, 4H), 



2.60-2.78(m, 2H), 2.95-3.03(m, 4H), 4.37(t, 2H, 



J = 6.9), 5.48(d, 1H, J = 7.2), 7.28-7.46(m, 5H),



8.14(s, 1H), 10.60(d, 1H, J = 6.9)


I-504
DMSO-d6 0.92(d, 6H, J = 6.9), 1.25-1.90(m, 10H),



2.17(m, 1H), 2.62-2.72(m,2H), 2.90-3.01(m, 2H), 



2.92(s, 3H), 3.04-3.14(m, 2H), 4.06-4.22(m,



2H), 4.39(dd, 1H, J = 4.8 and 8.4), 7.15(t, 1H, 



J = 6.0), 8.12(s, 1H), 10.27(d, 1H, J = 8.4), 



12.95(brs, 1H)


I-505
DMSO-d6 1.26-1.88(m, 10H), 2.60-2.70(m, 



2H), 2.90-3.00(m, 2H), 2.91(s, 3H), 3.03-3.13(m, 



2H), 4.08-4.19(m, 2H), 5.49(d, 1H, J = 7.2), 7.14(t, 1H,



J = 6.0), 7.30-7.45(m, 5H), 8.31(s, 1H), 10.73(d, 1H, 



J = 7.2), 13.12(brs, 1H)


I-506
DMSO-d6 1.25-1.88(m, 10H), 1.48(s, 6H), 2.60-



2.70(m,2H), 2.90-3.01(m, 2H), 2.93(s, 3H), 3.03-



3.12(m, 21), 4.07-4.18(m, 2H), 7.15(t, 1H, J = 6.0), 8.09(s, 



1H), 10.22(s, 1H), 12.40(brs, 1H)


I-507
DMSO-d6 0.84-1.00(m, 15H), 1.34-1.66(m, 10H), 



2.16(m, 1H), 2.45(t, 2H, J = 5.1), 2.64-2.76(m, 2H), 



3.92-4.16(m, 2H), 4.40(q, 1H, J = 4.5 and 8.1), 8.13(s, 



1H), 10.27(d, 1H, J = 8.1), 12.81(br, 1H)


I-508
DMSO-d6 0.88-1.00(m, 9H), 1.34-1.68(m, 10H), 



2.45(t, 2H, J = 5.1), 2.64-2.76(m, 2H), 3.92-4.14(m, 



2H), 5.48(d, 1H, J = 8.4), 7.30-7.45(m, 5H), 8.13(s, 1H), 



10.72(d, 1H, J = 8.4), 13.08(br, 1H)


I-511
DMSO-d6 0.88-1.00(m, 9H), 1.34-1.68(m, 16H), 



2.45(t, 2H, J = 5.1), 2.64-2.76(m, 2H), 3.92-4.10(m, 



2H), 8.10(s, 1H), 10.22(s, 1H), 12.43(br, 1H)

















TABLE 275





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-512
DMSO-d6 0.90-0.98(m, 9H), 1.16-1.78(m, 16H), 2.00-2.08



(m, 2H), 2.42-2.54(m, 4H), 2.61-2.77(m, 2H), 4.02-4.12(m, 2H), 



8.10(s, 1H), 10.26(s, 1H), 12.23(br, 1H)


I-513
DMSO-d6 1.26-1.84(m, 10H), 1.48(s, 6H), 1.82(s,3H), 2.60-2.68



(m,2H), 2.87-2.96(m, 2H), 3.00-3.20(m, 2H), 4.02-4.14(m, 2H), 



7.99(t, 1H, J = 5.7), 8.08(s, 1H), 10.23(s, 1H), 12.41(brs, 1H)


I-514
DMSO-d6 1.26-1.82(m, 10H), 1.81(s, 3H), 2.60-2.70(m,2H), 2.86-



2.96(m, 2H), 3.10-3.20(m, 2H), 4.00-4.16(m, 2H), 5.48(d, 1H, 



J = 6.9), 7.30-7.44(m, 5H), 7.99(m, 1H), 8.10(s, 1H), 10.73



(d, 1H, J = 6.9), 13.06(brs, 1H)


I-516
DMSO-d6 0.88(d, 3H, J = 6.9), 0.90(d, 3H, J = 6.9), 1.26-



1.50(m, 4H), 1.50-1.68(m, 4H), 2.27(m, 1H), 2.68(t, 2H, J = 6.0), 



2.80(t, 3H, J = 6.0), 4.40(dd, 1H, J = 5.1 and 8.1), 



5.51(br, 2H), 7.27(d, 2H, J = 8.4), 7.82(d, 2H, J = 8.4),



8.24(s, 1H), 10.09(d, 1H, J = 8.1), 12.75(br, 1H)


I-517
DMSO-d6 1.20-1.52(m, 4H), 1.65-1.80(m, 4H), 2.67(t, 2H, 



J = 6.0), 2.79(t, 2H, J = 6.0), 5.40-5.82(m, 3H), 7.27(d, 2H, 



J = 8.1), 7.30-7.42(m, 5H), 7.81(d, 2H, J = 8.1), 8.22



(s, 1H), 10.56(d, 1H, J = 6.6), 13.06(br, 1H)


I-518
DMSO-d6 1.24-1.82(m, 10H), 1.48(s, 6H), 2.60-2.68(m, 2H), 



2.86-2.96(m, 2H), 3.05-3.16(m, 2H), 3.53(s, 3H), 4.00-4.14



(m, 2H), 7.27(m, 1H), 8.08(s, 1H), 10.21(s, 1H), 12.42(brs, 1H)


I-520
DMSO-d6 1.07(d, 3H, J = 6.6), 1.08(d, 3H, J = 6.6), 



1.34-1.52(m, 4H), 1.62-1.78(m, 4H), 2.41(m, 1H), 2.64(t, 2H, 



J = 6.0), 2.82(t, 2H, J = 6.0), 4.47(dd, 1H, J = 5.4 and 7.5), 5.42



(br, 2H), 6.94-7.10(m, 4H), 8.38(s, 1H), 10.52(d, 1H, J = 7.5)


I-521
DMSO-d6 1.34-1.54(m, 4H), 1.54-1.80(m, 4H), 



2.62(t, 2H, J = 6.0), 2.78(t, 2H, J = 6.0), 5.42(br, 2H), 



5.71(d, 1H, J = 6.6), 6.92-7.12(m, 4H), 7.30-7.42(m, 3H), 



7.49(d, 2H, J = 6.6), 8.36(s, 1H), 10.84(d, 1H, J = 6.9)


I-523
DMSO-d6 0.91(d, 6H, J = 6.9), 0.98-1.25(m, 5H), 1.46-1.86



(m, 6H), 2.16(m, 1H), 2.94(brt, 2H), 3.08(brt, 2H), 



3.72(s, 2H), 4.02(br, 2H), 4.40(dd, 1H, J = 4.8 and 8.4), 



8.14(s, 1H), 10.22(d, 1H, J = 8.4), 12.81(br, 1H)


I-524
DMSO-d6 0.91(d, 6H, J = 6.9), 1.00-1.26(m, 5H), 



1.48-1.88(m, 6H), 2.17(m, 1H), 3.06-3.28(m, 4H), 3.92(d, 



1H, J = 16.2), 4.03(d, 1H, J = 16.2), 4.42(dd, 1H, J = 4.5 



and 8.1), 8.16(s, 1H), 10.16(d, 1H, J = 8.1), 12.82(br, 1H)


I-527
DMSO-d6 1.34-1.54(m, 4H), 1.60(s, 6H), 1.62-



1.78(m, 4H), 2.67(t, 2H, J = 6.0), 2.80(t, 2H, J = 6.0), 



5.50(br, 2H), 7.26(d, 2H, J = 8.4), 7.82(d, 2H, 



J = 8.4), 8.20(s, 1H), 10.08(br s, 1H), 12.44(br, 1H)


I-531
DMSO-d6 0.93(d, 6H, J = 6.9), 1.28-1.52(m, 4H), 



1.54-1.79(m, 4H), 1.85-2.03(m, 2H), 2.26(m, 1H), 2.60-



2.75(m, 4H), 2.88-3.00(m, 2H), 4.16(br, 2H), 4.35-



4.44(m, 1H), 8.13(s, 1H), 10.27(d, 1H, J = 6.9), 12.70(br, 1H)

















TABLE 276





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-532
DMSO-d6 1.34-1.56(m, 4H), 1.62-1.85(m, 4H), 1.85-



2.00(m, 2H), 2.58-2.77(m, 4H), 2.87-3.00(m, 2H), 



4.10-4.23(m, 2H), 5.47(d, 1H, J = 6.9), 7.25-7.49(m, 5H), 



8.11(s, 1H), 10.69(d, 1H, J = 8.1), 13.16(br, 1H)


I-536
DMSO-d6 1.08(d, 3H, J = 6.6), 1.09(d, 3H, J = 6.6), 1.34-



1.58(m, 4H), 1.60-1.96(m, 8H), 2.37-2.50(m, 3H), 2.46(t, 



2H, J = 6.9), 2.58-2.68(m, 2H), 4.10-4.24(m, 3H), 4.53(dd, 



1H, J = 5.1 and 7.5), 8.30(s, 1H), 10.52(d, 1H, J = 7.5)


I-537
1.32-1.58(m, 4H), 1.60-1.94(m, 10H), 2.23-2.46(m, 2H), 



2.42(t, 2H, J = 6-9), 2.89(t, 2H, J = 6.6), 4.10-4.24(m, 4H), 



5.73(d, 1H, J = 6.6), 7.20-7.41(m, 3H), 7.46-7.53(m, 2H), 



8.29(s, 1H), 10.89(d, 1H, J = 6.6)


I-538
DMSO-d6 1.05(t, 3H, J = 7.5), 2.19(s, 3H), 2.67(q, 



2H, J = 7.5), 5.43(brs, 2H), 5.76(d, 1H, J = 6.6), 7.01(dd, 1H, 



J = 3.3 and 5.1), 7.11-7.21(m, 5H), 7.49(dd, 1H, J = 1.2 



and 5.1), 8.25(s, 1H), 10.62(d, 1H, J = 6.9), 13.31(br, 1H)


I-543
DMSO-d6 1.24-1.74(m, 8H), 2.65(brt, 2H), 3.04(brt, 2H), 



5.34(d, 1H, J = 16.2), 5.42(d, 1H, J = 16.2), 5.49(d, 1H, 



J = 6.9), 6.33(dd, 1H, J = 0.6 and 3.3), 6.41(dd, 1H, 



J = 1.8 and 3.3), 7.31-7.43(m, 5H), 7.60(dd, 1H, J = 0.6 and



1.8), 8.15(s, 1H), 10.62(d, 1H, J = 6.9), 13.10(br, 1H)


I-544
DMSO-d6 1.22-1.76(m, 8H), 2.63(brt, 2H), 2.84(brt, 2H), 



2.93(brt, 2H), 4.28(brt, 2H), 5.51(d, 1H, J = 7.2), 7.10-7.18(m, 



2H), 7.27-7.44(m, 7H), 8.12(s, 1H), 10.72(d, 1H, J = 7.2), 



13.10(brs, 1H)


I-545
DMSO-d6 1.02-1.08(m, 6H), 1.24-1.47(m, 4H), 1.54-1.69(m, 



4H), 2.15(m, 1H), 2.60-2.74(m, 2H), 2.75-2.88(m, 2H), 4.39(m, 



1H), 5.45(br, 2H), 7.07(d, 2H, J = 7.5), 7.20-7.40(m, 3H), 8.22(s, 



1H), 10.19(d, 1H, J = 8.4), 12.78(br, 1H)


I-546
DMSO-d6 1.24-1.47(m, 4H), 1.54-1.69(m, 4H), 2.60-2.74



(m, 2H), 2.75-2.88(m, 2H), 5.30-5.60(m, 3H), 7.06(d, 2H,



J = 6.9), 7.22-7.45(m, 8H), 8.20(s, 1H), 10.65(d, 1H, 



J = 6.9), 13.09(br, 1H)


I-547
DMSO-d6 0.91(d, 3H, J = 6.6), 0.92(d, 3H, J = 6.6), 1.24-1.48(m, 



4H), 1.52-1.68(m, 4H), 2.16(m, 1H), 2.66(t, 2H, J = 6.0), 2.81(t, 



2H, J = 6.0), 3.72(s, 3H), 4.39(dd, 1H, J = 5.1 and 8.7), 5.38(br, 



2H), 6.91(d, 2H, J = 8.7), 7.03(d, 2H, J = 8.7), 8.36(s, 1H), 



10.39(d, 1H, J = 8.1), 12.80(br, 1H)


I-548
DMSO-d6 1.24-1.48(m, 4H), 1.52-1.68(m, 4H), 2.66(t, 2H, 



J = 6.0), 2.81(t, 2H, J = 6.0), 3.71(s, 3H), 5.38(br, 2H), 6.91(d, 



1H, J = 8.7), 7.00(d, 2H, J = 8.7), 7.03(d, 2H, J = 8.7), 



7.30-7.46(m, 5H), 8.16(s, 1H), 10.70(d, 1H,



J = 6.9), 13.08(br, 1H)


I-550
DMSO-d6 1.22-1.74(m, 8H), 2.67(brt, 2H), 2.85(br, 2H), 



5.49(br, 2H), 5.50(d, 1H, J = 6.9), 7.16(d, 2H, J = 8.4), 



7.29-7.48(m, 8H), 7.62-7.65(m, 4H), 8.23(s, 1H), 10.69(d, 



1H, J = 6.9), 13.09(br, 1H)

















TABLE 277





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







I-552
DMSO-d6 0.89(d, 6H, J = 6.9), 1.22-1.50(m, 4H), 1.55-1.73(m, 



4H), 2.16(m, 1H), 2.65-2.74(m, 2H), 2.74-2.89(m, 2H), 4.37(dd, 



1H, J = 5.1 and 8.1), 5.54(br, 2H), 7.29(d, 2H, J = 8.1), 7.72(d, 



2H, J = 8.1), 8.24(s, 1H), 10.05(d, 1H, J = 8.1), 12.65(br, 1H)


I-553
DMSO-d6 1.22-1.50(m, 4H), 1.55-1.73(m, 4H), 2.65-2.74(m, 



2H), 2.74-2.90(m, 2H), 5.48(d, 1H, J = 6.9), 5.53(br, 2H), 



7.28-7.44(m, 7H), 7.71(d, 2H, J = 8.1), 8.24(s, 1H), 



10.58(d, 1H, J = 6.6), 13.05(br, 1H)


I-554 
DMSO-d6 0.90(d, 3H, J = 6.9), 0.91(d, 3H, J = 6.9), 1.22-1.47(m, 



4H), 1.52-1.70(m, 4H), 2.18(m, 1H), 2.62-2.70(m, 2H), 2.76-



2.90(m, 2H), 4.39(dd, 1H, J = 5.1 and 8.1), 5.36(br, 2H), 5.99(s, 



2H), 6.50(d, 1H, J = 1.8 and 8.1), 6.73(d, 1H, J = 1.8), 6.86(d, 



1H, J = 8.1), 8.20(s, 1H), 10.20(d, 1H, J = 8.1), 12.62(br, 1H)


I-555 
DMSO-d6 1.22-1.47(m, 4H), 1.52-1.70(m, 4H), 2.62-2.70(m, 



2H), 2.76-2.90(m, 2H), 5.35(br, 2H), 5.47(d, 1H, J = 6.6), 5.99(s, 



2H), 6.50(d, 1H, J = 1.8 and 8.1), 6.73(d, 1H, J = 1.8), 6.86(d, 



1H, J = 8.1), 7.30-7.46(m, 5H), 8.20(s, 1H), 10.20(d, 1H, 



J = 8.1), 12.62(br, 1H)


I-557 
1.07(d, 6H, J = 6.9), 1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 2.26(m, 



1H), 2.31(s, 3H), 2.62(t, 2H, J = 6.0), 2.80(t, 2H, J = 6.0), 4.65



(dd, 1H, J = 5.1 and 8.1), 5.45(br, 2H), 6.95(d, 2H, J = 8.1), 7.12



(d, 2H, J = 8.1), 8.37(s, 1H), 10.60(d, 1H, J = 7.5), 14.41(br, 1H)


I-558 
1.32-1.52(m, 4H), 1.60-1.76(m, 4H), 2.31(s, 3H), 2.62(t, 2H, 



J = 6.0), 2.80(t, 2H, J = 6.0), 5.45(br, 2H), 5.69(d, 1H, J = 6.6), 



6.92(d, 2H, J = 8.1), 7.09(d, 2H, J = 8.1), 7.26-7.39(m, 3H), 7.44-



7.52(m, 2H), 8.35(s, 1H), 10.91(d, 1H, J = 6.9)


I-559 
DMSO-d6 0.89(d, 3H, J = 6.9), 0.91(d, 3H, J = 6.9), 1.24-



1.48(m, 4H), 1.54-1.67(m, 4H), 2.15(m, 1H), 2.60-2.69(m, 



2H), 2.70-2.88(m, 2H), 4.39(dd, 1H, J = 5.1 and 8.4), 



5.45(br, 2H), 7.11(d, 2H, J = 8.4), 7.41(d, 2H, J = 8.4), 



8.22(s, 1H), 10.15(d, 1H, J = 8.4), 12.98(br, 1H)


I-560
DMSO-d6 1.24-1.48(m, 4H), 1.54-1.67(m, 4H), 2.60-2.69(m, 



2H), 2.70-2.88(m, 2H), 5.45(br, 2H), 5.47(d, 1H, J = 6.9), 7.11(d, 



2H, J = 8.1), 7.30-7.43(m, 7H, J = 8.1), 8.21(s, 1H), 



10.62(d, 1H, J = 6.9)


I-563
DMSO-d6 0.88(d, 3H, J = 6.9), 0.89(d, 3H, J = 6.9), 1.15-



1.74(m, 8H), 2.12(m, 1H), 2.65(brt, 2H), 2.96(brt, 2H), 3.98(br, 



2H), 5.49(d, 1H, J = 7.2), 7.31-7.41(m, 5H), 8.11(s, 1H), 10.73(d, 



1H, J = 7.2), 13.06(m, 1H)


II-003
1.00-1.30(m, 4H), 1.56-1.92(m, 7H), 2.16(s, 3H), 2.38(s, 3H), 



3.00(dd, 2H, J = 1.8 and 5.7), 3.70(s, 3H), 3.77(s, 3H), 4.02(br, 



2H), 4.72(m, 1H), 8.27(s, 1H), 10.65(d, 1H, J = 7.5)


II-004
0.99(t, 3H, J = 7.2), 1.39-1.51(m, 2H), 1.62-1.73(m, 2H), 



2.17(s, 3H), 2.41(s, 3H), 2.96(dd, 1H, J = 5.4 and 16.8), 3.04(dd, 



1H, J = 5.4 and 16.8), 3.71(s, 3H), 3.77(s, 3H), 4.13(q-like, 2H), 



5.09(m, 1H), 8.27(s, 1H), 10.67(d, 1H, J = 8.1)

















TABLE 278





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







II-005 
1.00-1.30(m, 4H), 1.56-1.92(m, 7H), 2.16(s, 3H), 2.38



(s, 3H), 3.00(dd, 2H, J = 1.8 and 5.7), 3.71(s, 3H), 3.77(s, 3H), 



4.01(br, 2H), 5.08(m, 1H), 8.27(s, 1H), 10.65(d, 1H, J = 7.5)


II-007
1.00(t, 3H, J = 7.5), 1.41-1.55(m, 2H), 1.66-1.78(m, 2H), 2.20



(s, 3H), 2.43(s, 3H), 3.99(s, 3H), 4.19-4.24(m, 2H), 7,12(m, 1H), 



7.53(m, 1H), 8.03(m, 1H), 8.38(s, 1H), 8.64(m, 1H), 13.01(s,1H)


II-008 
0.99(t, 3H, J = 7.2 Hz), 1.39-2.05(m, 12H), 2.16(s, 3H), 2.39(s, 



3H), 2.81(m, 1H), 3.67(s, 3H), 4.04-4.16(m, 4H), 4.55(m, 1H), 



8.26(s, 1H), 10.41(d, 1H, J = 9.0 Hz)


II-011
1.00(t, 3H, J = 7.2), 1.08(t, 3H, J = 7.5), 1.17(t, 3H, J = 7.5), 



1.38-1.76(m, 6H), 2.47(q, 2H, J = 7.5), 2.59-2.69(m, 2H), 2.85- 



3.08(m, 2H), 3.62(s, 3H), 4.00-4.12(m, 2H), 5.64(q, 1H, J = 7.2), 



7.19-7.44(m, 5H), 8.33(s, 1H), 10.63(d, 1H, J = 8.4)


II-012
0.98(t, 3H, J = 7.5 Hz), 1.38-1.50(m, 2H), 1.60-1.95(m, 6H), 



2.59(t, 2H, J = 6.0 Hz), 2.73(t, 2H, J = 6.0 Hz), 2.85-3.08(m, 2H), 



3.62(s, 3H), 4.01-4.07(m, 2H), 5.64(m, 1H), 7.20-7.44(m, 5H), 



8.21(s, 1H), 10.63(d, 1H, J = 7.8 Hz)


II-013
1.00-1.30(m, 6H), 1.58-1.90(m, 9H), 2.60(t, 2H, J = 6.0 



Hz), 2.70(t, 2H, J = 6.0 Hz), 2.86-3.08(m, 2H), 3.62(s, 3H), 



3.80-4.06(m, 2H), 5.64(m, 1H), 7.20-7.45(m, 5H), 



8.22(s, 1H), 10.62(d, 1H, J = 8.1 Hz)


II-018
1.04-1.31(m, 7H), 1.56-1.88(m, 7H), 2.17(s, 3H), 2.38(s, 



3H), 2.64(t, 2H, J = 6.9), 3.66-3.76(m, 2H), 4.01(br, 2H), 



4.16(q, 2H, J = 7.2), 8.30(s, 1H), 10.13(m, 1H)


II-019 
0.99(t, 3H, J = 7.2), 1.27(t, 3H, J = 7.2), 1.39-1.51(m, 2H), 



1.61-1.71(m, 2H), 2.17(s, 3H), 2.40(s, 3H), 2.64(q, 2H, J = 



7.2), 3.71(q-like, 2H), 4.11(t-like, 2H), 4.17(q, 1H, 



J = 7.2), 8.29(s, 1H), 10.15(brs, 1H)


II-020 
0.89-2.46(m, 20H), 2.62-2.66(m, 2H), 2.78-2.96(m, 



2H), 3.15-3.32(m, 3H), 3.87-4.19(m, 5H), 4.33(m, 1H), 



4.55(m, 1H), 8.27(s, 1H), 10.42(s, 1H)


II-021 
1.13-2.20(m, 22H), 1.22(t, 3H, J = 7.2), 2.61(m, 2H), 2.78(m, 



1H), 2.91-3.19(m 2H), 3.72(dd, 1H, J = 6.3, 3.6), 3.82-3.98(m, 



2H), 4.07-4.65(m, 5H), 8.27(s, 1H), 10.38(t, 1H, J = 8.4)


II-022
0.98(t, 3H, J = 7.2 Hz), 1.22(t, J = 7.2 Hz, 3H), 1.38-



1.52(m, 214), 1.59-2.05(m, 10H), 2.15(s, 3H), 2.38(s, 3H), 



2.79(m, 1H), 4.05-4.19(m, 4H), 4.54(m, 1H), 8.26(s, 1H), 



10.40(d, 1H, J = 9.3 Hz)


II-024 
0.98(t, 3H, J = 7.2 Hz), 1.16(t, 3H, J = 7.2 Hz), 1.37- 



1.51(m, 2H), 1.59-2.14(m, 8H), 2.16(s, 3H), 2.39(s, 3H), 



3.11(m, 1H), 4.03-4.14(m, 4H), 4.71(m,1H), 8.27(s, 1H), 



10.15(d, 1H, J = 6.8 Hz)


II-027
0.98(t, 3H, J = 7.2 Hz), 1.23(t, 3H, J = 6.9 Hz), 1.34-



2.05(m, 16H), 2.60(t, 2H, J = 6.0 Hz), 2.72(t, 2H, J = 



6.0 Hz), 2.79(m,1H), 4.00-4.22(m, 4H), 



4.55(m, 1H), 8.19(s, 1H), 10.41(d, 1H, J = 8.4 Hz)

















TABLE 279





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







II-028
0.99-1.23(m, 6H), 1.22(t, 3H, J = 7.2 Hz), 1.36-2.05(m, 12H), 



2.60(t, 2H, J = 6.0 Hz), 2.69(t, 2H, J = 6.0 Hz), 2.80(m,1H), 



3.85-4.04(m, 2H), 4.13(dd, 2H, J = 7.2 and 14.4 Hz), 



4.53(m, 1H), 8.19(s, 1H), 10.40(d, 1H, J = 9.0 Hz)


II-029
0.99(t, 3H, J = 7.2), 1.07(t, 3H, J = 7.5), 1.17(t, 3H, J = 7.5), 



1.23(t, 3H, J = 7.2), 1.38-1.81(m, 12H), 1.86-2.07(m, 2H), 



2.48(q, 2H, J = 7.5), 2.59-2.68(m, 2H), 2.78(m, 1H), 3.96-



4.23(m, 4H), 4.55(m, 1H), 8.30(s, 1H), 10.43(d, 1H, J = 8.7)


II-030
0.99(t, 3H, J = 7.5), 1.08(t, 3H, J = 7.5), 1.19(t, 3H, J = 7.5), 



1.27(t, 3H, J = 7.2), 1.38-1.74(m, 6H), 2.49(q, 2H, J = 7.5), 



2.60-2.69(m, 4H), 3.71(q, 2H, J = 7.2), 4.00-4.12(m, 2H), 



4.17(q, 2H, J = 7.2), 8.33(s, 1H), 10.16(m, 1H)


II-031
1.21(t, 3H, J = 7.2), 1.30-2.06(m, 18H), 2.06(s, 3H), 



2.63(t, 2H, J = 6.0), 2.78(m, 1H), 2.86-2.93(m, 2H), 



3.06-3.38(m, 2H), 4.02-4.42(m, 4H), 4.53(m, 1H), 



7.07(m, 1H), 8.30(s, 1H), 10.43(d, 1H, J = 9.0)


II-032
1.23(t, 3H, J = 7.2), 1.32-2.08(m, 18H), 2.57-2.66(m, 



2H), 2.78(m, 1H), 2.84-2.92(m, 2H), 3.12-3.26(m, 2H), 



3.68(s, 3H), 4.06-4.32(m, 4H), 4.53(m, 1H), 5.74(m, 



1H), 8.28(s, 1H), 10.39(d, 1H, J = 9.0)


II-033
1.18(t, 3H, J = 6.9), 1.34-1.80(m, 11H), 1.60(s, 



6H), 1.80-2.14(m, 3H), 4.00-4.20(m, 2H), 4.50-4.54(m, 



2H), 5.52(br, 2H), 7.16(d, 2H, J = 8.4), 7.62(d, 2H, 



J = 8.4), 8.36(s, 1H), 10.22(br s, 1H)


II-036
DMSO-d6 1.00-1.26(m, 4H), 1.47-1.85(m, 7H), 2.16(s, 3H), 



2.42(s, 3H), 2.70-2.85(m, 2H), 3.90-4.12(m, 2H), 4.75(m, 



1H), 8.13(s, 1H), 10.33(d, 1H, J = 8.1), 12.57(br, 2H)


II-037
DMSO-d6 0.94(t, 3H, J = 7.2), 1.32-1.45(m, 2H), 



1.52-1.62(m, 2H), 2.14(s, 3H), 2.43(s, 3H), 2.74(dd, 1H, 



J = 5.1 and 16.8), 2.84(dd, 1H, J = 5.1 and16.8), 4.06-



4.12(m, 2H), 4.75(m, 1H), 8.12(s, 1H), 10.36(d, 1H, 



J = 7.8), 12.64(br, 1H)


II-040
DMSO-d6 1.00-1.26(m, 4H), 1.47-1.85(m, 7H), 



2.15(s, 3H), 2.42(s, 3H), 2.6-2.86(m, 2H), 3.90-



4.18(m, 2H), 4.74(m, 1H), 8.13(s, 1H), 10.33(d, 1H, 



J = 8.1), 12.57(br, 2H)


II-041
DMSO-d6 1.00-1.31(m, 4H), 1.46-1.88(m, 7H), 



2.14(s, 3H), 2.40(s, 3H), 2.47(t, 2H, J = 6.6), 3.39-



3.60(m, 2H), 3.94-4.16(br, 2H), 8.12(s, 1H), 9.95(t,


II-043
DMSO-d6 0.93(t, 3H, J = 7.2), 1.31-1.43(m, 2H), 



1.51-1.61(m, 2H), 2.14(s, 3H), 2.42(s, 3H), 



3.34(br, 2H), 3.48(q-like, 2H), 4.08(t-like, 2H), 8.12(s,



1H), 9.97(brt, 1H, J = 6.0), 12.31(br, 1H)


II-044
DMSO-d6 0.95(t, 3H, J = 7.5), 1.32-1.46(m, 2H), 1.54-1.66



(m, 2H), 2.17(s, 3H), 2.45(s, 3H), 4.10-4.15(m, 2H), 7.17



(m, 1H), 7.56(m, 1H), 7.90(m, 1H), 8.22(s, 1H), 8.54(m, 



1H), 12.86(s, 1H), 13.24(brs, 1H)


II-045 
0.92-3.08(m, 29H), 3.36-3.92(m, 3H), 4.31-4.84(m, 



3H), 8.23(s, 1H), 10.19(d, 1H, J = 9.0)


II-046
1.13-2.16(m, 20H), 2.60-3.14(m, 5H), 3.74(m, 1H), 



3.81-3.98(m, 2H), 4.27(m, 1H), 4.57-4.65(m, 



2H), 8.29(s, 1H), 10.50(d, 1H, J = 7.8)

















TABLE 280





Comp.
1H-NMRCCDCl3/TMS)


No.
δ







II-047
DMSO-d6: 0.94(t, 3H, J = 7.2 Hz), 1.32-1.92(m, 



12H), 2.14(s, 3H), 2.42(s, 3H), 2.63(m, 1H), 4.02-



4.16(m, 4H), 4.39(m, 1H), 8.10(s, 1H), 10.24



(d, 1H, J = 9.0 Hz), 12.11(br.1H)


II-049
DMSO-d6 0.94(t, 3H, J = 7.2), 1.30-2.10(m, 9H), 



2.14(s, 3H), 2.42(s, 3H),2.63(m, 1H), 2.91(m, 1H), 



3.98-4.15(m, 2H), 4.38 and 4.54(m, total 1H),



8.11(s, 1H), 10.04(d, 1H, J = 6.9), 12.15(br, 1H)


II-053
DMSO-d6 0.93(t, 3H, J = 6.6 Hz), 1.22-1.85(m, 



16H), 2.56(t, 2H, J = 6.0 Hz), 2.65(m, 1H), 2.80(t, 2H, 



J = 6.0 Hz), 3.98-4.03(m, 2H), 4.40(m, 1H), 8.01(s, 



1H), 10.24(d, 1H, J = 9.0 Hz), 12.13(br, 1H)


II-054
DMSO-d6 0.98-1.90(m, 23H), 2.57(t, 2H, J = 6.3 Hz), 



2.62(m, 1H), 2.77(t, 2H, J = 6.3 Hz), 3.83-4.06(m, 



2H), 4.38(m, 1H), 8.02(s, 1H), 10.22(d,



1H, J = 9.0 Hz), 12.13(br, 1H)


II-056
DMSO-d60.94(t, 3H, J = 7.2), 1.00(t, 3H, J = 7,2), 



1.11(t, 3H, J = 7.5), 1.18-1.94(m, 14H), 2.53-2.75(m, 



4H), 3.90-4.14(m, 3H), 4.41(m, 1H), 8.14(s,



1H), 10.24(d, 1H, J = 9.0), 12.10(brs, 1H)


II-057
DMSO-d6 0.94(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 1.12(t, 



3H, J = 7,2), 1.32-1.65(m, 6H), 2.43-2.55(m, 4H), 2.64- 



2.74(m, 2H), 3.48(q, 2H, J = 6.3), 3.96-4.08(m, 



2H), 8.16(s, 1H), 9.96(m, 1H), 12.28(brs, 1H)


II-058
DMSO-d6 0.94(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.2), 1.11(t, 



3H, J = 7,5), 1.33-1.66(m, 6H), 2.43-2.55(m, 2H), 2.63- 



2.74(m, 2H), 2.75-2.94(m, 2H), 3.96-4.08(m, 2H), 5.40(q, 



1H, J = 7.2), 7. 18.7.40(m, 5H), 8.15(s, 1H), 10.43(d,



1H, J = 8.1), 12.27(brs, 1H)


II-059
DMSO-d6 0.93(t, 3H, J = 7.2), 1.37(m, 2H), 



1.51-1.65(m, 4H), 1.77(m, 2H), 4.00(2H. m), 5.40(1H, 



dd, J = 7.8, 7.2), 7.22-7.38(m, 6H), 10.44(d,



1H, J = 8.4), 12.25(brs, 1H)


II-060
DMSO-d6 1.0-1.9(m, 4H), 1.4-1.8(m, 8H), 2.57(m, 



2H), 2.7-2.87(m, 4H), 3.93(br, 2H), 5.39(dd, 1H, 



J = 8.1, 6.9), 7.2-7.4(6H, m), 10.41(d, 1H,



J = 8.1), 12.33(br, 1H)


II-061
DMSO-d6 1.24-1.96(m, 18H), 1.82(s, 3H), 2.58-



2.68(m, 3H), 2.84-2.94(m, 2H), 3.08-3.19(m, 2H), 3.94-



4.17(m, 2H), 4.42(m, 1H), 7.99(t, 1H, J = 5.4),



8.09(s, 1H), 10.24(d, 1H, J = 9.0), 12.11(brs, 1H)


II-062
DMSO-d6 1.15-1.96(m, 18H), 2.50-2.70(m, 3H), 



2.83-2.96(m, 2H), 3.03-3.17(m, 2H), 3.54(s, 3H), 3.92-



4.18(m, 2H), 4.42(m, 1H), 7.28(m, 1H),



8.10(s, 1H), 10.24(d, 1H, J = 8.7), 12.13(brs, 1H)


II-063
DMSO-d6 1.10-1.84(m, 11H), 2.58-2.82(m, 6H), 1.80-



2.14(m, 3H), 4.00-4.20(m, 2H), 5.40-5.60(br, 2H), 



7.24(d, 2H, J = 8.1), 7.82(d, 2H, J = 8.1),



8.22(s, 1H), 10.08(d, 1H, J = 5.7)


III-002
1.05-2.05(m, 26H), 2.49-2.57(m, 3H), 2.85(t, 2H, 



J = 6.6), 2.97-3.14(m, 2H), 3.54(m, 1H), 3.95-4.02(m, 



2H), 4.13(q, 2H, J = 7.2), 4.49(m, 1H),7.32(s, 1H)


III-003
DMSO-d6 1.09-1.91(m, 23H), 2.54-



3.16(m, 8H), 3.76-3.96(m, 2H), 4.29(m,



1H), 7.26(s, 1H), 12.26(s, 1H)


III-006
1.00-1.38(m, 10H), 1.57-1.95(m, 7H), 2.17(s, 



3H), 2.39(s, 3H), 3.90-4.26(m, 7H), 



8.27(s, 1H), 10.20(d, 1H, J = 7.8)

















TABLE 281





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







III-007
1.00(t, 3H, J = 7.2 Hz), 1.22-1.31(m, 8H), 1.40-1.52(m, 



2H), 1.63-1.73(m, 2H), 2.13(m,1H), 2.17(s, 3H), 2.39(m, 



1H), 2.45(s, 3H), 4.08-4.25(m, 6H), 



4.79(m, 1H), 8.27(s, 1H), 10.43(d, 1H, J = 7.8 Hz)


III-009
DMSO-d6 1.00-1.38(m, 4H), 1.50-2.34(m, 9H), 2.14(s, 



3H), 2.42(s, 3H), 3.84-4.20(m, 4H), 4.48(m, 1H), 8.12(s, 



1H), 10.20(d, 1H, J = 7.5), 12.54(br, 2H)


III-010
DMSO-d6 0.94(t, 3H, J = 7.2), 1.33-1.45(m, 2H), 1.53-



1.64(m, 2H), 1.90(m, 1H), 2.08(m, 1H), 2.15(s, 3H), 2.20-



2.32(m, 2H), 2.44(s, 3H), 4.03-4.18(m, 2H), 4.50(m, 1H), 



8.11(s, 1H), 10.23(d, 1H, J = 7.8), 12.48(br, 1H)


IV-005
0.89-2.33(m, 23H), 2.59-2.65(m, 2H), 2.94(m, 1H), 3.03-



3.26(m, 2H), 3.35(m, 1H), 3.68(s, 3H), 3.79-4.02(m, 2H), 



4.29(m, 1H), 8.30(s, 1H), 9.85(d, 1H, J = 7.2)


IV-006
1.62-2.32(m, 21H), 2.58-2.72(m, 2H), 2.92-3.26(m, 2H), 



3.68(s, 3H), 3.73-3.95(m 4H), 4.23(m, 1H), 4.56(dd, 1H, J = 



2.7, 13.8), 8.31(s, 1H), 9.79(d, 1H, J = 7.8)


IV-015
1.22-2.34(m, 21H), 2.59-2.71(m, 3H), 3.04-4.02(m, 



5H), 4.12-4.82(m, 3H), 8.33(s, 1H), 9.68(m, 1H)


IV-016
1.13-2.38(m, 23H), 2.57-2.73(m, 2H), 2.91-3.21(m, 2H), 3.73(dd, 



1H, J = 7.5, 15.0), 3.84-4.06(m, 2H), 4.25(m, 1H), 4.56(dd, 



1H, J = 2.7, 13.8), 8.32(s, 1H), 9.83(d, 1H, J = 8.4)


IV-030
DMSO-d6 1.24-1.48(m, 4H), 1.53-1.73(m, 4H), 2.65-



2.79(m, 2H), 2.82-2.97(m, 2H), 3.60(s, 2H), 5.14(s, 2H), 



7.02(s, 1H), 7.12-7.19(m, 2H), 7.24-7.39(m, 3H), 



8.38(s, 1H), 12.00-12.80(br, 1H), 13.23(s, 1H)


V-002
1.02-2.95(m, 24H), 2.26(m, 1H), 2.51-2.66(m, 



8H), 2.96(t, 2H, J = 5.7), 3.30(t, 2H, J = 8.1), 3.66(s, 3H), 



4.28(m, 1H), 8.29(s, 1H), 9.96(m, 1H)


V-008
1.04-2.06(m, 23H), 2.25(m, 1H), 2.61-3.00(m, 8H), 



3.31(t, 2H, J = 6.6), 3.17-3.40(m, 2H), 4.34-4.48(m, 



2H), 8.31(s, 1H), 9.87(t, 1H, J = 5.7)


X-35
DMSO-d6 1.30-1.85(m, 12H), 2.71(br, 2H), 



2.99(br, 2H), 3.61(s, 2H), 4.19(brs, 2H), 4.43(brs, 



1H), 4.59(t, 1H, J = 5.6), 7.01(s, 1H), 8.28(s, 1H), 13.45(s, 1H)


X-50
DMSO-d6 1.01-1.90(m, 15H), 2.64(t-like, 2H), 2.85(t-like, 



2H), 3.61(s, 2H), 4.02(brd, 2H), 7.02(s, 1H), 8.20(s, 1H), 



12,40(br, 1H), 13.50(s, 1H)


X-94
DMSO-d6 1.16-1.94(m, 18H), 2.65-2.80(m, 2H), 2.90-



3.09(m, 2H), 3.20(s, 3H), 3.62(s, 2H), 3.90-4.20(br, 2H), 



7.02(s, 1H), 8.29(s, 1H), 12.10-12.60(br, 1H), 13.47(s, 1H)


X-107
DMSO-d6 1.20-2.06(m, 22H), 2.65(br, 2H), 2.94(t, 2H, J = 



6.0), 4.12(br, 2H), 4.42(t, 1H, J = 5.4), 4.58(t, 1H, 5.7), 8.08(s, 



1H), 10.26(s,1H), 12.24(br, 1H)


X-111
DMSO-d6 0.94(t, 3H, J = 7.5), 1.00-2.05(m, 16H), 2.78(m, 



1H), 2.70-3.05(m, 3H), 3.61(s, 2H), 3.90-4.10(m, 2H), 7.02(s, 



1H), 8.20(s, 1H), 12.41(br s, 1H), 13.51(s, 1H)

















TABLE 282





Comp.
1H-NMRCCDCl3/TMS)


No.
δ







X-113
DMSO-d6 1.06(t, 3H, J = 7.4), 1.24-1.74(m, 8H), 



2.02(d, 2H, J = 13.5), 2.19(s, 3H), 2.58(q, 2H, J = 7.4), 



5.47(s, 2H), 7.09(d, 2H, J = 7.4), 7.25-7.38(m, 3H), 



8.20(s, 1H), 10.17(s, 1H), 12.23(s, 1H)


X-118
DMSO-d6 0.91(d, 6H, J = 6.6), .125-1.83(m, 



12H), 2.15(m, 1H), 2.63(br, 2H), 2.92(br, 2H), 



4.10(br, 2H), 4.35-4.43(m, 2H), 4.56(t, 1H, J = 5.7),



8.10(s, 1H), 10.24(d, 1H, J = 8.7), 12.70(br, 1H)


X-140
DMSO-d6 1.04-2.16(m, 12H), 2.60-2.80(m, 2H), 



2.94-3.22(m, 2H), 3.50-3.70(m, 3H), 3.72-3.84(m, 1H), 



4.00-4.24(m, 2H), 4.38-4.52(m, 1H), 7.02(s,



1H), 8.30(s, 1H), 12.39(br s, 1H), 13.40(s, 1H)


X-141
DMSO-d6 1.26-1.84(m, 8H), 2.65-2.78(m, 2H), 



3.05-3.20(m, 2H), 3.62(s, 2H), 5.44(s, 2H), 



6.40-6.50(m, 2H), 7.03(s, 1H), 7.62(d, 1H, 



J = 0.9), 8.32(s, 1H), 12.41(br, 1H), 13.29(s, 1H)


X-142
DMSO-d6 1.30-2.14(m, 15H), 2.60-



2.80(m, 2H), 2.90-3.10(m, 2H), 3.61(s,



2H), 4.05-4.30(br, 2H), 5.55-5.70(m, 



2H), 7.02(s, 1H), 8.30(s, 1H), 12.40(br



s, 1H), 13.46(s, 1H)


X-143
DMSO-d6 1.00-1.30(m, 6H), 1.07(d, 3H, J = 6.3), 1.25(d, 



3H, J = 6.6), 1.50-1.94(m, 8H), 2.39(dd, 1H, J = 11.4 



and 17.4), 2.82(m, 1H), 2.98(m,1H), 3.61(s, 2H), 3.90-



4.15(m, 2H), 7.03(s, 1H), 8.41(s, 1H), 12.41(br s, 



1H), 13.49(s, 1H)


X-145
DMSO-d6 0.94(t, 3H, J = 7.2), 1.04(t, 3H, J = 7.2), 



1.13(t, 3H, J = 7.5), 1.32-1.66(m, 6H), 2.47-



2.57(m, 2H), 2.63-2.78(m, 3H), 2.87(dd, 1H, J = 5.1 



and 16.5), 3.95-4.10(m, 2H), 5.16(m, 1H), 8.21(s, 1H), 



10.44(d, 1H, J = 9.3), 12.69(s, 1H)


X-146
DMSO-d6 2.19(s, 3H), 2.39(s, 3H), 3.80(s, 



2H), 5.52(br-s, 2H), 7.13-7.31(m, 4H), 



8.40(s, 1H), 13.69(s, 1H)


X-147
DMSO-d6 1.12-1.18(m, 4H), 1.51-18.9(m, 



11H), 2.66(br-s, 2H), 2.87(br-s, 2H), 3.81(s, 2H), 4.04(br-s, 



2H), 8.25(s, 1H), 12.66(br-s, 1H), 13.88(s, 1H)


X-152
DMSO-d6 1.12-1.84(m, 8H), 2.60-2.80(m, 2H), 3.00-



3.15(m, 2H), 3.63(s, 2H), 5.60(s, 2H), 6.98(dd, 1H, J = 3.6 



and 5.1), 7.04(s, 1H), 7.22(m, 1H), 7.45(dd, 1H, J = 



1.2 and 5.1), 8.34(s,1H, 12.44(br s, 1H), 13.33(s, 1H)


X-153
DMSO-d6 0.50-0.60(m, 4H), 1.12-1.84(m, 9H), 



2.67-2.78(m, 2H), 2.97-3.09(m, 2H), 3.62(s, 2H), 



4.16(d, 2H, J = 6.6), 7.02(s, 1H), 8.29(s, 1H),



12.40(br s, 1H), 13.43(s, 1H)


X-161
DMSO-d6 1.20-1.80(m, 16H), 2.76(m, 1H), 



2.65-2.77(m, 2H), 2.90-3.10(m, 2H), 3.62(s, 2H), 



4.20(d, 2H, J = 7.2), 7.02(s, 1H), 8.29(s, 1H), 



11.80-12.80(m, 1H), 13.48(s, 1H)


X-174
DMSO-d6 0.94(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 



1.12(t, 3H, J = 7.5), 1.30-1.64(m, 14H), 2.18-2.30(m, 2H), 2.42-



2.56(m, 2H), 2.62-2.74(m, 2H), 2.77(s, 2H), 3.95-



4.08(m, 2H), 8.17(s, 1H), 9.94(s,1H), 11.90(br, 1H)


X-175
DMSO-d6 1.15-1.95(m, 16H), 2.65-2.92(m, 



4H), 2.97-3.10(m, 2H), 3.61(s, 2H), 4.27(m, 1H), 7.01(s, 



1H), 8.25(s, 1H),12.46(br s, 1H), 13.51(s, 1H)


X-176
DMSO-d6 1.26-2.04(m, 16H), 2.65-2.76(m, 2H), 



2.80-295(m, 2H), 3.61(s, 2H), 4.60-4.80(br, 2H), 4.97(m, 



1H), 7.02(s,1H),8.32(s, 1H), 12.40(br s,



1H), 13.40(s, 1H)

















TABLE 283





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







X-178 
DMSO-d6 0.93(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 1.12(t, 3H, 



J = 7.5), 1.32-1.46(m,2H), 1.48-1.68(m, 9H), 2.18-2.30(m, 



2H), 2.42-2.56(m, 2H), 2.63-2.74(m, 2H), 2.76-2.84(m, 2H), 



4.01(t, 2H, J = 7.2), 8.13(s, 1H), 12.56(br, 1H)


X-190 
DMSO-d6 1.10-1.94(m, 16H), 2.65-2.80(m, 2H), 2.90-3.10(m, 



2H), 3.62(s, 2H), 3.76(br s, 1H), 3.90-4.20(br, 2H), 4.20-4.40(br, 



1H), 7.02(s, 1H), 8.29(s, 1H), 12.00-12.60(br, 1H), 13.49(s, 1H)


X-196
DMSO-d6 0.80(t, 6H, J = 7.5), 0.94(t, 3H, J = 7.5), 1.03(t, 3H, 



J = 7.5), 1.12(t, 3H, J = 7.5), 1.32-1.46(g, 2H, J = 7.5), 



1.46-1.66(m, 4H), 1.66-1.81(m, 2H), 1.81-1.96(m, 2H), 



2.44-2.56(m, 2H), 2.64-2.76(m, 2H), 2.76(s, 2H), 



3.93-4.09(m, 2H), 8.15(s, 1H), 9.82(s, 1H), 11.94(br, 1H)


X-198
DMSO-d6 0.96(t, 3H, J = 7.5), 1.05(t, 3H, J = 7.5), 1.16(t, 



3H, J = 7.5), 1.36-1.68(m, 6H), 2.56(q, 2H, J = 7.5), 2.71-



2.77(brm, 2H), 4.08-4.13(brm, 2H), 6.58(d, 1H, J = 16.2), 7.59(d, 



1H, J = 15.9), 8.21(dd, 1H, J = 2.4, 9.0), 8.30(d, 1H, J = 8.7), 



8.33(s, 1H), 8.61(d, 1H, J = 2.1), 12.43(br, 1H), 12.80(s, 1H)


X-207 
DMSO-d6 0.96(t, 3H, J = 7.2), 1.06(t, 3H, J = 7.2), 1.17(t, 



3H, J = 7.2), 1.34-1.50(m, 2H), 1.52-1.72(m, 4H), 2.58(q, 



2H, J = 7.5), 2.72-2.83(m, 2H), 3.82(s, 2H), 4.10-4.20(m, 2H), 



8.35(s, 1H), 12.68(br s, 1H), 13.81(s, 1H)


X-208 
DMSO-d6 0.96-1.38(m, 12H), 1.38-1.92(m, 13H), 2.10-



2.24(m, 2H), 2.40-2.56(q, 2H, J = 7.5), 2.56-2.76(m, 4H), 



3.93-4.11(m, 3H), 8.37(s, 1H), 10.58(d, 1H, J = 6.6)


X-209 
DMSO-d6 0.96(t, 3H, J = 7.2), 1.05(t, 3H, J = 7.5), 1.16(t, 



3H, J = 7.8), 1.34-1.50(m, 2H), 1.50-1.72(m, 4H), 2.56(q, 2H, 



J = 7.5), 2.70-2.80(m, 2H), 3.62(s, 2H), 4.05-4.20(br, 2H), 



7.02(s, 1H), 8.32(s, 1H), 12.40(br s, 1H), 13.45(s, 1H)


X-211 
DMSO-d6 0.87(dd, 6H, J = 3.6 and 6.3), 0.94(t, 3H, J = 7.5), 



1.03(t, 3H, J = 7.5), 1.12(t, 3H, J = 7.5), 1.20-1.66(m, 9H), 2.35-



2.55(m, 4H), 2.63-2.75(m, 2H), 3.93-4.10(m, 2H), 4.34(m, 



1H), 8.16(s, 1H), 9.84(d, 1H, J = 8.7), 12.10(brs, 1H)


X-215 
DMSO-d6 1.20-1.80(m, 22H), 2.00-2.15(m, 1H), 2.67-



2.78(m, 2H), 2.93-3.07(m, 2H), 3.62(s, 2H), 3.90-4.20(br, 



2H), 7.02(s, 1H), 8.30(s, 1H), 12.41(br s, 1H), 13.47(s, 1H)


X-223 
DMSO-d6 0.94(t, 3H, J = 7.5), 1.02(t, 3H, J = 7.5), 1.12(t, 



3H, J = 7.5), 1.32-1.78(m, 10H), 1.84-1.96(m, 2H), 2.10-2.24(m, 



2H), 2.44-2.56(m, 2H), 2.64-2.76(m, 2H), 3.93-4.09(m, 2H), 8.13



(s, 1H), 10.20(s, 1H), 12.29(br, 1H)


X-227
DMSO-d6 0.96(t, 3H, J = 7.5), 1.05(t, 3H, J = 7.5), 1.16(t, 



3H, J = 7.5), 1.35-1.72(m, 6H), 2.56(q, 2H, J = 7.5), 2.68-2.79(m, 



2H), 4.00-4.16(m, 2H), 6.45(d, 1H, J = 15.9), 7.55(d, 1H, 



J = 15.9), 7.68(d, 2H, J = 8.7), 7.76(d, 2H, J = 8.7), 



8.31(s, 1H), 12.30(brs, 1H), 12.44(s, 1H)


X-229
DMSO-d6 1.02-1.86(m, 19H), 2.62-2.75(m, 2H), 



2.92-3.05(m, 2H), 3.85-4.15(br, 2H), 5.43(m, 1H), 8.18(s, 1H), 



10.83(d, 1H, J = 9.0), 14.22(brs, 1H)

















TABLE 284





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







X-230 
DMSO-d6 0.95(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 



1.14(t, 3H, J = 7.5), 1.32-1.68(m, 20H), 1.80-1.96(m, 2H), 



2.08-2.20(m, 2H), 2.44-2.55(m, 2H), 2.64-2.76(m, 2H), 



3.93-4.09(m, 2H), 8.12(s, 1H), 10.03(s, 1H), 12.19(br, 1H)


X-233 
DMSO-d6 0.94(t, 3H, J = 7.5), 1.03(t, 3H, J = 7.5), 1.12(t, 



3H, J = 7.5), 1.30-1.82(m, 12H), 2.00-2.15(m, 2H), 



2.42-2.56(m, 2H), 2.60-2.74(m, 2H), 2.87(s, 2H), 



3.93-4.09(m, 2H), 8.14(s, 1H), 9.93(s, 1H), 11.90(br, 1H)


X-237 
DMSO-d6 1.25-1.50(m, 4H), 1.55-1.75(m, 4H), 2.64-



2.78(m, 2H), 2.84-2.98(m, 2H), 3.61(s, 2H), 5.41(br s, 



2H), 6.00(s, 2H), 6.60(d, 1H, J = 8.1), 6.81(s, 1H), 6.86(d, 1H, 



J = 8.4), 7.02(s, 1H), 8.36(s, 1H), 12.40(br s, 1H),


X-241 
DMSO-d6 0.95(t, 3H, J = 7.2), 1.03(t, 3H, J = 7.5), 



1.11(t, 3H, J = 7.5), 1.33-1.66(m, 16H), 1.91-2.17(m, 



4H), 2.44-2.56(m, 2H), 2.63-6(m, 210, 3.96-4.10(m, 2H), 



8.11(s, 1H), 10.14(s, 1H), 12.17(brs, 1H)


XI-001 
DMSO-d6 1.05(t, 3H, J = 7.5), 1.25-1.91(m, 8H), 2.03(d, 



2H, J = 13.5), 2.18(s, 3H), 2.68(q, 2H, J = 7.4), 3.72(s, 



3H), 5.39(br s, 2H), 6.91(d, 2H, J = 9.0),7.04(d, 2H, J = 9.0), 



8.18(s, 1H), 10.19(s, 1H), 12.17(br s, 1H)


XI-005 
DMSO-d6 1.06(t, 3H, J = 7.4), 1.24-1.73(m, 8H), 2.02(d, 



2H, J = 13.8), 2.18(s, 3H), 2.27(s, 3H), 2.66(q, 2H, J = 



7.4), 5.42(br s, 2H), 6.97(d, 2H, J = 8.1), 7.16(d, 2H, J = 



8.1), 8.18(s, 1H), 10.17(s, 1H), 12.18(br s, 1H)


XI-006 
DMSO-d6 1.02-1.32(m, 6H), 1.40-2.08(m, 9H), 3.20-



3.40(m, 2H), 3.45(m, 1H), 3.73(m, 1H), 3.89(dd, 1H, 



J = 8.7, 12.9), 4.18(dd, 1H, J = 6.0, 12.9), 6.99(s, 1H), 



8.35(s, 1H), 12.37(3r s, 1H), 13.49(s, 1H)


XI-007 
DMSO-d6 1.03(s, 6H), 1.28(s, 6H), 0.90-1.90(m, 



11H), 2.69(s, 2H), 3.62(s, 2H), 4.00-4.15(m, 2H), 7.04(s, 



1H), 8.49(s, 1H), 12.40(br, 1H), 13.49(s, 1H)


XI-009 
DMSO-d6 1.26-1.50(m, 4H), 1.56-1.74(m, 4H), 2.68-



2.78(m, 2H), 2.85-2.95(m, 2H), 3.60(s, 2H), 5.52(s, 2H),



6.96(d, 1H, J = 7.8), 7.02(s, 1H), 7.05-7.16(m, 2H), 



7.39(m, 1H), 8.39(s, 1H), 12.42(br s, 1H), 13.27(s, 1H)


XI-015 
DMSO-d6 1.13(t, 3H, J = 6.9), 1.27-1.75(m, 8H), 2.05(d, 



2H, J = 14.1), 2.16(s, 3H), 2.70(q, 2H, J = 7.4), 2.95(t, 2H, J =



7.5), 4.28(t, 2H, J = 8.1), 7.14(t, 2H, J = 8.9), 7.31(dd, 2H, 



J = 8.9 and 5.6), 8.11(s, 1H), 10.23(s, 1H), 12.18(br s,


XI-016 
DMSO-d6 1.05(t, 3H, J = 7.7), 1.24-1.73(m, 8H), 2.01(d, 



2H, J = 14.7), 2.19(s, 3H), 2.65(q, 21-1, J = 7.2), 5.45(br s, 



2H), 7.12(d, 2H, J = 8.4), 7.42(d, 2H, J = 8.7), 8.20(s, 1H), 



10.12(s, 1H), 12.21(br s, 1H)


XI-019
DMSO-d6 1.20-1.50(m, 4H), 1.58-1.74(m, 4H), 2.70-



2.80(m, 2H), 2.87-2.97(m, 2H), 3.59(s, 2H), 5.50(s, 



2H), 6.85(m, 1H), 7.02(s, 1H), 7.13(m, 1H), 7.23-7.42(m, 



2H), 8.40(s, 1H), 12.38(br s, 1H), 13.23(s, 1H)


XI-024 
DMSO-d6 1.07(t, 3H, J = 7.5), 2.24(s, 3H), 2.74(q, 



2H, J = 6.9), 3.60(s, 2H), 5.49(s, 2H), 7.02(s, 1H), 7.22(d, 



2H, J = 8.4), 7.41(d, 2H, J = 8.4), 8.40(s, 1H),



12.40(br s, 1H), 13.28(s, 1H)


XI-026 
DMSO-d6 1.07(t, 3H, J = 7.5), 2.24(s, 3H), 2.74(q, 2H, 



J = 7.5), 3.60(s, 2H), 5.52(s, 2H), 7.02(s, 1H), 7.14-7.20(m,



2H), 7.24-7.39(m, 3H), 8.40(s, 1H),



12.41(br s, 1H), 13.33(s, 1H)

















TABLE 285





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







XI-028
DMSO-d6 1.07(t, 3H, J = 7.5), 1.24-1.73(m, 8H), 



2.01(d, 2H, J = 13.8), 2.21(s, 3H), 2.63(q, 2H, J = 7.4), 



5.46(br s, 2H), 7.08(d, 2H, J = 5.7), 8.22(s, 1H), 8.52(d, 



2H, J = 6.0), 10.05(s, 1H), 12.18(br s, 1H)


XI-029
DMSO-d6 1.06(t, 3H, J = 7.4), 1.25-1.73(m, 8H), 2.02(d, 2H, 



J = 12.9), 2.19(s, 3H), 2.66(q, 2H, J = 7.4), 5.45(br s, 2H), 



6.88(d, 1H, J = 8.1), 6.98(d, 1H, J = 9.9), 7.12(td, 1H, J = 8.6 



and 2.3), 7.40(m, 1H), 8.20(s, 1H), 10.11(s, 1H), 12.20 (br s, 1 H) 


XI-030
DMSO-d6 1.08(t, 3H, J = 7.7), 2.25(s, 3H), 2.74(q, 2H, 



J = 7.6), 3.59(s, 2H), 5.51(br s, 2H), 6.97-7.15(m, 4H), 7.39(m, 



1H), 8.40(s, 1H), 12.37(br s, 1H), 13.26(s, 1H)


XI-037
DMSO-d6 1.09(t, 3H, J = 7.5), 1.24-1.69(m, 8H), 2.01(d, 



2H, J = 13.8), 2.21(s, 3H), 2.66(q, 2H, J = 7.5), 5.45(br s, 2H), 



6.72(t, 1H, J = 7.4), 7.15(t, 1H, J = 7.5), 7.25-7.39(m, 2H), 



8.21(s, 1H), 10.06(s, 1H), 12.18(br s, 1H)


XI-038
DMSO-d6 1.11(t, 3H, J = 7.4), 2.27(s, 3H), 2.76(q, 2H, 



J = 7.4), 3.59(s, 2H), 5.50(br s, 2H), 6.86(t, 1H, J = 8.0), 7.11(s, 



1H), 7.14(t, 1H, J = 7.5), 7.25-7.37(m, 2H), 8.42(s, 1H), 



12.34(br s, 1H), 13.22(s, 1H)


XI-049
DMSO-d6 1.04(t, 3H, J = 7.5), 1.22-1.74(m, 8H), 2.03



(d, 2H, J = 13.5), 2.17(s, 3H), 2.68(q, 2H, J = 7.2), 5.34(br s, 



2H), 6.73(d, 211, J = 8.4), 6.92(d, 2H, J = 8.4), 8.16(s, 1H), 



9.39(s, 1H), 10.21(s, 1H), 12.17(br s, 1H)


XI-060
DMSO-d6 1.25-1.50(m, 4H), 1.55-1.75(m, 4H), 2.67-



2.80(m, 2H), 2.82-2.95(m, 2H), 3.60(s, 2H), 5.50(s, 



2H), 6.85-6.97(m, 2H), 7.02(s, 1H), 7.16(m, 1H), 



8.38(s, 1H), 12.38(br s, 1H), 13.21(s, 1H)


XI-061
DMSO-d6 1.33(br s, 2H), 1.43(br s, 2H), 1.63(br s, 



4H), 2.74(br s, 2H), 2.89(br s, 2H), 3.59(s, 2H), 5.58(br s, 



2H), 7.02(s, 1H), 7.35(d, 2H, J = 8.1), 7.81(d, 2H, J = 8.1), 



8.40(s, 1H), 12.38(br s, 1H), 13.21(s, 1H)


XI-062
DMSO-d6 1.07(t, 3H, J = 7.5), 2.23(s, 3H), 2.77(q, 2H, 



J = 7.4), 3.60(s, 2H), 5.39(br s, 2H), 6.72(d, 2H, J = 8.4), 



7.01-7.04(m, 3H), 8.37(s, 1H), 9.42(br s,



1H), 12.34(br s, 1H), 13.38(s, 1H)


XI-064
DMSO-d6 1.25-1.74(m, 16H), 2.01(d, 2H, J = 13.2), 



2.68(br s, 2H), 2.80(br s, 2H), 5.54(br s, 2H), 7.27(d, 



2H, J = 8.4), 7.83(d, 2H, J = 8.4), 8.20(s, 1H),



10.08(s, 1H), 12.21(br s, 1H)


XI-069
DMSO-d6 1.16-1.80(m, 16H), 1.96-2.08(m, 



2H), 2.63-2.74(m, 2H), 2.77-2.88(m, 2H), 5.46(s, 



2H), 6.76-6.88(m, 2H), 7.17(m, 1H), 8.19(s, 1H),



10.09(s, 1H), 12.24(br s, 1H)


XI-238
DMSO-d6 0.96(d, 6H, J = 7.0), 1.16(t, 3H, J = 7.0), 1.18-



1.28(m, 2H), 1.30-1.53(m, 8H), 1.60-1.78(m, 3H), 



2.14(s, 3H), 2.17-2.24(m, 2H), 2.43(s, 2H), 2.72(q, 2H, 



J = 7.0), 3.97-4.13(m, 2H), 8.08(s, 1H), 9.73(s, 1H)


XI-239
DMSO-d6 0.94(d, 6H, J = 6.5), 1.14(t, 3H, J = 7.5), 1.40-



1.93(m, 10H), 2.02(m, 1H), 2.12(s, 3H), 2.40(s, 2H), 



2.69(q, 2H, J = 7.5), 3.97-4.09(m, 2H),



8.04(s, 1H), 9.76(s, 1H)


XI-240
DMSO-d6 0.85-0.88(m, 6H), 0.96(d, 6H, J = 6.5), 1.17(t, 3H, 



J = 7.0), 1.33(m, 1H), 1.45-1.65(m, 4H), 1.72(m, 1H), 2.16(s, 



3H), 2.44(t, 2H, J = 6.5), 2.73(q, 2H, J = 7.0), 3.96-4.15(m, 



2H), 4.34(m, 1H), 8.12(s, 1H), 9.82(d, 1H, J = 9.0)

















TABLE 286





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







XI-245
DMSO-d6 1.01(t, 3H, J = 7.2), 1.12(t, 3H, J = 7.5), 



1.26-1.59(m, 12H), 2.19(s, 2H), 2.52(t, 2H, J = 7.5), 2.79(t, 2H, 



J = 8.3), 3.23(s, 3H), 3.40(d, 2H, J = 6.0), 3.61(t, 2H, J = 5.4), 



4.26(t, 2H, J = 5.3), 8.20(s, 1H), 9.97(t, 1H, J = 6.0),



12.16(br s, 1H)


XI-248
DMSO-d6 0.98(d, 6H, J = 6.6), 1.21(t, 3H, J = 7.5), 



1.48-1.62(m, 2H), 1.76(m, 1H), 2.24(s, 3H), 2.82(q, 1H, 



J = 7.8), 3.81(s, 2H), 4.10-4.22(m, 2H), 8.34(s, 1H), 



12.66(br s,1H), 13.84(s, 1H)


XI-251
DMSO-d6 0.98(d, 6H, J = 6.6), 1.21(t, 3H, J = 7.5), 



1.48-1.60(m, 2H), 1.75(m, 1H), 2.23(s, 3H), 2.80(q, 2H, 



J = 7.8), 3.82(s, 2H), 4.10-4.20(m, 2H), 7.31(s,



1H), 8.30(s, 1H), 12.64(br s, 1H), 13.39(s, 1H)


XI-255
DMSO-d6 0.99(d, 6H, J = 6.6), 1.20(t, 3H, J = 7.5), 



1.46-1.60(m, 2H), 1.76(m, 1H), 2.22(s, 3H), 2.79(q, 1H, J = 



7.5), 3.60(s, 2H), 4.08-4.20(m, 2H), 7.72(dd, 1H, J = 2.1, 8.7), 



8.19-8.24(m, 2H), 8.28(s, 1H), 12.45(br s, 1H),


XI-256
DMSO-d6 0.95(t, 3H, J = 7.5), 1.04(t, 3H, J = 7.2), 



1.13(t, 3H, J = 7.2), 1.30-1.82(m, 8H), 2.14-2.74(m, 6H), 



2.84(s, 2H), 3.50(t, 2H, J = 10.5), 3.60-4.15(m, 



4H), 8.15(s, 1H), 10.12(s, 1H)


XI-257
DMSO-d6 0.96(s, 3H), 0.98(s, 3H), 1.15-1.80(m, 



9H), 1.71(t, 3H, J = 7.2), 2.16(s, 3H), 2.20-2.65(m, 4H), 



2.74(q, 2H, J = 7.2), 3.95-4.15(m, 2H),



8.07(s, 1H), 10.40(s, 1H)


XI-258
DMSO-d6 0.95(s, 3H), 0.98(s, 3H), 1.18(t, 3H, J = 



7.5), 1.40-1.85(m, 5H), 2.15-2.30(m, 2H), 2.16(s, 3H), 



2.74(q, 2H, J = 7.5), 2.84(s, 2H), 3.50(t, 2H, J = 11.1), 



3.60-4.20(m, 4H), 8.11(s, 1H), 10.09(s, 1H)


XI-259
DMSO-d6 0.92(s, 9H), 0.95(s, 3H), 0.97(s, 3H), 



1.17(t, 3H, J = 7.5), 1.40-1.82(m, 4H), 2.17(s, 3H), 2.74(q, 



2H, J = 7.5), 3.95-4.20(m, 2H), 4.44-4.56(m, 



1H), 8.12(s, 1H), 10.15(d, 1H, J = 8.4)


XI-268
DMSO-d6 0.83(s, 3H), 0.89(s, 3H), 1.05(t, 4H, J = 7.5), 



1.10-1.36(m, 3H), 1.54-1.72(m, 2H), 2.02-2.16(m, 2H), 2.18(s, 



3H), 2.65(q, 2H, J = 7.8), 2.82(s, 2H), 5.41(br, 2H), 6.93(m, 



1H), 7.24(m, 1H), 7.40(m, 1H), 8.21(s, 1H),



9.80(s, 1H), 12.02(br, 1H)


XI-271
DMSO-d6 0.96(d, 6H, J = 6.6), 1.18(t, 3H, J = 7.5), 1.45-



1.62(m, 4H), 1.73(m, 1H), 2.00-2.16(m, 6H), 2.16(s, 3H), 



2.74(q, 2H, J = 7.5), 3.40-3.52(m, 2H), 3.62-3.74(m, 2H), 



4.00-4.14(m, 2H), 8.11(s, 1H), 9.96(s, 1H), 12.01(brs,


XI-272
DMSO-d6 0.96(d, 614, J = 7.0), 1.17(t, 3H, J = 7.0), 



1.21-1.56(m, 12H), 1.72(m, 1H), 2.17(s, 3H), 2.19(s, 2H), 



2.74(q, 2H, J = 7.0), 3.40(d, 2H, J = 6.5), 4.02-4.12(m, 2H), 



8.14(s, 1H), 10.0(s, 1H), 12.1(s, 1H)


XI-273
DMSO-d6 0.97(d, 6H, J = 7.0), 1.17(t, 3H, J = 7.0), 1.43-



1.52(m, 2H), 1.73(m, 1H), 1.80-1.91(m, 2H), 2.16(s, 3H), 2.16-



2.30(m, 4H), 2.74(q, 2H, J = 7.0), 2.89(s, 2H), 4.00-4.10(m, 



2H), 8.15(s, 1H), 10.1(s, 1H), 12.0(s, 1H)


XI-274
DMSO-d6 0.87(s, 9H), 0.96(d, 6H, J = 7.0), 1.17(t, 3H, J = 



7.0), 1.43-1.54(m, 2H), 1.59(m, 1H), 1.65-1.80(m, 2H), 



2.16(s, 3H), 2.18(t, 2H, J = 7.5), 2.74(q, 2H, J = 7.0), 4.01-



4.15(m, 3H), 8.13(s, 1H), 9.74(d, 1H, J = 9.5), 12.0(s, 1H)

















TABLE 287





Comp.
1H-NMR(CDCl3/TMS)


No.
δ







XI-276
DMSO-d6 0.97(d, 6H, J = 6.6), 1.18(t, 3H, J = 7.5), 



1.51(brdt, 2H, J = 6.3), 1.7-2.3(m, 9H), 2.17(s, 3H), 



2.76(q, 2H, J = 7.2), 4.05-4.5(br,2H), 8.10(s,



1H), 10.36(s, 1H)


XI-281
DMSO-d6 0.99(d, 6H, J = 6.6), 1.21(t, 3H, J = 7.5), 1.47-



1.60(m, 2H), 1.76(m, 1H), 2.22(s, 3H), 2.79(q, 1H, J = 7.5), 



4.06-4.22(m, 2H), 6.58(d, 1H, J = 16.2), 7.59(d, 1H, J = 



15.9), 8.21(dd, 1H, J = 2.4, 8.7), 8.30(d, 1H, J = 8.7), 8.30(s,



1H), 8.61(d, 1H, J = 2.1), 12.81(s, 1H)


XI-282
DMSO-d6 1.20-1.85(m, 10H), 2.10-2.25(m, 2H), 



2.60-2.75(m, 2H), 2,85(s, 2H), 2.95-3.05(m, 2H), 3.24(s, 



3H), 3.50(t, 2H, J = 11), 3.61(t, 2H, J = 5.4), 3.64-3.74(m, 2H), 



4.16-4.4(m, 2H), 8.11(s, 1H), 10.06(s, 1H)


XI-286
DMSO-d6 1.02(t, 3H, J = 7.5), 1.12(t, 3H, J = 7.2), 



1.45-2.90(m, 10H), 2.84(s, 2H), 3.24(s, 3H), 3.50(t, 



2H, J = 11), 3.61(t, 2H, J = 5.3), 4.26(t, 2H,



J = 5.4), 8.17(s, 1H), 10.05(s, 1H)


XI-294
DMSO-d6 0.99(d, 6H, J = 6.6), 1.21(t, 3H, J = 7.5), 



1.48-1.70(m, 2H), 1.76(m, 1H), 2.27(s, 3H), 2.79(q, 2H, 



J = 7.5), 4.08-4.22(m, 2H), 6.73(d, 1H, J = 16.5), 7.57(d, 



1H, J = 15.9), 8.27(s, 1H), 9.02(s, 2H), 12.54(br s, 



1H), 13.04(s, 1H)


XI-296
1.08(t, 3H, J = 7.5), 1.20(t, 3H, J = 7.5), 1.55(m, 2H), 



1.78-1.87(m, 6H), 2.20(m, 2H), 2.51(q, 2H, J = 7.5), 2.79-



2.85(m, 2H), 3.05(s, 2H), 3.30(s, 3H), 3.67-3.71(m, 2H), 



4.31(t, 2H, J = 5.1), 8.37(s, 1H), 10.47(s, 1H)


XI-298
0.92(s, 3H), 0.96(s, 3H), 1.09(t, 3H, J = 7.5), 1.22(t, 



3H, J = 7.5), 1.35-1.65(m, 6H), 2.05-2.24(m, 4H), 2.53(q, 2H, 



7.5), 2.82-2.88(m, 2H), 3.30(s, 3H), 3.70(t, 2H, J = 5.4), 



4.34(t, 2H, J = 5.4), 8.37(s, 1H), 10.66(1H, s)


XI-300
DMSO-d6 0.85(d, 3H, J = 7.0), 0.87(d, 3H, J = 7.0), 



0.96(d, 6H, J = 7.0), 1.17(t, 3H, J = 7.0), 1.29(m, 1H), 1.36-



1.65(m, 5H), 1.65-1.82(m, 2H), 2.17(s, 3H), 2.20(t, 



2H, J = 7.0), 2.24(q, 2H, J = 7.0), 4.00-4.10(m, 2H),



8.13(s, 1H), 9.64(d, 1H, J = 9.0), 12.0(s, 1H)


XI-301
DMSO-d6 0.95(d, 6H, J = 7.0), 1.16(t, 3H, J = 7.0), 



1.42-1.52(m, 2H), 1.71(m, 1H), 2.17(s, 3H), 2.27(dd, 1H, 



J = 9.0 and 15.5), 2.48(dd, 1H, J = 7.5 and 15.5), 2.74(q, 2H, 



J = 7.0), 4.00-4.10(m, 2H), 5.18(m, 1H), 8.17(s, 1H),


XI-302
DMSO-d6 0.88(s, 9H), 0.96(d, 6H, J = 6.5), 1.17(t, 



3H, J = 7.0), 1.41-1.55(m, 2H), 1.72(m, 1H), 



2.16(s, 3H), 2.16(m, 1H), 2.56(m, 1H), 2.74(m, 2H), 



3.98-4.16(m, 2H), 4.26(m, 1H), 8.13(s, 1H), 



9.95(d, 1H, J = 9.0)


XI-304
0.92(s, 3H), 0.96(s, 3H), 1.01(t, 6H, J = 6.6), 1.26(t, 



3H, 7.5), 1.38-1.61(m, 6H), 1.73-1.81(m, 1H), 



2.21(s, 3H), 2.05-2.24(m, 4H), 2.77(q, 2H, 7.5),



4.14(m, 1H), 8.30(s, 1H), 10.75(1H, s)


XI-306
DMSO-d6 1.04(t, 3H, J = 7.5), 1.14-1.59(m, 



8H),2.09(m, 2H), 2.18(s, 3H), 2.65(q, 2H, J = 7.2), 



3.71(s, 2H), 3.96(s, 2H), 5.42(br s, 2H), 7.11-7.21(m,



4H), 8.21(s, 1H), 9.74(s, 1H), 12.51(br s, 1H)


XI-307
DMSO-d6 0.98(d, 6H, J = 6.6), 1.04(t, 3H, J = 7.2), 1.12(t, 



3H, J = 7.5), 1.16-1.80(m, 13H), 1.98-2.10(m, 2H), 2.45-



2.55(m, 2H), 2.63-2.75(m, 2H), 4.00-



4.14(m, 2H), 8.13(s, 1H), 10.25(s, 1H), 12.19(br s, 1H)









The testing examples of the above-mentioned compounds of the present invention are shown below.
Testing Example 1
Human Cannabinoid Receptor Bonding Inhibition Test
The human cannabinoid receptor used the membrane preparation (fraction) of the CHO cell which had made CB1 or CB2 receptor reveal stably. A prepared membrane sample product and a compound being tested, and [3H] CP55940 of 38,000 dpm (the final concentration 0.5 nM: manufactured by NEN Life Science Products Corp.) were incubated in an assay buffer solution (50 mM tris-HCl buffer solution (pH 7.4) containing serum albumin of cattle, 1 nM EDTA, 3 mM MgCl2) at 25° C. for 2 hours. After the incubation, they were filtered by a glass filter which had been processed with 1% polyethylene imine, and washed with 50 mM Tris-HCl buffer solution (pH 7.4), and then the radiation activity on the glass filter was found in the liquid scintillation counter. The nonspecific bonding was measured in the presence of WIN55212-2 of 10 μM (a cannabinoid receptor agonist described in U.S. Pat. No. 5,081,122, manufactured by Sigma Corp.), and 50% inhibition concentration of the compound being tested (IC50 value) to specific bonding was obtained. The Ki value of the compound being tested was calculated from the obtained IC50 value and the Kd value of 3H CP55940. The results are shown in a table.
Testing Example 2
cAMP Formation Inhibition Experiment Through a Cannabinoid Receptor
A compound being tested was added in the CHO cell which had mad human CB1 or CB2 receptor reveal and incubated for 15 minutes, and then forskolin (the final concentration 4 μM, and manufactured by SIGMA Corp.) was added and the mixture was incubated for 20 minutes. After the reaction had been stopped by adding 1M hydrochloric acid, the amount of cAMP in the supernatant was measured with the use of Cyclic AMP kit (made by the CIS Diagnostic Corp.). The cAMP formation by the forskolin stimulation was assumed to be 100% to that with no forskolin stimulation, and the concentration (IC50 value) of the compound being tested which showed the depressant effect of 50% was obtained. The compound being tested showed the agonist effect to the CB1 or CB2 receptor as shown in the table.
The results of Testing example 1 and Testing example 2 were shown in the following tables.











TABLE 288








Binding

Agonist



The numbers
activity

activity


of the
(nM)

(nM)











compounds
CB1
CB2
CB1
CB2














I-001
<2
<2
<2



I-002
48
7.1
11
4.4


I-019
2.9
<2
8.1


I-038
7.1
<2
34
<2


I-048
118
2.6
328
17


I-052
32
7.3
49
8.1


I-054
11
6
51
15


I-084
<2
<2
<2
<2


I-089
<2
<2
<2
<2


I-094
<2
<2
9.0
<2


I-111
3.5
<2
<2


I-124
3.6
<2
<2


I-133
5.0
<2
4.0


I-134
<2
<2
<2


I-196
<2
<2
<2


I-203
<2
<2
<2


I-211
2.4
<2
<2


I-252
<2
<2
<2


I-253
<2
<2
<2


I-255
2.1
<2
<2


I-263
<2
<2
<2


I-266
12
<2
12.0


I-300
<2
<2
<2


I-301
<2
<2
<2


I-305
<2
<2
<2


I-306
<2
<2
<2


I-402
34
<2
>2000
5.7


I-411
>2000
382
>2000
556


I-424
357
3
>2000
5.9


I-493
>2000
36
>2000
24


I-530
7
<2
305


I-533
21
<2
>2000
<2


I-551
50
2.2
135
<2


I-556
8.1
<2
357
3.5


I-570
68
11
709
12


I-572
39
4.4
397
2.4


I-579
158
7.3
431
27


I-580
24
7.4
41
48


I-588
41
10
72
5.7


I-590
66
16
51
2.4


I-595
354
9.5
1208
30


I-596
341
22
312
30


I-599
37
4
37
13


I-601
47
3.9
186
6.3


I-604
16
2.5
55
4.8


I-606
60
4.4
118
8.7


















TABLE 289








Binding activity (nM)
Agonist activity (nM)












CB1
CB2
CB1
CB2














The numbers of






the compounds






I-608
527
11
>2000
3.5


I-617
295
6.6
79
18


II-031
>2000
2.5

9.9


II-067
>2000
13
685
4.9


II-069
88
3.4
5.6
2.1


II.073
88
6.2
11
0.2


II-075
652
48
290
4.6


II-076
>2000
41
>2000
1.2


II-078
1452
27
252
<2


III-017
149
15
322
35


IV-023
425
22
398
11


IV-029
1318
43
606
22


X-21
1767
3.3
>2000
30


X-54
93
<2
>2000
3.7


X-64
580
18
454
15


X-66
>2000
92
549
50


X-67
>2000
96
>2000
40


X-115
1216
3.3
>2000
8.6


X-126
873
31
131
35


X-128
608
10
152
3


X-133
>2000
5.5
>2000
<2


X-138
>2000
42
>2000
30


X-157
270
3.4
268
<2


X-174
>2000
8.9
>2000
9.8


X-196
>2000
31
>2000
45


X-197
1264
41
708
7.2


X-202
1182
46
>2000
81


X-216
1767
3.3
>2000
30


X-220
555
18
1550
231


X-222
1621
43
>2000
57


X-229
482
12
369
27


X-231
>2000
38
>2000
35


X-232
>2000
15
>2000
29


X-233
>2000
24
>2000
15


X-234
482
4
375
6.1


X-235
950
3.7
270
4.7


X-239
1420
10
>2000
3.6


X-240
793
6.2
468
<2


X-241
>2000
57
>2000
26


XI-017
441
6.6
127
11


XI-025
1361
54
>2000
209


XI-027
1361
54
>2000
209


XI-035
>2000
31
>2000
47


Comparative






compounds






4-101*1
890
1.9




10-035*1
19
0.2





*1: The numbers of the compounds described in WO 02/053543.















Testing Example 3
Anti-Pruritic Activity Test by Application
1) Preparation of the compound and the reagent: The compound being tested was dissolved in acetone (SIGMA). Compound 48/80 (SIGMA) was dissolved in physiological saline (m by Otsuka Pharmaceutical Co., Ltd.) so as to be 60 μg/mL.
2) Animals: Female Crj: CD-1 (ICR) mice of 6 to 10 age in week (Japan Charles Liver) were used as laboratory animals. The animals were fed in the barrier breeding room where 233° C. in room temperature, 30 to 70% in humidity, and the light and shade condition existed every 12 hours and feed (CE-2: Japan Crea) and the drinking water were freely taken. The hair of dorsa (from the cervical region of the back to the center of the back) of the animals were cut with a hair clipper two days or more before the anti-pruritic activity is evaluated, those with no wound, rubefaction, and thickening of the skin on the dehaired part were chosen and supplied to the experiment on the day of the evaluation.

3) Evaluation procedures: The acetone solution of the compound being tested was applied by 50 μL on the dehaired parts of the mice with a pipeter. On the mice of the control group, 50 μL of acetone was applied. The 15 minutes later, 50 μL (corresponding to 3 μg) of Compound 48/80 solution was injected intradermally in the compound applied parts with the use of a injector (Terumo Corporation), the mice were individually put in five observation cages made of acrylate resin at once, and the scratching action (action of scratching the injection part by the hind leg) frequency during 30 minutes was measured. The evaluation was carried out in one group of 5 to 7 mice.

4) Data processing: The experiment results were shown by the mean values. The test of the significant difference of the compound applying group to the control group was conducted with Welch's t-test, and p<0.05 was assumed to be significant.

The results were shown in the following table.












TABLE 290






Itching

Itching

Itching



inhibition

inhibition

inhibition


The
ratio
The
ratio
The
ratio


numbers
%
numbers
%
numbers
%


of the
(Concentration
of the
(Concentration
of the
(Concentration


compounds
%)
compounds
%)
compounds
%)







I-001
53 (0.5)
I-002
68 (2.5)
I-019
74 (1.0)


I-038
67 (3.0)
I-048
58 (3.0)
I-052
80 (3.0)


I-054
63 (2.0)
I-084
60 (0.1)
I-089
65 (0.5)


I-094
60 (0.5)
I-111
55 (0.1)
I-124
49 (0.5)


I-133
56 (0.5)
I-134
91 (0.5)
I-196
47 (0.5)


I-203
86 (0.5)
I-211
70 (1.5)
I-252
96 (1.5)


I-253
70 (1.5)
I-255
93 (1.5)
I-263
57 (1.5)


I-266
64 (2.0)
I-300
41 (0.5)
I-301
39 (0.5)


I-305
61 (0.5)
I-306
83 (0.5)
I-402
59 (3.0)


I-411
80 (0.5)
I-424
62 (3.0)
I-530
74 (2.0)


I-533
73 (3.0)
I-551
51 (2.0)
I-556
76 (3.0)


I-570
84 (3.0)
I-572
97 (1.0)
I-579
99 (3.0)


I-580
98 (3.0)
I-588
81 (1.0)
I-590
75 (3.0)


I-595
108 (3.0) 
I-596
60 (3.0)
I-599
67 (0.5)


I-601
67 (1.0)
I-604
95 (3.0)
I-606
86 (1.0)


I-608
75 (3.0)
I-617
96 (1.0)
II-031
55 (2.0)


II-067
68 (3.0)
II-069
84 (3.0)
II-073
58 (3.0)


II-075
95 (3.0)
II-076
86 (3.0)
II-078
94 (3.0)


III-017
76 (3.0)
IV-023
116 (3.0) 
IV-029
93 (1.0)


X-21
106 (1.0) 
X-54
100 (1.0) 
X-64
99 (1.0)


X-66
71 (1.0)
X-67
79 (1.0)
X-115
67 (0.5)


X-216
106 (1.0) 
X-220
97 (0.5)
X-229
105 (0.5) 


XI-035
69 (0.5)











Comparative compounds
4-101*1
7.5 (5.0)
10-035*1
22 (5.0)





*1The numbers of the compounds described in WO02/053543.






The above-mentioned compounds of the present invention except 4-101 and 10-035 described in WO 02/053543 showed significant differences by being p<0.05.
Testing Example 4
Anti-Pruritic Activity Test by Oral Administration
1) Preparation of the compound and the reagent: The compound being tested was suspended in 0.5% aqueous solution of methyl cellulose (Kanto Chemicals Co., Ltd.). Compound 48/80 (SIGMA) was dissolved in physiological saline (m by Otsuka Pharmaceutical Co., Ltd.) so as to be 60 μg/mL.

2) Animals: Female Crj:CD-1 (ICR) mice of 6 to 10 age in weeks (Japan Charles Liver) were used as laboratory animals. The animals were fed in the barrier breeding room where 23±3° C. in room temperature, 30 to 70% in humidity, and the light and shade condition existed every 12 hours and feed (CE-2: Japan Crea) and the drinking water were freely taken. The hair of dorsa (from the cervical region of the back to the center of the back) of the animals were cut with a hair clipper two days or more before the anti-pruritic activity is evaluated, those with no wound, rubefaction, and thickening of the skin on the dehaired part were chosen and supplied to the experiment on the day of the evaluation.

3) Evaluation procedures: The suspension of the compound being tested was orally administered by volume of 5 mL/kg on the dehaired parts of the mice with an oral sonde. To the mice of the control group, methyl cellulose was orally administered by volume of 5 mL/kg. The 30 minutes later, 50 μL (corresponding to 3 μg) of Compound 48/80 solution was injected intradermally in the back dehaired regions with the use of a injector (Terumo Corporation), the mice were individually put in five observation cages made of acrylate resin at once, and the scratching action (action of scratching the injection part by the hind leg) frequency during 30 minutes was measured. The evaluation was carried out in one group of 4 to 8 mice.

4) Data processing: The experiment results were shown by the mean values. The test of the significant difference of the compound administration group to the control group was made with Welch's t-test, and p<0.05 was assumed to be significant.

Testing Example 5
Test with a Rat OVA Asthma Model
Egg albumin (OVA) of 0.1 mg/mL and aluminum hydroxide gel of 1 mg were administered in the abdominal cavity of Brown Norway (BN) rat, and the rat was sensitized to them. On 12, 19, 26, and 33 days after the sensitization, 1% OVA solution was made an aerosol with ultrasonic nebulizer (NE-U17), the rat which had put in the chamber for the exposure was subjected to the inhalation exposure of this aerosol for 30 minutes. A compound of the present invention was orally administered by 10 mg/kg once a day continuously for three days since one hour before an antigen exposure of the fourth times. To the control group, 0.5% methyl cellulose was administered instead of a compound of the present invention.
On the three days after the antigen exposure of the fourth times, under the pentobarbital anesthesia (80 mg/kg, i.p.), acetylcholine (3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 μg/kg) was injected in the cervix region vein of the rat with one by one in five minutes from a low dosage, and the airway shrinkage reaction (increase in insufflation pressure) caused immediately after the injection was measured by Konnzett & Rossler method partly modified. The depressant rate of airway hyperreactivity exacerbation to the control group was calculated from the area under the curve (AUC) calculated from the concentration reaction curve of the acetylcholine.
After the measurement of the airway hyperreactivity had ended, the bronchus alveoli of the rat were washed three times with the physiological saline of 5 mL, the total cell count in the cleaning solution was counted by using the hemacytometer under an optical microscope, and the depressant rate of the inflammatory cellular infiltration to the control group was calculated. In addition, the mucin in the airway cleaning solution is measured by the ELISA method using jacalin which is mucin binding lectin, and the depressant rate of the mucus secretion to the control group was calculated.
Testing Example 6
Test with a Guinea Pig Nosal Congestion Model
The methods of measuring the nosal resistance and evaluating the nosal decongestion with the use of a guinea pig are shown below. One percent egg albumin (OVA) solution was made an aerosol, and this aerosol was made to be inhaled in a Hartley male guinea pig for ten minutes for each twice every week and the guinea pig was sensitized to it. On the seven days later, the antigen was exposed and the reaction was caused. Under the pentobarbital anesthesia (30 mg/kg, i.p.), the guinea pig's trachea was incised and cannulas were installed in the nasal cavity side and the lung side respectively, and on the lung side, an artificial respirator, which supplies with air 60 times per minute and 4 mL each time, was connected. After guinea pig's spontaneous respiration had been stopped with galamine (2 mg/kg, i.v.), the air of 70 times per minute and 4 mL once was sent to the nosal rostrum from the cannula on the nasal cavity side with the artificial respirator, and air pressure necessary for the air supplying was measured by transducer which installed in the side branch and the pressure was assumed the index of the nasal resistance. The antigen was exposed by generating the aerosol of 3% OVA solution for three minutes between the artificial respirator and the nosal cavity cannula. A compound of the present invention was injected in the vein ten minutes before the antigen exposure. As for the result, the nasal resistance was continuously measured during 30 minutes from 0, and the depressant rate to the vehicle was obtained based on the index of the AUC (nasal resistance (cm H2O) in the vertical axis and time (0 to 30 minutes) in the horizontal axis) of the 30 minutes.
Testing Example 7
Influence of Cigarette Smoke Exposure on the Deterioration of Guinea Pig's Breath Function (a COPD Model)
The main current smoke of a cigarette with a filter tip commercially available (Highlight, nicotine 1.4 mg content, and tar 17 mg content, Japan Tabaco Inc.) was exposed to the nose and the mouth of a Hartley guinea pig (obtained from Japan SLC Co., Ltd.) at the rate of 30 pieces of the cigarettes a day for five days a week during 30 days with a cigarette smoke exposure device for an animal (manufactured by Thinker N Co., Ltd.). (Wright J L, Churg A. Cigarette smoke causes physiologic and morphologic changes of emphysema in the guinea pig Am. Rev. Respir. Dis. 1990 142:1422-8).
The compound (I) was suspended in 0.5% methyl cellulose, and orally administered at the rate of 10 mg/kg three times a day. To the medium group, 0.5% methyl cellulose of 5 ml/kg was orally administered three times a day.
After 16 to 24 hours had passed from the final cigarette smoke exposure, the trachea incision of the guinea pig was conducted under urethane (100 mg/kg, i.p.) anesthesia, and a cannula was intubated and installed in a respiratory function measuring device system, a maneuver (manufactured by Baxco Co., Ltd.) for small animals. The respiratory function of the guinea pig was measured according to the protocol of the maneuver.
In the medium administered control group and the medicine administered group, the amount of a functional residual air, the increase in the total lung capacity, and the decrease in the dynamic lung compliance by the cigarette smoke exposure were compared and the test of the significant difference was conducted. The data will be shown by the average±the standard deviation. The statistical test was conducted by the two-tailed test of the t-test method of Student, and judged to be a significant difference at P<0.05.
The compound (1) showed a significant difference of P<0.05 to the increase in the amount of a functional residual air by administering 30 mg/kg a day.
The compound (1) showed a significant difference of P<0.05 to the increase in the total lung capacity by administering 30 mg/kg a day.
Testing Example 8
Depression Effect on the Formalin Nociceptive Stimulus in ICR Mouse
The depression effect of a compound of the present invention on the formalin nociceptive stimulus is examined by using a ICR male mouse (five age in week) for the examination. The compound being tested is dissolved in sesame oil, and the solution is orally administered in the mouse two hours before the formalin administration, then formalin (2%, 20 μL) is subcutaneously administered in the right hind leg. In this experiment, the measurement is conducted for 30 minutes after the administration of formalin, and the measurement will be divided in two phases of 5 minutes immediately after the administration of formalin (the first phase) and 20 minutes from 10 to 30 minutes after the administration (the second phase). As for the strength of the pain, the depression effect of the compound being tested is measured based on the index of the total time of licking action and biting action to the right hind leg, and the ED50 value is calculated.
Testing Example 9
Dermatitis Model Inducing DNFB
Female BALB/cmouse was used for the test. 30 μL of 0.5% acetone solution of 1-fluoro-2,4-dinitrobenzene (DNFB) was applied on the mouse abdomen once a day for two days. On 6, 8, and 10 days after the first sensitization, 10 μL of 0.3% acetone solution of DNFB was applied on the inside and outside of both ears. The compound was suspended in the 0.5% methyl cellulose solution and orally administered once a day on 6 to 12 days after the first sensitization. The thickness of the pinnae of the mouse (the degree of the edema) was measured with calipers (a micrometer) every day during the experiment from the sixth day of the sensitization. Each data will be shown by the average±the standard error. The statistical test was conducted by the t-test method of Welch, and judged to be a significant difference at P<0.05.
Formulation Examples
The following formulation examples of 1 to 10 are nothing but exemplification and do not intend any ranges of the invention to be limited. The term of “active constituent” means the compound of the present invention, a pharmaceutically acceptable salt or a solvate thereof.
Formulation Example 1
The Hard Gelatin Capsule is Manufactured by the Use of the Following Constituents













Dosage



(mg/capsule)



















Active constituent
250



Starch (dried)
200



Magnesium stearate
 10



Total
460 mg










Formulation Example 2
The Tablet is Manufactured by the Use of the Following Constituents













Dosage



(mg/tablet)



















Active ingredient
250



Cellulose (microcrystal)
400



Silicon dioxide (fume)
 10



Stearic acid
 5



Total
665 mg










The constituents are mixed and compressed to make the tablet of 665 mg in weight each.
Formulation Example 3
An Aerosol Solution Containing the Following Constituents is Manufactured













Weight



















Active ingredient
0.25



Ethanol
25.75



Propellant (chlorodifluoromethane)
74.00



Total
100.00










The active constituent is mixed with ethanol, and this mixture is added in part of propellant 22 and cools to −30° C., and then the mixture moves to the filling device. After that, the necessary amount is supplied to a stainless steel container and diluted with the remaining propellant. A bubble unit is installed in the container.
Formulation Example 4
Tablets Containing 60 mg of an Active Constituent are Manufactured as Follows

















Active ingredient
60
mg



Starch
45
mg



Microcrystalline cellulose
35
mg



Polyvinyl pyrrolidone (10% aqueous solution)
4
mg



Sodium carboxymethyl starch
4.5
mg



Magnesium stearate
0.5
mg



Talc
1
mg



Total
150
mg










The active ingredient, the starch, and the cellulose are passed through No. 45 meshes U.S. sieve and mixed enough. The aqueous solution containing the poly vinylpyrrolidone is mixed with the obtained powder, and then the mixture is passed through No. 14 mesh U.S. sieve. Thus obtained granules are dried at 50° C. and passed through No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, the magnesium stearate, and the talc, all of which have been passed through No. 60 mesh U.S. sieve in advance, are added to the granules and mixed, and then the mixture is compressed with a tableting machine and tablets of 150 mg in weight each are obtained.
Formulation Example 5
Capsules Containing 80 mg of an Active Constituent are Manufactured as Follows
















Active ingredient
80 mg



Starch
59 mg



Microcrystalline cellulose
59 mg



Magnesium stearate
 2 mg



Total
200 mg 










The active ingredient, the starch, the cellulose, and the magnesium stearate are mixed and passed through No. 45 mesh U.S. sieve, and then the mixture is filled to the hard gelatin capsule by 200 mg each.
Formulation Example 6
Suppositories Containing 225 mg of an Active Constituent are Manufactured as Follows
















Active ingredient
 225 mg



Saturated fatty acid glyceride
2000 mg



Total
2225 mg










The active ingredient is passed through No. 60 mesh U.S. sieve, and suspended in the saturated fatty acid glyceride which has been melted by being heated to the minimum necessary in advance Then, this mixture is put in a mold of 2 g in appearance and cooled.
Formulation Example 7
A Suspension Agent Containing 50 mg of an Active Constituent is Manufactured as Follows
















Active ingredient
  50 mg



Sodium carboxymethyl cellulose
  50 mg



Syrup
1.25 ml



Benzoic acid solution
0.10 ml



Perfume
q.v.



Coloring matter
q.v.



Total after adding refined water
  5 ml










The active ingredient is passed through No. 45 mesh U.S. sieve and mixed with sodium carboxymethyl cellulose and syrup to make a smooth paste. The benzoic acid solution and the perfume are diluted with part of the water, and they are added in the paste and stirred. Then, the sufficient quantity of water is added to make the necessary volume.
Formulation Example 8
A Drug Product for a Vein is Manufactured as Follow
















Active ingredient
 100 mg



Saturated fatty acid glyceride
1000 ml










The solution of the above-mentioned constituents is usually administered to the patient at the speed of one ml per minute in the vein.
Formulation Example 9
A Gel Agent is Manufactured as Follows
















Active ingredient
100 mg



Isoptopanol
500 mg



Partially hydrophobic hydroxymethyl celloulose
150 mg



Total after adding refined water
10000 mg 










The active ingredient is dissolved in the isopropanol, and the solution is added in partially hydrophobic hydroxymethyl cellulose which has been uniformly dispersed. In addition, water is added, and then the mixture is uniformly mixed with a stirrer to dissolve all constituents.
Formulation Example 10
A Droplet Distributed Ointment is Manufactured as Follows

















Active ingredient
100
mg



Benzyl alcohol
400
mg



Sorbitan sesquistearate
400
mg



Liquid paraffin
500
mg



White petrolatum
8600
mg



Total
10000
mg










The active ingredient is dissolved in benzyl alcohol, and the solution is added in the mixture of the sorbitan sesquistearate, the liquid paraffin, and the white petrolatum and mixed with a stirrer to adjust.
Industrial Applicability
Such 3-carbamoyl-2-pyridone derivatives were found that have a strong agonistic activity to the cannabinoid receptor, are low in inhibition activity for enzyme (CYP) and in the central nerve side effects, are excellent in photostability, and/or have excellent transdermal absorbency or oral absorbency. Moreover, the pharmaceutical composition, which contains the said compound as an active ingredient, was found showing anti-pruritic effect, especially excellent anti-pruritic effect as a drug for external use.

## Claims

1. A compound of the formula (I):




wherein, R1 is C1-C8 alkyl optionally substituted with one to three substituents chosen from halogen, C3-C8 cycloalkyl, and C6-C14 aryl optionally substituted with one or two substituents selected from substituent group F;
R2 is C1-C6 alkyl or C1-C6 alkoxy C1-C6 alkyl;
R3 is C1-C6 alkyl or C1-C6 alkoxy;
R4 is hydrogen or hydroxy;
G is a group represented by formula:




wherein R5 is hydrogen;
X1 is a single bond;
X2 is C3-C8 cycloalkanediyl optionally substituted with one or two substituents selected from substituent group C, C3-C8 cycloalkenediyl optionally substituted with one or two substituents selected from substituent group C, aryldiyl optionally substituted with one or two substituents selected from substituent group C, heteroaryldiyl optionally substituted with one or two substituents selected from substituent group C, or non-aromatic heterocyclediyl optionally substituted with one or two substituents selected from substituent group C;
X3 is a single bond or C1-C4 alkylene;
Y is —O—;
Z is hydrogen;
substituent group C: halogen, C1-C8 alkyl, halo C1-C8 alkyl, C1-C8 alkoxy, halo C1-C8 alkoxy, oxo, cyano, azide, nitro, and phenyl;
substituent group F: halogen, C1-C8 alkyl, halo C1-C8 alkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, methylenedioxy, benzyloxy, carbamoyl optionally substituted with one or two C1-C8 alkyl, cyano, azide, nitro, oxo, and phenyl;
or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein R1 is C1-C5 alkyl optionally substituted with one to three substituents chosen from halogen C3-C8 cycloalkyl, and C6-C14 aryl optionally substituted with one or two substituents selected from substituent group F, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, wherein R2 is C1-C4 alkyl, or C1-C4 alkyloxy C1-C4 alkyl, and R3 is C1-C4 alkyl or C1-C4 alkyloxy, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1, wherein R2 is ethyl, n-propyl, isopropyl, or methyloxymethyl, and R3 is methyl, ethyl, or methyloxy, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, wherein R4 is hydrogen, or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1, wherein the group of the formula:



is a group selected from the groups represented by the formulas:










wherein Me is methyl; Et is ethyl; n-Pr is n-propyl; i-Pr is isopropyl, the group represented by the formula:




is a group selected from the groups represented by the formulas:




wherein Me is methyl;

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

8. The pharmaceutical composition according to claim 7, comprising the active ingredient in an amount effective as an atopic dermatitis treating agent.

9. The pharmaceutical composition according to claim 7, comprising the active ingredient in an amount effective as an anti-pruritus agent.

10. A method of preparing a medicament for treating atopic dermatitis, comprising:
selecting a compound or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient for use in treating atopic dermatitis, and
formulating an amount of the active ingredient effective for treating atopic dermatitis and at least one pharmaceutically acceptable excipient into a pharmaceutical composition for treating atopic dermatitis.

11. A method of treating atopic dermatitis in a mammal including human, which comprises administering to said mammal a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 1, in an amount effective to alleviate symptoms of the atopic dermatitis.

12. A method for preparing a medicament for treating itching, comprising:
selecting a compound or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient for use in treating itching, and
formulating an amount of the active ingredient effective for treating itching and at least one pharmaceutically acceptable excipient into a pharmaceutical composition for treating itching.

13. A method of alleviating itching in a mammal including human, which comprises administering to said mammal a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 1.

14. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 14 as an active ingredient.

16. The pharmaceutical composition according to claim 15, comprising the active ingredient in an amount effective as an atopic dermatitis treating agent.

17. The pharmaceutical composition according to claim 15, comprising the active ingredient in an amount effective as an anti-pruritus agent.

18. A compound of the formula (I):



wherein, R1 is C1-5 alkyl optionally substituted with one to three substituents chosen from halogen, C3-C8 cycloalkyl, and C6-C14 aryl optionally substituted with one or two substituents selected from substituent group F;
R2 is C1-C4 alkyl or C1-C4 alkoxy C1-C4 alkyl;
R3 is C1-C4 alkyl or C1-C4 alkoxy;
R4 is hydrogen;
G is a group represented by formula:




wherein R5 is hydrogen;
X1 is a single bond;
X2 is C3-C8 cycloalkanediyl;
X3 is a single bond;
Y is —O—;
Z is hydrogen; and
substituent group F: halogen, C1-C8 alkyl, halo C1-C8 alkyl, hydroxy, C1-C8 alkoxy, halo C1-C8 alkoxy, methylenedioxy, benzyloxy, carbamoyl optionally substituted with one or two C1-C8 alkyl, cyano, azide, nitro, oxo, and phenyl;
or pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 18 as an active ingredient.

20. The pharmaceutical composition according to claim 19, comprising the active ingredient in an amount effective as an atopic dermatitis treating agent.

21. The pharmaceutical composition according to claim 19, comprising the active ingredient in an amount effective as an anti-pruritus agent.